Archive.

What Happened

The Ministry of Food and Drug Safety (MFDS), Korea's medicines and medical-device regulator, has set a target to run "the world's fastest" product approval system. In its 2026 administrative plan, reported by Minister Oh Yu-kyoung, MFDS said it will cut review periods that ran as long as 420 days for biosimilars down to 240 days, applying the target across new drugs and medical devices.

The mechanics are procedural, not cosmetic. MFDS plans deeper pre-submission reviews to improve data completeness, parallel review of assessment items rather than sequential ones, dedicated review teams, and more face-to-face consultations. It will add an "AI Approval and Review Support System" to summarise and translate submitted data and draft review documents.

Two structural changes matter most for device makers. MFDS will shift to a negative-list change-approval system, requiring pre-approval only for changes that affect a device's safety or performance, with other modifications managed by the company. And it will introduce self-certification of performance for digital medical and health-support devices.

This sits on top of a separate January 2026 reform, the "Market Immediate Entry Medical Technology" system, which lets devices that clear MFDS's reinforced clinical evaluation skip the separate New Medical Technology Assessment and reach hospitals in as little as 80 days, down from up to 490, across 199 device categories.

Why It Matters

Korea has long been a procedure-heavy market with two distinct bottlenecks: MFDS approval, then a market-access assessment before clinical use. Korea is now compressing both ends at once.

For Swiss and European companies, the negative-list change system is the quiet headline. Iterative digital and AI-enabled devices previously risked re-approval on minor updates; limiting pre-approval to safety- or performance-relevant changes lowers a real lifecycle cost. Self-certification for digital-device performance removes another familiar friction for SaMD firms.

The trade-off is evidence. The fast lane is reserved for devices that pass an "internationally enhanced clinical evaluation." Faster timelines raise, not lower, the bar on the clinical package, and European data may need bridging for Korean review.

What to Watch

Whether the 240-day figure actually holds for medical devices. The headline number comes from the biosimilar track, and device reviews may compress more slowly.

How "changes affecting safety or performance" are defined in practice. That definition decides how much lifecycle burden genuinely falls for AI and software devices.

Whether the digital self-certification route is recognised only by MFDS, or also carries weight with payers. Approval speed means little without a matching reimbursement path through HIRA.

What Happened

South Korea is dismantling a long-standing feature of its hospital-supply market: the affiliated intermediary. Most Korean hospitals buy medical devices and consumables not directly from manufacturers but through a single "middle distribution" company. Many of those intermediaries are owned or controlled by the hospital's director or its founding medical foundation.

At the end of December 2025, the National Assembly amended the Medical Devices Act to ban transactions between a hospital and an intermediary tied to it by a special relationship. The trigger points are concrete: ownership of 50% or more of the intermediary's shares, control by a relative within the second degree of kinship (for example, a director's spouse), or dominant influence over the company's management. The Ministry of Health and Welfare (MOHW), which oversees the sector, made cleaning up device distribution a national policy priority.

Hospitals are already moving. The Asan Foundation is selling its 51% stake in Medigood Partners, the intermediary that supplies Asan Medical Center. Seoul St. Mary's and Severance have unwound their equity ties. Of the "Big 5" hospitals, Seoul National University Hospital and Samsung Medical Center hold no majority stakes and are unaffected. Most large hospitals outside the Big 5 are expected to follow, and private-equity buyers are circling the assets that come loose.

Why It Matters

For European device makers, the affiliated intermediary has been an invisible gatekeeper. Where a hospital owned its distributor, the channel was effectively closed: pricing, product choice and access ran through a captive middleman aligned with the hospital, not the manufacturer. That structure has frustrated foreign entrants for years and is one reason Korea rewards relationship-driven selling.

Severing these ties does two things. It loosens a barrier that favoured incumbents, and it puts a wave of newly independent distributors — some soon backed by private equity — into play as potential partners. A European manufacturer that has struggled to place products through a hospital-owned intermediary may find a more neutral, commercially motivated channel emerging in its place.

What to Watch

Watch which intermediaries change hands and who buys them. Private-equity ownership tends to professionalise a distributor and make it more open to new suppliers and clearer terms.

Watch the transition timeline. Hospitals are divesting ahead of the ban's effective date, so the channel will look different across 2026 and into 2027 — a window to reassess distribution partners.

Watch for workarounds. Korean commentators already warn that some hospitals may restructure ownership to stay under the thresholds rather than genuinely open their procurement.

What Happened

On 7 September, Dong-A ST, a Korean drugmaker with a growing digital-health arm, said it had signed a supply agreement with Schiller Asia Pacific to distribute its wearable patient-monitoring platform, HiCardi, across six Asia-Pacific markets: Thailand, Malaysia, the Philippines, Taiwan, Australia and Singapore. Schiller Asia Pacific will act as master distributor, selling through local partners in each country.

The counterparty is the point. Schiller Asia Pacific is the regional arm of Schiller AG, a Swiss medical-device maker founded in 1974 and known for electrocardiogram (ECG) systems, defibrillators and patient monitors. HiCardi, developed by Korean company MeZoo and marketed by Dong-A ST, is a lightweight patch that tracks ECG, heart rate, respiratory rate, skin temperature and oxygen saturation, then streams the data for remote monitoring. It is used in more than 800 Korean hospitals. The deal follows an earlier push into Brazil and Latin America.

Why It Matters

For European MedTech, the signal is not the Asian geography but the Swiss name on the contract. Schiller is a recognised European cardiology and monitoring brand. Choosing to carry a Korean wearable, rather than build or buy its own, is a quiet endorsement of MeZoo's technology and a reminder that Korean ambulatory remote-monitoring firms have reached a quality bar Western incumbents will now distribute.

It also hints at what could come next. MeZoo already holds a CE mark and counts the European Union among nine markets where it has regulatory clearance. A distribution relationship that begins in Asia can migrate to Europe once a partner grows comfortable with a product. European remote-monitoring and cardiac-diagnostics companies should read this as competitor intelligence: the Korean patch they may soon meet in a tender could arrive through an established European channel, not cold.

This is primarily an Asia-Pacific commercial move. The European relevance is indirect, but real.

What to Watch

Whether the Schiller relationship extends beyond Asia. Schiller's core market is Europe; if HiCardi enters its European catalogue, a low-cost Korean patch gains instant reach into European hospitals.

MeZoo's European regulatory and reimbursement progress. A CE mark opens the door, but ward-based continuous monitoring becomes a business only once hospitals can bill for it. Watch for pilots in Germany, France or the Nordics.

Consolidation in cardiac monitoring. The Brazilian partner in Dong-A ST's earlier HiCardi deal, CARDIOS, belongs to Italy's Cardioline group, a sign that remote-diagnostics distribution is consolidating across borders and that Korean device makers are plugging into these networks rather than building their own.

What Happened

Mediwhale, a Seoul-based medical AI company founded in 2016, is moving its retinal cardiovascular AI into Europe through an established local partner. In February 2026, iCare — the ophthalmic-diagnostics brand of Finland's Revenio Group, listed on Nasdaq Helsinki — signed a memorandum of understanding to integrate Mediwhale's Dr. Noon CVD software into its DRSplus fundus camera and iCare Screening Solution. The combined system lets clinicians estimate cardiovascular risk from a routine retinal photograph, without blood tests, radiation or a cardiac CT.

Dr. Noon CVD analyses images of the retina — the one place where blood vessels can be viewed directly — to predict cardiovascular and chronic kidney disease risk. Mediwhale says its accuracy is comparable to the coronary artery calcium score derived from a CT scan. The software is already used in more than 170 hospitals worldwide, including Korea's Yonsei University Health System. In April 2026 the company raised a 20 billion won (about $13 million) Series C led by Premier Partners, taking total funding to roughly $34 million, and said it is preparing a Kosdaq listing in the first half of 2027.

Why It Matters

For European MedTech, the signal is who did the choosing. Revenio is not a startup; it is a profitable European eye-care specialist, with 2024 net sales of 103.5 million euros, that sells screening hardware across the region. Its decision to embed a Korean algorithm rather than build or buy a European one is a competitive data point for any European firm in ophthalmic imaging, cardiovascular diagnostics or preventive screening.

The deeper shift is the retinal exam becoming a gateway to systemic health. If a low-cost, radiation-free fundus photograph can flag cardiovascular and kidney risk, it competes with parts of the cardiac-CT and lab-based risk-scoring pathways that European diagnostics companies serve today. Switzerland's strengths in cardiology, precision prevention and diagnostics sit directly in that path. Mediwhale is best read as a scoutable partner, a distribution opportunity for firms with European hospital channels, or an emerging competitor whose technology a European incumbent has already validated.

What to Watch

Whether the iCare partnership moves from MoU to a shipped product with CE-covered clinical claims. Integration announcements are common; reimbursed clinical use is the harder test.

How European payers and guideline bodies treat retina-based cardiovascular risk. Adoption will hinge on evidence accepted in Europe, not Korea.

Mediwhale's regulatory path. It is pursuing US FDA De Novo clearance and a 2027 Kosdaq listing, both of which would strengthen a company that a European partner is already building into its platform.

What Happened

Sky Labs, the Korean digital-health company behind a ring-shaped cuffless blood-pressure monitor, listed on Kosdaq — Korea's tech-heavy secondary exchange — on 4 September. The stock opened sharply higher, trading around 27,150 won on the first morning, up about 171% from an initial public offering price of 10,000 won a share. The company sold 2 million new shares at that price, raising roughly 20 billion won (about $15 million) to fund research and global expansion.

The listing closes a loop the company opened in August. Its flagship device, CART BP Pro, is a finger-worn ring that records blood pressure continuously over 24 hours, replacing the inflatable arm cuff. By June 2026 it was in use at around 2,000 Korean hospitals and clinics, including all five of the country's largest hospitals. The device is reimbursed under national health insurance and listed in the Korean Society of Hypertension's 2026 guidelines. Overseas sales already accounted for 52% of first-half revenue.

Why It Matters

For European MedTech, the signal is not the ring itself but the balance sheet behind it. A Korean remote-monitoring firm now has fresh capital, a strong market debut and majority-overseas revenue — and it is pointing that firepower at Europe. Sky Labs holds CE-MDR certification and UK MHRA registration, and in late August signed a supply deal with Germany's IEM GmbH to move its clinic device into UK and European hospitals. It is also working with Omron Healthcare and Otsuka on European and Japanese expansion.

That combination — clinical validation at home, an incumbent European channel, and now public-market funding — is what turns a promising device into a durable competitor. European makers of ambulatory and remote blood-pressure monitoring should treat Sky Labs as a funded rival, a possible partner, or an acquisition target, not a distant startup. The stronger reading is strategic: the listing frames Sky Labs less as a device maker than as a medical-data platform, using continuous vital-sign data for clinical research and AI.

What to Watch

Whether the IEM rollout converts into hospital adoption and local reimbursement in the UK and Germany — the step where Korean health-tech firms most often stall in Europe.

How the Omron and Otsuka relationships evolve. Deeper co-development or distribution would widen European reach quickly.

The platform pivot. Sky Labs' CART NET data services and multi-vital devices, CART O2 and CART VITAL, signal ambitions beyond blood pressure, into real-world evidence and trials that European pharma and contract research organisations may find relevant.

What Happened

On 28 August, Classys — a Korean maker of energy-based aesthetic devices, built on high-intensity focused ultrasound (HIFU) and radiofrequency (RF) — reported second-quarter 2026 consolidated revenue up 26.7% year on year to 105.5 billion won, yet cut its full-year guidance to 430–460 billion won, about 9% below its earlier target. The reason was at home: domestic equipment sales fell 39% and a post-merger integration at its Brazilian unit slipped.

The split underneath the numbers is the story. While the Korean market slumped, overseas equipment and consumables sales rose 26% and 31%. European equipment volume jumped to 450 units in the quarter, from 300 in the first, and North America to 150 from 110. Overseas sales reached 79% of the total, at a standalone operating margin above 50%. Classys is not alone: Seoul Economic Daily reports the sector — Wontech, Jeisys Medical and others — is shifting from Asia-centric, low-price sales toward higher-priced North American and European markets, lifting margins as it goes.

Why It Matters

For Europe's aesthetic-device makers — Alma, Fotona, Candela, Lumenis, Cynosure — this is a competitive-intensity signal in their own backyard. Korean firms have moved from cheap challengers to premium-market peers, competing on equipment performance and accumulated clinical data rather than price.

The business model is the point. Like razors and blades, an installed base of HIFU and RF platforms pulls recurring, high-margin consumable revenue, so every unit placed in a European clinic compounds. Classys drawing 79% of sales from abroad — and Jeisys around 85% — shows how far the export pivot has already run.

The nuance European strategists should not miss: this growth comes despite a weak Korean home market, not because of it. Domestic equipment sales fell 39%; the overseas push is a necessity as much as an ambition. That makes Western clinics the battleground where these firms must now win, on distribution, pricing and consumables lock-in.

What to Watch

Classys' approval pipeline — monopolar RF in China late this year, HIFU in the United States and China in the first quarter of next year — which would widen the fronts on which it meets European incumbents.

Placement velocity, not revenue, as the leading indicator. Once a clinic installs a Korean platform, switching costs favor the incumbent; 450 European units in a single quarter is the number European makers should track.

Consolidation. European private equity has already moved in — France's ARCHIMED took Jeisys Medical private — and Classys itself grew by absorbing Ilooda. Expect scale and installed base to become the currency of further deals.

What Happened

At KHF 2026 (K-HOSPITAL+HEALTHTECH FAIR), Korea's largest hospital-technology exhibition, held at COEX in Seoul from 19 to 21 August, the message from the floor was less about new algorithms and more about how hospitals run them.

Speaking at the K-Digital Healthcare Summit, Lee Dae-wook, chief strategy, marketing and operations officer at GE HealthCare Korea, argued that a hospital's AI performance now depends less on which model it buys than on how it operates the technology. Two hospitals with the same model, vendor and contract, he said, routinely achieve very different results.

Lee drew a line between "AI-attached" hospitals, which layer tools on top of existing workflows — adding logins and screens — and "AI-native" hospitals, which redesign work, staffing and governance around the technology from the outset. He framed hospital AI as five layers: data and infrastructure, models, agents, workflows and governance, and said governance must be built in from adoption, not bolted on later.

The signal arrives as the state pushes AI procurement. The Ministry of Health and Welfare (MOHW), Korea's health ministry, is funding post-approval commercialisation of AI medical devices through 2027, requiring vendors to form consortia with hospitals for multi-centre studies, real-world evidence and reimbursement work — part of the ₩754bn AX-Sprint programme.

Why It Matters

Korea is one of the most concentrated and fastest-moving medical-AI markets in the world, and its lead hospitals are now redefining what they buy. For European MedTech and digital-health companies selling AI into Korea, the competitive test is shifting from model accuracy to operational fit: integration with existing infrastructure, workflow redesign, staff adoption and embedded governance.

That changes go-to-market. A strong standalone algorithm is no longer enough. Korean buyers increasingly want workflow infrastructure, deployment support and measurable operational gains, such as shorter reporting times and fewer handoff delays. Vendors positioned as point tools risk losing to those that sell integration.

It also reshapes deals. The MOHW consortium model means market entry may run through a hospital partnership rather than a distributor, making the choice of Korean clinical partner an early strategic decision rather than a late one.

What to Watch

Watch how tenders at major Korean hospitals word their AI requirements. A shift toward integration, workflow and governance criteria — rather than model benchmarks — would confirm the trend and reward vendors who can prove deployment, not just performance.

Watch the MOHW consortium awards through 2027. They indicate which hospitals are actively building AI programmes and are therefore the most credible entry partners for foreign vendors.

Watch "physical AI" — logistics robots, fall-detection, medication dispensing — moving from exhibition floors into procurement, an area where European robotics and monitoring firms hold real strengths.

What Happened

Roen Surgical, a Korean surgical-robotics company, has pushed its Zamenix kidney-stone robot onto the global stage in quick succession. On 11 August the system won 510(k) clearance from the US Food and Drug Administration, allowing sale of the Class II device in the United States. On 1 September Korea's Ministry of Food and Drug Safety (MFDS), the national device regulator, approved a software upgrade adding integrated suction and automated control.

Zamenix is built for retrograde intrarenal surgery (RIRS), a minimally invasive procedure that threads a flexible ureteroscope through the urinary tract to reach kidney stones. The robot lets a surgeon steer the scope from a console instead of by hand, adding AI functions such as respiratory compensation, stone-size guidance and autonomous navigation. Roen calls it the first AI-based flexible ureteroscopic surgical robot to win FDA clearance. It was named Korea's 17th innovative medical device in 2021, validated in a 232-patient multicentre trial, and cleared by the National Evidence-based Healthcare Collaborating Agency (NECA) in May 2026. It runs at 20 Korean hospitals and one abroad, and the company says it will now pursue approvals in Europe, Japan, the Middle East and Southeast Asia.

Why It Matters

This is competitor intelligence for European surgical-robotics and urology-device firms. Robotic surgery is dominated by general-purpose platforms; robots purpose-built for kidney-stone RIRS are rare. Roen is entering that gap with a narrow, validated indication and a cost-focused model — a software-upgradable platform that gains features without a hardware refresh and works with hospitals' existing endoscopes and lasers.

The European ambition is the signal to track, but it is prospective. Zamenix holds FDA clearance and Korean approvals; it does not yet hold a CE mark, and European availability depends on clearing CE-MDR, a slower route than a US 510(k). For now this is primarily a Korean market signal — an emerging exporter building a regulatory record — not a competitor already on European soil. The direction, though, is clear: a validated Korean robot aimed at an underserved niche is the kind of challenger European incumbents and hospital buyers should map early.

What to Watch

Whether and when Roen files for CE-MDR certification. That, not the FDA clearance, is the concrete trigger for European availability.

Whether niche RIRS robotics gains traction against the robotic majors, and whether Roen's free-software-upgrade model pressures the hardware-refresh pricing European buyers are used to.

Roen's partnering moves — a telesurgery MOU with US firm Sovato, a UC San Diego collaboration, a first export to Indonesia — as early markers of how it scales.

What Happened

Sky Labs, a Korean digital-health company, said on 31 August it has signed a European supply agreement with IEM GmbH, a German ambulatory blood-pressure monitoring (ABPM) specialist. Under the deal, IEM will distribute Sky Labs' clinic-use CART BP monitor — a finger-worn, cuffless ring that records blood pressure over 24 hours — to hospitals and clinics across the United Kingdom and Europe. The ring will be integrated with IEM's established ABPM software, FLOW, so clinics can slot it into routine practice. Rollout begins in the UK, then extends across Europe. Sky Labs reported 2.6 billion won (about $1.9 million) in initial sales from the deal in the first half of 2026.

The ring replaces the inflatable arm cuff patients normally wear for a day of monitoring. Sky Labs argues the form factor avoids the sleep and activity disruption of cuff devices, improving detection of nighttime hypertension. The product holds CE-MDR certification, obtained in January 2026, is reimbursed under Korea's National Health Insurance, and is listed in the Korean Society of Hypertension's treatment guidelines. The company says that makes it the first cuffless monitor to hold both a domestic reimbursement and a guideline listing.

Why It Matters

This is a channel and competitor signal for European MedTech. A differentiated Korean device is entering Europe not on its own, but by plugging into an incumbent's installed base and software. IEM already sells blood-pressure monitors to European hospitals; rather than build a rival cuffless product, it chose to distribute one. European makers of ambulatory monitoring, remote patient monitoring and wearable diagnostics should read that decision carefully.

The validation package is the point. Korean reimbursement plus a national guideline listing gives the ring clinical credibility that a consumer wearable lacks — evidence European buyers and procurement bodies will weigh. Cuffless blood pressure remains contested on accuracy, so this is a market to monitor rather than a settled outcome. But the go-to-market template — Korean hardware, European channel, shared software — is one more European firms will meet.

What to Watch

Whether the UK launch converts into hospital adoption, and how IEM positions the ring against its own cuff-based line.

Whether the device earns European reimbursement or guideline traction. Korean credentials do not transfer automatically, and clinical acceptance of cuffless measurement is still debated on the continent.

Sky Labs' planned Kosdaq listing, expected in September, which would give it capital for the European push and signal confidence in the commercial model.

What Happened

South Korea's Coreline Soft, a medical-AI company specialising in chest CT analysis, has secured a 10-year contract to support a lung cancer screening programme in Lostau, Germany. The deal, reported by Korea Biomedical Review on 7 August, runs through Canon Medical Systems GmbH: Canon won the regional procurement with Coreline's software included in its bid, making the Japanese imaging major Coreline's direct customer. The agreement covers software delivery, installation, training and long-term technical support.

Behind the single contract is a fast build-out. Germany began reimbursing low-dose CT (LDCT) lung screening for high-risk smokers under statutory health insurance in April 2026, covering the whole care pathway rather than the scan alone. Coreline signed 55 new German customers in the first half of 2026 and another 22 in July — 77 in total, against just 10 for all of last year. Reference sites now include Charité, Heidelberg University Hospital and Hannover Medical School. First-half sales rose 45.7 percent to a record 2.89 billion won, with overseas revenue up 123 percent and now close to two-thirds of the total.

Why It Matters

This is competitive intelligence in Europe's own backyard. A Korean challenger, not a home-grown vendor, is capturing the most valuable segment of Germany's new screening market — and doing it through a global imaging vendor's procurement channel rather than direct selling. For European medical-AI and diagnostics firms, the Lostau deal shows the go-to-market that works: attach the product to a reimbursed pathway, embed it in an OEM's bid, and sell workflow infrastructure — nodule detection, structured reporting, follow-up, quality assurance — not a standalone algorithm.

The revenue model matters as much as the wins. Coreline is shifting from one-off perpetual licences to subscription and usage-based contracts tied to screening volume. By its own account, only about half of the first-half German contracts have converted to revenue so far, so the reimbursed screening base becomes a recurring annuity as hospitals go live. That is the model European incumbents must now match or beat.

Switzerland sits inside this story. Coreline already holds supply deals in Switzerland, France, Spain and Austria, so the German playbook is portable across the reimbursed screening programmes now spreading through Europe.

What to Watch

Whether other national payers follow Germany in reimbursing LDCT screening. Each one opens a similarly structured market that Coreline and peers such as Lunit are already positioned to enter.

Whether Canon and other imaging OEMs deepen their reliance on Korean AI, in effect distributing it into European hospitals at scale.

How fast Coreline's unconverted German contracts turn into recurring revenue — the test of whether the reimbursement-linked model delivers durable margins, not just signings.

What Happened

South Korea's Ministry of Food and Drug Safety (MFDS), the national regulator for drugs and medical devices, has revised the guidance it uses to separate regulated medical devices from "wellness" products. The distinction is not academic. It decides whether a company must pass through MFDS authorisation, certification or notification before selling in Korea, or whether it may enter the market with no device approval at all.

The revised guidance, issued in February 2026, defines wellness products as tools for everyday health management or for self-management by people with chronic conditions. Anything intended to diagnose, treat or prevent disease falls outside that category and must be handled as a medical device. The document draws its definitions from Korea's newer frameworks for in-vitro diagnostics and digital medical devices, and partially mirrors a January update to the US FDA's own wellness guidance.

Why It Matters

For European digital-health, wearable and diagnostics companies, this line sets the cost and speed of entering Korea. A product classified as wellness avoids the MFDS approval pathway entirely. The same hardware, described as a diagnostic or therapeutic tool, triggers device authorisation and, where reimbursement is sought, assessment by the Health Insurance Review and Assessment Service (HIRA) and the National Evidence-based Healthcare Collaborating Agency (NECA) — a process that can run well past a year.

The guidance makes the boundary more predictable, but it rests on Korea's own legal definitions under the Digital Medical Products Act, in force since January 2025. A company that assumes its US "general wellness" positioning transfers automatically to Korea may be wrong. MFDS gives concrete examples: a device measuring blood glucose or blood pressure and showing trends as a graph can be a wellness product, but only if it is not presented for diagnosis or treatment. The claim, not the sensor, sets the category.

What to Watch

How MFDS treats borderline digital products — stress-relief, sleep, diet and motivational tools for people with hypertension or diabetes. These sit closest to the line and are where European app-based and coaching products will be judged.

Whether Korea's reading of "wellness" stays aligned with the FDA's or drifts. The guidance only partially follows the US update, so a product cleared as low-risk in one market is not guaranteed the same treatment in the other.

How the classification interacts with reimbursement ambition. Staying on the wellness side speeds entry but forecloses National Health Insurance coverage; crossing into the device category is slower but opens the reimbursed market.

What Happened

South Korea is dismantling a long-standing feature of its hospital supply chain: the captive intermediary. Most large Korean hospitals buy medical devices and consumables not directly from manufacturers but through a single middle distributor. Many of those distributors are owned or controlled by the hospital's director or its founding medical foundation.

The Ministry of Health and Welfare (MOHW), which sets national health policy, treated this self-dealing as a distortion of the distribution order. In December 2025 it revised the Medical Devices Act to ban transactions between a hospital and an intermediary tied to it: where a relative within the second degree of the director or a foundation executive runs the distributor, where the hospital holds 50% or more of its shares, or where it otherwise controls the distributor's management. The ban takes effect at the end of 2027.

Hospitals are already moving. The Asan Foundation is selling its 51% stake in Medigood Partners, the intermediary that supplies Asan Medical Center, taking preliminary bids in late July. Seoul St. Mary's Hospital and Severance Hospital have already unwound their equity ties. Of the "Big 5" hospitals, only Seoul National University Hospital and Samsung Medical Center were already clean.

Why It Matters

For a European manufacturer, this hidden layer has quietly shaped who reaches a Korean hospital's wards. A distributor owned by the hospital has little reason to favour an outside supplier over incumbent arrangements, and its economics are opaque. Severing these ties makes the channel more contestable.

As affiliated distributors are sold, the procurement layer is consolidating into fewer, independent, professionally run companies, several backed by private equity. That cuts both ways. Access to hospital shelves becomes less locked-in and more open to negotiation on price and clinical merit. But the new counterparties are larger and more commercially aggressive, with more bargaining power than a captive affiliate had. Suppliers that built Korean sales around one hospital-linked distributor should expect that relationship to change hands or dissolve before end-2027.

What to Watch

Who buys the divested intermediaries. Private-equity ownership of the procurement layer points to consolidation and harder terms; watch Affinity Equity Partners, MBK Partners, and platforms such as ServeOne and Geo-Young.

Whether the reform genuinely opens access or simply replaces captive affiliates with a few dominant distributors that European suppliers must still go through.

How quickly hospitals outside the Big 5 follow. Mid-tier and regional hospitals are where distribution relationships are least visible to foreign manufacturers and hardest to re-source.

What Happened

Korea's two best-known medical AI companies are rewriting their overseas strategies, and Europe now sits at the centre of the plan. In April 2026 interviews with Korea Biomedical Review, both Coreline Soft and Lunit described a shift away from selling one hospital at a time toward embedding their software inside national screening programmes that governments pay for.

The trigger is a change in Germany. On 1 April 2026, Germany added low-dose CT lung cancer screening to its statutory health insurance, following a 2025 decision by the Federal Joint Committee (G-BA), which sets what public insurance covers. Screening is offered to people aged 50 to 75 with a heavy smoking history, with AI-assisted reading and a mandatory second read. First reads are reimbursed at about €49.56, second reads at a certified centre at about €95.04.

Coreline Soft's chief executive put the logic plainly: in the United States, winning one hospital means one hospital, but in Europe, once a country decides to pay for screening, "the system moves." Coreline has renewed work with Italy's national lung screening network (RISP), placed its AVIEW software on France's central public purchasing platform (UGAP), and expanded German deployments. Lunit is prioritising large public-sector screening contracts, arguing that once a national programme adopts a platform, rivals struggle to displace it.

Why It Matters

For European MedTech and diagnostics companies, this is competitor intelligence, not distant news. Korean AI vendors are treating Europe's reimbursed screening as a primary growth market, moving early into the tenders, purchasing platforms and screening networks that decide who wins.

The dynamic favours incumbency. Screening reimbursement turns a fragmented buying market into a structured one, where a single national or regional decision can lock in a supplier for years. European companies selling into their own home screening programmes should assume Korean competition is already bidding — often with FDA clearances, CE marks and reference sites behind it.

A Swiss thread runs through it: Coreline has run a lung-cancer AI study alongside AstraZeneca and a Swiss hospital, building clinical credibility inside Europe rather than merely selling into it.

What to Watch

Germany's rollout is the test case. Watch whether Korean vendors convert early positioning into signed regional screening contracts as the programme scales through 2026 and 2027.

Watch the procurement platforms. Placement on France's UGAP or inclusion in Italy's RISP network is a leading indicator of who will hold these markets, worth tracking as closely as regulatory approvals.

Watch pricing. Germany's fixed fees for first and second reads set a reference other European systems may follow, shaping the margins available to every screening-AI vendor.

Executive Summary

Korea has spent three years building faster routes to reimburse expensive drugs for rare and severe diseases. It keeps discovering that speed was never the hard part.

A pilot launched in June 2023 promised to cut the time to list a new drug under national health insurance from about 330 days to 150. Most drugs chosen for it have missed that target. Some have not been listed at all. In response, the government announced in January 2026 an even faster lane, aiming for 100 days, and in May set out how it would work. The pattern is telling: each reform attacks the calendar, while the thing that actually stalls these drugs sits untouched at the centre of the process.

That thing is the value test. Korea reimburses a new medicine only after it clears a cost-effectiveness assessment built for ordinary drugs in large populations. Rare-disease therapies fail that arithmetic almost by design. For international pharmaceutical companies weighing Korea against Japan or Europe, this is the point worth understanding before a launch plan is drawn.

What Happened

The programme in question is known in Korea as Heo-Pyeong-Hyeop, a shorthand for approval, reimbursement evaluation and price negotiation. Launched in June 2023, it runs in parallel three steps that were previously sequential, handled by three separate bodies: the Ministry of Food and Drug Safety (MFDS), which approves the drug; the Health Insurance Review and Assessment Service (HIRA), which judges whether insurance should cover it; and the National Health Insurance Service (NHIS), which negotiates the price. Run together rather than in sequence, the process was meant to compress listing to 150 days.

The record is mixed at best. Qarziba, a neuroblastoma treatment and the first drug selected, moved smoothly, listed for reimbursement in December 2024. Others did not. Bylvay, for a rare liver disease, took more than a year to list after approval, and well over 400 days counting from application. Among the drugs picked in the 2024 second round, Winrevair, a treatment for pulmonary arterial hypertension, sat at the reimbursement-evaluation stage for roughly nine months after its July 2025 approval. Fintepla, for the childhood epilepsy Dravet syndrome, waited months. Limkato, Korea's first home-grown CAR-T cell therapy, had not even secured approval.

The Seoul Economic Daily, reporting in April 2026, framed the gap bluntly through the case of a patient in his fifties whose pulmonary arterial hypertension eased within a month of starting a new drug, but who faced monthly costs above 10 million won, roughly 7,300 US dollars, with no clear path to coverage. Patient organisations issued a joint statement arguing the parallel-review promise "is not working at all" and demanded the government disclose the causes of the delays.

In January the Ministry of Health and Welfare (MOHW) went further, promising a lane that would list eligible rare-disease drugs within 100 days. At a public hearing in May, the ministry set out the design. Approval, evaluation and price talks would again run in parallel, with each post-approval step compressed to about a month. Eligibility would be limited to drugs already reimbursed in at least three of the A8 reference countries, a group that includes the United States, Germany, France, Japan and Switzerland. Prices would be set near 90 per cent of the A8 average. Crucially, where evidence is thin at listing, coverage could proceed and be re-examined after four years of real-world data, at which point HIRA could hold the price, cut it, or drop the drug back to full out-of-pocket status. It is, in effect, a reimburse-first, evaluate-later contract for a narrow set of drugs.

Why It Matters

The reforms share a diagnosis that is only half right. They treat delay as a scheduling problem. Running three reviews at once does remove dead time between steps. But the ministry itself conceded the underlying evaluation framework "remained unchanged", and that is where these drugs stall.

The binding constraint is the incremental cost-effectiveness ratio, the ICER. It divides the extra cost of a new drug by the extra health benefit it delivers against existing care. Rare and severe diseases produce high ratios almost mechanically. Patient populations are small, so fixed costs spread thin. Treatment is long-term, so cumulative spending is large. And there is a genuine paradox: the more a drug extends survival, the longer patients take it, and the higher the lifetime cost the system must absorb. A test designed to reward cheap, broadly used medicines will keep failing therapies that are, by their nature, neither.

Clinicians have started to say so directly. In August 2026, a cardiology professor at Gachon University argued that essential medicines for rare and intractable diseases should be exempt from cost-effectiveness review altogether, noting that Korea was still assessing a drug on economic grounds that other countries had reimbursed a decade earlier. He contrasted Korea's roughly 72 per cent five-year survival in pulmonary arterial hypertension with the more than 90 per cent achievable under fuller treatment access. Whatever one makes of a blanket exemption, the complaint points at the mechanism, not the timetable.

For pharmaceutical companies, three implications follow. First, Korea's headline speed reforms should be read as necessary but not sufficient. MFDS is separately pushing to become one of the world's fastest approval agencies, cutting biosimilar reviews toward 240 days. Faster approval simply delivers a drug to the value gate sooner. Second, the real negotiation is moving from price to evidence and risk-sharing. The 100-day lane's four-year re-evaluation, and a parallel rule change letting the NHIS and companies agree confidential ceiling prices for minister-designated severe diseases, both signal a shift toward managed-entry deals in which access is granted against a commitment to prove value later. Companies that arrive with a real-world evidence plan and appetite for outcome-based terms will fare better than those expecting a clean list price. Third, the comparison that matters to Korean patients and payers alike is Japan. Sotatercept reached Japanese patients at an insurance price in 2025, with out-of-pocket caps tied to income, while Korea debated. That contrast shapes both political pressure and the reference prices Korea itself uses.

For European and Swiss firms specifically, the read is that Korea remains an attractive but demanding market for rare-disease and specialty drugs. It pays well once a drug is listed, and it is visibly trying to move faster. But the entry route now runs through evidence generation and risk-sharing, not through a faster queue.

Executive Summary

A Seoul private equity firm has put one of Korea's quiet MedTech successes up for sale. STIC Investments has begun the sale process for RF Medical, a radiofrequency ablation device maker, in a transaction expected to fetch between 150 billion and 200 billion won, or roughly 106 million to 141 million US dollars. The news is a single deal. The pattern behind it is the story.

RF Medical is not a domestic-market player. It exports to more than 50 countries, and overseas sales account for around 80 percent of its revenue. It is precisely the kind of company international strategists tend to overlook: a profitable, export-led Korean device maker with a narrow specialty and a global footprint. That such a firm is now changing hands as a financial asset says something about where Korea's MedTech industry sits in its life cycle.

The deal also lands in a shifting ownership landscape. Global buyout funds have overtaken domestic firms in Korea's mergers and acquisitions market this year, helped by a weaker won and cheaper dollar funding. STIC itself, once Korea's first home-grown private equity house, passed to the control of a US investor earlier in 2026.

For international MedTech leaders, the takeaway is not about one ablation company. It is that Korea's device sector is maturing into a market where assets are built, financed, and traded — and where ownership, not just regulation, is becoming a variable to track.

What Happened

STIC Investments, a Seoul-based private equity firm, kicked off the sale of RF Medical in early August 2026. According to The Korea Economic Daily, the process is expected to value the company at 150 billion to 200 billion won. People familiar with the matter said STIC could continue to hold the company through another fund if bids fail to match its expectations, citing RF Medical's strong profitability and growth.

RF Medical is a specialist. Founded in 2005, it makes radiofrequency ablation systems — devices that use heat to destroy tumours and other tissue without open surgery. Its flagship MYGEN generator and MYOBLATE electrode line received US Food and Drug Administration clearance in 2022, opening the American market for uses including uterine fibroid treatment. The company was among the first in Korea to build an oncology ablation device, a category only a handful of global firms produce.

Its business is built on exports. RF Medical sells into more than 50 countries, with overseas sales making up about 80 percent of revenue, and has expanded across Europe, Taiwan, Southeast Asia, Eastern Europe, and South America. A tight product focus and high margins made it an attractive private equity holding — STIC first backed the company several years ago and is now seeking an exit.

The wider backdrop matters. In a separate analysis published the same week, The Korea Economic Daily reported that global private equity firms have overtaken their Korean rivals in the country's M&A market. A weaker won and abundant dollar funding have handed foreign buyers an advantage, while several domestic houses have pulled back under regulatory scrutiny and political backlash. STIC embodies the shift from the inside: in January 2026, founder and chairman Do Yong-hwan sold his controlling stake in the firm to Miri Capital Management, a US activist investor, which later lifted its holding to roughly 27 percent.

So the RF Medical sale sits inside two nested stories. A profitable Korean device maker is being traded. And the firm trading it is itself now foreign-controlled, part of a broader reordering of who owns Korea's deal market.

Why It Matters

The first point is what RF Medical represents. International MedTech executives tend to picture Korea's device industry as either large conglomerates — Samsung Medison, Osstem Implant — or early-stage AI start-ups. RF Medical is neither. It is a mid-sized, profitable, export-first specialist that most foreign strategy teams have never mapped. Its sale is a reminder that Korea has a deep bench of these companies, and that they are commercially serious enough to command nine-figure valuations. Anyone building a competitive picture of Korean MedTech should be tracking the specialist tier, not only the household names.

The second point is that ownership is becoming a live variable. When a private equity firm owns a device maker, the company runs on an exit clock. Pricing discipline tightens, R&D and sales priorities are set against a return horizon, and the business is groomed for sale rather than held indefinitely. For a competitor, a partner, or an acquirer, the identity and intentions of the financial owner now shape how a Korean counterpart behaves. That is a different analytical lens than regulation or clinical demand, and it is one foreign firms have been slower to apply in Korea than in the United States or Europe.

The third point is the entry route. Consolidation cuts both ways. A profitable Korean exporter changing hands is also an acquisition opportunity for an international MedTech company seeking a manufacturing base, a regulatory track record, and ready-made distribution across 50-plus markets. Buying an established local player can leapfrog the slow, relationship-driven path of building a Korean sales operation from scratch. As Korean device assets come to market through private equity exits, strategic buyers — not only financial ones — should be at the table. The RF Medical process is a test of whether foreign MedTech strategics will compete for these assets or leave them to buyout funds.

The fourth point is the macro tilt. Foreign buyout funds gaining ground in Korea's M&A market, aided by a weak won, means more Korean healthcare assets will be priced and marketed to international capital in the near term. For MedTech acquirers, the window for deals may be unusually favourable while the currency and funding conditions hold. For Korean sellers, it means more of their industry's ownership migrates offshore — a dynamic that could eventually draw its own regulatory attention, as large foreign acquisitions in sensitive sectors often do.

A note of proportion. This is one mid-market transaction, and it may not even close: STIC has signalled it could hold RF Medical longer if bids disappoint. No single deal remakes an industry. But the combination — a profitable specialist exporter on the block, a foreign-controlled seller, and a buyout market tilting toward international capital — is a coherent signal. Korea's MedTech sector is no longer just a place to sell devices or clear regulatory hurdles. It is becoming a place where device companies themselves are bought and sold.

Executive Summary

On 11 August 2026, Korea's National Evidence-based Healthcare Collaborating Agency (NECA) confirmed that three medical technologies had cleared the country's New Health Technology Assessment. Among them were a quantitative blood test for a blood-cancer mutation and a tablet-based cognitive test for older adults. Individually, these are small items. Together, they are a reminder of how Korea actually decides what enters clinical practice.

For international healthcare and MedTech companies, the useful point is structural. A product that has passed Korea's Ministry of Food and Drug Safety has not, by that fact, reached the market. Approval and payment are two separate decisions, made by two different bodies. The assessment NECA runs sits between them, and it determines whether a new test, device or procedure can be used and billed at all.

This second gate is well established, but it is routinely underestimated in launch planning. Companies budget for regulatory clearance and treat reimbursement as an afterthought. In Korea, the order is reversed: clearance is the easy part, and the assessment that follows is where time, evidence and revenue are won or lost.

What Happened

NECA announced that the Ministry of Health and Welfare's fifth New Health Technology Assessment Committee of 2026 had confirmed the safety and effectiveness of three technologies during its final review. The first is a quantitative JAK2 V617F mutation test for patients with myeloproliferative neoplasms, which uses real-time PCR on whole blood to measure the mutant allele burden. The second is the computerised Seoul Cognitive Status Test, a tablet-based assessment for people aged 50 to 90 with, or suspected of having, cognitive impairment. The third is an autologous platelet-rich fibrin treatment used after removal of a jaw cyst.

The mechanism behind these notices is the point of interest. Korea introduced its New Health Technology Assessment, known as nHTA, in 2007 to evaluate the safety and clinical effectiveness of emerging medical technologies and to keep unproven procedures out of routine care. Its results are published as official notices under Article 53 of the Medical Service Act. A technology that is not listed cannot, in practice, be used and reimbursed as an established medical service.

Three agencies divide the work. MFDS approves the product and certifies its manufacturing quality. NECA assesses the clinical, and where relevant the economic, evidence through its Committee for New Health Technology Assessment. The Health Insurance Review and Assessment Service (HIRA) then decides whether the national health insurance system will pay, and at what price, with the National Health Insurance Service (NHIS) acting as the insurer. The Ministry of Health and Welfare (MOHW) oversees the whole system.

The sequence is slow when run step by step. Guidance compiled for foreign developers by the Digital Medicine Society sets out a conventional progression of roughly 80 days for MFDS approval, 30 to 60 days for a HIRA eligibility check, 140 to 250 days for the NECA assessment, and a further 100 days to register for insurance benefit. In practice the elapsed time is often longer, because reviews queue behind committee schedules. Aware of the complaint, NECA introduced a simultaneous review of the assessment and the coverage decision that cuts the maximum duration from 490 days to 390. It is an improvement measured in months, not a removal of the gate.

Why It Matters

The first implication is commercial sequencing. A Korean MFDS clearance is a credential, not a customer. Revenue begins only when a technology is both listed through nHTA and priced by HIRA. Firms that plan for the first milestone and assume the rest will follow discover that the value-generating step is the one they scheduled last. The practical response is to treat evidence generation for NECA as a parallel workstream from the start, not a task that begins after approval.

The second implication is about how novelty is judged. The assessment rewards technologies that can show a distinct clinical benefit over what is already in use. That standard is comfortable for a genuinely new diagnostic and awkward for software that improves an existing task. Reporting by Korea Biomedical Review this month set out the problem plainly for medical artificial intelligence: because many tools assist with work doctors already perform, such as reading a scan, they are often treated as an addition to an existing service rather than a service in their own right, and so receive no separate price. A product can be approved, used in real clinical settings, and still earn very little. For any company whose value case rests on making an established procedure faster or more accurate, the lesson is to build the comparative evidence the assessment will demand.

The third implication is that Korea is actively reworking this gate, which creates both opportunity and uncertainty. The simultaneous-review track shortens the sequence. Temporary and conditional routes, including a framework introduced in 2023 for selected digital therapies, let some products reach patients while evidence is gathered. A 2026 fast-track for innovative devices folds an earlier performance assessment into a quicker lane. Each of these is a genuine opening. Each also carries the risk of premature listing, and none removes the underlying requirement to prove value. The direction is faster access in exchange for stronger post-market evidence, which shifts the burden rather than lifting it.

For European and Swiss MedTech and diagnostics leaders, the read is concrete. Korea is a serious, well-run market, but its two-gate structure means market-entry timelines should be modelled around the assessment, not the approval. Firms with mature clinical evidence and a clear comparator will move through faster. Firms that arrive with a cleared product and no reimbursement strategy will wait, and waiting in Korea has a cost that compounds, because domestic use is increasingly what foreign buyers ask to see.

Executive Summary

Korea has finished assembling something few health systems have: a dedicated legal category for digital medicine. As of 24 January 2026, the Digital Medical Products Act is fully in effect, with its final provisions on software labelling and digital health support devices now active. Around it, the Ministry of Food and Drug Safety (MFDS) has layered a modernised device rulebook, a formal definition of software as a medical device, and a plan to make Korea's approval system the fastest in the world.

This is not another single-product approval. It is infrastructure. Korea has decided that software, artificial intelligence, and connected devices need their own regulatory lane rather than a corner of the medical device law, and it has built one.

For international digital health and MedTech companies, the signal is twofold. The rules are clearer than they were, which lowers the cost of entering a wealthy, ageing market. But the rules are also more demanding, and one of them — how Korea handles AI algorithms that keep learning — is worth studying closely, because it points to where the whole field is going.

What Happened

The Digital Medical Products Act, known as the DMPA, first entered into force on 24 January 2025. It created a distinct legal framework for three product types: digital medical devices, digital medical and health support devices, and drug-digital combinations. The final tranche of provisions took effect on 24 January 2026, including new labelling requirements for digital medical device software and the rules governing digital health support devices.

The DMPA does not sit alone. In February 2026 the MFDS issued Notice 2026-6, a comprehensive revision of its medical device approval and review regulation, alongside an updated Korea Good Manufacturing Practice framework. Notice 2026-6 introduces an internationally aligned definition of software as a medical device (SaMD), gives explicit regulatory treatment to AI-driven functionality, and standardises how software documentation, data storage, and embedded-versus-standalone software are handled. Manufacturers of digital products must now comply with both the DMPA and Notice 2026-6 at once.

The MFDS is pushing on speed at the same time. Under its 2026 administrative plan, reported to the government in December 2025, the ministry set a target of becoming the world's fastest approval and review agency. It will cut biosimilar review times from as long as 420 days to 240, deploy an AI-based system to help summarise submissions and draft review documents, and move medical device change approvals to a negative-list model, where only changes affecting safety or performance need pre-approval. For digital medical and health support devices specifically, the ministry plans to standardise performance criteria and introduce a self-certification system, explicitly to help Korean-developed products expand overseas.

Underlying all of this is a demographic clock. Korea became a super-aged society in 2025, when the share of people aged 65 and over passed 20%. Its home medical device market is estimated to have grown from roughly 6 trillion won in 2019 to about 15 trillion won by 2025. A country ageing this fast needs monitoring, diagnostic, and chronic-disease software at scale, and it is building the regulatory plumbing to license and export it.

Why It Matters

Start with the most forward-looking piece, because it is the one that separates Korea's framework from a routine tidying-up. The DMPA permits pre-approved change management plans for AI algorithms. A company can define, in advance, the parameters within which its algorithm may update, and then ship those updates without a full re-approval, provided it stays inside the agreed envelope. Changes that could affect patient safety still require review.

This matters because it addresses the central awkwardness of regulating machine learning. Traditional device law assumes a product is fixed once approved. An AI model is not fixed; it improves as it sees more data. Regulators everywhere are grappling with this, and Korea has now written a concrete answer into an operating law. It is close in spirit to the predetermined change control plans that other advanced regulators have been piloting. For a company building AI-enabled diagnostics or decision support, a market that lets the model evolve within guardrails is structurally more attractive than one that forces a new submission for every update.

The clarity of the wider framework is the second gain. Korea's older system left software in an uncomfortable place, classified case by case, with review outcomes hard to predict. The new SaMD definition, the alignment with international documentation standards, and the formal pre-submission procedures reduce that uncertainty. For a foreign company, predictability is not a cosmetic benefit. It shortens planning cycles and makes the cost of a Korean launch easier to model.

The demands rise in parallel, and this is where entrants should be careful. Documentation must increasingly be prepared in Korean or dual-language form. Korea Good Manufacturing Practice certification remains a separate, mandatory hurdle that an ISO 13485 certificate does not satisfy, and first-time applicants should expect an on-site audit. Digital product makers now carry a dual compliance load under both the DMPA and Notice 2026-6. The lane is clearer, but it is not lighter.

Then there is the gap the framework does not close. Regulatory approval is not reimbursement. A digital therapeutic or AI tool can clear the MFDS and still face a separate, slower path through health technology assessment and the National Health Insurance system before a hospital has a financial reason to use it. Korea has moved faster on approving digital medicine than on paying for it. Companies that read the 2026 reforms as an open door should remember that market access in Korea has two locks, and the DMPA only turns one of them.

For international readers, the strategic read is about direction more than any single rule. Korea is positioning itself as a place that both regulates digital medicine coherently and intends to export it. The self-certification route for performance is aimed squarely at making Korean digital devices travel. Foreign companies will meet Korean competitors who have been hardened in a demanding home system and are now backed to go abroad. The framework is an invitation to enter, and a warning about who else is being trained to compete.

Executive Summary

Korea's medical device market is climbing out of a two-year slump. The US International Trade Administration (ITA) expects it to return to moderate growth in 2026, as hospitals resume the equipment purchases they postponed during the country's long trainee-doctor strike. Fortune Business Insights puts the market at USD 7.11 billion in 2024, rising to USD 7.57 billion in 2025 and a projected USD 12.58 billion by 2032, a compound annual growth rate of 7.5%.

The headline is recovery. The detail matters more. This is not organic growth returning to trend. It is a backlog of deferred demand releasing into a hospital system that is still short of cash. Buyers want the scanners and analysers they delayed, but many are asking for extended payment terms and staggered delivery to protect their balance sheets.

For international MedTech and diagnostics companies, 2026 is a re-entry window rather than a boom. The suppliers who win it will be the ones who read three things correctly: which purchases were merely delayed, which buyers can actually pay, and where the government is now pushing the money.

What Happened

Korea's device market slowed across 2023 and 2024. The 2023 dip reflected the end of the pandemic demand surge. The 2024 decline had a sharper, more local cause: a nationwide strike by trainee doctors.

The strike began in February 2024 and ran until September 2025. It was triggered by a government plan to sharply raise medical-school admissions, which the medical community argued would erode training quality. Junior doctors walked out. Routine care was disrupted, surgeries were delayed, and hospitals cut back on equipment procurement. When operating theatres run below capacity, hospitals stop buying.

The strike ended in September 2025, and sentiment began to turn. The ITA reports that hospitals are now resuming deferred equipment replacement and infrastructure upgrades, and that importers see purchasing plans being reviewed again. The government's move to address trainee concerns has helped restore institutional confidence.

Recovery, though, is expected to be gradual rather than sudden. Many hospitals still carry the financial strain of reduced patient volumes during the strike. As a result, procurement departments are negotiating extended payment terms and staggered delivery schedules to manage cash flow. Demand is real, but the money behind it is being paced.

Two structural features frame the rebound. Korea remains a market where the state shapes almost all purchasing: the Ministry of Food and Drug Safety (MFDS) controls device approval, and the National Health Insurance Service (NHIS) sets the reimbursement prices that determine what hospitals can recover. And it remains a market with strong domestic competition — Osstem Implant, Samsung Medison and others hold entrenched positions — while global names such as Medtronic, Johnson & Johnson, GE HealthCare and Philips lead at the high end.

Why It Matters

Start with the shape of the demand. This rebound is a release of backlog, not a fresh wave. That has a practical consequence: the fastest-moving categories in 2026 will be replacement purchases — the CT scanner, the analyser, the surgical system a hospital had already decided to buy before the strike froze the budget. Suppliers with installed bases and existing hospital relationships are positioned to capture this first. A cold market-entry attempt, by contrast, is competing against purchases that were effectively pre-decided two years ago.

The cash-flow signal is the part most vendors will underweight. When a customer asks for extended payment terms and staggered delivery, that is not a negotiating tactic to wave away — it is a description of the buyer's balance sheet. Commercial teams that can offer flexible financing, leasing, or phased installation will convert deferred intent into orders faster than teams that can only quote a price. In 2026, terms may matter as much as specification.

Where the money is moving is the third read, and the most strategic. The ITA is explicit that the recovery will be led not only by replacement demand but by government initiatives supporting digital health and AI-assisted technologies. That is already visible in budget lines. In January 2026 the Ministry of Health and Welfare (MOHW) committed 14.2 billion won, roughly USD 10 million, to deploy commercial AI systems across all 17 regional medical centres — university hospitals that coordinate care outside the capital. The targeted systems monitor patients in intensive care, flag deterioration such as cardiac-arrest risk, assist image interpretation, and automate clinical documentation. Health Minister Jeong Eun-kyeong has repeatedly tied such spending to closing regional care gaps.

For device and diagnostics companies, that is a demand signal with an address. Growth capital is being steered toward AI-enabled monitoring, imaging analytics and the infrastructure of regional hospitals — not toward the large Seoul academic centres that dominate most vendors' coverage maps. Diagnostics deserve particular attention: in-vitro diagnostics is the single largest device segment in Korea and the one Fortune Business Insights expects to lead through the forecast period. Robotic surgery is the other clear pull, with tertiary hospitals continuing to invest — Seoul National University Hospital added Medtronic's Hugo system in 2025, and Asan Medical Center passed 3,000 robotic colorectal procedures in the same year.

The risks are equally concrete. MFDS approval remains slow, which continues to delay foreign product launches. NHIS reimbursement pricing remains the industry's most cited constraint, because a device without a favourable code struggles to sell regardless of clinical merit. And domestic incumbents, backed by government export support, are strengthening at home even as they expand abroad. A rebound does not soften any of these structural barriers. It simply means there is more volume to compete for while they stay in place.

There is also a timing trap. Because the recovery is gradual and cash-constrained, revenue may lag the optimistic 2026 headlines by several quarters. A vendor that staffs up for a boom in the first half of the year may find the orders arriving in the second half, or in 2027, once hospital finances normalise. The prudent posture is to be present and financeable now, and patient on the revenue curve.

Executive Summary

Korea has spent 2026 tightening what it pays for. Drug prices, device margins and reimbursement rules have all been squeezed. Now the government is turning to the other side of the ledger: what it collects.

On 23 July, the Ministry of Health and Welfare reported a plan to raise both the ceiling and the floor of national health insurance premiums. The ceiling on the highest earners will rise by a third. The floor, effectively frozen for 26 years, will more than double and, for the first time, track the minimum wage each year.

Together the two moves add roughly 317 billion won a year in revenue. The government has already named where it goes: coverage for rare and severe diseases, essential care, and the regions.

For international healthcare and MedTech leaders, the signal matters more than the sums. Korea is choosing to shore up the revenue base of its single-payer system rather than let coverage narrow. The market that bargains hard on price is also committing to keep paying.

What Happened

Korea runs a single national health insurance scheme. The National Health Insurance Service (NHIS) collects premiums from the whole population and pays providers; the Ministry of Health and Welfare (MOHW) sets policy; and the Health Insurance Policy Deliberation Committee, the scheme's top decision body, signs off on the numbers. On 23 July a subcommittee of that committee received the premium reform plan.

The plan lifts the ceiling first. Today, premiums stop rising once income passes a set level, so an employee earning 120 million won a month pays the same as one earning a billion. Under the reform, the cap on salary-based premiums rises from 30 times to 40 times the average premium. The maximum monthly premium a worker actually pays climbs from 4.59 million won to 6.12 million won. A parallel cap that applies to high earners with large investment income, and to self-employed "regional" subscribers, rises from 15 times to 20 times the average, reaching the same 6.12 million won ceiling. The change touches the top 0.04% of salaried members — about 7,060 people — and 1,891 of the highest-earning regional households. It raises an estimated 175.1 billion won a year.

The floor moves in the opposite direction, and it moves further. The minimum premium for salaried members has sat at a base of 280,000 won a month since the National Health Insurance Act took effect in 2000 — unchanged for a generation. It will now be tied to the annual minimum wage. The minimum monthly premium more than doubles, from 10,080 won to 22,260 won. To cushion low-income members, the increase phases in: half of it applies from January 2027, the full amount from January 2029. The floor adjustment reaches roughly 193,000 salaried members and 4.86 million regional households, and adds about 141.7 billion won a year.

These changes sit on top of a structural reform reported in February. Property-based premiums for regional subscribers are shifting from a coarse bracket system, which sometimes charged the owner of a modest home proportionally more than the owner of a far larger building, to a flat-rate calculation. The lag between earning income and having it reflected in premiums, currently up to 23 months, is being cut using near-real-time tax data. And the government is moving to write its own subsidy to the fund into law rather than leave it to annual negotiation.

Why It Matters

The context is a fund under strain. National health insurance ran a current-account deficit of about 3.9 trillion won in the first quarter of 2026, its first quarterly shortfall since 2021. Reserves fell from 30.2 trillion won at the end of 2025 to 26.3 trillion won, and parliamentary budget analysts have warned that, on current reform spending, the reserve could be exhausted as early as 2027. Against that backdrop, adding around 317 billion won a year is not a rescue. It is a signal of intent.

That intent is the story. Faced with a widening gap, Korea could have let coverage drift — slower listings, tighter criteria, more out-of-pocket cost. Instead it is rebuilding the revenue side and, crucially, earmarking the proceeds. Rare and severe disease coverage, essential care and regional hospitals are the named beneficiaries. For companies in oncology, rare-disease therapeutics, and high-acuity hospital equipment, that is a directional read on where fresh coverage money is meant to flow.

The mechanism also changes the trajectory, not just the level. Linking the premium floor to the minimum wage converts a number that Seoul had to unfreeze by political fight into one that rises automatically each year. Raising the ceiling multiple deepens the same income-based logic. Korea is building a revenue escalator that tracks wages, which makes the fund's income base harder to erode and harder to reverse. A payer with a growing, rules-based revenue line is a more durable customer than one dependent on discretionary top-ups.

None of this loosens price discipline. The sums are modest next to a multi-trillion-won deficit, so the pressure that has defined Korean market access in 2026 — confidential net pricing, weighted cost-effectiveness tests, and post-launch real-world evidence used to hold prices down — will continue. If anything, a government that can show taxpayers it is asking the highest earners to pay more gains political room to keep bargaining hard with suppliers. Expect both to happen at once: selective coverage expansion funded by new revenue, alongside relentless containment on unit prices.

The equity framing carries a final message for foreign observers who read Korea as merely cost-cutting. The reform is being sold as fairness — those with more income paying more, a floor that no longer traps the low-paid on a 26-year-old figure. That framing is politically sticky. It suggests the government intends to preserve a broad, universal benefit package rather than quietly shrink it, and to keep the single-payer model solvent enough to keep expanding at the margin. For anyone sequencing launches or planning a Korea entry, the base case remains a large, disciplined, and — on this evidence — deliberately sustained market.

Executive Summary

Samsung is best known in healthcare as an imaging company. It makes ultrasound systems, computed tomography scanners, and digital X-ray machines. Those are diagnostic tools. They help doctors see a problem, not fix it.

That boundary is starting to move. On 5 August 2026, Samsung's medical device business signed a preliminary agreement with Accuray, a US radiation therapy specialist, to explore combining Samsung's mobile CT scanner with Accuray's robotic cancer-treatment platform. It is the second such tie-up in four months. In April, Samsung Medison began working with another US firm, HistoSonics, on ultrasound-guided tumour treatment.

The individual deals are early and non-binding. The direction is not. Samsung is trying to move from the diagnosis side of medicine into the treatment side, and it is doing so by partnering with established American therapy companies rather than building alone.

For international MedTech executives, this is a signal worth reading. Korea's largest MedTech player is climbing the value chain, and the imaging-to-therapy border it is crossing is one that global incumbents such as Siemens Healthineers and GE HealthCare have guarded for years.

What Happened

On 5 August, Samsung HME America, the US arm that houses Samsung's ultrasound, CT, and digital X-ray businesses, signed a non-binding letter of intent with Accuray. Accuray owns the CyberKnife, a robotic system that delivers precisely targeted radiation to tumours.

The plan is to test whether Samsung's mobile CT scanner, called BodyTom, can feed high-quality three-dimensional images into Accuray's treatment system. In principle, that would let clinicians confirm exactly where a tumour sits, and how surrounding tissue has shifted, at the moment of treatment, then adjust the radiation dose and aim to the individual patient. The two companies plan to present the concept at the American Society for Radiation Oncology meeting in September.

This is not an isolated experiment. In April 2026, Samsung Medison, the group's ultrasound subsidiary, started working with HistoSonics, a US company whose Edison system destroys tumours using focused ultrasound rather than surgery. The idea there is to pair Samsung Medison's premium R20 ultrasound scanner with the Edison system so clinicians can see and treat in real time.

Both moves share a logic. Samsung supplies the eyes; the partner supplies the hands. Yoo Kyu-tae, who runs Samsung's medical device business and leads Samsung Medison, framed the Accuray talks as part of a strategy to extend Samsung's imaging technology "from precision diagnosis to precision treatment."

The push comes from a position of growing strength. Samsung Medison's revenue rose from 517.4 billion won in 2023 to 665.1 billion won in 2025, a record. Its estimated share of the global ultrasound market climbed from 8.4 percent to about 10.2 percent over the past year. Roughly nine in ten of its sales are made abroad. In June, it placed its R20 scanner in University College London Hospitals, a demanding reference account in Europe, which is already its largest regional market. Research and development now runs at about 17 percent of revenue, and in 2024 the company made its first-ever acquisition, buying the French fetal-imaging AI firm Sonio for 130 billion won.

Why It Matters

The first point is about the value chain. Diagnostic imaging is a good business, but it sits below therapy in both price and strategic weight. Treatment systems command higher margins, deeper hospital relationships, and longer replacement cycles. A company that only sees the disease is more replaceable than one that also treats it. Samsung is trying to move up, and it is using imaging as the entry ticket to the treatment room.

The second point is about method. Samsung is not attempting to invent radiation therapy or surgical ultrasound from scratch. It is partnering with firms that already have regulatory clearance, installed bases, and clinical credibility in those fields. This lowers risk and shortens time. It also tells you something about how Korean MedTech now expands: through cross-border alliances that trade Korea's imaging and manufacturing strength for a foreign partner's therapeutic platform. Expect more of this pattern, not less.

The third point is competitive. The imaging-to-therapy combination is precisely the territory that Siemens Healthineers and GE HealthCare have built their franchises on, integrating diagnosis, guidance, and in some cases treatment into a single workflow. Samsung entering that space, backed by the balance sheet and global sales network of Samsung Electronics, adds a well-capitalised new competitor to a segment that European incumbents dominate. For those incumbents, a Korean challenger with 90 percent overseas revenue and rising market share is not a domestic curiosity. It is a global one.

The fourth point is national. Samsung's move fits a larger Korean ambition to push its device industry into higher-value categories. In late 2025, the government announced a plan worth more than 900 billion won, around 622 million US dollars, to advance next-generation medical technologies, with AI diagnostics, medical robotics, and advanced implants named as priorities. The stated goal is to help Korean manufacturers move up the value chain into premium segments long held by global players. Samsung's diagnosis-to-therapy pivot is the corporate version of that national strategy, and the alignment is unlikely to be coincidental.

The fifth point is a caution. These are letters of intent and early collaborations, not products. Radiation therapy and focused-ultrasound treatment carry heavy regulatory burdens, and clearance in the United States or Europe is neither quick nor certain. Integrated imaging-and-therapy systems must prove clinical benefit, not just technical elegance. The strategy is clear; the execution is unproven. Readers should treat this as a direction of travel to monitor, not a finished repositioning.

For European MedTech companies, the practical takeaway is twofold. Watch Samsung as an emerging competitor in image-guided therapy, particularly in oncology. And note the partnership template: a specialist therapy firm with the right platform is now an acquisition or alliance target for a cash-rich Korean group looking to buy its way into treatment. The next Sonio-style deal may not be in imaging at all.

Executive Summary

Korea has doubled the reach of its national dementia care model. On 4 August 2026, the Ministry of Health and Welfare (MOHW), the ministry that runs the country's health system, expanded its Dementia Primary Physician Pilot Program to 92 local districts, up from 42, and raised the number of participating doctors from 315 to 417.

The expansion signals intent. Korea became a super-aged society in 2025, and dementia is the demographic cost the system fears most. A designated community doctor who manages dementia alongside a patient's other conditions is Korea's chosen answer to keeping those patients out of expensive institutions.

Days later, the same government published the uncomfortable other half of the story. An evaluation by the Health Insurance Review and Assessment Service (HIRA), the body that reviews claims and prices care, found the model works clinically but loses most of its patients. Only about one in eight stayed enrolled over time.

For international healthcare and MedTech companies, the two announcements together are more useful than either alone. Korea is committing to community-based chronic care at national scale, and it has just named its weakest link: retention. That gap is where demand for coordination, monitoring, and adherence tools is about to concentrate.

What Happened

The Dementia Primary Physician Pilot Program launched in July 2024. Under it, a patient registers with a designated primary-care doctor who manages not only dementia but the patient's overall health, through continuous, coordinated follow-up. The model is deliberately built around a single accountable physician rather than fragmented specialist visits.

The services are concrete and reimbursed. A participating doctor draws up an individualised care plan once a year after a comprehensive assessment. The doctor provides in-person education and counselling for the patient and caregiver up to eight times a year, at least ten minutes each. Remote follow-up by phone or video is allowed up to twelve times a year to check medication adherence and complications. Home visits are covered up to four times a year for patients with limited mobility.

The 4 August expansion widened the program from 42 districts to 92, after MOHW selected an additional 102 physicians and 79 medical institutions in a second round open to applicants nationwide. During the first phase, 250 institutions and 315 physicians took part across 42 districts, and roughly 7,000 patients received care while remaining in their communities.

Then came the assessment. On 7 August, HIRA released its evaluation of the pilot as of the end of 2025. Among enrolled patients, the continuity-of-care index rose to 95.5 percent, up 7.1 points. Medication adherence ran 2.6 points above a control group, and the gap widened to 4.6 points in severe dementia. Clinical Dementia Rating scores, a standard measure of severity, came in 0.25 points lower than the control. Behavioural and psychological symptoms fell from an average of 4.4 to 2.6. Depression scores on the PHQ-9 scale dropped from 11.87 to 6.89.

The benefits were real. The retention was not. Only 12.4 percent of participants kept using the program over time. An integrated-care option that also managed chronic disease drew just 5.3 percent. HIRA's own investigator concluded the model needs redesigning around stronger, stage-specific care and better links to regional dementia support centres.

Why It Matters

Begin with the demographic pressure behind the policy. Korea's health ministry projects dementia cases to pass one million in 2026 and two million by 2044. The economic weight follows the headcount. Peer-reviewed estimates put the national cost of dementia in the billions of dollars a year, with per-patient care running far higher in institutions than in the community. Every patient the system keeps at home instead of in a long-term care hospital is a direct saving. That is the fiscal case for the primary-physician model, and it is why MOHW is scaling it despite an underwhelming retention record.

The retention number is the strategic signal, not the failure it first appears. A government that has just doubled a program while publicly flagging that seven in eight patients drop out is, in effect, describing its own procurement gap. The clinical model is sound. The delivery around it is thin. Dementia patients and their caregivers disengage when the pathway is hard to sustain between visits. That is precisely the space where digital adherence tools, remote monitoring, caregiver-support platforms, and care-coordination software earn their place.

The reimbursement architecture reinforces the point. The program already pays for structured education, remote follow-up, and home visits. These are bundled, recurring, physician-led activities rather than one-off procedures. For a vendor, that matters. It means the buyer is a primary-care practice operating inside a defined fee structure, not a tertiary hospital running a capital tender. The product that fits is one that helps a community doctor deliver twelve remote check-ins and eight counselling sessions a year without drowning in administration.

There is a diagnostics thread here too. In the same week, Korea recognised a computerised cognitive assessment, the Seoul Cognitive Status Test, as a new health technology eligible for use in the system. Community-based dementia care depends on repeatable, low-friction cognitive screening that a primary-care doctor can run on a tablet. As the physician network widens, demand for validated screening and staging tools that fit a short consultation grows with it. Foreign diagnostics and digital-health firms with tablet-based or software cognitive tools should read the two developments as one market forming.

The caveats are familiar. This remains a pilot, not permanent policy, and its final shape depends on the redesign HIRA has called for. Reimbursement rates for community dementia services are modest, which caps what practices will spend on supporting technology. Public procurement in Korea still rewards local partnership over product merit, so a foreign entrant needs a domestic delivery route. And the retention problem could equally be solved by workflow changes rather than new tools. The opportunity is real, but it is a coordination market, not a device windfall.

Executive Summary

Korea has decided that the answer to its most expensive health problem is artificial intelligence. In April 2026, the Ministry of Health and Welfare (MOHW), the ministry that runs the country's health system, launched a "Full-Cycle AI Transformation" project for chronic disease patients. The plan runs AI across the entire arc of care, from lifestyle coaching on a phone to imaging interpretation in a university hospital.

The framing matters more than any single tool. Chronic disease is the largest and fastest-growing cost in an ageing system, and the national insurer has just swung into deficit. Korea is treating AI not as a research curiosity but as a way to manage that cost at population scale.

For international healthcare and MedTech companies, this reads as a national procurement signal. The government is defining the specific service categories it wants to buy, funding the infrastructure to validate them, and setting a one-to-two-year clock to real revenue. The opportunity is concrete. So is the gate that controls access to it.

What Happened

MOHW announced the "Full-Cycle AI Transformation (AX) Project for Chronic Disease Patients" at a briefing in Seoul, held to walk AI companies, local governments, public health institutions, and medical facilities through the project and its application process. The ministry began accepting applications for implementing organisations on 1 January 2026.

The project sits inside a wider programme called the "AX Sprint," which is built to push AI services past the pilot stage into early commercialisation. The stated goal is tangible results, either revenue or a live public service, within one to two years. That timeline is the point. This is not another sandbox.

The work is organised into five service categories. The first covers AI tools that manage exercise and diet in daily life. The second supports primary care. The third coordinates medical information between healthcare institutions. The fourth assists with medical imaging interpretation. The fifth builds remote consultation models. Together they trace the full path a chronic disease patient takes, from home to clinic to hospital.

Underneath the services, the government is building shared plumbing. MOHW plans to develop what it calls a public medical AX infrastructure, covering data standardisation, medical information exchange, and an upgraded healthcare big data platform. That infrastructure is already taking shape elsewhere. A separate MOHW committee is linking clinical data from three national university hospitals to the national Health and Medical Big Data Platform, preparing public access to a 400-million-dollar biobank of 770,000 people in the second half of 2026, and funding at least 20 projects to verify medical AI tools before hospitals adopt them. A data-access voucher scheme that gives AI startups up to 400 million won, roughly 280,000 US dollars, to work with hospital data is expanding from eight projects in 2025 to 40 in 2026.

The direction was set from the top. "Through this project, AI technology will permeate all aspects of healthcare from citizens' daily lives to university hospitals," said Kim Hyun-sook, Director General for Advanced Medical Support at MOHW, adding that the ministry aimed to publish an "AI Basic Medical Strategy" in the first half of 2026 to give the effort a formal structure.

Why It Matters

Start with the reason Korea is moving now. In the first quarter of 2026 the National Health Insurance Service (NHIS), the single public payer, posted a current-account deficit of almost 3.9 trillion won, close to 2.9 billion US dollars. It was the system's first serious deficit trajectory since 2021, and accumulated reserves fell by nearly 4 trillion won in three months. The National Assembly Budget Office has warned that, factoring in planned medical reforms, those reserves could be exhausted by 2027 rather than 2029. A payer under this kind of pressure does not fund AI for novelty. It funds AI to bend the cost curve on the conditions that drive the most spending, which are chronic ones.

That fiscal logic gives the five service categories real weight. They are, in effect, a published shopping list. Primary care decision support, cross-institution interoperability, imaging AI, remote consultation, and lifestyle management each map to a product category that foreign MedTech and digital health firms already sell. For a company entering Korea, the strategic question shifts from whether the government wants AI to which of these five lanes fits the product, and who the local delivery partner is.

The one-to-two-year commercialisation clock changes the calculation further. Many national AI schemes stall in perpetual piloting. By tying the project to revenue or a live public service on a short horizon, MOHW is signalling a route to actual reimbursement or public purchase, not just a demonstration. That is rare, and it rewards vendors who arrive with evidence rather than ambition.

The gate is validation. The same government building the demand is also building the checkpoint. At least 20 hospital-based verification projects will test AI tools before adoption, and the data-access vouchers and biobank favour firms that can partner locally and clear Korean data-governance rules. For an international vendor, this means Korean clinical validation and a domestic data strategy are no longer optional add-ons. They are the price of entry, and they take time to build. Firms that treat validation as an early workstream will move faster than those that treat it as paperwork at the end.

There is a wider signal here for anyone watching Asia. Korea is assembling the three things a national medical-AI market needs at the same time: standardised data, a validation pathway, and a payer motivated to buy. Few systems have all three aligned. That combination makes Korea an attractive early proving ground for AI in chronic care, and a reference others in the region may copy. The forthcoming "AI Basic Medical Strategy" is the document to read when it lands, because it will show how the pieces are meant to lock together.

The caveats are real. Reimbursement for AI remains unsettled, and much of the near-term demand runs through public procurement, which rewards local relationships over product merit alone. The fiscal squeeze that motivates the programme could equally constrain what the payer will pay. And a five-lane framework announced in spring is not yet a track record. This is a well-designed opening, not a finished market.

Executive Summary

South Korea's government has announced a 900 billion won (approximately $622 million) national investment program to advance next-generation medical device technologies, with explicit focus on artificial intelligence diagnostics, medical robotics, and next-generation implant systems. The initiative marks a deliberate strategic pivot: moving Korea's medical device industry from cost-competitive manufacturing toward premium, innovation-driven segments traditionally dominated by large multinational firms. For international MedTech companies already operating in Korea, this represents both opportunity and pressure—the government is actively supporting domestic competitors to climb the value chain.

What Happened

In August 2026, the Ministry of Trade, Industry and Energy announced a pan-government collaboration to invest in high-value medical device categories. The program prioritizes technologies with strong clinical and commercial potential: AI-based diagnostic tools, medical robotics, and next-generation implant systems. The domestic medical device market is projected to grow at 5% compound annual growth rate between 2024 and 2034. South Korea currently accounts for approximately 7% of the Asia-Pacific medical device market, with multinationals including Siemens Healthineers, GE HealthCare, Osstem Implant, Medtronic, Abbott, and Stryker maintaining substantial presence.

The announcement aligns with Korea's long-term industrial policy: manufacturing strength in consumables and diagnostic equipment is well established, but the government now seeks to position domestic manufacturers to compete in premium segments. Officials expect the program to streamline development and commercialization by expanding resources for companies working on high-value products, improving regulatory pathways, and encouraging export-ready innovation.

Why It Matters

This investment signals Korea's recognition that commodity-margin medical devices alone cannot sustain industrial competitiveness or healthcare employment. AI diagnostics and robotics carry significantly higher margins and technology moats than traditional consumables. By concentrating capital on these segments, the government is deliberately steering domestic manufacturers—including Osstem Implant and other Korean players—toward direct competition with Siemens, GE, Medtronic, and Stryker.

For international MedTech companies, the implications are three-fold. First, the Korean market will see accelerated innovation cycles and shorter time-to-regulatory-approval for domestically-backed AI and robotics projects, potentially shifting market share. Second, government-backed R&D will likely create competitive pressure on margins in premium segments, which Korean exporters can then leverage in other Asia-Pacific markets. Third, the initiative strengthens Korea's appeal as a manufacturing and innovation hub for MedTech partnerships—foreign companies seeking Asia-Pacific regional strategy may find Korean partnerships increasingly attractive.

The timing matters. This investment arrives as Korea's labor costs rise and aging demographics intensify demand for automation in healthcare delivery. The government is positioning Korea not as a low-cost medical device manufacturer, but as a center for precision medicine and innovation-driven healthcare—a higher-value identity that sustains pricing power and attracts talent.

Executive Summary

Korean medical devices have long been treated as a value proposition — competent, cheaper, and rarely a threat at the top of the market. Samsung Medison is testing that assumption. In the space of a few months, the company has won premium ultrasound contracts at three of the most demanding hospital systems in the West: the Cleveland Clinic and Mayo Clinic in the United States, and University College London Hospitals in the United Kingdom.

These are not volume deals. They are reference wins at institutions that set purchasing norms for thousands of other hospitals. For a segment dominated for decades by GE HealthCare, Philips and Siemens Healthineers, a credible fourth name at the premium tier is a meaningful shift.

The strategic point for European and Swiss healthcare leaders is straightforward. A Samsung-backed competitor, differentiating on artificial intelligence rather than price, is now selling into the same flagship accounts that anchor the incumbents' pricing and prestige. Korea's MedTech industry is moving up the value chain, and the imaging market is the first place it shows.

What Happened

Samsung Medison is the ultrasound arm of Samsung Electronics. According to reporting by Seoul Economic Daily in June 2026, the company signed supply contracts with two of the largest US medical institutions. It will provide its R20 premium radiology ultrasound to a regional hospital within the Cleveland Clinic system, where it has secured official "preferred supplier" status, and its HERA Z20 obstetrics-and-gynaecology system to the Mayo Clinic's Maternal-Fetal Medicine division, which handles high-risk pregnancies.

A parallel win followed in Europe. Samsung Medison agreed to supply the R20 to the radiology department of University College London Hospitals, described within the Korean industry as a "wall of tears" that must be breached to build European market share. Europe is already the company's largest region, at 34 percent of first-quarter revenue, with Asia at 32 percent and North America the smallest of the three.

The commercial trajectory is clear in the numbers. Group revenue rose from 517.4 billion won in 2023 to 665.1 billion won in 2025 — roughly 480 million US dollars — with about 90 percent generated overseas. North American revenue climbed from 16.4 billion won in 2023 to 27.7 billion won in 2025, and its share of total revenue doubled year-on-year to 5 percent in the first quarter of 2026. The company's estimated global ultrasound market share moved from 8.4 percent in 2024 to about 10.2 percent in early 2026.

Underneath the sales figures sits a deliberate technology bet. Samsung Medison lifted research and development to 17 percent of revenue in the first quarter of 2026, up from 14 percent in 2023. In 2024 it acquired the French fetal-diagnosis AI firm Sonio for 130 billion won, its first acquisition since founding. Its selling point is AI that reduces the operator-to-operator variability inherent in ultrasound: the R20 flags suspected lesions in the liver and breast in real time, while a deep-learning feature maps nerves and vessels to support precision procedures.

The company is also pushing past diagnosis into treatment. In August 2026, Korea Biomedical Review reported that Samsung's medical-device division signed a letter of intent with the US radiosurgery specialist Accuray to combine its BodyTom mobile CT with Accuray's CyberKnife platform, following an earlier tie-up with the ultrasound-therapy firm HistoSonics. The direction is from imaging alone toward image-guided therapy.

Why It Matters

The first implication is competitive. The premium imaging market has behaved as a stable oligopoly, with GE HealthCare, Philips and Siemens Healthineers rarely disturbed at the top accounts. Reference hospitals are the mechanism that keeps it stable: when the Cleveland Clinic or UCLH standardises on a vendor, smaller institutions follow, and switching costs compound. Samsung Medison is now using that same mechanism in reverse. Each flagship win becomes a credential for the next tier of buyers. Incumbents should expect the challenge to arrive account by account rather than as a price war.

The second implication is about the basis of competition. Samsung is not entering on cost. It is entering on AI-assisted consistency, an argument that lands hardest in ultrasound precisely because results have always depended on the sonographer's skill. If AI can narrow that variability, it reframes a premium ultrasound purchase from a hardware decision to a diagnostic-quality decision. That is a durable position, and it is reinforced by Samsung Electronics' distribution — 14 global subsidiaries plus local networks — and by the consolidation of its US ultrasound, CT and X-ray businesses under a single Samsung HME America unit in early 2026.

The third implication is strategic direction. The Accuray and HistoSonics moves signal an intent to sell across the diagnosis-to-therapy continuum rather than a single imaging box. For hospital buyers, a vendor that can connect imaging to image-guided treatment is a different kind of partner, with a larger share of the capital budget in play. For competitors, it widens the ground on which Samsung must be answered.

For European and Swiss MedTech leaders, the read is twofold. Two of the three incumbents under pressure are European champions, and their most defensible accounts are the ones now being contested. At the same time, Korea's move up-market creates partnership as well as rivalry: AI, componentry and co-development are all on the table for firms that would rather collaborate than collide. The wider signal is that Korean MedTech should no longer be filed under low-cost. The next Korean challenger may arrive in surgical robotics, endoscopy or CT — and it may again lead with software.

The caveats are real. A 5 percent North American revenue share and a roughly 10 percent global share still leave Samsung Medison well behind the leaders. Reference wins do not guarantee fleet-wide conversion, and ultrasound is a more contestable segment than CT or MRI, where the incumbents' installed base and service economics are harder to dislodge. This is a beachhead, not a takeover. But beachheads are how premium markets are entered, and this one is now established.

Executive Summary

For years, global drug and device makers treated Korea as a market to launch late. The reasons were structural: slow reimbursement, low state-set prices, and public price lists that leaked into other countries' pricing formulas. Seoul is now dismantling all three barriers at once.

A reform package from the Ministry of Health and Welfare, phased across 2026 to 2028, introduces confidential net pricing, a fast-track "reimburse first, evaluate later" pathway for rare and innovative drugs, and a more flexible cost-effectiveness threshold. Taken together, the changes could move Korea from the back of the global launch queue toward the front.

The timing carries a warning. In the first quarter of 2026, Korea's National Health Insurance ran a current-account deficit of nearly 3.9 trillion won, its first slide into the red since 2021. The state is opening the reimbursement door to high-cost therapies at the exact moment its payer is running short of money. For international healthcare leaders, that tension — wider access, tighter budget — is the real story, and it will shape how the reforms are implemented in practice.

What Happened

Korea's health system is run through a single public payer. The National Health Insurance Service (NHIS) negotiates prices and pays claims. The Health Insurance Review and Assessment Service (HIRA) assesses clinical value. The Ministry of Health and Welfare (MOHW) sets policy and gives final approval. A new medicine has historically had to clear each body in sequence, a design that stretched real-world timelines well beyond the formal 240-day review period — sometimes past three years for rare-disease therapies.

Three reforms target that machinery. The first, a flexible contract system implemented in June 2026, lets a manufacturer publish a high list price — up to the top of an eight-country reference range that includes Germany, Switzerland and the United States — while the price actually reimbursed is negotiated confidentially with the NHIS. The publicly visible number no longer reflects the real transaction. That matters because other countries use Korea's disclosed prices in their own international reference pricing (IRP) formulas; a confidential net price shields a global launch from that spillover.

The second reform is a fast-track pathway. Under a "reimburse first, evaluate later" model piloted in the second half of 2026, rare-disease treatments would target reimbursement within 100 days, with HIRA and NHIS reviewing in parallel rather than in series. Full economic modelling at listing may be replaced by international price benchmarks, with formal reassessment coming after launch using real-world evidence. The government intends to extend the approach to selected innovative medicines from 2028.

The third reform loosens the cost-effectiveness test. Korea's unofficial threshold — roughly 25 million won per quality-adjusted life year for standard drugs, 50 million for oncology and rare disease — has barely moved since 2006 and is considered conservative by international standards. From 2027, value assessment is set to weigh disease severity, clinical benefit and budget impact more explicitly. Recent approvals already point that way: Imfinzi in biliary tract cancer and Trodelvy in triple-negative breast cancer were cleared despite exceeding the traditional range.

Then came the fiscal signal. On 9 August 2026, data submitted to the National Assembly showed the health insurance fund posted a 3.9 trillion won current-account deficit in the first quarter, against a 30.2 trillion won accumulated reserve at the end of 2025. The surplus streak that ran from 2021 has ended. The National Assembly Budget Office projects that, once the government's medical reforms are factored in, reserves could be depleted by 2027 rather than 2029.

Why It Matters

The first read is opportunity, and it is real. Korea remains one of Asia-Pacific's largest pharmaceutical markets, valued at about $29.2 billion in 2025 and projected to grow at roughly 9 percent a year. It is also a "super-aged" society, with more than a fifth of the population over 65, driving demand across oncology, neurology and metabolic disease. For companies that had parked Korea late in their launch sequencing to protect global pricing, the flexible contract system removes the single biggest reason to wait. High-cost therapies that were uneconomic to list under transparent, low prices become viable when the reimbursed price is confidential.

The second read is that speed now comes with strings. The "reimburse first, evaluate later" model does not remove scrutiny; it moves it after launch. Reimbursement becomes the start of an evidence dialogue, not the end of the access process. Price reassessment will lean on real-world data generated inside Korea. A manufacturer that treats local evidence generation as an afterthought risks a downward price revision once the data arrives. The practical implication is that Korea-specific real-world evidence strategy has to be built into launch planning from day one, not bolted on later.

The third read is that first movers set the terms. Fast-track pathways, weighted thresholds and post-market evaluation together create an unusually favourable window for innovative medicines in oncology, rare disease and neurology. That window is widest before the pathway becomes crowded. Early entrants will establish the pricing precedents and stakeholder relationships that later applicants inherit. Companies with launches due in the next two years should be reassessing Korea's position in their global sequence now, not in 2028.

The fourth read is the discipline the deficit imposes. A payer that has just slipped into the red, with reserves possibly exhausted by 2027, will not fund open-ended access. The confidential net price is the mechanism that squares the circle: it lets Korea display a face-saving list price to the world and to its own industry while paying a lower, negotiated figure at home. Expect hard bargaining on that net figure, expect budget-impact caps and volume conditions to feature heavily, and expect the government to lean on real-world evidence to claw back price where post-launch performance disappoints. The reforms widen the door; the fiscal position controls how far it opens.

There are caveats. Much of the detail — eligibility for the flexible contract system, the final shape of the weighted threshold, the RWE requirements — is still being written. Policy direction is set, but operational rules will decide who actually benefits. And a single payer under fiscal stress can tighten as quickly as it loosens.

Executive Summary

Roche has built a standing channel between Korean biotech and Basel. In early May, Roche Korea signed a four-party agreement with the Korea Health Industry Development Institute (KHIDI), a public agency under Korea's health ministry, the Korea Technology Finance Corporation (KOTEC), and Basel Area Business & Innovation, the development body for Switzerland's life sciences hub. The alliance formalises a pipeline that moves promising Korean companies into one of Europe's densest research clusters.

The money behind it is not small by Korean standards. The deal builds on a memorandum Roche signed with the Ministry of Health and Welfare (MOHW) on 3 March, under which Roche will invest 710 billion won, about 480 million US dollars, in Korea over five years. The ministry called it the largest investment it had ever attracted from a foreign pharmaceutical company.

For international healthcare and MedTech leaders, the strategic signal matters more than the ceremony. This is how market access in Korea is starting to work. A multinational is not buying its way in with a sales force or a factory. It is investing in the innovation ecosystem itself, and earning standing with the regulator, the payer, and the domestic industry in return. For Swiss and European readers, there is a second signal: Korean biotech now has a direct line into Basel.

What Happened

The four-party memorandum, reported by Korea Biomedical Review on 6 May, ties together four roles. Roche Korea sponsors the programme, selects the companies, and provides grants and mentoring. KHIDI runs planning and operations through its "K-BioPharma Next Bridge" platform and picks companies whose science fits Roche's priorities. KOTEC, a state-backed technology financier, evaluates the technology and supplies funding. Basel Area Business & Innovation opens the door to local infrastructure and networks in Switzerland.

The vehicle is a programme called the Korea–Switzerland BioPass, or K-Swiss BioPass. It is designed as a one-stop system that carries a company from technology validation through financing to overseas market entry, rather than a short mentoring sprint. About 100 companies applied when recruitment opened in February. Four were chosen and announced in June.

The four winners split across two tracks. Illimis Therapeutics and Survivant Biologics entered a research-support track, each receiving 100 million won in funding, roughly 65,000 US dollars, plus mentoring from Roche accelerator experts and access to Roche's global network. UBIX Therapeutics and ILAb took a residency track at the Swiss Innovation Park in Basel, with a year of support and settlement funding to help them establish a presence on the ground.

Basel is the point of the exercise. The region employs more than 33,000 life sciences professionals, hosts around 800 life sciences companies, and holds more than 1,000 research groups. Roche, founded there in 1896 and now operating in more than 150 countries, sits at its centre. For a Korean startup, the value is not the 100 million won. It is a curated path into that concentration of capital, talent, and dealmaking.

Why It Matters

Read this as a template for how large pharma now enters Korea. The old model was straightforward: win regulatory approval, secure reimbursement, and sell. The new model adds a layer underneath. By committing 480 million dollars to clinical trials, talent, and open innovation, Roche is buying something a sales team cannot: a seat at the table with MOHW and a reputation as a builder of the domestic ecosystem rather than an extractor of it. Other multinationals weighing Korea should note the shape of the play. Ecosystem investment is becoming a condition of strategic access, not a philanthropic add-on.

Korea's side of the logic is just as deliberate. The country has strong early-stage science and genuine clinical-trial capacity, but a persistent weakness in global commercialisation. Its companies build promising assets and then stall at the border, short of the networks, capital, and regulatory fluency that turn a Korean pipeline into a global product. Rather than build those networks from scratch, the government is renting them. KHIDI is wiring institutional bridges to specific foreign clusters, Basel here, and a new hub at the Texas Medical Center in the United States, and letting partners who already own the networks handle the last mile of scale-up.

The timing lines up with a policy shift. On 30 July, MOHW overhauled its Innovative Pharmaceutical Company Certification for the first time in fourteen years and, for the first time, created a distinct category for foreign-invested drugmakers. Under the new rules, multinationals earn greater weight for attracting research and manufacturing to Korea, bringing in overseas investment, and running collaborative research and open innovation. Roche's alliance is almost a definition of the behaviour the new certification now rewards. Policy and market strategy are moving in the same direction, and a foreign firm that invests in Korean innovation is set to be recognised for it in the reimbursement-adjacent status that certification confers.

For European and Swiss players, the practical implication is deal flow. A curated set of Korean biotech companies, pre-screened by Roche and financed by a Korean state body, is now landing in Basel. That is a pipeline of assets for Swiss investors, licensing teams, and contract developers to watch, arriving with more due diligence attached than a cold inbound approach. The Swiss Innovation Park residency track means the first of these companies will have a physical presence in the region within the year.

The limits are worth stating plainly. The sums per company are small, and the first cohort is only four firms, so this is a signal of intent more than a market in itself. There is also a value-capture question. Roche gets an early look at Korean innovation, and some in Korea will read the arrangement as a channel that routes the country's best science toward a foreign headquarters. Whether the bridge carries traffic both ways, Korean assets out, and durable capability back, is the variable that will decide if this is partnership or pipeline harvesting. For now, the direction of travel is clear: Korea is building formal on-ramps to the global clusters it cannot replicate at home, and multinational pharma is paying to build them.

Executive Summary

Korea is rewriting the rulebook that decides whether a medical device may be manufactured, imported, and sold. The change is quiet and technical. Its consequences are not.

For years, the core quality requirements for devices sold in Korea lived in administrative notices — rules the Ministry of Food and Drug Safety (MFDS), the country's drug and device regulator, could set and adjust with limited legislative weight. A December 2025 amendment to the Medical Device Act moved those requirements up into statute. The follow-on regulations arriving through 2026 fill in the detail: how quality systems are assessed, who assesses them, and what happens when an assessment is faked or fails.

For international MedTech leaders, this is a market-access story, not a compliance footnote. Korea is hardening the gate every foreign device must pass. It is also aligning that gate with international standards, which cuts both ways. Harmonisation lowers some friction. Codification raises the cost of getting the quality file wrong.

The practical message is simple. In Korea, quality-system approval is becoming a legally entrenched, separately audited hurdle — distinct from the certifications most manufacturers already hold, and no longer a box to tick late in the process.

What Happened

The anchor is a revision to the Medical Device Act, promulgated as Act No. 21263 on 30 December 2025. It established, for the first time, a clear legal basis for the Korea Good Manufacturing Practice (KGMP) conformity recognition system — the process by which a manufacturer's quality management system is judged fit before its devices reach the market.

MFDS has spent 2026 building out that basis. In early April 2026, the ministry issued a legislative notice proposing amendments to the Medical Device Act Enforcement Rules, reported by the Seoul Economic Daily. The amendment elevates KGMP conformity recognition standards — previously governed by administrative notices — to the level of law. That single move clarifies review criteria, procedures, and reviewer qualifications, and it specifies in far more detail what manufacturers and importers must submit.

The reform also reorganises the machinery around quality assessment. It systematises how quality management review agencies are designated and renewed, obliges the MFDS commissioner to publicly announce those designations, and sets explicit criteria for revoking conformity recognition or issuing corrective orders. Technical document review agencies get a defined four-year validity period, with renewal applications required 180 days before expiry and certificates reissued 30 days ahead when requirements are met. The intent is predictability: fewer gaps, fewer surprises, clearer rules for who holds authority.

A separate strand tightens the underlying standards. In June 2026, MFDS announced a partial amendment — Notice No. 2026-282 — to the Standards for Medical Device Manufacturing and Quality Management, streamlining the conformity-assessment provisions and moving the administration of review institutions and quality-manager training bodies into a dedicated notification. Earlier in the year, MFDS Notice 2026-6 overhauled the broader Regulation on Medical Device Approval, Notification and Review, aligning it with the International Medical Device Regulators Forum (IMDRF) — the global body that harmonises device rules. The IMDRF STED format, a standardised structure for technical documentation, became mandatory for applicable submissions, and Software as a Medical Device gained a formal definition.

One provision runs the other way, toward relief. Orphan medical devices — those serving domestic patient populations of fewer than 20,000, or conditions with no alternative therapy — may now be exempted from post-market surveillance if they carry a track record of use overseas. That surveillance typically tracks safety and performance for four to seven years, a burden that had proved impractical for tiny patient groups and had occasionally disrupted supply. Kim Young-min, chairman of the Korea Medical Devices Industry Association, welcomed the change as a stabiliser for rare-disease device supply.

Why It Matters

The first point is durability. Rules written into administrative notices are easier to bend, waive, or reinterpret. Rules written into statute are not. By codifying KGMP conformity recognition, Korea has made its quality gate harder to negotiate around and harder for a regulator to relax under industry pressure. Foreign manufacturers should read this as a permanent fixture, not a phase.

The second point is the certification trap. A common assumption among European and North American manufacturers is that an ISO 13485 quality certificate clears them for most markets. In Korea it does not. KGMP is based on ISO 13485 but requires formal certification under MFDS supervision, and it is assessed separately. For a manufacturer that has never faced an MFDS audit, an on-site inspection is close to certain. Companies holding MDSAP certification — the single-audit programme recognised across several regulators — may qualify for a lighter, paper-based review, but that path succeeds only about half the time. The codification now gives this separate hurdle the full force of law.

The third point is sequencing. KGMP certification typically takes two to three months once an audit is scheduled, and delays there are among the most common causes of extended time-to-market in Korea. Treated as a final administrative step, it stalls launches. Treated as a parallel workstream begun early, it does not. The reform's added documentation detail — clearer criteria, mandatory STED files, Korean or dual-language submissions — rewards companies that plan the quality file as seriously as the clinical dossier, and penalises those that leave it late.

The fourth point is convergence. Aligning with IMDRF standards makes Korea more legible to a global compliance team. A manufacturer already building STED technical files and IMDRF-aligned classifications carries less of that work anew into Seoul. Over time, harmonisation should lower the marginal cost of entering Korea for firms that run mature, internationally standardised quality systems — and widen the gap for those that still manage compliance market by market.

The orphan-device exemption deserves a measured read. It is a genuine opening for makers of low-volume, rare-disease devices with an overseas record, removing a surveillance obligation that had deterred supply. It is narrow by design. But it signals a regulator willing to trade rigidity for access where patient populations are small — the same instinct visible across Korea's wider 2026 reform agenda.

Executive Summary

South Korea's Ministry of Health and Welfare is rolling out a phased, nationally integrated bio big data platform that will unlock access to clinical and genetic information from 770,000 individuals starting in the second half of 2026. This $400 million initiative, paired with expanded data-access vouchers for startups and new hospital-based AI verification programs, removes a critical infrastructure bottleneck that has historically limited AI medical software adoption in Korea.

For international healthcare companies and digital health investors, this signals both a market opening and a structural shift: Korea is moving from pilot AI projects to systematic, government-backed validation pathways. Hospitals will have the funding and data access to test and integrate AI tools at scale before clinical deployment, reducing market-entry friction for MedTech firms and accelerating Korea's position as a testbed for precision medicine innovation.

What Happened

In late December 2025, the Health and Medical Data Policy Deliberation Committee within the Ministry of Health and Welfare announced a comprehensive data-infrastructure expansion tied to Korea's broader National AI Strategy. Three linked programmes are now active:

The Bio Big Data Platform. By mid-2026, Korea will begin phased public access to a nationally integrated bio big data database containing clinical and genomic information from 770,000 individuals (400,000 patients and 600,000 healthy controls). The platform, anchored by clinical data from three national university hospitals linked to the existing Health and Medical Big Data Platform, will reach full accessibility by 2028. This represents the culmination of the government's $400 million bio-big-data project, first announced in late 2024 and designed to support precision medicine research and AI model training.

Hospital-Based AI Verification. The Ministry plans to fund at least 20 new projects to validate medical AI solutions before they enter clinical practice. These hospital-led verification programmes allow healthcare systems to test and assess AI tools at scale, evaluate their integration into existing workflows, and develop internal capability to manage AI deployments. This addresses a persistent gap in Korean healthcare: hospitals have lacked structured, funded pathways to move from pilot to production AI.

Data Access Vouchers for Startups. The government is expanding its data-access voucher programme, growing from eight projects in 2025 to 40 in 2026. Each AI startup or small enterprise receives up to 400 million won (approximately $280,000 USD) to access curated medical datasets from partner hospitals for training, validation, and proof-of-concept. This programme has already generated momentum: the Seoul city government launched a parallel scheme in April 2025.

These three initiatives are coordinated by the same policy committee, which is also standardising institutional review board procedures and developing a shared data-review system to accelerate approvals across institutions.

Why It Matters

For Healthcare Executives and MedTech Leaders:

Korea has long been a paradox for digital health: a wealthy, tech-literate nation with leading hospital systems and a history of healthcare innovation (telemedicine pioneering, electronic health records adoption), yet AI software uptake has lagged behind the US and Europe. The bottleneck was data. Hospitals had no reliable pathway to access clinical datasets; startups faced months of negotiation and fragmented data-sharing agreements with individual institutions; validation protocols were inconsistent; and regulatory clarity on AI-powered diagnostics and clinical decision support remained nascent.

This platform removes those frictions. By 2026, a Danish medtech startup, a Korean AI biotech firm, or a Singapore digital health platform can now propose a use case (diabetic retinopathy screening, patient flow optimisation, treatment outcome prediction), apply for a data-access voucher, access curated datasets from multiple partner hospitals, and pilot their solution at scale in a government-funded, hospital-run verification programme—all within one fiscal cycle. The hospital gets AI-literacy support, the startup gets validated evidence in a credible market, and the Ministry gets faster AI adoption.

For Precision Medicine and Rare Disease Research:

The bio big data platform, when fully open in 2028, will be one of the largest integrated clinical-genomic datasets outside China. It will enable population-scale research into treatment response heterogeneity, rare disease phenotyping, and precision oncology in an Asian population cohort that has historically been underrepresented in global precision medicine databases. This attracts not only Korean researchers but also multinational pharma, diagnostics, and genomics companies looking to validate AI-driven drug discovery or companion diagnostics in non-European populations.

For Asia's Healthcare Market Position:

This is a deliberate state strategy to position Korea as the testbed for medical AI in Asia. The Medical Korea 2026 conference (held March 19–22, 2026) was explicitly framed as "AI-Powered Global Healthcare: Bringing the Future and the World Closer," and featured 46 speakers across eight sessions on AI's impact on diagnosis, treatment, physician productivity, and the future of anti-aging and regenerative medicine. The data platform, voucher scheme, and hospital validation programmes are the operational infrastructure behind that strategic positioning.

Executive Summary

After fifteen years of deadlock, South Korea has given telemedicine a permanent legal home. The National Assembly passed an amendment to the Medical Service Act on 2 December 2025. President Lee Jae-myung promulgated it on 23 December. It takes effect on 24 December 2026.

The significance is the permanence, not the scope. Remote care in Korea has run for years on temporary permissions that could be withdrawn overnight. A statute changes that. It tells hospitals, platforms and investors that telemedicine is now a recognised form of medical practice, not a pilot that might be switched off.

The design, though, is deliberately cautious. The law keeps in-person care as the norm, limits telemedicine to clinics, prioritises follow-up for existing patients, and bans companies built only for remote care. For international digital-health and MedTech firms, 2026 is a transition year — the window to help shape the technical standards and reimbursement rules that will decide how large this market becomes.

What Happened

The amendment ends one of the longest regulatory standoffs in Korean healthcare. Telemedicine was first proposed around 2010 and blocked repeatedly, largely by opposition from doctors' groups worried about clinic revenue and safety. Remote care only ran at scale under emergency exceptions. During the COVID-19 period, and again during the 2024–2025 hospital crisis triggered by junior-doctor resignations, the government permitted remote consultations under temporary rules. Between February 2024 and February 2025, monthly telemedicine consultations averaged about 200,000, according to the Ministry of Health and Welfare (MOHW), the country's top health authority.

When the "serious" medical crisis alert ended in October 2025, Korea reinstated limits — capping remote consultations at 30% of an institution's total visits and confining them to clinic-level care — pending the permanent law. That law now rests on four core principles: in-person care remains the primary norm; telemedicine is focused on clinic-level institutions; follow-up care for existing patients comes first; and institutions dedicated entirely to telemedicine are prohibited.

Much of the detail is still to be written. The government will spend 2026 building a public telemedicine support system and drafting the subordinate regulations — technical standards and reimbursement structures — through a presidential decree. Officials plan to limit first consultations to institutions within a patient's home region, cap prescription durations and restrict certain drug categories. The current 30% premium fee for telemedicine and the existing pilot framework stay in place until the law takes effect. Fees will be set through the Health Insurance Policy Deliberation Committee, the body that decides what the National Health Insurance covers and pays. Korea's domestic telemedicine market is still small — an estimated 48 billion to 50 billion won a year — but the government wants the legal change to expand it.

Korea has, in parallel, opened remote care to foreign patients on more generous terms. A separate amendment to the Medical Overseas Expansion Act lets registered medical-tourism providers offer telemedicine — including to first-time patients, and at hospital as well as clinic level. Korea drew 2.01 million foreign patients in 2025, a record. The domestic law does not reach that far.

Why It Matters

The first change is confidence. A pilot can be cancelled; a statute is harder to unwind. During the pilot years, hospitals, platforms and local governments held back from investing because the programme might end at any moment. Legal status removes that risk and, over time, makes telemedicine a service most institutions are expected to offer, much as electronic prescriptions became standard. The Korea Health Industry Development Institute (KHIDI), a government agency, projects the global telemedicine market will reach roughly $900 billion by 2032. Korea wants a defined share of it, and the statute is the precondition for a real market rather than a run of experiments.

The second point is that the limits are the market. By keeping telemedicine clinic-level, follow-up-first and anchored to in-person care, Korea is signalling where demand will sit. The near-term opportunity is not a consumer app that replaces the clinic visit. It is technology that supports the existing doctor–patient relationship: remote monitoring for chronic conditions, decision support for primary-care physicians, and tools that slot into a follow-up appointment. The government has, in effect, told vendors which problems it will pay to solve.

The third point is reimbursement, and it is unresolved. Consultation fees are capped at around 20,000 won, and even with the 30% premium, most doctors do not find telemedicine more profitable than an in-person visit, which can add revenue through tests, injections and procedures. If the decree sets fees too low, adoption will stall regardless of the law. The US International Trade Administration (ITA), part of the Department of Commerce, advises foreign firms to bring evidence that their telemonitoring tools reduce physician workload and improve patient management — the argument most likely to justify a workable fee. Companies that can quantify that value have a reason to engage in 2026 rather than wait.

The fourth point is timing. The standards written this year will shape the market for years, and 2026 is a defined transition window. Foreign digital-health companies can contribute through the restructured pilot programmes and real-world studies with Korean partners before the rules harden. One design choice deserves close watching. Limiting first consultations to a patient's home region is meant to protect local clinics, but specialists for conditions such as diabetes are concentrated in the Seoul metropolitan area. Drawn too tightly, the geographic rule could blunt the access gains telemedicine is meant to deliver, and narrow the addressable market further.

There is also a strategic asymmetry. Korea has opened remote care to inbound medical tourists more freely than to its own citizens, permitting first-time and hospital-level consultations for foreign patients. For international hospital groups and platform vendors, the faster commercial opening may lie in cross-border care — pre-visit and post-return consultations for the two million patients Korea now attracts each year — rather than the domestic market, at least until the enforcement decree is written.

Executive Summary

Korea is not waiting for a medical-AI market to appear. It is building one.

Over the past eight months, three arms of the Korean state have moved in the same direction. The Ministry of Health and Welfare (MOHW), the country's top health authority, has launched a programme to commercialise artificial intelligence across chronic-disease care. It has widened access to the health data that AI needs to work. And the Korea Disease Control and Prevention Agency (KDCA) has begun rebuilding its infectious-disease systems around AI. Officials describe the effort with one term: AX, short for AI transformation.

For international MedTech, digital-health and diagnostics companies, the strategic point is the mechanism. Korea is using public money, commercialisation deadlines, demonstration funding and data access to manufacture demand where little existed. That creates real openings. It also concentrates them inside government-defined lanes, and history suggests domestic suppliers reach those lanes first.

What Happened

On 9 April 2026, MOHW held a briefing in Seoul for what it calls the Full-Cycle AI Transformation Project for Chronic Disease Patients. The plan threads AI through the entire arc of chronic care, from daily habits to hospital treatment. It sits inside a broader programme, the AX Sprint, which funds the early commercialisation of AI-based services. MOHW began accepting applications from implementing organisations on 1 January, and it wants tangible results — revenue or a working public service — within one to two years.

The project defines five service categories: AI for managing diet and exercise in daily life; support for primary-care doctors; the exchange of medical information between institutions; collaboration on medical-image interpretation; and remote consultation models. Alongside the services, MOHW said it would build the public "AX infrastructure" underneath them — standardising data, activating medical-information exchange, and upgrading the national healthcare big-data platform. "AI technology will permeate all aspects of healthcare from citizens' daily lives to university hospitals," said Kim Hyun-sook, MOHW's Director General for Advanced Medical Support. A wider "AI Basic Medical Strategy" is due in the first half of 2026.

The data groundwork is already moving. In December 2025, MOHW's health-data policy committee set out how it would open the information that medical AI depends on. The number of projects granted rights to use medical data is set to rise from eight in 2025 to 40 in 2026, aimed at AI start-ups and smaller firms. The ministry will fund 20 new medical-AI demonstration projects in 2026 to test performance before adoption. It is integrating clinical data from national university hospitals into the healthcare big-data platform, and it plans a National Integrated Bio-Big Data platform covering 770,000 people by 2028, with phased access from the second half of 2026.

The public-health system is following the same template. In July 2026, the KDCA launched a Disease Control AI Transformation Committee and began drafting a mid- to long-term AX strategy for 2027 to 2031. The agency is already testing AI tools for epidemiological investigation, quarantine and outbreak response, drawing on a public AX project run with the Ministry of Science and ICT (MSIT). It aims to consolidate scattered records — vaccinations, notifiable diseases, chronic conditions, clinical and genomic data — into a single platform, Disease Data ON, by 2029.

Read together, the three moves describe one strategy. Korea is not funding isolated pilots. It is assembling the data, the demonstration money and the commercialisation deadlines to turn medical AI into a functioning market.

Why It Matters

The first implication is demand. In most markets, AI vendors must persuade individual hospitals to buy. In Korea, the government is helping create the buyer. When the state funds demonstration projects, sets commercialisation targets and names the service categories it wants, it signals where budgets will flow. For companies working in remote monitoring, primary-care support, image interpretation or medical-record automation, Korea is shifting from a market of scattered pilots toward one with policy behind the cheque.

The second implication is data. Medical AI is only as good as the data it trains on, and access to Korean clinical data has long been tight. Widening data-use rights from eight projects to 40, opening a 770,000-person biobank, and integrating university-hospital records lower a barrier that has constrained foreign and domestic developers alike. For any company whose product improves with local data, this is the part of the plan to watch most closely. Approval to sell is not the same as access to train.

The third implication is a filter. Korea is not promising to buy AI because it is new. It is funding demonstration projects and testing performance before adoption. That is a higher bar than a procurement tender, and it rewards companies that plan for Korean evidence from the start — local clinical partners, real-world results, and proof that a tool reduces workload rather than adding to it. Regulatory clearance opens the door; demonstrated value wins the contract.

The fourth implication is competitive, and it cuts against new entrants. Industrial transformation programmes tend to route early funding, demonstration sites and first contracts to domestic firms and national champions. The commercialisation goal here is explicit: build a Korean medical-AI industry that can generate revenue. Foreign companies should expect to meet well-funded local players and should weigh partnership, licensing or joint development against direct sales. The US International Trade Administration notes that American suppliers remain the largest foreign source of advanced medical technology in Korea, and that government support for digital health and AI-assisted technologies is now a named driver of the market's expected 2026 recovery. The opening is real; the field is tilted.

The usual caution applies. Much of this is strategy and roadmap, not yet budget lines or reimbursement codes. Korea has announced ambitious digital-health plans before, and the gap between announcement and adoption is where many have stalled. The signals worth tracking are concrete: whether the AI Basic Medical Strategy sets firm funding; whether demonstrated tools win reimbursement from the National Health Insurance Service (NHIS) and clear assessment by the Health Insurance Review and Assessment Service (HIRA); and whether data access and procurement open to foreign suppliers or stay close to home.

Executive Summary

Korea's reimbursement agency is changing the deal it offers manufacturers. For years, the Health Insurance Review and Assessment Service — HIRA, the body that judges whether a drug or device is worth covering — tried to remove almost all uncertainty before it agreed to pay. That front-loaded model was thorough. It was also slow, and it kept high-cost therapies out of reach for years.

In his 2026 New Year address, HIRA President Kang Joong-gu signalled a different approach. For expensive treatments for rare and serious diseases, the agency will lower the barrier to coverage and shift more of the scrutiny to what happens after a drug is paid for. Kang described the goal plainly: provide treatment opportunities first, then verify effectiveness and value through real-world data.

For international healthcare and MedTech leaders, this is a structural signal, not a headline. Korea is moving the moment of evidence from before listing to after it. That reordering changes how market access is planned, how prices are set, and how long a company's data obligations last. Reimbursement stops being the finish line. It becomes the start of an ongoing conversation with the payer.

What Happened

Kang made the remarks in a New Year's address in early January 2026. His message was aimed at a specific problem: high-priced new drugs, especially for rare and serious diseases, have faced long reimbursement reviews in Korea because of cost concerns and uncertain clinical evidence. Those reviews delayed patient access, sometimes for years.

His answer was to reweight the process. HIRA will make more active use of tools it already has — conditional coverage and risk-sharing agreements, arrangements where the payer and the manufacturer share the financial risk of an uncertain therapy — to let patients start treatment earlier. In exchange, the agency will intensify its monitoring of real clinical outcomes, safety, and cost-effectiveness after coverage begins. "There are limits to trying to eliminate all uncertainty at the initial stage of determining coverage," Kang said. The direction, in his words, is to "provide treatment opportunities first, then verify effectiveness and value through real-world data."

This is not rhetoric floating free of policy. It sits on top of a concrete reform package from the Ministry of Health and Welfare (MOHW), the ministry that sets health policy. Under a "reimburse first, then evaluate" design, rare-disease treatments are targeted for reimbursement within 100 days, with HIRA's clinical assessment and price negotiation by the National Health Insurance Service (NHIS) — the single national insurer — running in parallel rather than in sequence. A pilot is planned for the second half of 2026, implementation for 2027, and expansion to selected innovative drugs from 2028. At listing, full economic modelling may be streamlined in favour of international price benchmarks, with formal price reassessment happening later using real-world evidence.

The change matters because of what it replaces. Korea's formal reimbursement review runs 240 days on paper, but real timelines have often stretched far longer, with some rare-disease therapies taking more than three years from regulatory approval to coverage. Part of the delay is structural: HIRA assessment, NHIS price negotiation, and MOHW approval have happened one after another, compounding at each step. Kang's shift attacks that sequence directly by moving verification to the back end.

HIRA also plans to rebuild the capability the new model depends on. Kang stressed that the ability to collect and analyse data from actual clinical settings is now central to every stage of review. The government is exploring an AI-enabled digital infrastructure to speed evaluation. Appropriateness reviews will move away from formal checklist indicators toward treatment outcomes, with more input from medical specialty societies.

Why It Matters

The first implication is timing. A payer that covers first and verifies later is a faster payer at the point of entry. For rare-disease and oncology companies that have long treated Korea as a late, difficult market, the calculus changes. A 100-day target — against a history of multi-year waits — makes Korea a plausible early launch market rather than one to postpone. First movers into the new pathway will help set the pricing and evidence precedents that later entrants inherit.

The second implication is where the work moves, not whether it disappears. Front-loaded evidence review was a barrier, but it was a defined one. The new model spreads the burden across the product's life. Under "cover first, verify later," reimbursement is the beginning of a continuous evidence and pricing dialogue with HIRA, NHIS, and MOHW. Companies that treated real-world data as a post-launch afterthought will find it has become a listing-critical asset. A Korea-specific data strategy now needs to exist before the first patient is treated, not after.

The third implication is price durability. When formal price reassessment happens after listing and leans on real-world evidence, the price a company wins on day one is no longer settled. Weak or thin post-market data can invite a downward revision. This is a meaningful shift for planning. It rewards manufacturers who can demonstrate value in Korean clinical practice, and it exposes those who cannot. Because several Asian systems reference Korean prices and decisions, a post-listing revision in Seoul can travel across the region.

The fourth implication is the value framework itself. The reforms pair the sequencing change with a move toward weighted cost-effectiveness thresholds, allowing disease severity and clinical benefit to count more heavily than a single rigid ratio. Korea's unofficial thresholds have sat at roughly KRW 25 million per quality-adjusted life year for standard therapies and about KRW 50 million for oncology and rare disease — benchmarks largely unchanged since 2006 and long seen as conservative. Recent decisions already point the other way, with oncology therapies cleared under flexible criteria despite exceeding traditional ranges. Read together, the reforms describe a payer trying to say yes more often, sooner, and then holding the manufacturer accountable for the promise.

One caution belongs here. A "verify later" system is only as strong as the verification. It depends on data infrastructure that works at scale, on analytic capacity HIRA is still building, and on the discipline to act when real-world results disappoint. If the back-end evidence loop is weak, the model risks becoming faster access without the accountability that justifies it. That is the part international partners should watch as the pilot runs.

Executive Summary

South Korea's government has committed more than 900 billion won, about $622 million, to build a domestic medical device industry capable of competing at the high end. The target is deliberate. The money is aimed at AI-based diagnostics, medical robotics and next-generation implants — precisely the premium categories where foreign multinationals now dominate Korean hospitals.

This is industrial policy, not a research grant. Korea already exports medical devices in volume, but its manufacturers sit mostly in the lower and mid-range tiers. In the country's top hospitals, foreign brands hold close to nine in ten of the advanced systems installed. The new plan is an explicit attempt to close that gap.

For international MedTech, the signal matters more than the sum. The threat to incumbents is slow, not immediate. But the direction is clear: Korea intends to move up the value chain into the segments that international firms have treated as safe. The companies that read this early can position as partners rather than wait to be displaced.

What Happened

In late 2025, Korea's Ministry of Trade, Industry and Energy (MOTIE) — the ministry responsible for industrial strategy and export competitiveness — announced a pan-government investment plan of more than 900 billion won to advance next-generation medical technologies. The programme prioritises technologies with strong clinical and commercial potential, concentrating on AI-based diagnostic tools, medical robotics and advanced implant systems.

The stated goal is competitiveness. Korea's domestic device market is projected to grow at a 5 percent compound annual rate between 2024 and 2034, according to GlobalData, and the country is expected to account for roughly 7 percent of the Asia-Pacific medical device market in 2025. Yet the premium end of that market belongs to others. Siemens Healthineers, GE HealthCare, Medtronic, Abbott and Stryker all maintain a substantial presence. GlobalData's analysis frames the investment as a possible turning point that could help domestic manufacturers move up the value chain into segments long dominated by global players.

The gap the policy targets is well documented. The US International Trade Administration notes that Korean companies make comparatively lower-end and mid-range devices, and depend on the United States, Europe and Japan for high-end equipment. US devices alone hold 40 to 50 percent of Korea's import market. The imbalance is starkest in elite hospitals. Analysis of tertiary institutions — the large teaching hospitals that handle the most complex cases and command the biggest budgets — finds that foreign devices account for about 88.7 percent of the roughly 54,000 advanced units installed. In high-end ultrasound imaging, domestic penetration in these hospitals sits near 21 percent.

The wider market is sizeable and growing. Fortune Business Insights values Korea's medical device market at $7.11 billion in 2024, rising toward $12.58 billion by 2032 at a 7.5 percent annual rate, with in-vitro diagnostics the largest single segment. Domestic champions such as Osstem Implant and Samsung Medison already compete strongly in dental and imaging niches. The MOTIE plan is designed to extend that success into the categories where imports still rule.

The investment lands alongside a demand-side reform. In January 2026, Korea launched an Immediate Market Entry system that compresses the approval timeline for internationally validated innovative devices — AI diagnostics and surgical robots among them — from as long as 490 days to as few as 80. A new Digital Medical Products Act created a dedicated framework for software as a medical device. Both measures pull advanced technology into clinics faster. Both, for now, benefit the foreign firms that lead those categories.

Why It Matters

The first point is that this is a value-chain strategy, not a spending headline. The 88.7 percent figure is not incidental to the plan — it is the plan's justification. Seoul has identified the exact segments where it is weakest and directed capital, clinical validation support and regulatory acceleration at them. When a government funds the specific categories a competitor owns, the intent is substitution over time. International suppliers should treat the premium segments as contested, not protected.

The second point is timing. The threat is real but gradual. Building credible AI-diagnostic, robotic and implant capability takes years of clinical evidence, surgeon training and installed-base trust — advantages that incumbents have compounded over decades. Korea's domestic firms will not displace Medtronic or Siemens Healthineers in a tertiary operating room next year. The pressure will show first in price negotiations, in tender shortlists that suddenly include a funded local option, and in categories where the technology gap is narrowest. Incumbents have a window to entrench before that pressure matures.

The third point is that the fast-track pathway cuts both ways. The Immediate Market Entry system speeds foreign devices into Korean hospitals today. The same accelerated route will, in time, carry domestic innovators to market with the state behind them. A regulatory advantage that looks like a gift to importers now becomes a launchpad for local competitors later. Firms that use the current speed to build reference sites and reimbursement track records will be better placed when the field crowds.

The fourth point is the most actionable. Korea's policy rewards local clinical validation, joint development and technology transfer. That creates an opening for international firms to shift from pure import to partnership — licensing, co-development, or manufacturing arrangements that align them with the industrial agenda rather than against it. Under the Korea-US free trade agreement, device makers can also seek independent review of government pricing and reimbursement decisions, a channel worth understanding as procurement tightens. The multinationals that engage as collaborators may find the value-chain climb easier to ride than to resist.

The caveats are real. Government technology targets have slipped before, and ambition does not guarantee capability. Reimbursement remains the ceiling: the National Health Insurance Service and the Health Insurance Review and Assessment Service (HIRA) pursue cost containment aggressively, which limits how quickly any premium device — domestic or foreign — can scale. And an ageing, cost-pressured system may favour value over novelty. The direction of travel is clear; the pace is not guaranteed.

Executive Summary

Korea has long been a market global pharmaceutical companies admired but launched in late. It is large, ages fast, and runs some of the world's best clinical trial infrastructure. Yet its low, publicly disclosed reimbursement prices leaked into other countries through international reference pricing, so many manufacturers delayed Korean launches to protect their global price architecture.

A reform package approved on 26 March 2026 by the Ministry of Health and Welfare targets that exact problem. Two measures stand out. A new "flexible pricing contract" lets a company post a high public list price while the price Korea actually pays stays confidential. And a planned overhaul of Korea's cost-effectiveness threshold will let regulators pay more for drugs that treat severe or rare conditions.

Together these tools attack the two reasons Korea sat at the back of the launch queue: prices that were too low, and prices that were too visible. The state is not paying more across the board. It is changing what the rest of the world can see, and lifting the ceiling for high-value medicines.

For international pharma and MedTech, the signal is that Korea is repositioning itself in global launch sequencing. The window to shape pricing precedent is opening now, and it will favour companies that arrive early with Korea-specific evidence.

What Happened

On 26 March 2026 the Ministry of Health and Welfare (MOHW), Korea's health authority, convened the Health Insurance Policy Deliberation Committee and approved a comprehensive overhaul of the drug pricing system. The plan builds on a direction MOHW first set out in November 2025. It is being implemented through a staged series of amendments rather than a single switch.

Most attention has gone to the supply side, where Korea is cutting generic reimbursement toward 45 percent and phasing down prices on already-listed drugs. The more strategic change for innovators sits on the access side, in two mechanisms.

The first is the flexible pricing contract, targeted for the first half of 2026. Under it, the National Health Insurance Service (NHIS), the single public payer, and a manufacturer can agree a reimbursed price that differs from the listed price. The publicly visible list price can be set as high as the top of an eight-country reference range spanning the United States, United Kingdom, Germany, France, Italy, Switzerland, Japan and Canada. The price Korea actually pays is negotiated in confidence. Patients are charged against the confidential net price. Crucially, the mechanism is no longer reserved for severe-disease risk-sharing deals. It extends across new drugs, patent-expired originators, products leaving risk-sharing arrangements, incrementally modified drugs and biosimilars.

The second is a change to Korea's cost-effectiveness test. Reimbursement here turns on the incremental cost-effectiveness ratio, or ICER, the extra cost a drug incurs for each unit of health it adds. Korea's unofficial ICER ceiling has sat near KRW 25 million per quality-adjusted life year, about USD 17,000, for standard drugs, and near KRW 50 million, about USD 33,000, for oncology and rare disease treatments. Those benchmarks have barely moved since Korea introduced pharmacoeconomic evaluation in 2006, and are low by the standards of other assessment agencies. The reform, with policy research in 2026 and implementation targeted for 2027, would add weightings for disease severity, therapeutic benefit and budget impact, allowing a structured move upward. Regulators have already signalled the direction: recent listings of Imfinzi in biliary tract cancer and Trodelvy in triple-negative breast cancer cleared review under flexible ICER criteria despite exceeding the traditional range.

A parallel fast-track, piloting in the second half of 2026, aims to compress rare-disease reimbursement to 100 days against a formal 240-day clock that in practice has stretched past three years for some therapies. Health Insurance Review and Assessment Service (HIRA) clinical review and NHIS price negotiation would run in parallel rather than in sequence.

Why It Matters

Start with why Korea was skipped. Korea's pharmaceutical market was worth roughly USD 29.2 billion in 2025 and is projected to near USD 54 billion by 2032, the third largest in Asia-Pacific behind China and Japan. The country became a super-aged society in 2024, with more than a fifth of its population over 65. Demand for oncology, neurology and rare-disease therapies is rising. The problem was never attractiveness. It was that a low Korean price, published for all to see, travelled into other markets' reference baskets and dragged down prices there. For a global launch, the maths often favoured waiting.

The flexible pricing contract rewrites that calculation. By separating a defensible public list price from a confidential net price, it lets a manufacturer accept a lower effective price in Korea without broadcasting it. The reference-pricing leak narrows. That removes the single biggest reason to deprioritise Korea for high-cost therapies, and it does so at a useful moment. Korea sits inside the reference basket proposed under the United States' most-favoured-nation drug pricing framework, so a visible low Korean price now carries downstream risk in the largest market of all. A confidential net price is a shield against that exposure, not only a domestic convenience.

The weighted ICER change works in the same direction from the other side. A higher, severity-adjusted threshold means Korea can say yes to innovative oncology and rare-disease drugs it would previously have priced out. Combined with the fast-track, the effect is a more predictable and quicker route to a reimbursed price for exactly the high-value products that used to stall.

For commercial teams the implication is concrete. Korea should be re-scored in global launch sequencing, particularly where reference-pricing fear, not clinical merit, kept it late. Early entrants will set the pricing precedents and build the payer relationships before the new pathways become crowded.

There is a catch that reshapes the work. Under Korea's emerging "reimburse first, verify later" logic, a listing is the start of an evidence dialogue, not the end of it. Prices will be revisited using real-world data gathered after launch. Manufacturers that treat Korean real-world evidence as an afterthought will find later reassessments moving against them. Evidence generation has to be designed into the launch, not bolted on once coverage is won.

The final caution is that much of this is still being drafted. The net-price mechanics, the weighted-ICER formula and the interaction with existing risk-sharing rules are not yet fixed. Published policy documents lag the real state of negotiations. The direction is clear; the operating detail will reward those who track it closely in Seoul rather than from a distance.

Executive Summary

Korea has spent two decades building one of Asia's most hospital-dense healthcare systems. In March 2026 it began, quietly, to build the opposite. The Act on the Integrated Support for Community Care took full effect on 27 March, obliging every one of Korea's 229 municipalities to deliver medical, nursing, housing and welfare support to older residents where they live rather than where the beds are.

The infrastructure arrived first. By February 2026 the Ministry of Health and Welfare had placed a Home-Based Medical Care Centre in every city, county and district in the country. A June expansion added 50 more institutions, bringing the total to 463. Teams of a physician, a nurse and a social worker now visit long-term care insurance beneficiaries at home, with the explicit aim of keeping them out of hospitals and nursing facilities.

For international MedTech and healthcare companies, the significance is not the policy. It is the relocation of the buyer. Korea's care demand is moving out of the tertiary hospital and into 463 distributed, thinly staffed, multidisciplinary teams working in homes — many of them in regions foreign suppliers have never called on. And it is happening while the fund that pays for the care moves toward deficit, which means every device and service entering this channel will be judged on cost avoided, not capability added.

What Happened

Korea crossed the United Nations' super-aged threshold in 2024, when more than 20 per cent of the population passed 65. By 2025 roughly 10.84 million people — 21.21 per cent of about 51.11 million — were in that group. The transition from "aged" to "super-aged" took Japan eleven years and France thirty-nine. Korea did it in about seven.

The policy response has a long runway. The Ministry of Health and Welfare (MOHW), the ministry that sets health and welfare policy, announced a Basic Plan for Community Care in 2018 and ran pilots in sixteen local governments from 2019. The National Assembly then passed the Act on the Integrated Support for Community Care, Including Health and Care Services, on 26 March 2024. Nationwide enforcement followed two years later, on 27 March 2026.

The delivery vehicle is the Home-Based Medical Care Centre. MOHW introduced the model in December 2022 with 28 sites. By the end of 2025 there were 344, covering 195 of 229 municipalities. In February 2026 coverage reached every district in the country — one month before the Act came into force. The latest open call, run from 21 April to 22 May 2026, added 50 more, taking the network to 463.

Every person served is a beneficiary of long-term care insurance (LTCI), the compulsory scheme administered by the National Health Insurance Service (NHIS) that covers care for those aged 65 and over, and for younger people with dementia, stroke or similar conditions. Physicians visit at least monthly, nurses twice a month, and social workers connect households to community services.

The June round also loosened the rules to reach thinner markets. Eligibility, previously limited to rural counties, now extends to cities classified as medically underserved. Nurses on these teams no longer need an affiliation with a public health centre and can be based at the medical institution itself. A public health centre may now partner with two medical institutions rather than one. Fourteen of the 50 new centres were designated under the revised framework.

The financing behind all this is under strain. A study published in Health Economics Review in November 2025, using NHIS financial data and Statistics Korea population projections, found that National Health Insurance expenditure overtook revenue in 2025 and that accumulated reserves will be depleted by 2030. Annual deficits are projected at 21.8 trillion won in 2032, rising to 123.3 trillion won by 2042. Because the LTCI contribution is set as a fixed percentage of the health insurance contribution, the two funds move together.

Why It Matters

Start with where the money will be spent. A system that pays for hospital admission buys imaging suites, monitors and surgical platforms. A system that pays to prevent admission buys something else: remote monitoring, point-of-care diagnostics, medication management, fall detection, wound care, portable ultrasound, and the software that lets a three-person team manage a caseload across a district. The 2024 pilot evaluation reported a 53 per cent fall in hospitalisation rates among participants. That figure is the reason the programme survived two changes of government, and it is the metric any supplier will be measured against.

The second point is geography. Foreign MedTech in Korea has historically sold to a short list of large academic hospitals in Seoul. This channel has 463 endpoints across every district in the country, and the newest ones are deliberately sited in underserved areas. That is a different commercial map, a different distributor requirement, and a different price point. It is also consistent with the direction of the 2026 payment-structure reform, which is moving reimbursement weight away from metropolitan academic centres toward regional and essential care.

Third, the fiscal position sets the sales argument. When the fund paying for a service is heading toward depletion in 2030, procurement does not reward feature depth. It rewards demonstrable cost avoidance per episode. Suppliers who can show — in Korean data, not European data — that a device reduces emergency transfers or delays institutional admission will find a receptive audience. Suppliers leading with specification will not.

There are real constraints, and it would be a mistake to read the rollout as settled. Soong-nang Jang of Chung-Ang University, writing in the Annals of Geriatric Medicine and Research in September 2025, noted that participation by private medical institutions has remained limited, that long-term care insurance infrastructure has expanded slowly, and that municipalities with weak finances and workforce shortages have struggled to design workable local models. Formal home care is typically capped at three to four hours a day. Housing adaptation, the least glamorous component, remains underdeveloped. Governance across central and local government is still being worked out.

That last point is the practical one for a European executive. Integrated care in Korea is designed nationally and purchased locally. The Act sets the obligation; the municipality designs the model. Companies used to a single national tender will find 229 buyers with uneven budgets and very different capabilities. The districts that have moved fastest — Seo-gu in Gwangju, Bucheon in Gyeonggi, Jincheon in North Chungcheong — are the reference accounts worth understanding before the market matures.

Executive Summary

Korea's medical device market did not shrink because demand disappeared. It shrank because the hospitals that buy the devices spent much of the last two years in crisis. A walkout by trainee doctors that began in February 2024 delayed surgeries, cut patient volumes and froze hospital purchasing. With that dispute now resolved, the US Commercial Service expects the market to return to growth in 2026.

For foreign MedTech companies, this is a timing signal rather than a headline. Demand that was deferred is starting to return. Hospitals are reopening equipment-replacement and infrastructure plans that sat idle through the strike. The recovery is real, but it is gradual and cash-constrained, and the terms of re-entry now matter as much as the product.

The strategic question for 2026 is not whether Korea buys again. It is which suppliers are ready when procurement restarts, and on what commercial terms.

What Happened

Korea runs one of Asia's most advanced healthcare systems and one of its largest medical device markets. That market slowed for two years. In 2023, the decline reflected the end of the pandemic-era surge in demand for diagnostic kits. In 2024, a nationwide doctors' dispute took over.

The walkout began in February 2024. Thousands of trainee doctors left their posts, and many medical students boycotted classes, in protest at a government plan to raise medical school admissions by 2,000 places a year from 2025. Routine care was disrupted. Elective surgeries were postponed. Hospital procurement of medical devices fell. The standoff became one of the longest medical strikes on record.

The dispute eased in 2025. The government reversed the planned expansion, returning the medical school intake to its pre-strike level. In July 2025, medical students said they would end their boycott and return, after talks with the National Assembly and the Korean Medical Association. The US International Trade Administration (ITA), the trade arm of the US Department of Commerce, dates the market disruption as lasting until September 2025.

Sentiment has since turned. Hospitals are resuming deferred equipment replacement and infrastructure upgrades. Importers report that purchasing plans are under review again. The ITA expects the market to return to moderate growth in 2026, led by replacement demand for delayed purchases and by government programmes backing digital health and AI-assisted technology.

The market being re-entered is substantial. Fortune Business Insights values Korea's medical device market at USD 7.57 billion in 2025, rising to USD 12.58 billion by 2032, a compound annual growth rate of 7.5 per cent. In-vitro diagnostics — laboratory tests run on samples rather than on the patient — lead the market. Foreign manufacturers hold significant share, among them Medtronic, Johnson & Johnson, GE HealthCare, Philips, Siemens Healthineers and Stryker. In the high-end segment the reliance runs deeper: the ITA notes that imports from the United States alone have long held 40 to 50 per cent of the Korean market, with Korea depending on the United States, Europe and Japan for advanced equipment.

Why It Matters

The first read is on timing. A market recovering from a supply shock behaves differently from one growing steadily. Deferred demand does not return evenly. It returns as a wave of replacement orders once hospital operations normalise and budgets reopen. Suppliers with products registered, distributors briefed and stock ready will meet that wave first. Those still preparing will find a competitor already on the shortlist.

The second read is on terms, not just products. Many hospitals absorbed heavy losses during the strike, when patient volumes fell. The ITA reports that procurement teams are now asking for extended payment terms and staggered delivery schedules to manage cash flow. For a European MedTech exporter, that reshapes the commercial conversation. Winning in Korea in 2026 may depend less on specification and more on financing, leasing and delivery flexibility. A rigid payment structure will lose deals that a better-structured offer would win.

The third read is on where growth concentrates. Two forces point the same way. Hospitals are re-investing in the categories the government most wants to promote: digital health, AI-assisted diagnostics and robotic surgery. Adoption of robotic systems continued even through the disruption. Seoul National University Hospital added Medtronic's Hugo platform in 2025, and Asan Medical Center passed 3,000 robotic operations for colorectal cancer by mid-2025. At the same time, Korea's Immediate Market Entry system, launched by the health and drug-safety ministries on 26 January 2026, cuts the approval timeline for internationally validated innovative devices from as much as 490 days to as few as 80. It applies to exactly these segments: AI-based devices, in-vitro diagnostics and medical robots. A company selling into those categories now meets unfrozen demand and a faster regulatory path at once.

The risks are as concrete as the opportunity. Recovery is gradual, not guaranteed, and a fresh budget shock could stall it. For products outside the fast-track categories, approval by the Ministry of Food and Drug Safety (MFDS) remains a lengthy barrier. Reimbursement, governed by the National Health Insurance Service (NHIS), still decides whether a cleared device is actually used and at what price. Domestic incumbents such as Osstem Implant and Samsung Medison retain distribution strength and government preference. A rebound lifts the whole market; it does not remove the structural reasons foreign entrants underperform in Korea.

Executive Summary

Korea is changing the order in which it pays for medicines. For years, a drug had to clear a long, front-loaded value assessment before public insurance would cover it. Under a new "reimburse first, then evaluate" approach, the country will begin paying for selected rare-disease treatments first, then verify their value afterwards using real-world data.

The shift was signalled at the top. On 2 January 2026, the president of the Health Insurance Review and Assessment Service (HIRA), Kang Joong-gu, used his New Year address to call for lower reimbursement barriers on expensive treatments for rare and serious diseases, paired with tougher checks after coverage begins. "We need to move toward a structure where we provide treatment opportunities first, then verify effectiveness and value through real-world data," he said.

For international healthcare and MedTech leaders, this is more than an administrative tweak. It changes when a company gets paid in Korea, what evidence it must keep generating after launch, and where Korea sits in a global launch queue. The reform is phased and unfinished, but the direction is now set.

What Happened

Reimbursement in Korea has long run in sequence. After the Ministry of Food and Drug Safety (MFDS), the drug regulator, approves a product, HIRA assesses its clinical and economic value, the National Health Insurance Service (NHIS) negotiates price, and the Ministry of Health and Welfare (MOHW) signs off. Each stage follows the last. The formal review clock is 240 days, but in practice some rare-disease therapies have taken more than three years to move from approval to coverage.

Kang's New Year message named the trade-off directly: rapid patient access on one side, fiscal control on the other. HIRA would lean harder on tools it already has, such as conditional coverage and risk-sharing agreements, to get patients treated sooner. In return, it would intensify monitoring of real clinical outcomes, safety and cost-effectiveness once a drug is covered. He framed it as a limit of the old model: there are limits to trying to remove all uncertainty at the moment coverage is decided.

The mechanism behind the rhetoric is concrete. Under the emerging "reimburse first, then evaluate" paradigm, rare-disease treatments would target reimbursement within 100 days. HIRA and NHIS would review in parallel rather than in sequence, sharing information in real time to cut the hand-offs that compound delay. Value assessment at listing could be streamlined, with international price benchmarks used in place of full economic modelling, and a formal price reassessment would follow after listing using real-world evidence. The government is exploring AI-enabled infrastructure to speed that review.

The timeline is staged. The approach is set to be piloted in the second half of 2026, implemented in 2027, and expanded to selected innovative medicines beyond rare diseases from 2028. That expansion matters: it turns a targeted rare-disease fix into a broader signal about how Korea intends to reward innovation.

The reset does not stand alone. It sits inside a wider 2026-2028 reform package described by market-access analysts at Simon-Kucher. A flexible contract system, implemented in June 2026, lets a drug carry a high public list price while the actual reimbursed price is negotiated confidentially with NHIS, reducing the international reference-pricing exposure that has long deterred launches. Weighted cost-effectiveness thresholds, due in 2027, would let value assessments weigh disease severity and clinical benefit rather than lean only on a low, fixed cost-per-QALY line unchanged since 2006. On the regulatory side, MFDS has said it aims to cut biosimilar review times from up to 420 days to 240, and to formalise humanitarian access to high-cost orphan drugs. The pieces point the same way: faster access, paid for by tighter post-market scrutiny.

Why It Matters

The clearest read-across is launch sequencing. Korea has often been deprioritised in global launch plans, not because the market is small but because access was slow and prices, once set low and disclosed, could drag down negotiations elsewhere. Compressing the rare-disease pathway toward 100 days, and pairing it with confidential pricing, weakens two of the reasons companies held Korea back. Manufacturers with oncology, rare-disease and neurology launches ahead should reassess where Korea belongs in their sequence, because early entrants tend to set the pricing precedents others inherit.

The reform also changes what "getting reimbursed" means. Under a reimburse-first model, coverage is no longer the finish line. It is the start of an ongoing evidence and pricing dialogue with HIRA, NHIS and MOHW, with price reassessment leaning on real-world data. That raises the value of a Korea-specific evidence strategy built into clinical development from the outset, rather than assembled after listing. Companies that treat real-world data collection as a launch afterthought will be exposed when the reassessment arrives.

There is a fiscal logic worth naming. Paying first and verifying later transfers risk onto the payer, so Korea is balancing it with sharper post-market surveillance and the ability to unwind or reprice weak performers. For the state, the bet is that faster access plus disciplined follow-up costs less than the current mix of long delays and blunt price control. For companies, it means the scrutiny does not disappear; it moves downstream.

The read-across for MedTech and diagnostics is the direction of travel. A system moving toward value assessed on outcomes, and willing to weigh severity and benefit rather than a single threshold, favours technologies that can prove downstream impact. The risk sits on pace. The pathway is still a pilot, eligibility and operational detail remain unsettled, and a reform that is announced is not yet a reform that is reliable.

Executive Summary

On 26 January 2026, South Korea's Ministry of Health and Welfare (MOHW) and Ministry of Food and Drug Safety (MFDS) launched the "Market Immediate Entry Medical Technology" system, a fast-track approval pathway that compresses regulatory timelines by 70% for innovative medical devices, particularly AI-based diagnostics and surgical robotics. The reform applies to 199 device categories and permits market entry immediately after MFDS approval, bypassing the separate New Medical Technology (NMT) assessment that previously added 6–12 months to the process.

For international MedTech companies, this represents a strategic inflection point: Korea transforms from a sequential, multi-step approval system into a competitive launch market on par with major Western jurisdictions.

What Happened

The fast-track system became effective 26 January 2026, following a pilot phase in 2025. It applies to devices that meet specific innovation criteria and pass reinforced clinical evaluation during MFDS authorization.

Timeline compression: The old pathway required approval from MFDS, followed by a separate assessment by a government-designated institute under the New Medical Technology (NMT) framework, adding 200–300 days to the process. The total time-to-clinical use could exceed 490 days. Under the new system, after MFDS approval, innovative devices enter clinical use directly within 80–140 days total.

Scope: 199 device categories are eligible: - 113 digital health devices and Software as a Medical Device (SaMD), especially AI-based algorithms for diagnostics and monitoring. - 83 in-vitro diagnostic (IVD) reagents. - Robotic devices, including surgical robots, assistive exoskeletons, and orthopedic systems.

Regulatory basis: The framework amended two key regulations—the "Regulation on the Evaluation of New Medical Technologies" (MOHW) and the "Rules on the Authorization, Notification and Review of Medical Devices" (MFDS)—establishing a new "immediate-entry medical technologies" category for devices that passed reinforced clinical evaluation.

Why It Matters

Market timing: Korea's medical device market is valued at $7.5 billion (2025) and projected to grow at 7.5% CAGR through 2032. Diagnostics and monitoring devices are the fastest-growing segment, driven by aging demographics, healthcare AI integration, and government investment in smart hospitals. The fast-track system removes friction precisely when investor and corporate interest in Korea's AI-healthcare ecosystem is highest.

Competitive positioning: Foreign companies (which account for 88.7% of tertiary hospital device units in Korea) benefit immediately. A surgical-robot or AI-diagnostic manufacturer that would previously face a 12+ month wait after MFDS approval now enters clinics in 80–140 days. This advantage is particularly valuable for companies targeting the region's well-funded hospital systems and reimbursement infrastructure.

Policy signal: The reform reflects Korea's strategic pivot toward innovation-first healthcare. The concurrent 645 million USD ($940.8 billion won) medtech R&D initiative and 30 billion won AI-deployment program in regional hospitals signal that Korea is not just welcoming foreign innovation but building the infrastructure (clinical sites, reimbursement pathways, integration standards) to absorb it at scale.

Asia-wide context: China is simultaneously implementing similarly aggressive device fast-tracks; this Korean move signals competitive urgency among Asian economies to become preferred launch platforms for MedTech startups and multinational device companies before market maturity.

Executive Summary

South Korea implemented the "Immediate Market Entry Medical Technology System" in January 2026, cutting the approval timeline for internationally validated medical devices from 490 days to as few as 80 days. The fast-track applies to AI diagnostics, surgical robots, and other innovative technologies meeting pre-defined criteria. This regulatory acceleration arrives as Korea's healthcare sector stabilizes after a prolonged strike, foreign manufacturers dominate high-end hospital segments, and the country officially entered a super-aged society. The reform signals Korea's bet on fast innovation cycles over cautious regulatory gatekeeping—reshaping which companies win in Korean hospitals.

What Happened

In January 2026, Korea's Ministry of Food and Drug Safety (MFDS) launched the "Immediate Market Entry Medical Technology System" (IME-MTS), a regulatory pathway that allows internationally validated medical devices to enter the Korean market and be deployed in clinical practice within 80 days, bypassing the standard 490-day health technology assessment (HTA) process.

The fast-track targets specific device categories: AI-powered diagnostic systems, surgical robotics, and other innovations meeting three criteria. The device must be approved by a recognized international regulator (FDA, CE mark, or equivalent). The manufacturer must commit to post-market surveillance. The device must address an unmet clinical need or demonstrate clinically meaningful innovation.

The reform arrived alongside the Digital Medical Products Act (DMPA), enacted in 2026, which established a dedicated regulatory framework for software-as-a-medical-device (SaMD) and digital therapeutics. The DMPA introduced stringent cybersecurity mandates and data-protection requirements, creating a distinct pathway for digital health innovations separate from traditional physical devices.

Korea's broader healthcare context frames this shift. The country's two-year trainee doctors' strike (February 2024–September 2025) disrupted hospital operations and deferred capital expenditure on medical equipment. As the strike resolved, hospitals accumulated replacement demand. Simultaneously, South Korea officially entered a "super-aged society" in late 2024, with over 20% of the population now aged 65 or older, driving demand for remote monitoring, continuous glucose monitoring systems, and chronic disease management technologies.

The medical device market itself reflects structural dualism. South Korea imports roughly $4.4–5.3 billion USD annually in medical devices. The United States supplies 40–50% of all imports; Germany and Japan are secondary suppliers. Domestic manufacturers dominate volume-driven segments (primary clinics, mid-tier hospitals) through aggressive pricing and responsive local service. However, tertiary hospitals—which handle complex cases and command the highest budgets—procure 88.7% foreign devices. In high-end ultrasound imaging, domestic penetration in tertiary hospitals stands at just 21.1%.

Why It Matters

The fast-track reform tilts competitive advantage toward companies with international validation and innovation pedigree. If you hold FDA or CE approval, Korea now becomes a rapid incremental market. If you lack international credentials, the traditional 490-day pathway remains your only route—a material disadvantage.

For MedTech manufacturers already serving North America or Europe, the 80-day Korean entry now makes sense in near-real-time commercial planning. AI diagnostic vendors, surgical robot makers, and digital health companies can sequence launches across North America, Europe, and Korea within a single fiscal cycle, rather than staggering entries across years. This compressed timeline favors companies with capital to sustain parallel regulatory submissions, pricing strategies, and clinical evidence packages across multiple regions.

The tertiary-hospital dominance of foreign devices creates a concentration effect. These hospitals drive innovation adoption and set clinical standards. If your device clears the fast-track and secures tertiary-hospital pilot deployments, you gain clinical reference sites and reputational momentum in a market of 60+ million. The downstream effect—adoption by mid-tier hospitals and clinics—follows more slowly but is nearly assured once the tertiary-hospital bar is met.

Korean domestic manufacturers face a genuine constraint. Few hold FDA or CE approval; most build for the domestic market first. The fast-track effectively reserves the 80-day advantage for international players, widening the timeline gap domestic makers must overcome to compete in high-end segments. Over time, this could reshape the competitive balance between foreign and domestic suppliers.

The super-aged society dynamic amplifies this. Remote monitoring, AI-powered triage, and chronic disease management technologies will see sustained demand across the next decade. The fast-track makes Korea an attractive early-stage market for companies building these platforms. Pilot deployments in Korean hospitals—especially if they include geriatric-focused institutions—generate compelling clinical data for other aging markets (Japan, Taiwan, Europe).

Regulatory risk is not eliminated. The DMPA's cybersecurity mandates are stringent; companies unfamiliar with Korean data-protection expectations should budget for compliance review. Post-market surveillance commitments are binding. However, these are known costs. The 80-day timeline is certain.

Executive Summary

Korea has removed the most expensive step in biosimilar development. On 14 July, the Ministry of Food and Drug Safety (MFDS), the country's drug and device regulator, put into force a revised rule that lets biosimilar developers win approval without submitting Phase 3 clinical trial data. The condition is that similarity to the original biologic is already proven through laboratory, non-clinical, and pharmacokinetic testing.

The change reaches the core economics of the business. Phase 3 trials enrol large numbers of patients and absorb much of the time and money in bringing a biosimilar to market. Removing that requirement, where the science supports it, compresses both. Korea also dropped a repeat-dose animal toxicity requirement on the same logic.

For international readers, this is a market-structure signal, not a technical footnote. Korea is home to two of the world's largest biosimilar makers, Celltrion and Samsung Bioepis. The reform lowers their cost of shipping product and follows parallel moves by regulators in Europe, the United States, and Canada. The direction of travel is a global standard in which analytical science, rather than large efficacy trials, becomes the basis for approving a copy of a biologic drug.

What Happened

MFDS announced on 14 July that it had revised and implemented the Regulation on the Approval and Review of Biological Products. The revision eases the data a company must submit to prove a biosimilar matches its reference product.

The old rule was strict. A developer seeking marketing approval had to submit data from both a Phase 1 trial and a Phase 3 trial to demonstrate biosimilarity. Under the revised regulation, the sponsor may omit the Phase 3 data if comparability has already been established through quality, non-clinical, and pharmacokinetic studies. Pharmacokinetic studies track how the drug moves through the body. Where those measures line up with the reference product, the confirmatory efficacy trial is no longer automatic.

The regulation also reflects the global push to reduce animal testing. Companies will no longer need to submit repeated-dose toxicity study data when comparability in product quality and pharmacological behaviour has been adequately shown.

The reform did not appear overnight. It follows an initiative announced at Korea's presidential Bio Innovation Forum in September 2025 to strengthen the biosimilar industry, and MFDS drafted the change with industry through a public-private consultative body on biosimilar clinical development. Earlier steps came in March, when the ministry published guidance on the factors that decide whether a Phase 3 trial is needed and opened a pre-submission consultation system that lets developers settle trial requirements with regulators before filing.

Industry read the move quickly. Seoul Economic Daily reported that Celltrion and Samsung Bioepis stand to benefit most, since both draw the bulk of their revenue from biosimilars and carry deep development pipelines. A Samsung Bioepis official said the company is already advancing some undisclosed follow-on programmes on the assumption of a Phase 3 exemption, having received regulator feedback that approval is possible without it, and now plans to run only Phase 1 studies for those products.

Why It Matters

The reform changes the unit economics of a biosimilar. Analytical characterisation and pharmacokinetic work are comparatively cheap and fast. A large comparative-efficacy trial is neither. By allowing the expensive step to be waived when the cheaper evidence is convincing, MFDS shortens the path from cell line to launch and cuts the capital at risk in each programme. The US Food and Drug Administration has made the same argument for its own abbreviated pathway, noting that biosimilar makers do not need to run as many long and costly clinical trials because the goal is to prove similarity, not to re-establish a drug's safety and effectiveness from scratch.

The wider point is convergence. Korea is not moving alone. In March, the European Medicines Agency's human-medicines committee adopted a reflection paper concluding that analytical comparability and pharmacokinetic data can, in defined circumstances, be enough to approve a biosimilar without a Phase 3 trial. The FDA issued a draft guidance the same month aimed at trimming unnecessary clinical pharmacokinetic testing, estimating that the change could save developers up to half of their PK-study costs, or roughly 20 million dollars per programme. Health Canada revised its own guidance in May to say comparative clinical efficacy studies are not typically required. Korea's rule slots into that emerging consensus.

For companies that file across borders, harmonisation is the prize. A biosimilar developer builds one evidence package and takes it to many regulators. When Seoul, Brussels, Washington, and Ottawa converge on what that package must contain, a streamlined dossier can serve several markets at once. That lowers duplicate spending and speeds multi-market launches, which is precisely the model Celltrion and Samsung Bioepis run.

The competitive consequences cut in more than one direction. For Korea's biosimilar leaders, cheaper and faster development means more programmes and more shots at the large wave of biologics losing patent protection over the rest of the decade. For originator companies, it means biosimilar competition may arrive sooner and at lower cost, tightening the window in which a branded biologic enjoys open-field pricing. For the contract research industry, demand shifts away from large Phase 3 comparative trials toward analytical and pharmacology work. For investors, the barrier to entry in biosimilars falls, which favours scale and manufacturing quality over the ability to finance a long trial.

None of this is a free pass. The waiver is conditional, not automatic. A developer still has to prove biosimilarity through rigorous analytics and pharmacokinetics, and the regulator keeps discretion over when a confirmatory trial is warranted. Products seeking interchangeable status, or those where the analytical picture is less clean, may still face heavier evidence demands. A lower barrier also invites more entrants, which can compress prices and margins in crowded molecules. The reform improves the odds and the economics of biosimilar development in Korea. It does not remove the science.

Executive Summary

Korea delivers among the best health outcomes in the developed world using the fewest doctors. That is the paradox at the centre of the government's latest reading of OECD data, released on 23 July 2026.

The country has the second-lowest number of practising physicians in the OECD. It also has the most hospital beds, one of the highest scanner densities, the highest outpatient-visit rate, and near the longest hospital stays. In other words, Korea substitutes capital and volume for physician labour, and it does so at a level no other member country approaches.

For international healthcare and MedTech leaders, this is not a curiosity. It explains two things at once: why Korea is a structurally strong market for anything that stretches scarce clinical staff, and why the government is now moving to squeeze the capital-heavy, high-volume segments through reimbursement reform. The same data that shows opportunity also marks the target.

What Happened

On 23 July, the Ministry of Health and Welfare (MOHW) — the government department that sets health policy and oversees the national insurance system — published its analysis of OECD Health Statistics 2026. The dataset compares 27 indicators across seven categories, from workforce and infrastructure to spending and long-term care. The figures below are as of 2024.

The workforce numbers are the outlier. Korea had 2.6 practising physicians per 1,000 people, including doctors of traditional Korean medicine. The OECD average is 4.0, and only Costa Rica ranked lower. The pipeline is thin too: 7.3 medical graduates per 100,000 people, less than half the OECD average of 15.3. Registered nurses stood at 5.5 per 1,000, well below the average of 8.8.

Set against that scarcity, the infrastructure figures invert. Korea had 12.5 hospital beds per 1,000 people, nearly three times the OECD average of 4.2 and the highest in the group. It had 39.3 MRI units and 46.7 CT scanners per million people, both above OECD averages of 21.5 and 31.5. The average Korean visited a doctor 17.9 times in the year, about 2.7 times the OECD average of 6.6 and the highest of any member. The average hospital stay ran to 17.9 days, second only to Japan.

Utilisation follows the equipment. Korea recorded 338.7 CT examinations per 1,000 people, roughly double the OECD average and the highest anywhere. One detail matters for vendors: MRI use, at 83.2 per 1,000, actually sits below the OECD average, and it is growing faster than CT — 10.8 percent a year over the past decade against CT's 7.5 percent.

Spending is climbing. Current health expenditure was 8.5 percent of GDP, still below the OECD average of 9.3 percent. But per-capita spending reached $5,098.7 in purchasing-power-parity terms and grew at 8.5 percent a year over the decade, well ahead of the 6.1 percent OECD pace. Per-capita pharmaceutical sales, at $1,041.2, ran about 47 percent above the OECD average. The outcomes bought with all this are genuinely strong: life expectancy of 83.7 years, second only to Switzerland, and avoidable mortality a third below the OECD average.

The comparison with last year's release sharpens the trend. In the 2025 data, Korea had 2.7 physicians per 1,000 and per-capita spending of $4,586. In one year, the doctor ratio edged down and spending rose more than $500. The direction is consistent: fewer clinicians, more throughput, higher cost.

Why It Matters

The strategic reading runs in two directions at the same time, and executives need to hold both.

Doctor scarcity is a durable demand signal. Korea cannot expand its physician base quickly. Medical training takes a decade, the graduate rate is less than half the OECD norm, and the attempt to raise medical-school admissions triggered the prolonged trainee-doctor walkout of 2024 and 2025. That constraint is structural, not budgetary, which makes demand for anything that stretches clinical time unusually resilient. Imaging AI that helps a thin radiology workforce read a rising scan volume, decision-support tools, laboratory automation, and remote monitoring all sell into a genuine shortage rather than a discretionary preference. This is the same logic behind Korea's recent move to relax the full-time-radiologist rule for MRI sites and its state funding for AI-specialised hospitals: the system is looking for ways to do more with fewer doctors.

The capital-heavy model is now the reimbursement target. The figures that look like opportunity — top-ranked beds, high scanner density, world-leading CT use — are exactly what the payer has decided to rein in. Per-capita spending rising faster than the OECD, on a shrinking clinical base, is not sustainable, and MOHW has said as much. The 2026 payment-structure reform cuts the margin on imaging and laboratory tests and redirects money toward physician-intensive essential care. A public "only necessary scans" campaign targets CT overuse directly. For imaging and diagnostics vendors, the installed base is vast but the economics are tightening: tenders shift from premium features toward throughput, uptime and total cost of ownership, and replacement cycles lengthen as hospitals defend margins. The asymmetry inside the numbers is the useful part. CT is over-used and politically exposed; MRI use is below the OECD average and growing fastest, leaving more clinical and commercial headroom.

The pharmaceutical market is large, above average, and increasingly cost-controlled. Per-capita drug sales roughly 47 percent above the OECD average confirm Korea is a serious market, not a marginal one. But the fiscal arithmetic points one way. A separate OECD projection expects the number of new chronic-disease cases in Korea to rise about 58 percent between 2026 and 2050 — the steepest increase in the OECD — and per-capita spending on those diseases to grow around 119 percent. A payer facing that curve, on the current clinician base, will keep tightening. This is the backdrop to the pricing reforms, biomarker-gated coverage and "cover first, verify later" mechanisms already reshaping access. Volume can widen while price is squeezed; plan for both, not one.

There is a caveat worth stating plainly. These are snapshot statistics, and MOHW frames them explicitly as a basis for policymaking. The bed-and-scanner density that looks like a mature market is, in the government's eyes, a distortion to be corrected — through reimbursement cuts, gradual workforce expansion, and a deliberate shift of low-acuity demand out of hospitals and into community and home care, where the long-term-care numbers already show home-based use doubling over the past decade. A vendor that reads the infrastructure density as stable opportunity, rather than as a policy target, is reading only half the page.

Executive Summary

Korea is assembling one of the world's largest national genome collections, and in 2026 it starts opening the first of that data to researchers. The National Bio Big Data Project aims to gather genomic and clinical records from one million people by 2032. Its first phase, running to 2028, targets about 770,000 participants, with whole-genome sequencing run by a Macrogen-led consortium on Illumina machines.

There is a catch that matters more than the headline scale. As the data opens, Korea is also moving to wall it off. A bill introduced in November 2025 would prohibit, in principle, the overseas transfer of genomic and biometric data. The direction is access without export.

For international pharma, diagnostics and precision-medicine companies, this is the strategic point. Korea is becoming a first-tier genomic resource, enriched for cancer and rare disease and drawn from an Asian population that global datasets under-represent. But it is a resource to be used inside Korea, through local partners, not a dataset to be licensed and taken home.

What Happened

The National Bio Big Data Project — formally the National Integrated Biological Data Construction Project — launched in December 2024 at a ceremony in Seoul attended by the ministers of Health and Welfare, Science and ICT, and Trade, Industry and Energy, alongside the head of the Korea Disease Control and Prevention Agency (KDCA). Four ministries fund it; the Korea Health Industry Development Institute (KHIDI) coordinates it. The goal is a million-person genomic and clinical dataset by 2032, built through the voluntary consent of the general public, rare-disease patients and severely ill patients across 38 hospitals, including Seoul National University Hospital, Asan Medical Center and Samsung Medical Center.

The numbers put it in select company. The UK Biobank recruited 500,000 people; the United States' All of Us programme is targeting a million. Korea is aiming for a million in a country roughly one-fifth the size of the US. The Ministry of Health and Welfare (MOHW) has said phase one, from 2024 to 2028, will collect data from around 770,000 participants, prioritising cancer and rare-disease patients — the groups where whole-genome sequencing (WGS) most clearly outperforms narrower gene panels.

The sequencing engine is a public-private consortium. Illumina supplies its NovaSeq X platforms; Macrogen leads production alongside DNA Link, Theragen Bio and CG Invites. By mid-2025 Illumina had begun whole-genome sequencing for roughly 146,000 Koreans, with about 340,000 samples secured and being prepared. Illumina Korea's general manager framed the division of labour bluntly: Illumina "provides the car," Macrogen "drives the car," and the government "tells them where to go." A stated aim is to correct the European-ancestry skew that dominates the global genomics canon and weakens therapies for other populations.

Access is being staged, not thrown open. The anchor plan makes data available to university and hospital researchers from 2026, and reporting points to a gradual public opening of the integrated 770,000-person database in the second half of the year. The governance model is deliberately conservative. A peer-reviewed review of the project describes a tiered system: open summary statistics at the lowest tier, and, at the highest, only analysis results that may leave after computation inside a closed network. Genomic data is handed back as diagnostic reference reports rather than raw sequence, and it is held on government infrastructure, not company servers, in anonymised form.

Then came the counter-move. In November 2025, a National Assembly member introduced an amendment to the Personal Information Protection Act (PIPA) that would prohibit, as a matter of principle, the overseas transfer of sensitive genetic and biometric data. Transfers would be allowed only where the Personal Information Protection Commission (PIPC) deems them unavoidable, with criminal penalties for violations. The stated worry was that foreign genomics firms were analysing Korean samples abroad, and that leaked genomic data could threaten both national health security and the domestic bio industry.

Why It Matters

First, Korea has joined the front rank of national genome resources. A million-person target, cancer- and rare-disease-enriched, sequenced at whole-genome depth, in an under-represented Asian population, is exactly the kind of asset that made the UK Biobank indispensable to drug discovery. For pharma R&D, it is raw material for target identification and biomarker validation. For diagnostics and precision-oncology firms, it is a reference base for building and validating tests in a population their existing datasets describe poorly. The strategic value is not the row count alone; it is the linkage of deep genomic data to clinical records at national scale.

Second, the access model is "compute in Korea," not "download." Tiered access, reference reports instead of raw sequence, government-hosted analysis and a pending export ban all point the same way. Value will be captured by those who partner with Korean institutions and run their analysis inside the national environment, not by those who expect to move the data to a foreign cloud. This is not a Korean eccentricity. It mirrors a global shift — the UK Biobank's Trusted Research Environment, the European Health Data Space — toward data that stays put while researchers come to it. Companies accustomed to licensing a dataset and taking it in-house need a different playbook: a local collaborator and an in-country compute strategy.

Third, data sovereignty is turning into a market-access variable. The export-restriction bill is aimed at Chinese genomic-analysis firms, but if it passes it will set the terms for everyone. Foreign entrants should plan for data residency inside Korea, PIPC review of any cross-border flow, and a clear preference for partners already embedded in the national system. The Illumina-Macrogen structure is the template the government appears comfortable with: a foreign technology supplier, a domestic operator, and state control of direction and storage. The firms that localise — compute, partnerships, and governance — will have access. Those that assume Korean genomic data can move like ordinary data may find it cannot.

A measure of caution is warranted. This is a resource still being built. Access is opening gradually, and the same peer-reviewed review that praises the design flags real gaps: ambiguous roles across the four sponsoring agencies, unfinished rules on broad consent, and friction in researcher access that a single institutional review board could ease. Whether and how foreign researchers qualify is not yet fully defined. The pathway from a research finding to reimbursed clinical care remains unclear. And the export ban is a proposed bill, not yet law. The opportunity is real, but it should be sized against execution risk and a governance regime that is still hardening.

Executive Summary

In February 2025, Korea amended its Advanced Regenerative Bio Act to introduce a new regulatory category—Advanced Regenerative Medicine Treatment (ARMT)—that permits regenerative therapies to move directly from treatment plan approval into clinical practice without mandatory preliminary clinical research. For low- and medium-risk procedures, institutions can now proceed even without prior clinical trial data if sufficient supporting literature exists. The barrier to patient access has compressed: Korea's Ministry of Health and Welfare (MOHW) no longer requires years of preclinical validation before approval. This accelerates Korea's position as a regenerative medicine jurisdiction and signals opening for international cell-therapy developers—particularly in autologous and allogeneic cell therapies—to enter the Korean market with faster evidence-generation cycles than traditional approval pathways.

What Happened

Korea's regenerative medicine framework previously gated access tightly. Under the original Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products (enacted 2019), therapies could be administered only within approved clinical research protocols. Patients received investigational treatments for free. As of November 2025, only 50 clinical research plans had been approved—mostly cell-based therapies in advanced general hospitals. The pathway was slow, the scope narrow.

The February 2024 amendment, effective February 2025, split the framework into two tracks: the original clinical research pathway (unchanged) and a new ARMT track. ARMT allows approved institutions to provide regenerative therapies as medical procedures, outside formal clinical trials, and charge patients. Unlike reimbursable medical services, ARMT is classified as non-reimbursed—patients pay out of pocket—but this freedom from insurance negotiation means faster market access.

The critical gate shift is risk-based. High-risk therapies (human embryonic stem cells, induced pluripotent stem cells) still require prior clinical research completion. But medium-risk therapies—manipulated autologous cells, allogeneic cells, tissue-engineered products—no longer require the institution to have conducted prior clinical studies itself. If supporting literature from other groups is sufficient, an institution can submit a treatment plan for MOHW review. Low-risk therapies (minimally manipulated autologous cells) can proceed even without prior clinical research at all.

A centralized 25-member review committee, including medical professionals, scientists, and ethics experts, evaluates each submitted treatment plan. Institutions submit detailed plans describing purpose, method, and safety management. Once approved, providers are designated Advanced Regenerative Medicine Providers and may charge patients for 5 years. Interim and final safety reports are mandatory.

This structure eliminates the preliminary clinical study bottleneck. Seoul Economic Daily reported in July 2026 that the regulatory ease is expected to cut timelines by 2–3 years for treatments like autologous natural killer (NK) cell therapy, enabling Korea's NK cell sector to move into "full-fledged growth." The reimbursement door remains closed for now, but the clinical access door has opened.

Why It Matters

For international cell-therapy and regenerative-medicine developers, Korea has become a faster validation pathway than many alternatives. A biotech developer can move from laboratory evidence through treatment-plan approval to real-world patient data generation in Korea while still pursuing formal regulatory approval (MFDS) or market authorization elsewhere. Korea's advantage is compressed cycle time and living-lab validation using real patients under MOHW oversight—not undercover "medical tourism" or unregulated provision.

The strategic read for international biotech is threefold.

First, Korea is a faster Asia-Pacific validation hub. The US FDA's regenerative medicine advanced therapy (RMAT) designation and the Japanese ASRM (Act on Safety of Regenerative Medicine) both allow accelerated access, but both carry post-market surveillance burdens and data reporting to regulators. Korea's ARMT sidesteps that—it is non-reimbursed clinical practice under institutional oversight, not a formal regulatory track. Real-world evidence accumulation is faster. A developer can generate efficacy and safety signal in Korean patients across a risk-tiered cohort, then use that data to strengthen a subsequent FDA application or MFDS approval bid.

Second, the entry gate is institutional partnership, not regulatory negotiation. Unlike NHIS reimbursement (which requires HIRA review, NECA health-technology assessment, and price negotiation), ARMT entry depends on finding an Advanced Regenerative Medicine Provider—a hospital or clinical institution willing to offer the therapy. Korea's tertiary hospitals (Seoul's Big Five and regional university hospitals) compete for cutting-edge offerings. A biotech founder with promising NK cell data can pitch a Korean hospital director for partnership faster than can navigate a payer reimbursement committee.

Third, Korea's success here signals state commitment to cell therapy industrial policy. The MFDS, MOHW, and KHIDI (Korea Health Industry Development Institute) are treating regenerative medicine as a competitive advantage. Japan approved over 1,000 regenerative medicine provision plans under its ASRM and treated over 10,000 patients annually by 2025. Korea's amendment directly mimics Japan's framework—centralized review, treatment-plan approval, institutional provision—with the stated aim of catching up. This is not regulatory laxity; it is deliberate acceleration. International investors take note: Korea is signalling that regenerative medicine is a growth sector it will back.

Caveats exist. ARMT approval is not MFDS approval. A treatment may be approved for ARMT provision but still face the full regulatory review if the developer later seeks marketed-product status. The centralized review committee is new and learning; critics worry it may lack the regulatory-science depth of global regulators. Korea's framework also resembles Japan's on a point Japan has since regretted: the ability to proceed with moderate-risk therapies based on literature review rather than completed trial data. The International Society for Stem Cell Research (ISSCR) sent a formal letter to Japan's Ministry of Health, Labor and Welfare in 2025 urging stricter oversight. Korea should watch Japan's regulatory tightening and anticipate similar scrutiny.

Patient transparency is also incomplete. The Korean framework does not mandate that patients be informed that ARMT treatments are unapproved and investigational. International ethics standards (ISSCR, YOKOHAMA Declaration 2025) increasingly demand such disclosure. Korea's future amendments may require it.

Executive Summary

On 25 June, Korea's Ministry of Health and Welfare (MOHW) announced the largest rewrite of its health insurance payment structure in 25 years. The plan adds 3.6 trillion won a year to regional and essential care. It pays for that by removing roughly 2.6 trillion won of margin from diagnostic testing.

The reasoning is arithmetic, not ideology. MOHW's own Medical Cost Analysis Committee found that specimen testing earns a 190% margin and that CT and MRI earn 194.1%. Consultations, inpatient care and anaesthesia all run at a loss. Korean hospitals have been financing surgery with scanning. The government has decided to stop that, and has published a schedule for doing it.

For international MedTech and diagnostics companies, this is not a Korean domestic story. Your customer's return on an imaging suite and on laboratory volume is being reset by regulation, on a fixed timetable, and the money is moving to operating theatres, emergency departments and hospitals outside Seoul. The buyer has not disappeared. The buyer has moved.

What Happened

The Health Insurance Payment Structure Innovation Plan was presented by Health and Welfare Minister Jeong Eun-kyeong at a briefing in Seoul on 25 June. "Payment structure" here means the fee schedule — what the National Health Insurance pays a provider for each service. The current framework dates from 2001, which makes this the first structural revision in a generation.

The diagnostic cuts are specific. MOHW has set a roadmap to bring test fees down to 150% of cost in the second half of 2026, and to 110% by 2028. In practice, a standard abdominal CT at a general hospital falls about 22%, from 132,920 won to 103,340 won. A head and neck MRI falls about 33%, from 267,160 won to 179,560 won. The Korea Herald reported that laboratory testing reimbursement drops by up to 28% and CT and MRI by roughly 25% by 2028. Expected savings: 1.9 trillion won from specimen tests and 700 billion won from imaging.

One quieter change matters more than its size suggests. Since 1999, clinics without their own laboratories have sent blood to external labs and kept 10% of the testing fee as an "outsourcing management fee". MOHW has concluded that this arrangement drove price dumping between laboratories and unnecessary testing by clinics. The fee is being abolished, saving around 240 billion won.

The money goes in three directions. Basic consultation and hospitalisation fees receive 1.5 trillion won a year — the first increase in the consultation relative-value score in 20 years. Complex and emergency care receives 1.2 trillion won, with more than 1,600 complex surgeries at general hospitals repriced 20% higher, general and high-complexity anaesthesia up 50%, and night or holiday emergency surgery at regional emergency medical centres eligible for up to 5.5 times the standard fee. A new Regional Preferential Payment allocates 400 billion won a year: about 2,700 procedures at general hospitals in six designated underserved areas receive a 10% uplift, with another 10% for night and holiday emergencies.

Minister Jeong framed the plan as a continuation of the regional and essential care agenda she set out in her New Year address in January, which named regional healthcare disparities and a super-aged society as the ministry's central challenges.

The revision cycle also changes. Fee schedules were previously revisited every five to seven years. They will now be revisited within two.

Why It Matters

Take the imaging read first, because it is the most direct. A Korean hospital's decision to buy a scanner has, until now, rested on a service line that returned roughly double its cost. That premium is being legislated away in two steps, with the endpoint — 110% of cost — explicitly designed to leave no surplus.

This changes what wins a tender. When a scanner is a profit centre, buyers pay for premium features and clinical differentiation. When it is close to a cost-recovery service, they buy on throughput, uptime, service contracts and total cost of ownership. Replacement cycles lengthen. Refurbished and mid-tier configurations become defensible choices rather than embarrassing ones. Vendors whose Korean business case rests on premium positioning should expect the conversation to shift toward operating economics, and should expect it within the next 18 months rather than at some indefinite point.

The laboratory side is arguably the sharper change. Abolishing the 10% outsourcing fee removes the financial reason a clinic had to route specimens to any particular reference laboratory. Korea's reference-lab sector was built partly on that referral economics. Combine that with a fee cut of up to 28% and the squeeze arrives from both ends — fewer incentivised referrals and less revenue per test. Laboratories will defend margin the way laboratories always do: by pressing suppliers on reagent and consumable pricing, and by consolidating. If you sell IVD reagents, analysers or laboratory automation into Korea, the pricing conversation in 2027 will be harder than the one in 2026.

Now the opportunity, because there is a real one. Korea is putting 1.2 trillion won a year into surgery, anaesthesia, emergency and maternal-paediatric care, and it is doing so with unusually blunt multipliers — 20% on complex surgery, 50% on anaesthesia, up to 5.5 times for night emergency work, up to 2.5 times on neonatal intensive care hospitalisation outside the metropolitan area. Hospitals respond to fee schedules. Categories tied to the operating theatre, anaesthesia monitoring, emergency and critical care, and neonatal equipment are being handed a demand signal that did not exist a month ago.

The geography of that signal is also new. The Regional Preferential Payment is targeted at named places — six designated underserved areas including Uijeongbu, Namyangju, Icheon, Pocheon and Incheon — plus 84 population-decline areas receiving a 5% uplift on basic fees. Commercial coverage built around Seoul's large academic centres will not reach the hospitals whose economics improved most.

The two-year revision cycle deserves more attention than it will get. Korean reimbursement has been a slow-moving variable that a market-entry model could treat as fixed. It is now a fast-moving one. A price assumption in a Korea business case has roughly a two-year half-life. That cuts both ways: an undervalued category can be corrected upward quickly, and a profitable one can be corrected downward just as quickly.

Finally, the risk that the plan may not survive contact with provider behaviour. The Korea Herald reported medical groups warning that lower reimbursement could reduce the availability of screening and diagnostic testing — one of the acknowledged strengths of the Korean system. The precedent is recent and unflattering. When manual therapy was brought under national insurance at a fixed 43,850 won per session against a previous average charge of 113,296 won, a university hospital in Gangnam simply stopped offering it. Providers exit when a fixed price sits below their cost of delivery.

Two outcomes are plausible and they point in opposite directions. Hospitals may absorb the cut and reduce testing volume, in which case Korea's imaging and lab market contracts in units as well as in price. Or they may defend revenue by scanning more, in which case the projected savings do not materialise and a further round of cuts follows in 2028. Watch utilisation data through 2027; it will tell you which one is happening before the ministry does.

Executive Summary

Korea's healthcare investors have changed what they will pay for. Over the past year, sixteen bio and healthcare companies listed on the Korean market. Only five now trade meaningfully above their offer price. The winners were not the companies with the most interesting science. They were the ones with revenue on the books.

Seoul Economic Daily's analysis of those sixteen listings, published on 1 July and priced to the 30 June close, found the split running almost entirely along one line: earnings visibility. Wearable and robot makers with hospital sales rose. Clinical-stage developers listed under Korea's technology special listing system — a route that admits companies on the strength of their technology rather than their profits — mostly fell below their offer price. An industry official quoted in the report described it not as a bio-sector slump but as "a cold-headed shift of internal funds."

For international healthcare and MedTech executives, this is a pricing signal about competitors and partners, not a stock-market story. Korean device companies with commercial traction are being handed cheaper equity capital at precisely the moment they are expanding abroad. Korean clinical-stage biotechs are being denied it. The first group competes with you. The second group negotiates with you. Both are being repriced at once, and in opposite directions.

What Happened

The Seoul Economic Daily review covered every bio and healthcare company to list on the Korean market over the preceding twelve months. Five posted notable gains against their initial public offering price. Eleven did not.

The best performer was CosmoRobotics, a wearable rehabilitation robot specialist, which closed 30 June at 15,030 won against an IPO price of 6,000 won — a gain of 150.5%. The report attributes that to two things working together: actual revenue from supplying products to hospitals and industrial sites, and the ageing-population theme that Korean investors currently favour. RecensMedical, a cooling medical device maker, rose 47.5% on the expandability of its technology into cosmetic and ophthalmology markets.

Only some drug developers rose, and only where they sat inside a global theme. AimedBio, an antibody-drug conjugate developer, gained 128.2% on clinical approval momentum and technology-transfer expectations. Rznomics, an RNA therapeutics company, rose 82.2% on anticipation of a big-pharma deal.

The declines were concentrated among technology-listed firms whose science drew attention but whose earnings remained distant. IMBiologics, developing autoimmune antibody therapeutics, fell 14.6%. Quad Medicine, a microneedle platform company, dropped 60.1% as lock-up overhang from pre-listing investors coincided with widening losses.

The context matters. Korean investor money has been flowing toward artificial intelligence and semiconductors. Healthcare listings that could attach themselves to that current — robots, wearables, AI-adjacent devices — were carried along. Those that could not were left to be judged on cash flows they do not yet have.

RecensMedical illustrates the profile now being rewarded. The company raised 12.6 to 15.4 billion won in its March listing, offering 1.4 million shares at 9,000 to 11,000 won. Its lead product, OcuCool, cuts anaesthesia time before an eye injection from roughly ten minutes to about ten seconds. But the investment case rested on the boring part: TargetCool, its dermatology device, already sells in 44 countries, and the company had cut consumables production costs by more than half through automation. Installed base, consumables revenue, cost discipline. That is what cleared.

Why It Matters

Start with the competitive read, because it is the most immediate. Korea's medical device industry is not a fringe sector being lifted by sentiment. Ministry of Food and Drug Safety (MFDS) data released in May put 2025 domestic production at 12.36 trillion won, up 8.1%, with a trade surplus of 478.9 billion won — the sixth consecutive surplus year. The domestic market grew 12.6% to 11.88 trillion won. Employment across manufacturers and importers rose 7.8% to 162,531 people. Exports are also spreading: the shares taken by the United States, China, Japan and Russia declined last year while Germany, India, Thailand and France expanded.

Put those two facts together. Korean device makers are growing, exporting into European markets, and are now the segment their own equity market is willing to fund most cheaply. Cheaper capital buys automation, distribution and clinical evidence. For a European MedTech firm competing in dental implants, ultrasound, aesthetics or rehabilitation robotics, the cost of capital of your Korean competitor just fell — and it fell for reasons that have nothing to do with your product.

The mirror image is the licensing side. Korea now holds the world's third-largest pipeline of clinical-stage drug candidates, behind the United States and China. Yet the capital to develop those candidates domestically is thinning at exactly the moment their number is growing. Data presented by McKinsey's Jay Park at the Korea Drug Development Fund showcase in May put the consequence plainly: 68% of assets licensed out of Korea last year changed hands before reaching human trials, and 84% moved before a phase two trial. Most of the value those assets eventually create is captured after they leave the country.

An equity market that will not fund clinical-stage science makes early licensing the rational choice for a Korean founder rather than a reluctant one. For international pharma and investors, that means more Korean assets available earlier, and at terms set by a seller with fewer alternatives. It also means the asset arrives less de-risked than a comparable Western one. The discount is real; so is the reason for it.

Foreign capital is adapting to this by routing around Korea rather than into it. Novo Holdings, the investment arm behind Novo Nordisk, told Korea Biomedical Review in early July that Korea has become a strategic priority — while confirming it has no office there and no mechanism to invest directly in a Korean company. Its only route in is to license an asset into a newly formed company based outside the country, most often in Singapore. Its Asia team opens at five to ten million euros, scales to thirty-five million, and runs a roughly $200 million annual regional mandate. Nearly all of the Korean portion currently moves through intermediary structures. The firm has partnered with Seoul-based Premier Partners and opened its Singapore Biotech Bridge to Korean companies for the first time.

Not everyone accepts the structure. Boehringer Ingelheim's Manuel Baader called the NewCo model "not our preferred model," saying his firm avoids moving assets out of their home ecosystems. SV Health Investors' Jonathan Behr noted the practical cost: a thirteen-hour time difference and heavy dependence on local partners to monitor portfolio companies. Those objections are the argument for building a Korean presence rather than a Singaporean workaround — and they are currently the minority position.

One caution belongs on the record. The revenue premium is partly a theme, and themes reverse. CosmoRobotics rose on hospital sales and on the fact that robots are what Korean money currently wants to own. If liquidity rotates away from AI and robotics, some of that repricing goes with it. The structural facts — production growth, export diversification, an early-licensing pipeline — will outlast the sentiment. The multiples may not.

Executive Summary

Four of Korea's largest multinational drugmakers are simultaneously trimming their local commercial organisations. Bristol Myers Squibb (BMS), Takeda and MSD have each launched voluntary early retirement programmes (ERPs) for their Korean affiliates in recent weeks. Novartis is reportedly restructuring too, tied to a downsizing of its cardiovascular unit. None of this is being driven by a single bad quarter.

The trigger is portfolio, not performance. Each company's global headquarters has reallocated research and commercial priority toward oncology, immunology, cardiovascular-metabolic disease and, in BMS's case, radiopharmaceuticals — categories built substantially through recent acquisitions rather than organic growth. Korean affiliates are being resized to match a product mix that looks different from the one their sales forces were built to sell.

For international healthcare and MedTech executives, the relevant signal is not the job losses themselves. It is what determines who survives a Korean restructuring and who doesn't: proximity to a company's next growth category. Commercial teams built around ageing, off-patent brands are shrinking. Teams positioned around newly acquired or newly launched assets are not. That distinction is becoming a live filter on which local partners, distributors and commercial contacts will still be in their roles a year from now — and it lands as Korea simultaneously rewrites the pricing rules those same portfolios must be sold into.

What Happened

According to industry sources cited by DailyPharm on 15 July, BMS Korea has launched an ERP targeting commercial staff with ten or more years of tenure, covering sales, marketing, wholesale management and business development. The compensation formula reported is "2N+8" — years of service multiplied by two, plus eight months of salary — with additional individual severance on top. BMS said the move reflects "a comprehensive assessment of our Korean portfolio, patient needs, and market environment."

The context is BMS's own pipeline reshaping. The company has expanded into neuroscience, radiopharmaceuticals and oncology through the acquisitions of Karuna Therapeutics, RayzeBio, Mirati Therapeutics and SystImmune, while preparing for the patent expirations of two of its largest products, the anticoagulant Eliquis (apixaban) and the multiple myeloma treatment Revlimid (lenalidomide). Newer Korean launches — Zeposia, Sotyktu, Camzyos — have not yet matched the commercial scale of its immuno-oncology therapy Opdivo (nivolumab). The commercial organisation built around the old product mix is being resized around the new one.

Takeda Korea has run a parallel ERP under the same 2N+8 formula, with total severance for quinquagenarian-tenure staff reportedly reaching around KRW 150 million for employees with 15 years of service. The programme follows direction from Takeda's Japanese headquarters and the recent appointment of a new head for the Korean affiliate — read by industry observers as a signal that Korea's operations are being brought into line with a broader global restructuring, not treated as a standalone decision.

MSD Korea completed an ERP for its Human Health division — prescription medicines, vaccines, commercial operations and external affairs — the week before. The company was explicit that the programme was not driven by product performance or patent expiry, but by a shift in strategy: continued growth in oncology alongside expansion into cardiovascular-metabolic disease, infectious disease, immunology and ophthalmology. Novartis Korea, meanwhile, is reportedly restructuring around a downsized cardiovascular business unit, continuing a pattern that already saw it exit respiratory in 2022 and transfer its ophthalmology business to Santen Pharmaceutical last year.

Industry sources note the precedent: Pfizer ran a comparable restructuring in Korea after COVID-19 vaccine and antiviral sales declined. What is different this time is the number of companies moving together and the explicit framing — executives describe these programmes as portfolio-alignment exercises rather than cost-cutting, reflecting a broader pattern in which strategic decisions at global headquarters are increasingly mirrored directly in the structure of Korean affiliates.

Why It Matters

The commercial read is straightforward: Korea's multinational pharma workforce is being reshaped around where global R&D money has already gone. Oncology, immunology, cardiovascular-metabolic disease and radiopharmaceuticals are growing inside these organisations. Legacy primary-care and off-patent commercial teams are shrinking. For companies selling into or partnering with multinational affiliates — diagnostics makers seeking companion-test tie-ups, CROs, distribution partners, digital health vendors pitching adherence or monitoring tools — the practical implication is that the account team, therapeutic focus and even the legal entity structure a partner has dealt with for years may not be the one still standing in twelve months.

This restructuring wave is also arriving inside a live policy shift, not a stable one. Korea is in the middle of a sweeping overhaul of its drug pricing system, and — per a 9 July DailyPharm commentary — pharmaceutical and biotech companies are increasingly routing decisions through law firms rather than government relations teams, as domestic companies assess whether they qualify as "Innovative" or "Quasi-Innovative" under the new pricing framework and multinational affiliates work through the legal grey areas of the Flexible Pricing Agreement system and post-listing management rules. A multinational simultaneously cutting commercial headcount and re-litigating its pricing strategy through outside counsel is not a company retreating from Korea. It is a company reallocating scarce internal capacity toward the fights it judges matter most — regulatory and pricing strategy over field commercial presence.

The market backdrop explains why margin discipline is biting now. Korea's pharmaceutical market is valued at roughly USD 23.7 billion in 2026, growing at a modest 2.37% compound annual rate to an estimated USD 26.7 billion by 2031, according to Mordor Intelligence. Drug re-pricing policy is flagged as a direct drag on that growth, and oncology alone already absorbs an outsized share of new-drug spending — squeezing the funds available for other therapeutic areas. In a market growing this slowly, with reimbursement rules tightening around actual-transaction pricing, a multinational's fastest lever for protecting margin is its own cost base, not local pricing power it may no longer control.

For foreign MedTech and diagnostics companies, the near-term opportunity sits in exactly the categories these affiliates are reinforcing. Companion diagnostics tied to the biomarker-gated oncology reimbursement Korea has been building out, cardiometabolic monitoring technology, and services that support newly acquired radiopharmaceutical and cell-therapy pipelines are the areas where multinational Korean teams are adding capacity, not cutting it. The risk sits on the other side: any commercial relationship anchored in a legacy primary-care or off-patent portfolio should be treated as provisional until the affiliate's restructuring settles.

Executive Summary

Korea has spent two decades putting frail older people into beds. It is now trying to take them out. The Act on the Integrated Support for Community Care, Including Health and Care Services — the Integrated Care Support Act — came into force on 27 March 2026, two years after it was enacted. It is the country's first comprehensive legal framework for community-based integrated care, and it hands municipalities the job of coordinating health, long-term care, housing and social services for people who would otherwise be admitted somewhere.

The reform matters because of what it corrects. Korea built one of the highest per-capita supplies of long-term care hospital beds in the OECD, not by clinical design but by reimbursement accident. A generous per diem rate made long-stay admission the path of least resistance for medically stable but functionally dependent older adults. The Act attacks that incentive directly.

For international healthcare and MedTech companies, the strategic point is not the social policy. It is the buyer. Care decisions, budgets and procurement are being pushed down to 229 municipalities and out into homes. A market that was legible through a few hundred institutions is becoming something considerably harder to map — and considerably different in what it buys.

What Happened

The Act was passed on 26 March 2024 as Act No. 20415, with a two-year runway before enforcement on 27 March 2026. That gap was deliberate. Korea has been rehearsing this reform since the Ministry of Health and Welfare (MOHW), the government department responsible for health and social policy, announced a Basic Plan for Community Care in November 2018 and launched four-year pilots in 16 local governments from April 2019. A second wave followed in July 2023, when MOHW selected 12 municipalities for a Medical–Care Integrated Support Pilot Program for Older Adults. By August 2025, 57% of Korea's 229 municipalities were taking part in pilots of some kind.

The pilots produced numbers worth noting. The 2024 evaluation reported 92.8% user satisfaction and, comparing before and after participation, a 53% fall in hospitalisation rates and a 1.3% reduction in emergency room use. Caregiver burden fell and quality of life improved. Notably, activities of daily living did not measurably improve — the gains were in where care happened and what it cost, not in restored function.

The Act's provisions are structural. Local governments become the primary coordinators and planners of care in their jurisdictions. A certified care manager workforce is introduced to conduct holistic needs assessments and build individual service plans — the coordination role Korea conspicuously lacked and Japan has had for years. Integrated service platforms, physical and virtual, are to connect users with providers. And the Act pilots outcome-based financing, paying for measurable improvements in function and quality of life rather than for volume of services or occupied beds.

Behind all of it sits Korea's dual-track problem. Medical care is financed through National Health Insurance (NHI). Custodial and functional care runs through the separate Long-Term Care Insurance (LTCI) scheme introduced in 2008. The two systems expanded access and entrenched fragmentation at the same time — patients cycling between acute hospitals, long-term care hospitals and nursing homes, with families navigating the seams. Full interoperability between NHI and LTCI data is a stated prerequisite of the reform.

Why It Matters

Start with the buyer map, because that is what changes first. Korea's institutional care market has been relatively concentrated and relationship-driven: a manageable number of hospitals and nursing homes, known procurement patterns, predictable channels. Community-based integrated care fragments that. Purchasing authority disperses across municipalities with very different fiscal capacity and workforce depth. Companies whose Korean strategy runs through tertiary hospital relationships will find those relationships do not reach the new buyers.

The product mix shifts with it. Care delivered at home is not institutional care in a smaller room. It favours remote monitoring, home diagnostics, medication management, fall detection, rehabilitation technology and the connectivity that ties them to a coordinating clinician. MOHW's Home-Based Medical Centre pilots put physicians in the home at least monthly and nurses twice monthly — a cadence that only works if something is watching in between. Seo-gu in Gwangju has already built real-time monitoring of care recipients using ICT and big data, coordinated through a dedicated Bureau of Integrated Care. That is a template other districts will copy, and it is a procurement category that barely existed five years ago.

Outcome-based financing is the provision to watch hardest. If Korea genuinely pays for functional maintenance rather than bed-days, the value case for any product changes shape. Vendors would need to demonstrate contribution to an outcome a municipality is being paid on — avoided admissions, sustained independence — rather than unit price against a tender. That is a harder sale and a stickier one. It is also, for now, a pilot rather than a settled system, and the evidence that Korea's pilots improved placement but not ADL scores is a caution against assuming the outcome metrics will be easy to hit.

Then the constraints, which are real. Municipalities with low fiscal independence and thin workforces have struggled to design models suited to their local context. Private medical institution participation in the pilots remained limited. Home care by formal caregivers is typically capped at three to four hours a day, leaving gaps that families still absorb. Housing-linked supports remain underdeveloped. The care manager profession has to be built, trained and paid before it can coordinate anything. A nationwide legal mandate does not conjure any of this on the enforcement date.

Institutions are not disappearing, either, and executives should resist the tidier narrative. The evidence points to a rebalancing, not a replacement. Long-term care hospitals are to be repositioned toward post-acute and rehabilitative care with active discharge planning; nursing homes toward dementia, custodial and end-of-life care. Japan tried to eliminate long-term care beds and had to reverse course under public demand. Korean data show the tension plainly: 67.5% of care recipients preferred to die at home, while 59.6% of family caregivers preferred hospitals. Institutional demand has a floor, and that floor is cultural and demographic, not merely a policy artefact.

The wider point is that Korea is running an experiment other aged societies will read closely. It went from 7% of the population over 65 in 2000 to over 20% by 2025. No country has had less time to solve this. Whatever Korea learns about care managers, integrated financing and community capacity will arrive in European debates with the authority of a system that had to move fast.

Executive Summary

Korea is quietly redrawing the top of its hospital hierarchy. The change is administrative, not clinical, and it is easy to miss. It will nonetheless move where the highest-value medical procurement in the country concentrates.

Every three years, the Ministry of Health and Welfare (MOHW) redesignates the country's tertiary general hospitals — the top-tier academic centres that anchor the care system. The sixth-cycle review opens for applications in July 2026 and finalises in December, taking effect in 2027. This round the criteria are tougher, and the rewards for winning are larger.

The visible signal is a scramble. All of Korea's "Big 5" hospitals have applied for regional emergency medical centre status, a designation they once avoided, purely to bank bonus points in the redesignation review. Behind it sits a deeper shift: hospitals are cutting general beds and tilting their case-mix toward severe patients, while MOHW centralises control over hospital beds and high-end equipment.

For international MedTech, the map that matters is being redrawn. High-acuity demand is concentrating at a smaller set of centres, and a new government bureau is about to sit between hospitals and their capital-equipment plans.

What Happened

Tertiary general hospitals are the apex of Korea's medical delivery system. MOHW designates them every three years after a comprehensive review of medical function, facilities, equipment, and staffing. In the fifth cycle, decided in 2024, 47 hospitals nationwide earned the status. Applications for the sixth cycle are accepted in July 2026 and finalised in December, with the new list effective from 2027.

Two things make this round consequential. First, the bar is higher. The share of severe patients a hospital must treat has been raised to 38 percent, while the share of mild patients must fall to 5 percent or below. The number of medical service regions used to allocate designations has been widened from 11 to 14. Designation brings concentrated policy benefits — reimbursement premiums and preferential support — so failing carries real financial pain, especially for hospitals that already cut bed counts under a government structural-transformation pilot.

That pilot is the second thread. Since 2024, MOHW has pushed its largest hospitals to reduce general beds and reorient toward severe, emergency, and complex care rather than routine volume. Hospitals that shrank their beds to comply now must pass the review or absorb heavy losses. As one university hospital official put it, cutting beds and then failing designation would mean enormous losses over the three-year cycle.

The scramble for regional emergency medical centre status follows directly. These centres treat severe emergency patients around the clock and face demanding requirements for facilities, equipment, and staff, with low profitability. The Big 5 — Seoul National University Hospital, Asan Medical Center, Samsung Medical Center, Severance Hospital, and Seoul St. Mary's Hospital — historically saw no reason to apply. In the 2023 round, several regions fell short of applicants. In 2026, all five applied, because the designation earns bonus points in the redesignation review, where a single point can decide the outcome.

The government is also reorganising itself around this agenda. On 14 July 2026, a Cabinet meeting approved a sweeping restructuring of MOHW, effective 21 July. It creates a new Regional, Essential and Public Medical Care Office and a Medical Resource Policy Bureau that will centrally manage medical workforce supply, hospital beds, and special equipment such as magnetic resonance imaging (MRI) scanners. A dedicated Medical System Innovation Division will run the structural transformation of tertiary hospitals as an autonomous unit.

Why It Matters

The first implication is concentration. When the top tier is redefined around a 38 percent severe-patient threshold, the largest centres must double down on high-acuity work — critical care, trauma, complex surgery, oncology, cardiovascular intervention. Demand for the equipment and consumables that support that work concentrates at a defined set of hospitals. For vendors of intensive-care systems, surgical technology, advanced imaging, and emergency and trauma equipment, the highest-value buyers become easier to identify and more clearly committed to that mission.

The second implication is the mirror image. As big hospitals shed general beds and push routine cases outward, general-ward and low-acuity volume disperses toward regional and smaller institutions. Suppliers whose products sit in routine inpatient care should expect their demand to follow patients down the tiers, not stay concentrated at the academic centres. The single national account map that many foreign firms rely on will need two layers: high-acuity flagships and a broader regional base.

The third implication is procurement governance, and it deserves attention. The new Medical Resource Policy Bureau will centrally manage hospital beds and special equipment including MRI. Korea already regulates the deployment of high-end imaging through quantity controls tied to bed counts and regional need. Centralising that function signals tighter, more coordinated oversight of where big-ticket equipment can be installed. For capital-equipment vendors, the constraint is less about winning a hospital's preference and more about whether the system will authorise another unit in that location at all. Planning approvals, not just sales relationships, become the gate.

The fourth implication is timing. The redesignation review runs through the second half of 2026, and hospitals compete on measurable criteria — severe-case ratios, emergency capability, equipment, and staffing. That creates a window. Hospitals chasing designation have a concrete incentive to invest in the capabilities the review rewards, from emergency and trauma infrastructure to the case-complexity tools that lift their severe-patient mix. Vendors who can tie their offer to the review's scoring have a sharper commercial argument in 2026 than they will once the list is fixed for three years.

The fifth implication is fiscal, and it is supportive. MOHW's 2026 budget of 137.64 trillion won, up 9.7 percent, channels new money into exactly this part of the system: a 100 billion won loan programme for emergency medical institutions, 19.1 billion won for equipment at emergency institutions in vulnerable areas, and concentrated investment in severe-trauma hub centres. The national cancer management budget rises from 83.6 billion to 126.6 billion won. Public money is flowing toward severe, emergency, and essential care — the same direction the redesignation criteria push hospitals.

A note of proportion. Designation lists change at the margin, not wholesale, and Korea's academic hospitals guard their autonomy. The 47-hospital tier will not be unrecognisable in 2027. But the direction is clear and government-backed: fewer general beds at the top, a higher severe-case bar, and centralised control of beds and heavy equipment. That is a structural signal, not a one-year event.

Executive Summary

Korea has done something unusual for its public payer. In a single decision, it expanded reimbursement for one cancer drug across eleven new uses at once. The drug is Keytruda, MSD's PD-1 immunotherapy. The coverage took effect on 1 January 2026.

The number of uses is less important than how they were chosen. Most of the new coverage is gated by a biomarker, not by the cancer's location in the body. A patient qualifies based on PD-L1 expression, microsatellite-instability status, or HER2 status, measured by a laboratory test, rather than on the tumour type alone.

That is a quiet but consequential shift. Korea is moving toward reimbursing cancer treatment by molecular profile. The immediate effect widens patient access. The lasting effect moves diagnostics to the centre of market access, because the test now decides who the payer will cover.

For international pharma and diagnostics companies, the strategic read is direct. A Korean approval no longer implies a Korean market. Reimbursement is the real gate, and that gate increasingly opens on a biomarker result.

What Happened

On 23 December 2025, Korea's Health Insurance Policy Deliberation Committee (HIPDC), the Ministry of Health and Welfare (MOHW) body that sets national insurance coverage, approved a wide-ranging expansion of reimbursement for Keytruda (pembrolizumab). MSD Korea said coverage began on 1 January 2026. The decision added eleven new covered uses and took the drug from seven reimbursed indications to eighteen, spanning thirteen cancer types.

The company called it unusual for a single therapy to win reimbursement across multiple tumour types at the same time. MSD first requested the review in June 2023, arguing there was unmet need in cancers with limited access under the national framework.

The detail that matters is the gating. In gastric and gastro-oesophageal junction cancer, first-line coverage is split by HER2 status and tied to PD-L1 thresholds defined by a combined positive score (CPS): HER2-positive disease at CPS of at least 1, HER2-negative disease at CPS of at least 10. First-line coverage in triple-negative breast cancer requires a PD-L1 CPS of at least 10. Cervical cancer and head and neck squamous cell carcinoma are gated at CPS of at least 1, oesophageal squamous cell carcinoma at CPS of at least 10.

A large share of the expansion is carved out for tumours that are microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR), a molecular signature that predicts immunotherapy response. That covers Keytruda as a later-line option in MSI-H or dMMR endometrial, small bowel, and biliary tract cancers, and as a first-line option in dMMR or MSI-H metastatic colorectal cancer. In each case, the biomarker, not the organ, defines eligibility.

The Ministry of Food and Drug Safety (MFDS), Korea's drug and device regulator, has kept approving new uses since. On 9 July 2026, it cleared Keytruda for muscle-invasive bladder cancer and platinum-resistant ovarian cancer, taking the drug to 37 approved indications across eighteen cancer types. Those approvals are not yet reimbursed. The gap between what is approved and what is paid for is the point.

Why It Matters

Start with diagnostics, because that is where the value moves. When coverage is written around PD-L1 CPS, MSI-H, dMMR, and HER2, the companion test becomes the gatekeeper of a reimbursed prescription. Demand rises for PD-L1 immunohistochemistry, for MSI and mismatch-repair testing by immunohistochemistry or sequencing, and for standardised HER2 assessment. For diagnostics companies, Korea is turning biomarker testing from a clinical nicety into a reimbursement prerequisite. For pharma, a companion-diagnostic strategy is no longer a supporting detail of a Korean launch. It is the launch.

The second point is the widening gap between approval and coverage. MFDS has now cleared Keytruda for 37 indications, while national insurance reimburses eighteen. The July bladder and ovarian approvals sit in that gap, approved but not yet paid for. International teams often read a Korean approval as market entry. It is not. It is permission to be considered by the payer. The reimbursement decision, made separately by MOHW, HIPDC, the Health Insurance Review and Assessment Service (HIRA), and the National Health Insurance Service (NHIS), is the one that creates a market.

The third point is cost control riding alongside access. Korea did not widen coverage without levers. Reimbursement for these immunotherapy uses carries a two-year treatment limit, a cap that clinicians have already flagged as clumsy for patients still responding at the ceiling. Korean oncologists have floated an alternative: adjust patient copayment by the proven efficacy of the drug, so the insurance budget stays sustainable as more high-cost innovative medicines arrive. That idea points where Korean reimbursement is heading, toward outcomes-linked cost-sharing rather than open-ended coverage. It fits a broader 2026 pattern in which Korea expands access and installs a financial guardrail in the same motion.

The fourth point is competitive. A broad reimbursed indication base is an asset that outlasts a single product cycle. Keytruda faces an eventual loss of exclusivity, a subcutaneous reformulation, and biosimilar developers preparing to enter. Whoever holds the reimbursed footprint in each biomarker-defined population holds the position that competitors must dislodge. For companies building immuno-oncology or biosimilar strategies for Korea, the map of who is covered, in which biomarker group, is now the terrain of competition.

Finally, the decision does not stay inside Korea. Korean negotiated prices feed reference-pricing systems across Asia, so the terms attached to a high-cost immunotherapy in Seoul can echo through Singapore, Taiwan, and beyond. A generous listing lifts the regional benchmark. A hard-negotiated one compresses it. Either way, the Korean payer's choices on immuno-oncology travel.

Executive Summary

Most analysis of the Korean healthcare market watches two things: the hospitals that buy, and the companies that sell to them. A third layer sits in between. It is the procurement and distribution channel that moves supplies, devices, and services into hospitals. That layer rarely makes headlines. It is now being bought up by private equity.

In the second week of July 2026, Hong Kong-based Affinity Equity Partners moved to expand its Korean procurement business, Serveone, deeper into the hospital supply chain through two bolt-on acquisitions, Opera Salutaris and ValuePro. Both are tied to the procurement operations of the Catholic Medical Center, one of Korea's largest hospital networks.

The deals are small on their own. The direction is not. Affinity is assembling a professionalised, scaled intermediary that sits between global suppliers and Korean hospitals. A rival buyout firm, MBK Partners, has done something parallel in pharmaceutical distribution.

For international MedTech and pharmaceutical companies, this is worth attention. The channel you sell through in Korea is consolidating, and its new owners answer to a value-creation clock.

What Happened

Affinity Equity Partners is a Hong Kong-based private equity firm active across Asia. Its Korean healthcare position is built around Serveone, a procurement company that began life as the in-house maintenance, repair, and operations (MRO) unit of LG Group. Affinity acquired a controlling 60 percent stake in Serveone in March 2019 for about 602 billion won. In 2022 it recapitalised the business, raising roughly 700 billion won, close to 565 million US dollars, to recoup part of its investment while retaining control.

Serveone's original business is corporate procurement: sourcing the supplies and services large companies need to operate. The healthcare move takes that same capability into hospitals, where procurement is fragmented, relationship-heavy, and expensive to run well.

The two July acquisitions, Opera Salutaris and ValuePro, extend Serveone into hospital supply management connected to the Catholic Medical Center (CMC). CMC operates eight hospitals, including Seoul St. Mary's Hospital, and ranks among the country's major academic hospital systems. Bolting on procurement operations tied to a network of that size gives Serveone captive volume and a working template it can pitch to other hospital groups.

The pattern is not unique to Affinity. MBK Partners, one of the region's largest buyout firms, acquired the pharmaceutical distributor Geo-Young for close to 2 trillion won. Geo-Young handles drug distribution, medical-supply procurement, and third-party logistics for hospitals. Two of Asia's biggest private equity names are now building scale in the same layer of Korean healthcare from different entry points, one through corporate procurement, the other through pharmaceutical distribution.

None of this changes clinical practice. It changes who controls the pipes.

Why It Matters

The first point is structural. In Korea, the route from a foreign manufacturer to a hospital shelf runs through local distributors, agents, and procurement intermediaries. That layer has long been fragmented, which suited vendors: many small counterparties, none with much leverage. Consolidation reverses that. A single scaled procurement platform buying on behalf of many hospitals can negotiate as one large customer rather than several small ones.

The second point follows directly. Scaled buyers use scale. A professionalised procurement operator will push for volume discounts, standardised specifications, and consolidated vendor lists. It may favour private-label or own-brand alternatives where clinically acceptable. For suppliers, this tends to compress margins and shorten the list of approved products. Vendors whose position rested on a comfortable relationship with a hospital's purchasing office should expect a harder, more data-driven counterpart.

The third point is the other side of the same coin, and it is genuinely an opportunity. Korea's hospital procurement has been notoriously relationship-driven and slow, with long sales cycles and duplicated effort across institutions. A consolidated channel can simplify that. A supplier that wins a place on a scaled platform's approved list can reach many hospitals through one relationship rather than negotiating each account from scratch. For firms that lack the resources to cover Korea hospital by hospital, a professional intermediary can be a faster route in, not only a tougher gatekeeper.

The fourth point is about incentives and time. Private equity owners run to a clock. They buy, improve margins over three to five years, and exit through a sale or listing. That shapes behaviour. Expect aggressive cost discipline, measurable efficiency targets, and a steady push to widen margins ahead of an eventual exit. It also introduces channel risk: ownership can change again, terms can be renegotiated, and a supplier relationship built with today's operator may face a different owner in a few years. The intermediary is becoming more capable and more demanding at the same time.

The fifth point is signalling. When two of Asia's most disciplined buyout firms independently target the Korean hospital supply chain, they are betting that the layer is large, inefficient, and improvable enough to reward consolidation. That thesis usually proves self-fulfilling. Capital drives professionalisation, professionalisation drives pricing discipline, and the market that emerges is more concentrated than the one that preceded it. International suppliers should plan for a Korean channel that looks less like a network of local agents and more like a small number of large, sophisticated procurement businesses.

A note of proportion is warranted. These are bolt-on deals, not a national roll-up, and much of the Korean hospital market still procures the old way. Academic hospital systems guard their autonomy, and clinician preference still shapes what gets bought, especially in high-end devices. Consolidation of the supply chain is a direction of travel, not a finished state. The thing to watch is whether Serveone and Geo-Young extend beyond their anchor networks into other hospital systems, and whether their scale starts to show up in supplier contract terms.

Executive Summary

Korea is changing how a medical device proves its quality, and putting the rules in law. The Ministry of Food and Drug Safety (MFDS), Korea's drug and device regulator, is finalising an amendment that lifts its Good Manufacturing Practice (GMP) conformity-recognition system out of administrative notices and into statute.

The change reads as technical. Its effect is not. It fixes the criteria reviewers use, formalises the private bodies that certify devices, sets penalties for false conformity claims, and — separately — frees orphan medical devices with an overseas track record from years of post-market checks.

For international MedTech, this is not deregulation. It is the reverse. Korea is hard-coding its market gate. The rules become clearer and more predictable, and also more enforceable.

The 30-second point for an executive: a Korean market position is turning into a rules-based asset rather than a discretionary one. That rewards firms with a real quality system and disciplined documentation. It also opens a narrow, genuine lane for rare-disease device makers.

What Happened

Korea amended its Medical Device Act in 2025 to create a legal basis for the GMP conformity-recognition system. In April 2026 the MFDS issued a legislative notice for the enforcement rules that fill in the detail. The ministry framed the package as a way to stabilise device supply and to make its review system more transparent.

The central move is a promotion. GMP conformity-recognition standards, once governed by administrative notices, are being raised to the level of law. That fixes the review criteria, the procedures, and the qualifications a reviewer must hold. It also spells out, in more detail, what manufacturers and importers must submit.

The reform then turns to the certifiers. Designation and renewal procedures for quality-management review agencies are systematised. The MFDS commissioner must now publicly announce designations. The grounds for revoking a conformity recognition, and the requirements for corrective orders, are defined. Technical-document review agencies receive a four-year validity, must apply to renew 180 days before expiry, and are reissued certificates 30 days ahead when they still qualify.

The most striking provision sits in rare disease. Orphan medical devices — those serving Korean patient groups of fewer than 20,000, or conditions with no alternative therapy — may be exempted from post-market surveillance if they have a record of use abroad. That surveillance normally tracks safety and effectiveness over four to seven years. In small patient populations it is hard to complete, and it has caused supply to lapse. "This will help provide a more stable supply of medical devices needed by patients with rare and intractable diseases," said Kim Young-min, chairman of the Korea Medical Devices Industry Association (KMDIA), the domestic industry body. An MFDS official said the revision aims to "build a field-oriented, rational safety management system."

The amendment does not stand alone. Under its 2026 plan, the MFDS has said it wants the world's fastest approval system. It is cutting biosimilar reviews from as long as 420 days toward 240, building dedicated review teams and an AI review-support system, and shifting device-change approval to a "negative list" — only changes that affect safety or performance need clearance in advance. The same agenda institutionalises humanitarian access to high-cost orphan drugs and lengthens advance notice of shortages. The direction is consistent: faster at the front, firmer underneath.

Why It Matters

Start with the core shift. Korea is not loosening its device gate. It is re-basing it on statute. Written criteria, published designations, and defined revocation grounds reduce the discretion that once made outcomes hard for foreign applicants to predict. For a company planning a launch, predictability has a price, and Korea is now charging less for it.

Accountability rises in the same motion. The amendment adds sanctions for fraudulent conformity recognition and tightens oversight of distribution. A codified system is an enforceable one. A firm that treated Korean quality paperwork as a formality now faces a regime with legal teeth behind it.

The certifiers matter more to foreign firms than the headline suggests. Overseas manufacturers lean on Korea's designated review bodies for technical-document review and conformity recognition. Fixing those bodies in law — set validity, renewal deadlines, public designation — lowers the risk that a certifier loses standing in the middle of a review. It also turns the timing of designations into something worth tracking, because a lapsed or contested body can stall a file.

None of this removes the real barrier. Korea requires its own Korea GMP (KGMP) certification. An ISO 13485 certificate, or a clearance from the US or Europe, does not by itself open the market, and quality inspection often runs on-site. Elevating GMP conformity to law raises the documentation bar rather than lowering it. The advantage moves to firms that run a genuine quality system, not a paper one, and that can show it under a defined legal standard.

The orphan-device opening is small but real. Removing four to seven years of post-market surveillance for orphan devices with an overseas record cuts the cost of serving a tiny Korean patient pool. For niche and rare-disease device makers that had written Korea off as too expensive for the volume, the arithmetic changes. It is a targeted invitation, not a general one, and it favours companies that already sell the device elsewhere.

There is a portability dividend. Korea's regulator is gaining standing across Asia as a reference authority. A clean, statute-based Korean conformity record is easier to carry into markets that look to Korea when they judge a device. Codification makes the Korean stamp more durable, and more exportable, than a discretionary approval ever was.

Executive Summary

Korea has spent years approving medical AI. It is now paying to install it. In April 2026 the Ministry of Science and ICT (MSIT), the ministry that runs Korea's technology policy, opened applications for an "AI-specialised hospital" pilot. The programme funds whole-hospital adoption rather than a single diagnostic tool.

The budget is modest. Selected projects share 10 billion won, about $7.4 million, over two years. The intent is not modest. MSIT wants to move past point solutions that read one type of scan and toward an integrated system that touches diagnosis, treatment, hospital administration, and follow-up care. It calls this a "medical AI full-stack."

The pilot is one piece of a wider pattern. The health ministry is running its own AI programme for chronic disease. The disease-control agency has just started a five-year AI plan. Three arms of the Korean state are converging on the same idea at once.

For international healthcare and MedTech companies, the signal matters more than the money. Korea is defining what an AI-ready hospital looks like, and who gets to build one. The terms of that definition will shape which vendors sell into Korea for years.

What Happened

MSIT said in April 2026 it would accept applications until 26 May for the "AI-Specialised Hospital AX-Ready Pilot Program." AX is Korea's shorthand for "AI transformation." Selected consortia share a total budget of 10 billion won ($7.4 million) over two years.

The design is deliberate. Applicants must be consortia led by a public medical institution at general-hospital level or above. Each consortium must include an AI-solution company and a cloud-computing company. The programme funds an integrated package that follows the whole patient journey — diagnosis, treatment, administrative work, and prognosis management — rather than a tool aimed at one disease.

MSIT set three demonstration tasks: phased adoption and wider use of medical AI inside the hospital; a region-complete AI health-management platform that links care across institutions; and AI-driven automation of hospital operations with smart monitoring. The ministry framed the pilot as a test bed for models it intends to scale into a regional "AI-specialised hospital network." "This pilot program will serve as an opportunity to rapidly implement various AI technologies and solutions as integrated services," said Kim Kyung-man, director general of the AI Policy Bureau at MSIT.

The health system is moving in parallel. In April the Ministry of Health and Welfare (MOHW), which runs national health policy and insurance, launched a "Full-Cycle AI Transformation Project for Chronic Disease Patients" under its "AX Sprint" scheme. It covers five areas: daily diet and exercise coaching, primary-care support, data exchange between institutions, medical-image interpretation, and remote consultation. MOHW said it would publish a broader "AI Basic Medical Strategy" in the first half of 2026.

The pattern reaches public health too. On 7 July the Korea Disease Control and Prevention Agency (KDCA) launched a "Disease Control AI Transformation Committee" to write a mid- to long-term strategy for 2027 to 2031. It plans an integrated data platform, "Disease Data ON," by 2029, linking vaccination, infectious-disease, chronic-disease, and clinical and genomic data.

All of this sits on a regulatory base laid in 2025. Korea's Digital Medical Products Act, the first law written specifically for software-based medical products, gave digital therapeutics and software as a medical device a dedicated approval route under the Ministry of Food and Drug Safety (MFDS). Approval and deployment now advance on separate tracks. The state is funding the second.

Why It Matters

The strategic shift is from tools to systems. For most of the past decade, Korean medical AI meant discrete products: an algorithm that flagged a nodule on a chest X-ray, a triage aid in one department. Adoption was uneven, and many approved tools never reached daily use. The AI-specialised hospital model attacks that gap directly. It funds the integration, not the algorithm.

That changes what Korea is buying. A single-tool vendor sold a licence to a radiology department. A full-stack programme buys infrastructure, a platform, and a set of bound-together services. The mandatory role for a cloud company in each consortium is the tell. Korea is treating hospital AI as a platform problem, not a device problem. A vendor that sells one model will find the buyer now wants a stack.

The consortium rule also decides who is inside. Applications must be led by a public hospital and must pair an AI firm with a cloud provider. A foreign AI company that wants a share of this market needs a Korean hospital partner and, in practice, a cloud partner too. Entry runs through alliances, not direct sales. The firms that build those relationships early will hold the reference sites that later procurement rounds copy.

Weigh the money against the ambition. Ten billion won is a small sum for a national programme — enough to prove a model, not to equip a hospital system. That is the point. MSIT is buying a template, then intends to build a regional network on top of it. The commercial opportunity is not the pilot budget. It is the standard the pilot sets and the network it seeds.

The convergence of three agencies is the deeper signal. MSIT is funding hospital AI, MOHW is wiring AI into chronic-disease care, and KDCA is rebuilding disease surveillance around it. When a technology ministry, a health ministry, and a disease-control agency all adopt the same "AX" language in the same year, the direction is set at the level of the state, not the single hospital. For a foreign firm, that lowers the risk that AI demand disappears with one budget cycle. It raises the risk of being shut out of a standard defined without you.

One familiar caution holds. Korean approval and deployment funding do not yet guarantee payment. None of these programmes is national reimbursement, which still runs through the Health Insurance Review and Assessment Service (HIRA) on its own timetable. A pilot win builds evidence and reference accounts. It does not, by itself, create a reimbursed revenue line. The record on digital therapeutics — many approvals, few reimbursed products — is the reminder to plan for a separate, later payment campaign.

Executive Summary

Korea's digital therapeutics industry is starting to gather around a single place. Gyeonggi Province, the populous region that surrounds Seoul, has published a strategy to make itself the national hub for software that treats disease.

The plan arrived with a report from the province's economic-development agency and a claim to natural advantage. About four in ten of Korea's medical device companies already sit in Gyeonggi. So do major hospitals, technology firms, and the health data of 14 million residents. The province wants to convert that base into a cluster for digital therapeutics, known as DTx.

For international healthcare and MedTech executives, the interesting part is not the market forecast. It is the signal about where, and how, Korea intends to build this industry. A provincial government is now competing to own an emerging category, with its own ordinance, its own pilots, and its own money.

That changes the map for market entry. It also runs into an old wall. In Korea, national approval and national reimbursement are two different doors, and the second is still barely open for DTx.

What Happened

The Gyeonggido Business and Science Accelerator (GBSA), the province's industry-support agency, published a report in late April 2026 titled "Digital Therapeutics (DTx) Industry and Policy Trend Analysis and Implications for Gyeonggi Province." It set out both a market case and a plan.

Digital therapeutics are software-based medical devices that prevent, manage, or treat disease, usually through a smartphone app or an extended-reality programme. Instead of a drug, the mechanism is guided behavioural change. The appeal is speed and cost. A new medicine takes more than 15 years to develop, while a digital therapeutic can be built in about four, with fewer side effects.

GBSA framed the opportunity in global terms. Its report projected the worldwide DTx market at roughly $17.3 billion by 2030, growing more than 20 percent a year. In Korea, commercialisation is already underway, with 14 products cleared by the Ministry of Food and Drug Safety (MFDS), the national drug and device regulator, as of last year. Among them is Somzz, a treatment for insomnia.

The province's argument is that it holds the ingredients to lead. About 42 percent of Korea's medical device companies are clustered in Gyeonggi, alongside IT and biotech infrastructure, hospital-based clinical capacity, and a population of 14 million that generates health data at scale. Gyeonggi has also enacted the country's first ordinance dedicated to the digital medical products industry, giving the sector a legal footing at the provincial level.

The strategy itself is described as "full-cycle." The province plans to link public healthcare with industry, backing companies through clinical trials and commercialisation while creating demand on the other side. One proposal is a "digital welfare model" that would apply DTx for insomnia, depression, and anxiety to medically underserved residents, with the province covering the cost. GBSA also proposes advisory groups, training, and consulting to strengthen firms' regulatory capability.

All of this sits on top of a national framework that only recently took shape. Korea's Digital Medical Products Act, the first law written specifically for digital medical products, entered into force on 24 January 2025, with further provisions following in 2026. It gives software as a medical device and digital therapeutics a dedicated approval regime under MFDS rather than borrowing the rules written for physical devices.

Why It Matters

Start with the practical message for foreign companies. Geography now carries information. When a province concentrates the device firms, the hospitals, the data, and the supporting law in one place, it tells an entrant where partners, clinical sites, and pilot customers are easiest to find. For a European digital health company sizing up Korea, Gyeonggi is becoming the logical first address rather than one option among seventeen.

The deeper signal is political. Korea's central ministries have already treated advanced medicine as industrial policy. Now a subnational government is doing the same for a single software category, complete with its own ordinance and budget. That is a demand signal, not just a supply one. A province willing to pay for DTx pilots is a province creating a reference market, and reference markets are where new categories prove they can sell.

The wall, though, is real, and it is worth stating plainly. In Korea, clearance by MFDS lets a product reach the market. It does not mean the national health insurance system will pay for it. Reimbursement runs through a separate assessment by the Health Insurance Review and Assessment Service (HIRA) and the National Evidence-based Healthcare Collaborating Agency (NECA), the bodies that judge clinical and economic value. For digital therapeutics, that pathway is still young. Since August 2023, DTx have been reachable only through a temporary reimbursement arrangement while a permanent one is worked out. Fourteen approvals have not yet produced a settled way to get paid.

This is where the provincial move is clever, and where its limits show. Gyeonggi cannot set national reimbursement. What it can do is fund cost-supported pilots, connect companies to clinical data, and generate the real-world evidence that a national assessment later demands. The "digital welfare model" is, in effect, an evidence engine dressed as social policy. For a vendor, that lowers the cost and risk of the early years. It does not remove the eventual need to win over HIRA and NECA to reach national scale.

There is a note of caution the forecast invites. A $17.3 billion projection describes a market that is still mostly ahead of itself. Digital therapeutics have struggled worldwide to convert regulatory approval into durable revenue, precisely because payers move slowly and patient adherence is hard to sustain. Korea's own record, with more approvals than reimbursed products, fits that pattern. The Gyeonggi strategy is a serious attempt to build the demand side rather than wait for it. It is not proof the demand has arrived.

For international players, the read is simple enough to act on. Treat Gyeonggi as the entry cluster, use provincial pilots to build Korean evidence, and plan for the national reimbursement contest as a separate, later campaign. The province is lowering the barrier to getting in. It is not lowering the barrier to getting paid.

Executive Summary

Korea is reopening the rules that decide who can get its most sought-after diabetes drugs. The Korean Diabetes Association said in late April 2026 that health authorities are reviewing reimbursement criteria first written in 2011, with revisions possible by year-end.

The criteria in question gate access to GLP-1 receptor agonists, the drug class behind Novo Nordisk's Ozempic and, in obesity, Wegovy and Eli Lilly's Mounjaro. Under the current rules, a Korean patient reaches a reimbursed GLP-1 drug only after failing older medicines, clearing a blood-sugar threshold, and meeting a body-mass cut-off. Doctors say the sequence no longer matches how diabetes is treated.

The stakes are larger than one drug class. GLP-1 medicines are the fastest-growing category in global pharma, and Korea's private obesity market is already booming. A reimbursement reset would decide how much of that demand moves inside the insured system, and on what evidence.

For international pharma and MedTech, this is a market-access signal worth watching. Korea is weighing a shift from rigid step therapy toward criteria based on cardiovascular and kidney outcomes. That change would widen the eligible pool and reward drugs with proven organ-protection data.

What Happened

The trigger was a policy briefing by the Korean Diabetes Association (KDA), the country's main professional body for diabetes care. At a press conference in Seoul in late April 2026, the association said the Ministry of Health and Welfare (MOHW), Korea's health authority, and the National Health Insurance Service (NHIS), the single public payer, are assessing changes to diabetes drug reimbursement rules set in 2011. It said discussions also involve the Health Insurance Review and Assessment Service (HIRA), the body that assesses clinical and cost value, and that a financial-impact review is underway. The KDA expects the general principles to be revised by the end of the year at the latest.

The specifics show why the rules chafe. Ozempic, the injectable form of semaglutide, is reimbursed only after a patient has failed two to four months of metformin combined with a sulfonylurea, an older drug class now used less because of hypoglycaemia and weight-gain risk. The patient must also record an HbA1c, a measure of average blood sugar, of at least 7 percent, and either a body-mass index of at least 25 kg/m2 or an inability to use insulin.

The clinical objection is that the required sequence is out of date. The most common two-drug regimens in Korea now pair metformin with a DPP-4 inhibitor or an SGLT-2 inhibitor, not a sulfonylurea. The KDA wants reimbursement extended to those combinations, the BMI restriction eased, and access broadened for patients with cardiovascular disease, chronic kidney disease, or heart failure. Its central argument is that eligibility should rest on clinical benefit, such as preventing heart and kidney complications, rather than on blood sugar and body weight alone.

There is a deliberate wrinkle in the current design. Authorities wrote separate, tighter rules for Ozempic partly to prevent its diversion for weight loss, because semaglutide is also sold as the obesity drug Wegovy. That guardrail also catches diabetes patients who need to switch between GLP-1 drugs or adjust doses for medical reasons.

Two adjacent moves add momentum. From July 2026, pancreatic disorder becomes Korea's 16th recognised disability category, a designation that may cover many type 1 and some severe type 2 patients, though it will not by itself qualify them for the special copayment-reduction programme. Separately, the KDA is pressing to move continuous glucose monitors and insulin pumps from a pay-first, claim-back model to direct insurance coverage.

Why It Matters

Begin with scale. GLP-1 drugs are reshaping pharmaceutical revenue worldwide, and Korea is no exception. In 2025, Eli Lilly Korea's revenue jumped 193.6 percent to 482.1 billion won as Mounjaro passed 100 billion won in quarterly sales within months of launch. Novo Nordisk Korea's revenue rose 85.6 percent to 695.3 billion won, with Wegovy alone accounting for more than 70 percent of its sales. Much of that growth sits in the obesity market, which patients pay for privately. The reimbursement question decides how much of the diabetes demand runs through the insured system instead.

The proposed shift in logic is the real story. Moving from a fixed drug sequence toward criteria based on cardiovascular and renal outcomes would change what wins coverage. It rewards molecules with strong organ-protection evidence and penalises those that compete only on glucose control. For manufacturers, the lesson is that outcomes data, not just efficacy on blood sugar, becomes the route to a Korean listing. That aligns Korea with a global reimbursement trend and raises the evidentiary bar for anyone entering the category.

A wider eligible pool changes market size. Easing the BMI threshold and admitting the common metformin-plus-SGLT-2 or DPP-4 regimens would pull more patients into reimbursed GLP-1 therapy. That expands volume for the incumbents, but it also draws scrutiny to budget impact, which is why a financial-impact review is running in parallel. Expect any expansion to arrive with volume expectations, price negotiation, or risk-sharing attached. Korea rarely widens access without a cost-control lever in the other hand.

There is a device opportunity threaded through the same reform. The push to move continuous glucose monitors and insulin pumps to direct coverage would remove the cumbersome pay-first, claim-back barrier that currently dampens uptake. For diabetes-technology makers, direct reimbursement is the difference between a niche and a mainstream market. The disability-category change for pancreatic disorder points the same way, toward a system slowly widening structural support for severe diabetes.

The regional dimension should not be missed. Korea's negotiated prices feed reference-pricing systems across Asia. A reimbursement expansion that forces a sharper price negotiation on GLP-1 drugs could compress the regional benchmark that other markets cite. A generous listing does the opposite. Either way, the Korean decision will not stay inside Korea.

The caution is that none of this is settled. The KDA is an advocate, not the decision-maker, and the timeline it describes is a hope, not a schedule. MOHW, NHIS, and HIRA still have to agree on criteria and cost. But the direction is clear enough to plan around: Korea is trying to make its diabetes reimbursement rules look like current medicine, and the GLP-1 class is where the pressure is highest.

Executive Summary

Medtronic has signed a strategic partnership with Asan Medical Center, Korea's largest hospital, to expand clinical research, surgeon training and technology development around Hugo, its robotic-assisted surgery system. The agreement was signed on 6 May 2026 and announced by Medtronic Korea on 20 May.

On its face, this is one partnership around one platform. Strategically, it is a test of whether the world's most concentrated robotic-surgery market can host a second major player. Korea has been one of Intuitive Surgical's most loyal markets for two decades. It was the first country in Asia, and the second worldwide, to receive the latest da Vinci system. If a challenger can build clinical credibility anywhere in Asia, Korea is where the evidence accumulates fastest.

For international MedTech executives, the more durable lesson is the route Medtronic chose. It did not lead with price or procurement. It signed the country's highest-volume surgical institution as a research and training partner. In a hospital market where purchasing follows clinical relationships, that is what market entry looks like.

What Happened

Medtronic and Asan Medical Center agreed to cooperate on clinical research, training and technology development around the Hugo robotic-assisted surgery system, Medtronic's modular soft-tissue surgery platform. The agreement gives Medtronic a flagship Korean hospital partner as it works to broaden Hugo's use in Asia and other global markets.

Hugo is the most serious commercial challenger yet to Intuitive Surgical's da Vinci franchise, which has defined robotic soft-tissue surgery since the early 2000s. The system was approved in Korea in 2024 for laparoscopic and endoscopic procedures, including radical prostatectomy and gallbladder removal, and performed its first commercial procedure in the country in 2025. Its design differs from the da Vinci in two visible ways: an open console that lets the operating surgeon see and speak with the bedside team, and modular arm carts that can be positioned independently around the patient.

The Korean agreement follows a pivotal period for the platform globally. In December 2025, the US Food and Drug Administration cleared Hugo for urologic procedures — prostatectomy, nephrectomy and cystectomy, which together account for roughly 230,000 operations a year in the United States. Cleveland Clinic performed the first US commercial Hugo-assisted radical prostatectomy in February 2026. Outside the United States, Medtronic says the system has been used in urology, gynaecology and general surgery across more than 30 countries.

Asan Medical Center brings exactly what a challenger platform lacks: procedural volume and clinical authority. The Seoul hospital has performed more than 3,000 robotic colorectal cancer operations since 2010, within a colorectal programme of close to 39,000 cases. Korea's robotic adoption runs deep by international standards. Roughly 28 percent of the country's rectal cancer surgeries were performed robotically by 2023, and robotic platforms are concentrated in tertiary hospitals that handle most complex surgical volume.

The incumbent is not standing still. Intuitive has operated in Korea for about two decades, opened a Seoul training centre in 2017 that now trains surgeons from across Asia and the United States, and chose Korea as the first Asian market for its da Vinci 5 system after approval in October 2024. Severance Hospital alone has completed more than 40,000 robotic cases.

Why It Matters

The partnership shows what Korea has become in surgical robotics: not just a sales market, but an evidence engine. A handful of Korean hospitals concentrate more robotic procedures per surgeon than almost anywhere else. When a platform needs clinical publications, refined technique and trained advocates quickly, Korean volume delivers them faster than fragmented Western markets, where few surgeons exceed even thirty robotic cases a year. Medtronic is buying credibility production, not just placement.

For hospital buyers, a credible second platform changes negotiating dynamics. Korean tertiary hospitals have bought robotic systems for twenty years from what was effectively a single vendor. Even hospitals that never buy a Hugo system gain leverage from its existence — on system pricing, instrument costs and service contracts. The timing sharpens this effect. The US International Trade Administration expects Korea's medical device market to rebound in 2026 as hospitals resume capital procurement deferred during the long doctors' strike. Competitive tension is arriving exactly when purchasing resumes.

The choice of partner is a template other entrants should study. Korean hospital procurement is relationship-driven, and clinical champions matter more than tender terms. Medtronic's approach — anchor the platform at a flagship academic centre, invest in training and research, let reference cases pull demand — mirrors the playbook Intuitive used to build its Korean position. The lesson generalises beyond robotics: in Korea, the flagship partnership is the market entry.

The economics still carry a Korea-specific risk. Robotic surgery in Korea has largely been financed outside National Health Insurance coverage, with patients paying most costs directly. That private-pay channel funded the country's rapid robotic adoption, but it is precisely the kind of high-priced non-covered care the government has begun to squeeze — from July 2026 it started fixing prices for selected non-covered services. Nothing announced touches robotic surgery today. But any vendor building a Korean robotics business should model a future in which non-covered pricing is no longer free.

There is also a signal about direction of travel. Korean surgeons now train American surgeons; Korean hospitals serve as global reference sites; Korean procedural data feeds regulatory and clinical arguments worldwide. The country is exporting surgical expertise as much as it imports surgical machines. Vendors that treat Korean partners as co-developers, rather than customers, are reading the market correctly.

Executive Summary

Korea is closing the gap that let providers charge freely for care its national insurance never covered. Two reforms, arriving weeks apart, do the work.

On the demand side, a fifth-generation medical indemnity insurance product launched in early May 2026. It cuts premiums sharply, but only by stripping coverage for non-covered treatments such as manual therapy, extracorporeal shock wave therapy, and non-reimbursable injections. On the supply side, from 1 July 2026 the Ministry of Health and Welfare pulled manual therapy into a new "managed benefit" category, fixing its price at 43,850 won per session and capping how often patients can receive it.

The combined effect is a two-sided squeeze on Korea's large non-covered care market. Patients face higher out-of-pocket costs and lower private reimbursement. Providers face a regulated price where they once set their own. Within a day of the July rule, hospitals began halting manual therapy altogether.

For international healthcare and MedTech companies, the signal is bigger than one treatment. Korea has built a tool to reach into the private-pay market it could not previously control, and manual therapy is the first test. The channel that many devices and procedures relied on to earn revenue outside the reimbursement system is narrowing on purpose.

What Happened

Two separate arms of the Korean state moved on the same target: the money that flows outside national health insurance.

The first move came from the Financial Services Commission (FSC), Korea's financial regulator. On 5 May 2026 it detailed the launch of fifth-generation medical indemnity insurance, the private "real-loss" cover that roughly 40 million Koreans hold to reimburse out-of-pocket medical costs. The new product cuts premiums by at least half against first- and second-generation plans, and about 30 percent against the fourth generation. It funds those cuts by narrowing coverage. Manual therapy, non-reimbursable injections, and extracorporeal shock wave therapy are excluded. The annual cap for non-severe, non-covered items falls to 10 million won, from 50 million won under the fourth generation, and the patient's out-of-pocket share rises to 50 percent from 30 percent.

The reason is cost. According to the FSC, indemnity insurance payouts jumped 81 percent, from 8.4 trillion won in 2018 to 15.2 trillion won in 2024, driven by heavy use of a handful of non-covered items. Insurers raised premiums by an average of 7.8 percent this year in response. To move existing policyholders onto the leaner product, authorities added a 50 percent premium discount for three years for those who switch, and plan an "optional rider" from November 2026 that lets older policyholders drop the same non-covered items for a lower premium.

The second move came from the Ministry of Health and Welfare (MOHW), Korea's health authority. From 1 July 2026 it reclassified manual therapy as a "managed benefit." This mechanism is the important part. Managed benefit brings a non-covered service inside the insurance framework when its medical necessity is accepted but its overuse is a concern. It does not fully reimburse the service. Instead it standardises the price and controls the volume, with the patient carrying most of the cost.

For manual therapy the numbers are concrete. The price is now fixed at 43,850 won per session, against a previous average of about 110,000 won that varied widely between clinics. The patient pays 95 percent and national health insurance pays 5 percent. Coverage runs to twice a week and 15 times a year, extendable to 24 sessions for patients recovering from surgery or fractures, and only after basic physiotherapy has been tried at least four times over two weeks without improvement.

The trigger for the crackdown is visible in one figure. In 2024, private insurers paid out 1.39 trillion won on manual therapy alone, the single largest category of indemnity claims. Within a day of the rule taking effect, orthopedic and pain clinics in Seoul posted notices suspending the treatment, citing weakened profitability. The Korean Medical Association warned of clinic restructuring and reduced patient access. MOHW says it will review the system in the second half of 2026.

Why It Matters

Start with the structure the reform is aimed at. Korea's national health insurance is broad but shallow on many services, and a large private-pay layer grew up around the gaps. Indemnity insurance quietly financed that layer, reimbursing patients for treatments the state did not cover. For years this was the channel through which devices, procedures, and therapies that could not win national reimbursement still generated real revenue. The two reforms attack that channel from both ends at once.

The demand side matters first. When private insurance stops reimbursing an item and lifts the patient's out-of-pocket share to 50 percent, utilisation falls. Patients ration what they now pay for directly. Any product whose sales depend on high-volume, insurance-financed, non-covered use should expect that volume to compress as fifth-generation policies spread and older policies are converted.

The supply side matters more, because managed benefit is a new kind of instrument. Korea's system used to be binary: a service was either reimbursed or non-covered, and non-covered meant providers set their own price. Managed benefit creates a middle lane. The state can now reach into a lucrative non-covered service, fix its price, cap its volume, and leave the cost mostly with the patient, without committing to reimburse it. That is a durable tool, and manual therapy is the pilot.

The precedent is the point for MedTech planners. The items named across both reforms overlap and repeat: manual therapy, extracorporeal shock wave therapy, non-reimbursable injections, and non-covered MRI. These are the high-payout categories, and they are the obvious next candidates for the managed-benefit treatment. Companies with exposure in physical rehabilitation, pain management, shock wave equipment, injectable therapies, and elective imaging should map how much of their Korean revenue rides on the non-covered channel, and stress-test it against a fixed price and a volume cap.

There is an opportunity inside the pressure. A system that is deliberately draining low-value, high-volume non-covered care will reward technologies that can demonstrate outcomes and win a formal reimbursement or managed-benefit listing. Evidence becomes the currency that access used to be. Products that reduce unnecessary utilisation, or that can substitute for a capped service with a better-documented one, are positioned for a market that is being pushed toward value.

The caution is timing and reach. The medical community is already pushing back, and MOHW has left room to adjust the manual-therapy rules later in 2026. The exact price points and caps may soften. The direction is unlikely to. Korea has decided that its private-pay market is a policy problem, not a free market, and it has built the machinery to manage it item by item.

Executive Summary

Korea is quietly changing the rules for what counts as a certified senior-care product. On 26 June 2026, the Ministry of Health and Welfare opened public comment on an amendment that would broaden its "excellent senior-friendly" product designation to include artificial intelligence, connected devices, and robotics.

The change looks technical. It is strategic. Today the designation rests on a fixed list of 36 eligible items. The amendment replaces that list with seven function-based fields defined by what a product does for an older person, not what category it belongs to. A device that helps with mobility, safety, or cognitive support can qualify, whether it is a walker or a sensor-driven monitoring system.

For international healthcare and MedTech companies, this is a market-access signal in the world's fastest-ageing major economy. Korea is building a formal quality mark that AgeTech, digital health, and care-robot makers can now compete for. The mark shapes visibility, procurement, and credibility in a market that Korea intends to grow deliberately.

The window to influence the rules is short. Comments close on 13 July 2026.

What Happened

The Ministry of Health and Welfare (MOHW), Korea's senior health authority, issued an administrative notice on 26 June 2026 proposing to amend the "excellent senior-friendly" product designation under the Senior-Friendly Industry Promotion Act. The law governs how Korea supports and certifies products made for older citizens.

The core of the amendment is a shift from a closed list to an open framework. The current designation covers 36 specified items. The proposal replaces that list with seven function-based fields: posture, mobility, safety, hygiene, excretion, meals, and cognitive or emotional support. Products are judged by the function they serve rather than by a pre-set product type.

The practical effect is scope. Because the fields are defined by function, AI-driven, IoT-based, and robotic products become eligible for the first time. A fall-detection sensor, a medication-reminder system, or an emotional-support robot can now be assessed against the same mark that once applied mainly to conventional aids and equipment.

The amendment also sets out the machinery around the mark. It defines procedures for application, review, appeal, and re-evaluation. That detail matters. A designation with clear rules for how to apply, how to contest a rejection, and how status is renewed is one that companies can plan around.

MOHW has opened the proposal for public comment until 13 July 2026 before finalising it. This is the standard Korean rule-making step, and it is a genuine chance for industry to shape definitions and evidence requirements before they harden.

The move does not stand alone. In April 2026, MOHW and the Ministry of Science and ICT jointly announced an "AI Care Technology Full-Cycle Support Strategy," which frames AI and IoT as tools to offset a care-worker shortage, with physical-AI robotics targeted from 2028 and long-term care insurance and voucher reform meant to follow. The designation amendment fits that direction. It is the market-access piece of a broader industrial push.

Why It Matters

The first point is demographic weight. Korea became a "super-aged" society at the end of 2024, when more than a fifth of its people passed 65. It reached that mark in roughly seven years, against eleven for Japan, on the back of the world's lowest fertility rate. The care system is under strain, the average nursing-care assistant is in their sixties, and the government has declared a population emergency. This is not a niche market being tidied up. It is a national priority searching for supply.

The second point is what a designation actually buys. In Korea, an official quality mark carries more weight than in many Western markets. It signals state endorsement to conservative institutional buyers, supports inclusion in public programmes, and helps products stand out in a crowded field where trust is scarce. Opening the mark to AI, IoT, and robotics means these categories can now earn that signal. For a foreign AgeTech vendor, the designation is a credential that can shorten the long trust-building cycle Korean procurement usually demands.

The third point is the function-based logic. A closed list of 36 items favours established product types and lags behind innovation. A framework organised around function, posture, mobility, safety, and the rest, is built to absorb technologies that did not exist when the law was written. This is a more durable and more open door. It rewards companies that can show measurable benefit against a defined need, rather than those that happen to fit a legacy category.

The fourth point is competitive, and it deserves caution. Korean industrial policy consistently favours domestic suppliers, and the parallel AI care strategy is designed in part to build home-grown champions, with the robotics phase pointed at Korean firms from 2028. Foreign companies with a nearer-term advantage in software, sensing, and monitoring may find the current window more open than the robotics phase that follows. The designation is an opportunity, but it sits inside a system that is also trying to grow its own.

A final caution concerns the gap between a mark and a market. A designation is not reimbursement. Korea's long-term care insurance and voucher systems are still being reformed to pay for these technologies, and that reform is the harder, slower part. A product can earn the seal and still wait for the payment pathway that turns endorsement into volume. The mark is necessary. It is not sufficient. The companies that benefit most will treat the comment period as the moment to shape both the designation and the reimbursement logic that must eventually sit behind it.

Executive Summary

For decades, the most advanced medicine in Korea has been concentrated in a handful of Seoul hospitals. Patients with serious illness travel to the capital because that is where the proton beams, the surgical robots, and the senior specialists are. The government now wants to change that, and it is putting equipment budgets behind the intention.

In March 2026, the Ministry of Health and Welfare committed 74.2 billion won, about 52 million US dollars, to strengthen severe and complex care at regional hub hospitals outside the capital region. The money buys intensive care capacity, advanced cancer equipment, robotic surgical systems, and a hybrid operating theatre, spread across national university hospitals in the provinces.

The sum is modest. The signal is not. This is one step in a multi-year programme to build what the ministry calls a regionally complete medical system, where a patient can finish severe treatment near home rather than boarding a train to Seoul.

For international MedTech companies, the strategic point is about geography, not headline numbers. The set of Korean hospitals that buy high-end capital equipment is widening. For years the practical buyer map was the Seoul big five. It is now extending to roughly seventeen regional centres, and the budgets that follow them.

What Happened

The Ministry of Health and Welfare (MOHW), Korea's senior health authority, announced in early March 2026 that it would allocate 74.2 billion won to regional hub medical institutions. These hubs are mostly national university hospitals, designated across the country's seventeen metropolitan cities and provinces. Their job is to handle high-complexity essential care and to coordinate the smaller hospitals around them.

The spending is concrete and named. Pusan National University Hospital, Kangwon National University Hospital, and Jeonbuk National University Hospital receive support to expand intensive care units, so critical patients can be treated within the first hour. Kyungpook National University Hospital and Jeju National University Hospital build intensive care units for high-risk pregnant women. Chungbuk National University Hospital expands its paediatric emergency centre and paediatric ICU.

The capital-equipment items matter most for vendors. Chonnam National University Hospital receives robotic surgical systems. Chungnam National University Hospital installs a hybrid surgical system that allows real-time imaging and surgery in the same room. Most striking, Chilgok Kyungpook National University Hospital will introduce proton therapy, an advanced radiation technique that until now has been installed only at select hospitals in the Seoul metropolitan area.

This is not a one-off line item. MOHW has run facility and equipment support for regional hubs since 2025, and a second round of applications opens this year. It also sits inside a larger fiscal direction. The ministry's 2026 budget proposal, set at 137.64 trillion won, a 9.7 percent rise on 2025, lists expanding regional, essential, and public healthcare among its five core investment themes. Within that, support for regional responsible medical institutions rises by 14.1 billion won to 95.6 billion won, and regional cancer and cardiovascular centres gain operating and equipment funds.

The reasoning is demographic and political. Korea is a super-aged society with widening gaps between the capital and the provinces. Severe-trauma survival rates already vary sharply across the seventeen regional centres. The government's answer is to push capability outward, so that geography matters less to whether a patient lives.

Why It Matters

The first implication is the buyer map. International MedTech firms have long treated Korea as a Seoul story. The Asan, Samsung, Severance, Seoul National, and Catholic systems anchor the premium market, and a foreign sales plan that covered them covered most of the addressable spend on high-end devices. A deliberate, funded effort to seat proton therapy, surgical robotics, and hybrid theatres in provincial national university hospitals changes that calculus. The number of credible buyers for flagship capital equipment is growing, and growing in places foreign vendors have historically under-served.

The second implication is the product mix the programme rewards. This is not a digital-health or consumables story. The named purchases are heavy capital goods: radiation oncology platforms, robotic surgery, hybrid operating rooms, and ICU build-outs. Companies in oncology equipment, surgical robotics, advanced imaging, and critical-care systems have the clearest near-term opening. The buyers are public national university hospitals, which means formal tenders, specification-driven evaluation, and procurement cycles measured in budget years rather than quarters.

The third implication is service and installed-base economics. Proton therapy and hybrid theatres are not delivered and forgotten. They demand installation, training, maintenance contracts, and local clinical support, often for a decade or more. A regional hospital taking on this equipment for the first time needs a partner that can support it far from Seoul. Vendors with thin provincial service footprints will struggle to win or to keep these accounts. Those willing to invest in regional field engineering and clinical education gain an advantage that is hard to copy.

The fourth implication is competitive, and it cuts both ways. Korea's industrial policy favours domestic suppliers, and a parallel 645 million US dollar medical-device R&D programme is steering money toward home-grown AI and robotics. In imaging and some surgical categories, Korean firms are credible and politically preferred. But proton therapy and several advanced platforms remain dominated by foreign manufacturers, and foreign devices still account for the large majority of equipment in elite Korean hospitals. The regional build-out opens doors precisely in the high-end categories where domestic substitutes are weakest.

A note of proportion is warranted. This single allocation is small against the size of Korea's device market, and a budget proposal is not yet money in a hospital's account. National Assembly review can reshape figures, and a decentralisation drive that has run for years will take more before provincial hubs rival Seoul. The trend is real, but it is a multi-year reweighting, not an overnight shift. The thing to track is repetition: whether the second application round, and the 2027 budget, keep pushing capital equipment outward.

Executive Summary

Korea has changed who is allowed to run an MRI scanner. For years, a hospital needed a full-time radiologist on staff to install and operate one. From 17 June 2026, a single part-time radiologist will do.

The Ministry of Health and Welfare (MOHW), which sets the rules for hospitals and what the national insurer pays, revised the enforcement rule under the Regulations on the Installation and Operation of Special Medical Equipment. The aim is access. Many hospitals outside the big cities own MRI machines but cannot recruit a dedicated specialist to satisfy the staffing rule, leaving capacity idle. Loosening the rule is meant to switch that capacity on.

The same policy direction carries a second edge. The government is also moving to adjust reimbursement rates for imaging and laboratory tests. Korea's radiologists have objected to both, arguing the package treats diagnostic imaging as a cost-containment problem rather than a clinical one.

For international MedTech, the signal is concrete. A wider population of facilities can now operate MRI, the value of remote and AI-assisted image reading rises, and the price of imaging is under pressure. Each pulls a different part of the diagnostics market.

What Happened

Under the previous rule, a medical institution operating an MRI scanner had to employ at least one full-time radiologist. Full-time meant a physician working at least four days a week and a minimum of 32 hours. That requirement was hard to meet outside metropolitan areas, where radiology specialists are scarce. The result was a paradox: hospitals held the equipment but could not legally use it at full tilt.

The revised rule lowers the threshold sharply. MRI services may now be operated if at least one radiologist works in a non-exclusive capacity for at least one day per week, or for at least eight hours per week. The word non-exclusive matters. A radiologist no longer has to be tied to a single institution. One specialist can satisfy the staffing requirement at more than one site.

MOHW framed the change as relief for regional small- and mid-sized hospitals struggling to recruit. Kwak Soon-heon, the ministry's Director General for Healthcare Policy, said the revision should let providers "operate MRI services more smoothly in clinical settings," paired with a promise to strengthen imaging quality management so patients still receive high-quality examinations.

That quality promise is the counterweight. Korea's quality assessment agencies already run periodic inspections of MRI and other advanced imaging devices, covering personnel, facilities, record-keeping and image quality through phantom testing and clinical image review. The ministry now plans to refine that system: subdividing the evaluation process, registering dedicated inspection agencies separately, and adding indicators for equipment aging. Older MRI units will face a stricter, differentiated oversight framework. A further amendment formalising these quality measures was due to be preannounced within the month.

The reception was not uniform. On 18 June, the Korean Association of Radiologists called for the revision to be suspended and reconsidered. The group argued that the rules relaxed staffing without first publishing clear standards for interpretation responsibility, quality control, emergency response and post-management. If a full-time requirement had to be eased at all, it said, the change should be narrow — limited to underserved areas or single-unit facilities. The association also attacked the government's plan to adjust imaging and laboratory reimbursement, warning that across-the-board cuts could erode examination quality, drive essential staff away, and widen regional gaps in care.

Why It Matters

Start with the installed base. MRI is among the most expensive devices a hospital buys, and a machine that cannot be staffed is a stranded asset. By detaching MRI operation from a full-time radiologist, Korea makes the scanner viable at a wider set of facilities — exactly the regional and mid-sized hospitals that were previously locked out. For MRI manufacturers and their service partners, the addressable market for scanners, coils, maintenance contracts and contrast media broadens. A rule that turns idle capacity into billable capacity tends to support utilisation, and utilisation is what justifies the next purchase.

The more interesting effect is on reading, not scanning. If one radiologist now covers several sites on a part-time basis, someone or something has to bridge the gap between when an image is captured and when it is expertly interpreted. That is the natural habitat of teleradiology and AI-assisted image analysis. Korea already clears AI tools that triage and draft radiology reports, and demand for imaging support has been building. A staffing rule that spreads scarce radiologists thinner increases the practical need for software that helps them read more studies, faster, across more locations, without dropping quality. Vendors of AI radiology and remote reading should read this rule as a tailwind.

Then there is price. The staffing change arrives alongside a plan to adjust imaging and laboratory reimbursement. The direction of travel — more scanners running, tighter unit economics — is a classic payer move: expand access while containing the per-test cost. For device and diagnostics companies, that compresses margins on the imaging itself and rewards anything that lowers the cost per read or proves value at the system level. It also raises the stakes on the quality regime. With older machines under stricter oversight and new aging indicators coming, equipment refresh cycles and compliance-grade quality tools gain importance.

A note of proportion belongs here. This is an enforcement-rule change, not a wholesale redesign of imaging policy, and the quality amendments that are supposed to balance it were still being formalised. The professional pushback is real and could narrow the rule in practice. The parts to watch are concrete: how the promised quality framework is written, how far imaging reimbursement is actually cut, and whether the relaxed staffing standard stays broad or is confined to underserved areas. Each of those decisions moves the size of the opportunity.

For international readers, the broader lesson is about how Korea manages a workforce shortage. Rather than wait for more radiologists, the system is changing the rules around the ones it has — and leaning on equipment and software to fill the gap. That is a recurring pattern in Korean healthcare, and it consistently favours technology that substitutes for scarce specialist time.

Executive Summary

Korea has decided that selling health products to the world is a national project. In 2025 the country's biohealth exports — pharmaceuticals, biotech, medical devices and cosmetics combined — reached a record $27.9 billion. The government has set a 2026 target of $30.4 billion and is putting real money behind it, raising its support budget more than threefold.

The headline is impressive. The composition is the more useful intelligence. Two engines do almost all the work: biopharmaceuticals, much of it made under contract for foreign drug owners, and K-beauty cosmetics. Medical devices, the segment most international MedTech executives care about, remain a small and slower-growing slice. The customer base is also narrow, concentrated in a handful of US and European markets.

For international healthcare leaders, the strategic point is not that Korea exports a lot. It is what Korea exports, to whom, and what the government is now funding it to export next. Read correctly, the figures say more about Korea as a manufacturing and licensing partner than as a device rival — and they flag where the state intends to compete in the next cycle.

What Happened

In March 2026 the Ministry of Health and Welfare (MOHW), Korea's senior health authority, held a roundtable with industry to report the prior year's export performance and set the year ahead. Total 2025 biohealth exports came in at $27.9 billion, up 10.3 percent, the highest on record. That places biohealth eighth among Korea's major export industries, behind semiconductors ($173.4 billion), automobiles, machinery, petroleum products, petrochemicals, ships and steel.

Pharmaceuticals led. Drug exports passed $10 billion for the first time, reaching $10.4 billion. Biopharmaceuticals — biologics, biosimilars and contract-manufactured product — made up 62.6 percent of that and have grown roughly tenfold over the past decade. The United States, Switzerland and Hungary together took 39.5 percent of all biohealth exports, a concentration that reflects how much of the growth is biologics shipped into a few advanced markets.

Medical devices told a quieter story. Exports showed a recovery in in-vitro diagnostics and steady growth in general devices, with the United States, China and Japan accounting for a third of the total. First-quarter 2026 data, published by the Korea Health Industry Development Institute (KHIDI), the MOHW's industry-promotion agency, sharpened the picture. Biohealth exports rose 14.4 percent year on year to $7.3 billion. Cosmetics jumped 21.5 percent to a record $3.13 billion. Pharmaceuticals reached $2.71 billion. Medical devices grew 5.6 percent to $1.46 billion — the smallest of the three segments and the slowest-growing. Within devices, in-vitro diagnostics actually fell 6.1 percent, while ultrasound imaging systems, a genuine Korean strength, rose to $230 million.

Separate provisional data from the Ministry of Food and Drug Safety (MFDS), the drug and device regulator, underlined the biologics story: first-quarter biopharmaceutical exports hit a record $2 billion, with Switzerland overtaking the United States as the top destination as European demand for biosimilars and licensing deals climbed.

The state response is financial. For 2026 the MOHW set the $30.4 billion target and committed 233.8 billion won in support, a 3.5-fold increase. The money is aimed: a planned one-trillion-won mega-fund for domestic new-drug development, a dedicated 150-billion-won fund for late-stage phase 3 trials, more than one trillion won in national health R&D, a reformed Innovative Pharmaceutical Company Certification scheme, and a supply-chain stabilisation system for essential medicines. For devices, the plan centres on a Comprehensive Medical Device Industry Support Center and an AI-based Surgical Robot Innovation Lab running to 2030. "We will support the biohealth industry to grow into a major export sector, serving as a second pillar of growth after semiconductors," Second Vice Minister Lee Hyung-hoon said.

Why It Matters

The first read is about identity. Korea's export strength in health is, overwhelmingly, a manufacturing and biologics story. Biopharmaceuticals and contract production carry the pharma line; cosmetics carry the consumer line. For a foreign company, the most immediate opportunity is therefore partnership rather than competition: Korea is one of the best places in the world to have a biologic made, a biosimilar developed, or a brand manufactured at scale. The export figures are, in effect, a prospectus for Korea as a supplier to other people's pipelines.

The second read is the device gap. Korea has repeatedly stated an ambition to become a top-tier medical-device exporter, yet device exports sit at roughly $1.46 billion a quarter and grow in the mid-single digits, with diagnostics slipping. The strength is concentrated in a few categories — ultrasound, some imaging and electro-medical devices — not across the board. For international MedTech, this is reassuring in the near term. Korea is a formidable contract manufacturer and a rising force in selected imaging niches, but it is not yet exporting a broad, premium device portfolio that would displace established Western and Japanese suppliers in third markets. The competitive pressure is real but narrow.

The third read is concentration risk, and it cuts both ways. Korea's biohealth exports lean heavily on a few destinations and a few product classes. European demand, especially for biosimilars, is doing much of the lifting, while shipments to the United States have wobbled. That makes the whole export story sensitive to US trade policy, to pricing pressure in Europe, and to softening cosmetics demand in China. A company relying on a Korean CDMO should understand that its supplier sits inside the same concentrated, policy-exposed system — a strength in calm conditions, a shared vulnerability in turbulent ones.

The fourth read is where the public money points. State funding is the clearest signal a government gives about the markets it intends to win. Korea is putting capital into new-drug development, late-stage trials, biosimilar competitiveness and, on the device side, AI-enabled surgical robotics. The surgical-robot lab in particular is worth marking: it names a category where Korea wants to move from importer to exporter over the next five years. For incumbents in robotic surgery and AI imaging, that is a notice of intent, not a current threat — but the lead time to take it seriously is now.

The caveats are ordinary but real. Targets are aspirations, not results; the 2026 number may be helped or hurt by currency and by a single large contract. And national-champion funding tends to favour domestic firms first. The direction, though, is set and paid for.

Executive Summary

Korea is moving to give its biopharmaceutical contract manufacturers something most countries never bother to legislate: a regulatory regime built specifically to help them export. The Ministry of Food and Drug Safety (MFDS), Korea's drug and device regulator, is preparing the implementing rules for a new Special Act on Regulatory Support for Contract Development and Manufacturing Organizations for Biopharmaceuticals. The law was promulgated in late 2025 and takes effect by the end of 2026.

The headline is not a single approval or a single plant. It is the decision to treat contract manufacturing as a category of national policy. Korea already hosts two of the largest biologics manufacturers in the world. The state is now writing rules whose explicit purpose is to make those plants faster to certify, easier to supply, and more credible to foreign buyers and regulators.

For international pharma, the strategic read is about leverage. When a government turns its regulator into an export-support agency for an industry it has decided to win, the terms on which everyone else competes — for capacity, for partners, for regulatory recognition — begin to shift.

What Happened

The MFDS confirmed the plan in its 2026 key work programme. Ahead of the Special Act taking effect, the agency is drafting the subordinate regulations and building the computer systems needed to run them.

The core change is a new registration system for export-oriented biopharmaceutical manufacturing. Korea's Pharmaceutical Affairs Act, the country's foundational drug law, never contained one. Plants making product purely for export sat in a legal grey zone. The Special Act creates a formal category for them, with facility standards designed for export-focused work and a statutory basis for good manufacturing practice (GMP) certification and active pharmaceutical ingredient (API) certification at contract sites. GMP is the international quality standard that governs whether a plant may make medicines at all; putting its certification on a clear legal footing is what lets a Korean site reassure a foreign client and a foreign regulator at the same time.

Around that core sit a set of friction-removing measures. Customs procedures for importing the APIs that contract manufacturers depend on will be streamlined. The MFDS will offer pre-consultation services before GMP certification and technical advice for manufacturing facilities. A dedicated computer system will process the new filings — export-manufacturing registration, GMP and raw-material certification — and a standing CDMO Regulatory Support Task Force will pull together staff from MFDS headquarters, its regional offices, and the Vaccine Center for Assisting Safety & Technology.

The agency is pairing this with faster approvals. It has set a long-term goal of completing reviews of new biologics and biosimilars within 240 days, through more reviewers, earlier consultations, selective parallel reviews, and shorter GMP inspection periods. For biosimilars specifically, it is working through a Public-Private Consultative Body to rationalise clinical trial requirements in line with global trends. And it is preparing forward-looking rules for the next manufacturing wave: expanded testing infrastructure for mRNA vaccines, manufacturing standards for antibody-drug conjugates (ADCs), and a phased roadmap for AI-based gene therapies.

The export logic extends to regulatory diplomacy. In August 2025 the MFDS completed full-function listing on the World Health Organization's World List of Authorities, the WHO's register of regulators judged to meet international standards across the drug lifecycle. In January 2026 the United Arab Emirates designated the MFDS an official reference authority — placing Korea alongside the bodies whose approvals the UAE will lean on. Reference-country status can mean partial exemption from submission requirements, shorter reviews, and waived or simplified site inspections worth six months to a year. The Philippines, Egypt, and Ecuador already reference Korea in their own systems. "The biopharmaceutical industry is a national strategic sector that underpins future health security and global competitiveness," the MFDS said.

Why It Matters

The first point is what this signals about Korea's ambition. Contract manufacturing is usually treated as plumbing — necessary, low-glamour, lightly regulated as an export activity. Korea is treating it as strategic infrastructure, on the same footing as semiconductors or batteries. Samsung Biologics, the largest of the Korean players, reported record revenue and a profit milestone on the back of CDMO demand, and Lotte Biologics is building out mega-plants in Songdo. A bespoke legal regime is the policy layer that sits on top of that physical capacity. The combination — scale plus statute — is what competitors in the United States, Europe, and elsewhere in Asia will have to answer.

The second point is speed, and what speed is worth. A site that can be certified faster, supplied with imported APIs through lighter customs, and inspected on a shorter clock is a site that can take on a client's project and move it to commercial supply sooner. In contract manufacturing, time-to-batch is the product. Western biotechs and large pharma choosing where to place a manufacturing contract weigh exactly these frictions. Korea is legislating them down on purpose. For a company deciding between a Korean CDMO and an alternative, the regulatory environment has just become a reason to choose Korea rather than a reason to hesitate.

The third point is the reference-country mechanism, which is easy to underrate. When Korea's regulator is accepted as a reference by other governments, a product made and approved in Korea carries that credibility into those markets. A Korean-manufactured biologic can reach the UAE, and potentially the wider Middle East and North Africa, with fewer duplicated submissions and inspections. For a foreign drug owner, manufacturing in Korea is no longer only a cost-and-capacity decision. It can shorten the path into a string of third markets. That is a genuinely different value proposition from "we have open suites."

The fourth point is positioning in a nervous supply chain. Global biomanufacturing is being reshaped by trade risk, by US legislation aimed at certain offshore providers, and by every drug owner's wish for a second source outside their home region. Korea is presenting itself as the credible, rules-based, internationally referenced alternative — and writing the law to prove it. For international companies, the opportunity is dual-sourcing and capacity security; the risk is that the best Korean slots, like the best slots anywhere, go to the partners who engage while capacity is still being allocated.

The caveats matter. This is an enabling framework, not a finished one — the subordinate regulations and systems are still being built through 2026, and the 240-day approval target is a goal, not yet a guarantee. Capacity is finite, and a national champion strategy can favour domestic relationships. But the direction is unambiguous, and it is set in statute.

Executive Summary

Korea has decided that elderly care is no longer only a welfare question. It is now a technology and industrial one.

On 16 April 2026, the Ministry of Science and ICT (MSIT) and the Ministry of Health and Welfare (MOHW) jointly announced an "AI Care Technology Full-Cycle Support Strategy." The plan puts artificial intelligence, the Internet of Things (IoT) and, later, physical robots at the centre of how Korea intends to look after its rapidly ageing population. Specialised "physical AI" for nursing settings is slated to begin development as early as 2028.

The strategy sits inside a larger MOHW effort: a five-year Welfare and Care AI Innovation Plan covering 2026 to 2030, due to be finalised in the first half of this year. Together they signal a deliberate shift. Korea is treating care technology not as a cost to contain but as a market to build.

For international MedTech, digital health and care-robotics companies, this is the more important message. A government that frames elderly care as a science-and-technology priority tends to fund it, regulate for it, and create demand for it. The opportunity is real. So is the preference for domestic suppliers.

What Happened

The strategy was unveiled at the seventh Science and Technology Ministers' Meeting. Its logic is demographic. Korea crossed into "super-aged" status in 2024, when more than a fifth of its population passed the age of 65. The people who provide care are ageing too. The average age of a nursing care assistant in Korea is now around 61. The country faces a widening shortage of care workers at exactly the moment demand is rising.

The plan rests on three pillars: AI and IoT-based service innovation, technology development driven by field demand, and parallel changes to law, institutions and workforce training. In plain terms, the government wants to build the technology, prove it works in real care settings, and then change the rules and the funding so it can be adopted at scale.

Two delivery models anchor the plan. For people cared for at home, "smart home" systems combine AI and IoT to provide round-the-clock monitoring of health and activity, with rapid alerts when something looks wrong. The aim is to fill the gaps between caregiver visits. For residential care, "smart facility" models use AI to take over repetitive documentation and to assist with night-time rounds — the periodic checks on residents that currently rely on tired, scarce staff.

Physical AI — robotics that can bear part of the physical load of care — comes later. Development for nursing settings is expected to begin as early as 2028. In the near term, the government will prioritise mature AI and IoT technologies that can reach the field within three years, then layer robotics on top. MOHW will lead applied technologies aimed at real care problems; MSIT will handle foundational work, including data platforms.

The strategy is explicitly "full-cycle." It is meant to span basic research, demonstration, commercialisation and policy integration, rather than stopping at a pilot. The government plans to validate technologies through living-lab demonstrations at actual care sites and expand only those that prove effective. Crucially, it also commits to adjusting the systems that pay for care — long-term care insurance and social service vouchers — so that proven technologies have a route to reimbursement. Ethical guidelines and legal foundations are promised alongside, so AI can be used in care settings with confidence.

A more detailed "AI Welfare and Care Innovation Roadmap" is due within the first half of 2026. It draws on a task force MOHW established in August 2025 and a public consultation run through the spring. The roadmap will cover welfare administration as well as care technology.

Why It Matters

The first signal is demand. Governments shape healthcare markets through procurement and reimbursement, and Korea is now pointing both at care technology. When a state commits to "smart facility" and "smart home" models — and pledges to adjust insurance and voucher systems to pay for them — it is creating a buyer where one was uncertain before. For vendors of remote monitoring, fall detection, ambient sensing, AI documentation and care robotics, Korea is moving from a market of scattered pilots toward one with a policy mandate behind it.

The second signal is the validation gate. The plan does not promise to buy technology because it is new. It promises living-lab demonstrations and staged expansion of only what works. That is a higher bar than a procurement tender, and a familiar pattern in Korea, where approval and adoption are not the same thing. Foreign companies have repeatedly found that a Korean regulatory clearance does not guarantee hospital or facility uptake. The lesson here is to plan for evidence generation inside Korea — real-site data, local clinical and operational partners, and proof that a product reduces staff burden rather than adding to it.

The third signal is industrial intent, and it cuts two ways. Korea is not only solving a care problem. It is trying to "secure demand for physical AI applications" — to build a domestic care-technology industry with an early home market. That ambition has historically favoured Korean firms. Government strategies of this kind tend to channel research funding, demonstration sites and early contracts toward domestic suppliers and national champions. International entrants should expect to compete against well-funded local players and should weigh partnership, licensing or joint-development routes rather than assuming a direct sale.

There is also a timing structure worth reading carefully. The near-term money and demonstrations sit with AI and IoT software — monitoring, alerting, documentation — where products can reach the field within three years. The robotics layer is a 2028-onward proposition. Companies should map their offer to that sequence. Software and sensing have a nearer commercial window in Korea; physical robots have a longer runway and more uncertainty.

A note of proportion belongs here. This is a strategy and a forthcoming roadmap, not yet a budget line or a reimbursement code. Korea has announced ambitious care and digital-health plans before, and the gap between announcement and adoption is where many such plans slow. The parts to watch are concrete: whether long-term care insurance and voucher rules actually change to pay for these tools, how living-lab results are judged, and whether procurement opens to foreign suppliers or consolidates around domestic ones.

Executive Summary

For nearly a year and a half, Korean hospitals stopped buying. A trainee doctors' walkout that began in February 2024 and ran until September 2025 emptied operating rooms, postponed surgeries, and froze the equipment budgets that follow clinical volume. Medical device procurement fell with it.

That freeze is now thawing. The US International Trade Administration (ITA), the US government's export-promotion agency, expects Korea's medical device market to rebound in 2026 as hospitals resume deferred purchases and review shelved investment plans. The market is projected to grow from USD 7.57 billion in 2025 toward USD 12.58 billion by 2032, a compound rate of 7.5 percent.

For international MedTech, the strategic point is timing. A backlog of postponed replacement purchases is releasing into a market where foreign suppliers already dominate the advanced-technology segments. But the recovery comes with conditions attached — strained hospital finances, tighter payment terms, and a domestic industry the government is actively backing.

What Happened

In February 2024, more than 10,000 trainee doctors walked off the job. They were protesting a government plan to sharply raise medical school admissions. The dispute hardened into the longest healthcare labour crisis in Korea's modern history, lasting some 18 months before the trainees agreed to return in September 2025. Seoul formally declared the medical emergency over in October 2025.

The strike's effect on the device market was indirect but severe. Hospitals run on clinical throughput. When residents — the workforce that staffs surgeries, wards, and emergency departments at Korea's large training hospitals — stopped working, procedure volumes collapsed. Routine care was disrupted, surgeries were delayed, and the capital-equipment purchases tied to that activity were shelved. The ITA notes that 2024's market decline was "largely influenced" by the strike, compounding a 2023 slowdown as the pandemic-era demand surge faded.

Recovery began once the trainees returned. Hospitals are resuming deferred equipment replacement and infrastructure upgrades. Importers report that purchasing plans, frozen for over a year, are being reviewed again. The government's agreement to address the trainees' grievances has restored a measure of confidence among healthcare institutions.

The rebound, however, is described as gradual rather than sharp. Many hospitals absorbed real financial damage during the strike, when patient volumes and the revenue attached to them fell. That damage shows up in how they buy. Procurement departments are now requesting extended payment terms and staggered delivery schedules to manage cash-flow constraints. The demand is returning; the ability to pay for it quickly is not fully restored.

Underneath the cyclical story sits a structural market. Korea's device market reached USD 7.11 billion in 2024, and Fortune Business Insights projects it past USD 12.5 billion by 2032 on the back of an ageing population, rising chronic disease, and a hospital sector that competes on advanced technology. In-vitro diagnostics is the largest segment. Robotic and minimally invasive surgery is the fastest-moving trend, with tertiary hospitals such as Seoul National University Hospital and Asan Medical Center adding systems from Medtronic, Intuitive Surgical, and others. Government policy reinforces the direction: a USD 645 million next-generation device R&D programme and a January 2026 fast-track approval pathway both aim to pull advanced technology into hospitals faster.

Why It Matters

The first implication is a procurement window. Deferred demand does not disappear — it accumulates. Eighteen months of postponed imaging upgrades, surgical systems, and replacement equipment now sits as a backlog that hospitals must work through. For suppliers with the inventory, financing flexibility, and local service capacity to move quickly, 2026 and 2027 offer a concentrated opening that a normal demand year would not. The companies that pre-positioned during the freeze are better placed than those waiting for clear signals before re-engaging.

The second implication is that this window favours incumbents in the high end. Foreign suppliers are the largest source of advanced medical technologies in Korea, and the categories rebounding fastest — diagnostic imaging, robotic surgery, in-vitro diagnostics — are exactly where international firms hold their strongest positions. Medtronic, Johnson & Johnson, GE Healthcare, and Philips already anchor the competitive landscape. The recovery is less an opening for new entrants than an acceleration for companies with an established Korean footprint.

The third implication is financial, and it changes how deals close. Hospitals are asking for extended payment terms and phased delivery. A supplier's commercial flexibility — not only its technology — becomes a deciding factor. Vendors able to offer leasing, managed-equipment models, or staged rollouts that match a hospital's cash-flow recovery will win business that a rigid, pay-on-delivery posture would lose. The strike has, in effect, made financing terms part of the product.

The fourth point is competitive context. The same government that is loosening market entry is also investing heavily in domestic champions. Osstem Implant, Samsung Medison, and Vieworks benefit from industrial policy, export support, and a trusted local image. The USD 645 million R&D programme is explicitly aimed at building globally competitive Korean devices over seven years. As the market recovers, foreign suppliers re-enter a field where the domestic industry is stronger and better funded than it was before the strike. The rebound is real, but it is not a return to an unchanged playing field.

The caveats deserve weight. Recovery is gradual, not a snap-back, and hospital balance sheets remain stressed. A renewed flare-up of the underlying admissions dispute, or broader economic pressure on hospital revenues, could slow the pace. The reimbursement environment — governed by the National Health Insurance Service and tightening, as Korea ages — continues to cap how freely hospitals spend. The direction is upward; the slope is shallow.

Executive Summary

Korea is preparing to do something its health system has rarely done at scale: take things off the reimbursement list. The Health Insurance Review and Assessment Service (HIRA), the agency that reviews claims and sets benefit rules, has published a study laying the groundwork for a system that would periodically review medical procedures already covered by national insurance and adjust or remove those whose clinical value has faded.

The detail that gives this weight is a single number. Medical procedures account for 72.25 percent of health insurance spending in Korea, yet they have never had the kind of structured post-market review that drugs and medical devices already face. HIRA wants to close that gap.

For international MedTech, diagnostics, and digital health companies, the strategic point is about the direction of travel. Reimbursement in Korea has mostly moved one way — towards adding coverage. A working de-listing engine changes the calculus. Coverage becomes a position that must be defended with evidence over time, not a one-time victory.

What Happened

HIRA recently released a study titled "Establishing a Post-Review Surveillance System for Medical Procedures." It is not yet a regulation. It is the design document that typically precedes one in Korea, setting out the rationale, the mechanism, and the institutional steps.

The logic is one of consistency. Korea already manages drugs and therapeutic materials after they enter the benefit list, re-pricing or removing them as evidence and usage shift. Medical procedures — the largest single category of insurance spending — sit outside that discipline. They are adjusted only in limited ways under existing benefit-standard rules. There is no systematic, periodic review of procedures whose usefulness has declined. The study's authors argue that this gap undermines both the efficiency of national health insurance finances and the system's long-term sustainability.

The proposed mechanism rests on data. HIRA would monitor procedures using claims data that reflect how they are actually used in clinical practice, then run an evidence-based review of safety, efficacy, and cost-effectiveness. Candidates for adjustment would be identified by analysing claims data on a roughly five-year cycle. Four routes feed the candidate list: practices already in decline or under restriction; procedures flagged for re-evaluation through annual consultations with medical academic societies; procedures the National Evidence-based Healthcare Collaborating Agency (NECA), Korea's health technology assessment body, has rated "not recommended"; and procedures caught up in clinical or social controversy.

Once selected, a candidate moves through a defined sequence of committees — an initial feasibility review, expert evaluation subcommittees, a medical-procedure evaluation committee, and a suitability committee — before final deliberation by the Health Insurance Policy Deliberation Committee, the body that signs off coverage decisions. The outcomes fall into three types. "Restriction" applies where a procedure has almost no claims over three years and alternatives are already widespread; it can be shifted to selective coverage or converted outright to non-covered status. "Reduction" applies where claims are falling and use has narrowed to some institutions; coverage can be limited to specific indications. "Increase" covers procedures that are not de-listing priorities but whose runaway use may justify re-scoring their value and restructuring how they are paid.

This is not happening in isolation. NECA has run a health technology reassessment process since 2018, reviewing 262 technologies and issuing roughly 130 recommendations on in-use technologies over five years. In January 2026, HIRA's leadership publicly tied faster market entry to stronger post-market monitoring — coverage granted sooner, then watched more closely. And in June 2026, the Ministry of Health and Welfare (MOHW) pushed ahead with a managed-benefit scheme for manual therapy that caps sessions and tracks utilisation through a HIRA portal, over the objections of physician groups. The de-listing study is one piece of a wider shift towards active, evidence-led management of what insurance pays for.

Why It Matters

The first implication is conceptual. International firms tend to treat a Korean reimbursement listing as a milestone — difficult to win, durable once won. A periodic surveillance system reframes the listing as a status that can erode. A procedure that loses clinical favour, or that a newer technology displaces, becomes a candidate for reduction or removal. For any company whose product is tied to a reimbursed procedure — a device used in it, a diagnostic that triggers it, software that supports it — the revenue attached to that procedure now carries a lifecycle risk it did not visibly carry before.

The second implication concerns evidence. The proposed system runs on claims data and on safety, efficacy, and cost-effectiveness review. Procedures that cannot show continued real-world value are the ones exposed. This rewards companies that can generate and present post-market evidence, and it disadvantages those that rely on the inertia of an existing listing. Real-world data capability stops being a nice-to-have and becomes a defensive asset. The NECA "not recommended" verdict is now an explicit de-listing trigger, which raises the stakes of any health technology assessment a company's category passes through.

The third implication is an opportunity, not only a risk. A system designed to remove low-value, substitutable procedures is, by definition, a system that favours technologies which prove themselves superior to the incumbent. The "substitutability" test cuts both ways: it threatens the displaced procedure and rewards the displacing one. A diagnostic or device that can demonstrate it makes an older procedure unnecessary is arguing in exactly the terms the new framework is built to hear. Vendors who frame their value as replacing low-value care, rather than adding to it, are aligned with where the money is moving.

The fourth point is fiscal context. Korea is ageing faster than almost any country on record, and insurance finances are under structural strain. De-listing is, at bottom, a cost-control tool. Procedures are the largest spending category, so they are where the savings are. International readers should expect this discipline to tighten rather than relax, and to spread. A market that monitors and prunes its benefit list is a market where pricing pressure is permanent and where the burden of proof sits with the supplier.

The caveats are real. This is a study, not yet an enforced rule, and Korea's path from design document to regulation runs through committees and stakeholder resistance — the manual-therapy fight shows how hard physician groups will push back. Implementation will be gradual, and the first procedures reviewed are likely to be obviously obsolete ones. But the direction is set, and it is the direction that matters for planning.

Executive Summary

Korea is trying to move severe-disease care out of Seoul. Over the first half of 2026, the Ministry of Health and Welfare (MOHW) has committed a series of funding rounds to upgrade regional national university hospitals so that cancer, emergency, and complex surgical care can be completed in the provinces rather than in the capital.

The figures are modest individually but consistent in direction. In March, MOHW allocated 74.2 billion won, about 52 million US dollars, to expand intensive care, paediatric, and advanced cancer capacity at regional hub hospitals. In April, it added 14.2 billion won, about 8.4 million US dollars, to install AI clinical systems in the same institutions. On 15 June, MOHW and the Ministry of Education tied these into a comprehensive strategy to raise regional national university hospitals to the level of Seoul's top five.

For international MedTech, the strategic point is where the demand is going. For decades, the highest-value capital equipment in Korea concentrated in a handful of Seoul hospitals. The government is now deliberately seeding that equipment across seventeen provincial hubs. The buyer map for advanced devices in Korea is being redrawn.

What Happened

Korea's healthcare resources are heavily concentrated in the Seoul metropolitan area. The "Big 5" hospitals — Samsung Medical Center, Asan Medical Center, Seoul National University Hospital, Severance, and Seoul St. Mary's — anchor the country's most advanced care. The gap with the rest of the country is measurable. According to MOHW figures cited on 15 June, the amenable mortality rate differs by 12.7 percentage points between Seoul and North Chungcheong Province, and patients travelling from other regions to the capital for treatment cost an estimated 4.6 trillion won a year. Regional national university hospitals carry just 2.3 specialists per 10 beds, against 4.3 at the Seoul five.

The government's response has been to fund the provincial hubs directly. National university hospitals across the seventeen metropolitan cities and provinces are being designated as regional control towers for high-complexity care. MOHW frames the goal as a "regionally complete medical system," where patients receive final treatment locally.

The March round was about equipment and infrastructure. Pusan National University Hospital, Kangwon National University Hospital, and Jeonbuk National University Hospital received support to expand intensive care units. Kyungpook National University Hospital and Jeju National University Hospital are establishing ICUs for high-risk pregnant women. Chonnam National University Hospital is receiving robotic surgical systems. Chungnam National University Hospital is building a hybrid operating theatre that combines real-time imaging with surgery. Most notably, Chilgok Kyungpook National University Hospital is being funded to install proton therapy — an advanced cancer treatment currently available only at select hospitals in the capital region.

The April round was about software. MOHW funded AI clinical systems at the same hospitals: real-time prediction of cardiac arrest and sepsis at Chungbuk and Pusan, fall-risk monitoring at Kyungpook, chest imaging analysis for lung disease and cancer at Jeonbuk and Pusan, stroke and dementia imaging at Gyeongsang, and voice-recognition medical records at three more. These are framed as workforce tools, reducing the documentation and monitoring load on thinly staffed regional teams.

The June strategy bound these into a long-term plan. MOHW and the Ministry of Education committed to raising regional specialist density toward the Seoul level, expanding full-time faculty, relaxing labour-cost rules to close the wage gap with private hospitals, and introducing next-generation hospital information systems where AI analyses records and imaging to support treatment decisions. The plan also pairs each region with a specialisation — trauma and rehabilitation in the Southeast, AI-based remote diagnosis in the Southwest, regenerative medicine in the Central and Daegyeong regions.

Why It Matters

The strategic reading is that Korea is redistributing its advanced-equipment market. The country is not expanding total hospital capacity so much as relocating high-acuity capability outward. For suppliers of capital equipment — radiation oncology systems, surgical robots, hybrid-OR imaging, intensive-care platforms — that relocation creates a new set of buyers who previously could not justify or fund such purchases.

The opportunity is concentrated in named categories. Proton therapy is the clearest signal: a single Chilgok KNUH installation is a multi-year, high-value project, and the government's intent to spread such equipment beyond Seoul points to more to come. Robotic surgery, hybrid operating theatres, and advanced cancer-treatment devices are explicitly on the list. AI diagnostic software for imaging, cardiac risk, and patient monitoring is a parallel track with a separate, recurring budget. A vendor that maps its portfolio against this list can see exactly which provincial hospitals are being funded to buy.

The buyer profile is the part to read carefully. These are national university hospitals — public institutions, procuring through government-funded programmes with administrative reviews rather than the relationship-driven private-hospital cycle. MOHW has said it will streamline local fiscal investment reviews to accelerate spending, and it is running second-round applications, which means the buyer list is still expanding. For foreign firms, the entry motion is different from selling into the Big 5: it runs through public procurement, regional reference accounts, and alignment with the state's regional-specialisation map.

There is a reference-building logic worth weighing. A device installed at a regional hub under a government upgrade programme becomes a public reference account in a market where peer validation drives adoption. Winning early placements as the provinces re-equip creates a footprint that the Seoul-only vendors do not have. The regional-specialisation pairings also signal where specific technologies will cluster — a trauma-and-rehabilitation focus in the Southeast implies demand for surgical, imaging, and rehabilitation systems concentrated there.

The risks are real. The individual funding rounds are small relative to the scale of the gap, and the plan depends on sustained budget commitment across multiple years and, after the June strategy, across two ministries. Public procurement is slower and more price-sensitive than private-hospital sales, and the government's parallel push to cultivate domestic capability — including domestic AI clinical systems and equipment — may steer some categories toward Korean suppliers. The wider South Korea medical-device market, valued at about 7.1 billion US dollars in 2024 and projected to reach roughly 12.6 billion by 2032, is growing regardless; the regional-hub programme is best read as a signal of where inside that market the next wave of advanced-equipment demand will land, not as a guarantee of open tenders.

Executive Summary

Korea is changing the deal it offers drugmakers. For years, the country tried to remove most uncertainty about a medicine's value before agreeing to pay for it. That front-loaded scrutiny delayed access to high-cost drugs, especially for rare and serious diseases. The new approach inverts the sequence: cover the drug sooner, then verify its value using real-world data after patients are treated.

The Health Insurance Review and Assessment Service (HIRA), which evaluates what the national insurer pays for, has made the shift explicit. Its president, Kang Joong-gu, used his New Year address to describe a move toward a structure that provides "treatment opportunities first, then verify effectiveness and value through real-world data." HIRA officials have separately argued for a purpose-built reimbursement system for high-cost orphan drugs, including the idea of a ring-fenced fund modelled on the United Kingdom and Taiwan.

For international pharmaceutical and MedTech companies, this is a strategic signal, not a procedural tweak. Faster listing is the reward. A heavier, continuing evidence burden is the price. The companies that prepare for both will move first in one of Asia's most-referenced pricing markets.

What Happened

The change is being driven by arithmetic. Orphan drugs are no longer a niche. In 2025, 26 of the 44 new drugs approved in Korea were orphan drugs — about 60 percent. These medicines are expensive and often arrive with thin or uncertain clinical evidence, because rare-disease trials enrol few patients. Korea's older reimbursement logic, designed when such drugs were rare, struggled with that combination. The result was delay.

HIRA's response is to lean on tools it already has and to formalise a newer one. Korea has long used a "Risk-Sharing System," under which a manufacturer and the insurer share the financial risk of a drug whose benefit is not yet certain, often through confidential rebates or refunds tied to use. It has also used a "Cost-Effectiveness Assessment Exemption" to speed access for the most serious conditions. In March 2025, the government revised and announced an "Evidence-Generation Conditional Coverage" mechanism. Under it, a treatment for a severe disease can be reimbursed at listing even when its clinical usefulness and cost-effectiveness remain somewhat uncertain — on the condition that evidence is generated and the decision re-examined later.

The scale of the spending explains the urgency. Between 2020 and 2024, the number of patients under Korea's special billing system for rare diseases rose 27 percent, while related drug costs climbed 46 percent. The number of risk-sharing drugs grew from 29 to 65, and spending on them jumped 166 percent. Rare-disease treatments reached 34 percent of total health-insurance drug costs in 2025, or roughly 3.2 trillion won. HIRA's Drug Effectiveness Evaluation Division has argued that this trajectory is unsustainable under the old model and that a new system — potentially funded through a separate pool, as the UK does with its Cancer Drugs Fund and Innovative Medicines Fund — is needed.

This sits alongside a broader access push. The Ministry of Food and Drug Safety (MFDS), Korea's regulator, is targeting the world's fastest approval timelines, including cutting biosimilar reviews from up to 420 days to 240. The Ministry of Health and Welfare (MOHW) is piloting a 100-day reimbursement pathway for severe and rare diseases, compressing HIRA's review and the National Health Insurance Service's (NHIS) price negotiation. Faster approval and faster coverage are being engineered together. The post-market evidence regime is the counterweight that makes that speed politically and fiscally tolerable.

Why It Matters

The core implication is a shift in where the burden of proof sits. Under the old model, the heavy work happened before listing: assemble the dossier, prove cost-effectiveness, then negotiate. Under the emerging model, listing can come earlier, but the obligation does not end there. Manufacturers should expect to generate real-world evidence after launch, to accept re-evaluation, and to see price or coverage adjusted if outcomes disappoint. Access becomes a process, not a one-time decision.

That reshapes commercial planning. Companies built around a clean approval-then-reimbursement milestone will need to budget for continuous data collection, registry participation, and outcomes tracking across the product's life. The capabilities that matter shift from dossier preparation toward health-economics, data infrastructure, and the contractual fluency to negotiate risk-sharing terms. Firms that treat real-world evidence as a core function rather than a compliance afterthought will be better positioned. Those that cannot supply credible post-market data may find early access quietly withdrawn.

There is a contracting dimension worth weighing. Korea's growing reliance on risk-sharing agreements — confidential rebates, refunds, and outcome-linked terms — means the headline list price increasingly diverges from the real, negotiated net price. That matters beyond Korea. Several Asian markets reference Korean prices, so a transparent list price held high while value is delivered through confidential rebates can protect a manufacturer's regional pricing better than an openly discounted price would. The structure of a Korean deal, not just its level, now carries cross-border consequences.

The risks cut both ways. For companies, conditional coverage transfers uncertainty onto the manufacturer's balance sheet: reimbursement today can become a clawback tomorrow if the evidence falls short. The cautionary cases are real — HIRA officials have pointed to fast-tracked drugs that later failed to prove benefit, and to safety problems with accelerated therapies abroad. For the system, the model only works if HIRA can actually collect and analyse real-world data at scale, which is why the agency is investing heavily in that capability. If the data infrastructure lags the policy ambition, "verify later" risks becoming "never verify," and the fiscal discipline the reform promises would erode.

The proposed ring-fenced fund is the detail to watch. If Korea establishes a separate pool for high-cost rare-disease drugs, tied to evidence-based conditional reimbursement, it would create a more predictable route to coverage for orphan products and a clearer set of obligations attached to it. That would be a meaningful opportunity for rare-disease pipeline companies — and a template other Asian payers may study.

Executive Summary

Korea has decided that its care-worker shortage is a technology problem. On 16 April, the Ministry of Science and ICT (MSIT) and the Ministry of Health and Welfare (MOHW) jointly announced the "AI Care Technology Full-Cycle Support Strategy." The plan moves elderly care out of the welfare ministry's sole domain and into national science and technology policy.

The shift matters because of what it signals to suppliers. For years, Korea framed care as a service to be staffed. It is now framing care as a market to be equipped. The strategy commits the state to developing artificial intelligence (AI) and robotics for care settings, deploying smart-home systems for seniors who live alone, and steering procurement toward technology that lifts, monitors, and documents.

For international MedTech and digital health companies, this is a demand-creation event, not a press release. A government that controls long-term care insurance and social service vouchers is signalling where it intends to spend. The categories it named — remote monitoring, fall prevention, transfer assistance, and physical AI — are now policy priorities with a public budget behind them.

What Happened

MSIT and MOHW unveiled the strategy at the 7th Science and Technology Ministers' Meeting. The framing was deliberate. Care has traditionally sat outside science and technology policy, which prioritises industrial competitiveness. Korea has now reclassified it. Labour shortages have become acute, AI and robotics have matured to field-applicable levels, and the government has concluded the two facts belong together.

The strategy rests on three pillars: AI- and IoT-based service innovation, demand-driven technology development tied to real care sites, and the legal, institutional, and workforce changes needed to absorb the technology.

Two delivery models anchor the plan. For home-based care, a "smart home" model integrates AI and connected devices to provide 24-hour monitoring of a person's health and activity, with rapid alerts when something looks wrong. For institutions, a "smart facility" model uses AI to handle repetitive documentation and to replace part of the manual night-rounding that consumes staff time. Development of specialised "physical AI" — robotics for tasks such as lifting and transfers — is slated to begin as early as 2028.

The timing is driven by demographics. Korea entered super-aged society status in 2025, with more than ten million people aged 65 or older. The care workforce is itself ageing: the average nursing-care assistant is around 61. The country lacked roughly 190,000 care workers in 2023, a gap projected to reach 1.55 million by 2032. Long-term care insurance reserves are expected to be depleted by 2030. The strategy is a response to a system that cannot hire its way out of the problem.

The strategy is not only on paper. In May, the Seoul Welfare Foundation launched its 2026 Care Service Digital Transformation Support programme, selecting six institutions from 40 applicants for funding and technical consulting. The deployments are concrete: motorised repositioning beds at two nursing homes, non-contact radar sensors at Yongsan Senior Nursing Home to detect pre-fall movement, electric lifts and wearable exoskeletons for safe patient transfers, and bowel sensors that replace routine manual checks. These are the smart-facility model in miniature, already being tested.

Why It Matters

The strategic reading is that Korea is converting a chronic liability into a procurement pipeline. A labour shortage that cannot be solved with people is being redefined as demand for equipment. The government has named the high-value categories itself: remote patient monitoring, fall detection, transfer and lifting assistance, and documentation automation. For vendors, the guesswork about where Korea will spend has narrowed considerably.

The opportunity is real but the buyer is unusual. This is not tertiary-hospital procurement. The customers are nursing homes, home-care providers, and the public bodies that fund them through long-term care insurance and social service vouchers. The sales motion runs through municipal welfare foundations and reimbursement codes, not through hospital tender committees. The Seoul pilot's funding figures are modest — about seven million won per institution — which tells suppliers that early revenue comes from public co-funded demonstrations, not large capital orders. The companies that win will design for that channel: affordable, easy to install, and built to survive a living-lab evaluation.

The phasing is the part to read closely. The government plans to prioritise mature AI and IoT technologies first, aiming for field-ready models within three years, and only then expand to robotics-based physical AI from 2028. For now, the addressable market is sensors, monitoring platforms, and software — categories where foreign firms with proven products can compete immediately. The harder, robotics-heavy market arrives later and will likely favour domestic industrial champions that the strategy is partly designed to cultivate. International players should treat the next three years as the sensing-and-software window, and the robotics phase as a partnership question.

There is also a validation signal worth weighing. Korea is building a structured pathway from demonstration to commercialisation to reimbursement, with MOHW leading applied technology and MSIT handling foundational platforms and data. A device proven effective in a Korean living lab gains a reference that travels. Japan, Taiwan, and Europe face the same demographic curve, and the global eldercare robot market is projected to reach 7.7 billion US dollars by 2030. Korea is positioning itself not only as a buyer but as a proving ground and exporter — its Hyodol companion robots, already deployed to more than 12,000 seniors at home, are preparing for international launch.

The risks are equally clear. The plan depends on reform of a long-term care insurance system whose reserves may run dry by 2030, so the funding behind the strategy is not guaranteed. Procurement tied to public vouchers can be slow, fragmented across municipalities, and price-sensitive. And the emphasis on cultivating domestic physical-AI capacity means the most lucrative later-stage robotics contracts may be steered toward Korean industry. Foreign companies that arrive expecting open, hospital-style tenders will misread the market. Those that enter through the demonstration programmes, partner locally, and price for public budgets will be positioned when the spending scales.

Executive Summary

Korea treated 2.01 million foreign patients in 2025. The figure nearly doubled from 1.17 million in 2024 and is the highest since the government began counting in 2009. The Ministry of Health and Welfare (MOHW), Korea's health ministry, released the data in April. On the headline, Korea is now one of Asia's largest medical tourism destinations.

The composition matters more than the total. Dermatology accounted for 62.9 percent of all foreign patient visits. Cosmetic surgery added 11.2 percent. Clinic-level institutions, not hospitals, handled 87.7 percent of visits. And 87.2 percent of patients were treated in Seoul. The boom is real, but it is narrow: it is a K-beauty and aesthetics cluster concentrated in one city.

For international healthcare and MedTech leaders, this is a market-shape signal, not a vanity statistic. The growth is concentrated by specialty, by venue, and by geography. That tells you where the spending and the buyers actually are — and where Korea's stated ambition to export serious, complex medical care has not yet arrived.

What Happened

MOHW reported that 2.01 million foreigners came to Korea for medical treatment in 2025, a 71.9 percent rise on the prior year. The trajectory is steep. The country recorded 605,768 foreign patients in 2023, 1.17 million in 2024, and just over two million in 2025. Each of the past three years set a record.

The spending figure drew the headlines. The Korea Institute for Industrial Economics and Trade (KIET), a government research body, estimated that foreign patients and the companions who travelled with them spent 12.5 trillion won, about 8.4 billion US dollars, in 2025. Only 3.3 trillion won of that went on actual treatment. The rest was tourism — hotels, retail, food, and travel. Roughly three-quarters of the medical tourism economy is the tourism, not the medicine.

The patient mix shifted as well. Patients came from 201 countries or territories. For the first time, China led all nationalities at 30.8 percent. Japan followed closely at 29.8 percent, then Taiwan at 9.2 percent, the United States at 8.6 percent, and Thailand at 2.9 percent. Chinese and Taiwanese patient numbers more than doubled from 2024. American arrivals rose 70.4 percent and Canadian arrivals 59.1 percent.

The clinical and geographic concentration is the part that gets less attention. Dermatology alone was 62.9 percent of visits. Cosmetic surgery was 11.2 percent. Together, skin and aesthetic procedures are most of the market. Clinic-level establishments handled 87.7 percent of visits, and Seoul treated 87.2 percent of all foreign patients — a city that hosts 62.5 percent of the institutions registered to treat them.

Why It Matters

Set the 2025 numbers against the policy goal and the gap is clear. In 2023, the government set a target of 700,000 foreign patients by 2027, a 180 percent increase from about 250,000 in 2022. Korea passed that mark years early and nearly tripled it. But the same 2023 plan said the aim was to broaden the mix beyond cosmetics and dermatology toward severe and complex diseases, and to spread patients beyond Seoul to ease regional imbalance. On both counts, 2025 went the other way. Dermatology's share rose, and Seoul's dominance held. The volume target was met spectacularly. The structural target was not.

That distinction defines the commercial opportunity. The immediate, proven, fast-growing demand is in aesthetics. For MedTech and device companies, the addressable market that is actually expanding is the one that serves dermatology and cosmetic clinics: energy-based devices, lasers, injectable systems, skin diagnostics, and the consumables and service contracts around them. These are clinic purchases, made by private operators competing on outcomes and throughput, not by hospital procurement committees. The buyer profile is different from the tertiary-hospital sales motion most foreign MedTech firms are built around. Companies selling into Korea's foreign-patient boom should be calling on Gangnam clinic chains, not only university hospitals.

The high-acuity export Korea wants remains thin. Serious and complex care — oncology, cardiac surgery, transplantation — is where Korea's leading hospitals are genuinely world class, and where margins per patient are far higher than dermatology. That segment is not what is driving the volume. For companies positioned in advanced diagnostics, surgical robotics, and complex-care equipment, the lesson is that the medical tourism wave is not yet pulling their categories. It may, if Korea succeeds in steering the mix. The 2026 opening of telemedicine to foreign patients and the continued easing of medical visas are levers aimed precisely at converting one-off aesthetic visitors into longer-term, higher-acuity patient relationships. Whether they work is the variable to watch.

Concentration is also a risk. A market that is 30.8 percent Chinese, 62.9 percent dermatology, and 87.2 percent Seoul is exposed on three axes at once. A shift in Chinese outbound policy, a change in cross-border payment rules, or a diplomatic chill could compress a third of the inflow quickly. A K-beauty trend that cools would hit the largest specialty. And the Seoul concentration leaves the regional hospital capacity that the government has spent heavily to build — including new AI systems in regional centres — largely outside the foreign-patient economy. Diversification is not just a policy preference here. It is the difference between a durable export industry and a fashion-driven one.

There is a quieter signal for the broader healthcare market. The medical tourism boom is, in large part, a referendum on Korean clinical brand strength. Patients now fly in from 201 countries for procedures they could get closer to home, because Korean dermatology and aesthetics have become a global benchmark. That brand equity is an asset Korean device makers, clinic franchises, and digital health platforms can carry into export markets — selling the Korean method abroad rather than only importing patients. The most strategic players will treat 2025 not as a peak to defend but as proof of a brand to license.

Executive Summary

Korea has changed the rule that decides who gets treated for chronic hepatitis B. The Korean Association for the Study of the Liver (KASL), the country's professional body for liver medicine, released revised 2026 treatment guidelines that base the decision to start antiviral therapy on viral load rather than liver enzyme levels. The shift removes a long-standing test, alanine aminotransferase (ALT), from the centre of the treatment decision and replaces it with hepatitis B virus (HBV) DNA.

The practical effect is a larger treatment-eligible population. Under the old standard, patients with high viral loads but normal enzyme readings sat in a "gray zone" and were usually watched rather than treated. KASL now recommends starting therapy immediately in patients with moderate viremia, regardless of enzyme levels. Korea has about 1.2 million people living with chronic hepatitis B, and only 22 percent are currently treated.

For international pharma, diagnostics, and reimbursement strategists, the signal is twofold. A clinical-guideline change has just widened a market. And the gap between that guideline and what national insurance will actually pay for is now the variable that decides how fast the market opens.

What Happened

KASL unveiled its revised Clinical Practice Guidelines for Chronic Hepatitis B during The Liver Week 2026, the field's main Korean conference, held in mid-June. The central change is conceptual. The guidelines now treat chronic hepatitis B primarily as a viral infection to be managed by the degree of viral replication, rather than as an inflammatory liver disease tracked through enzyme levels.

Earlier guidelines, in Korea and abroad, leaned heavily on ALT to classify disease stage and decide who qualified for treatment. The problem, KASL argues, is that serious liver damage and elevated liver-cancer risk can exist even when ALT is normal. The association cited evidence that roughly 40 percent of hepatitis B patients with normal ALT showed significant fibrosis on biopsy, and that about 78 percent of patients with moderate viremia had clinically meaningful liver damage. A meta-analysis of 46 cohort studies found that moderate-viremia patients carried a six- to eight-fold higher risk of liver cancer than those with high viremia.

Under the new framework, KASL sorts patients into three groups by serum HBV DNA — low, moderate, and high viremia — and recommends immediate antiviral therapy for the moderate group, defined as HBV DNA between 2,000 and 10⁸ IU/mL, irrespective of ALT. ALT is downgraded to a supporting marker for monitoring, not a gatekeeper for treatment.

The clinical case rests on a randomised trial. The ATTENTION study, run in Korea and Taiwan and led by Professor Lim Young-suk of Asan Medical Center, KASL's chair, tested early treatment with tenofovir alafenamide (TAF) in non-cirrhotic patients with moderate or high viremia and little or no enzyme elevation. Interim results, published in The Lancet Gastroenterology & Hepatology, showed a 79 percent reduction in major composite clinical events — liver cancer, decompensated liver disease, and death — versus observation alone. The revised approach also carries the endorsement of the East Asia Liver Alliance (EALA), a consortium of liver societies from Korea, Japan, and Taiwan, giving it regional weight.

There is a catch, and KASL named it. Korea's national insurance still ties reimbursement for hepatitis B antivirals to ALT elevation. So some patients newly recommended for treatment under the 2026 guidelines will not yet qualify for coverage. KASL said it will ask the Health Insurance Review and Assessment Service (HIRA), the body that sets reimbursement rules, to expand coverage, and will open discussions with the Ministry of Health and Welfare. Much of the underlying evidence, the association noted, came from publicly funded research, including support from the National Evidence-based Healthcare Collaborating Agency (NECA), the government's health-technology assessment arm.

Why It Matters

The most immediate consequence is market size. Korea diagnoses about 83 percent of its hepatitis B cases but treats only 22 percent, far below the World Health Organization's 80 percent treatment target for eliminating viral hepatitis by 2030. A guideline that moves the treatment trigger from enzymes to virus pulls a large "gray zone" population into the treat-now category. KASL's own cost-effectiveness analysis estimates that broader early treatment could prevent roughly 43,000 liver-cancer cases and 37,000 deaths over fifteen years. For makers of oral antivirals — tenofovir and entecavir franchises, branded and generic — the eligible base expands without a new molecule.

The diagnostics implication is larger than it first appears. Moving the decision to HBV DNA makes quantitative molecular testing, not a routine enzyme panel, the gatekeeper of treatment. That raises sustained demand for HBV DNA viral-load assays and the instruments that run them, and it rewards standardised, accessible molecular testing across primary and secondary care. Non-invasive fibrosis assessment — elastography and serum-based scores — also gains relevance, because the new logic is built on detecting silent liver damage that enzymes miss. For the in-vitro diagnostics and imaging sector, a viral-load-led pathway is a structural tailwind, not a one-off.

Then there is the reimbursement lag, the recurring feature of Korean market access. Clinical eligibility and insurance eligibility have just diverged on purpose. Physicians can recommend treatment under the new science, but HIRA's criteria still reference the old enzyme threshold. Until the reimbursement rule is rewritten, the practical market will be smaller than the clinical one, and patients will face the familiar choice between paying out of pocket or waiting. The speed of the HIRA revision — not the guideline itself — will determine when the expanded population actually converts into treated, reimbursed demand. Companies should track the HIRA coverage decision as the real launch trigger.

The regional dimension is worth holding in view. Because the change comes with EALA backing, Korea is moving in step with Japan and Taiwan rather than alone. Aligned guidelines across three high-prevalence East Asian markets point toward a common direction of travel for hepatitis B management, which matters for any company planning a regional commercial strategy. Korea's habit of serving as a reference point in Asian pricing and policy adds to the case for watching how its reimbursement authorities respond.

A measure of caution is in order. A guideline is a recommendation, not a budget line. The expansion depends on HIRA agreeing to fund it, on testing capacity scaling to a viral-load standard, and on physicians changing long-set habits. None of that is automatic, and the fiscal cost of treating a much larger population is exactly the kind of pressure that slows reimbursement reform. The direction is clear; the timing is not.

Executive Summary

Korea is preparing to split its long-term care hospitals into two tiers. The Ministry of Health and Welfare (MOHW), the country's health ministry, will publish draft criteria in July for a new designation it calls the "medical-centered" long-term care hospital. Only hospitals that win the label will have nursing care costs folded into national health insurance coverage. The rest will not.

The mechanism is a quality filter. Early signals from the ministry point to limiting eligibility to hospitals graded 1 or 2 in the government's periodic quality assessments, and to weighing how much of a hospital's revenue comes from services insurance does not cover. Smaller operators have already pushed back hard, because the line the ministry draws will decide which businesses keep a viable reimbursement base and which lose one.

For international healthcare and MedTech leaders, this is a market-structure event in the fastest-aging society in the developed world. Korea crossed the 20 percent threshold for residents aged 65 and over in 2025, making it officially super-aged. The long-term care hospital sector is where a large share of elderly inpatient demand lands. A reform that ties insurance coverage to measured clinical quality will concentrate spending in fewer, better-equipped facilities — and that is where the equipment, monitoring, and rehabilitation budgets will follow.

What Happened

On June 12, MOHW officials briefed medical and pharmaceutical reporters on where the policy stands. Kong In-sik, who heads the ministry's Health Insurance Payment Innovation Promotion Team, said the specific standards are not yet final but that an advisory committee is reviewing them now. The ministry plans to release a draft in July and hold a public hearing before deciding.

The core idea is a new class of long-term care hospital — "medical-centered," in the ministry's language — that delivers genuine medical treatment rather than custodial stays. Hospitals that qualify would have nursing care costs included in national health insurance coverage, a meaningful change in a sector where families often pay for caregiving out of pocket or through privately hired aides.

The contested question is how to choose them. Reports that the ministry was considering restricting the designation to hospitals rated Grade 1 or Grade 2 in quality assessments triggered strong objections from small and mid-sized operators. They argue the assessment system is a relative ranking, runs on data up to two years old, and reflects only six-month windows — so a single grade is a blunt instrument for a permanent reimbursement decision. Kong acknowledged those concerns but defended the emphasis on quality. Officials note that extending eligibility to Grade 3 hospitals would sweep in roughly 960 facilities, which they say would dilute the point of the policy.

Quality grades are not the only filter. Kong said the share of non-covered services in a hospital's revenue would also count. Where uninsured services dominate the income statement, the ministry questions whether appropriate medical care is being delivered. It will not judge individual treatments, he said, but will look at the ratio of non-covered revenue to total income as one criterion. Patient cost-sharing is the third live issue: advocacy groups say the current 30 percent co-payment is too heavy, while the ministry weighs that against the fiscal cost of broadening coverage. The Health Insurance Review and Assessment Service (HIRA), the body that runs the quality assessments, sits at the center of the grading that will drive eligibility.

Why It Matters

The reform reprices an entire segment by clinical quality. Korea's long-term care hospitals expanded rapidly over the past two decades, and the system has long struggled with "social admissions" — elderly patients housed in hospitals for want of a care alternative rather than for active treatment. By attaching insurance coverage of nursing costs to a quality-graded designation, the ministry is trying to pull the sector toward medicine and away from custody. The financial consequence is direct. Hospitals that earn the label gain a stronger, insured revenue base; those that miss it face a widening disadvantage.

That points to consolidation. A designation pegged to Grade 1 and Grade 2 performance, plus a cap on non-covered revenue, rewards larger and better-run facilities and squeezes the long tail of small operators competing on price and amenities. Some will invest to qualify — credentialed staffing, modern monitoring, upgraded rehabilitation capacity, accreditation. Others will exit or merge. For suppliers, the addressable market shifts toward a smaller set of buyers with both the incentive and the insured cash flow to spend on quality differentiation. Patient-monitoring systems, fall-prevention technology, pressure-injury prevention, rehabilitation equipment, and infection-control infrastructure are the categories that map directly onto what a "medical-centered" grade will require.

There is published evidence that quality in these hospitals tracks resourcing. Korean research on long-term care hospitals has linked higher registered-nurse staffing to better inpatient outcomes — less moderate-to-severe pain, fewer pressure ulcers, fewer indwelling catheters, and higher rates of return to the community. A grading regime that pays for quality gives operators a reason to fund exactly the staffing and equipment that move those measures. That is a constructive alignment for vendors whose products improve documented clinical outcomes rather than merely cut cost.

The reform also fits a larger redesign of Korean elderly care. The Act on Integrated Support for Community Care, promulgated in 2024, reaches full implementation in March 2026, pushing the system toward keeping older people in their homes and communities rather than in institutions. Read together, the two policies sort demand: lower-acuity custodial cases move toward home and community care, while institutional long-term care hospitals are steered to justify their beds on medical grounds. For companies in home monitoring, telehealth, and automated care, the long-term direction is a market that splits between accredited medical facilities and a growing home-based segment.

The caution is that nothing is settled. The criteria are still in committee, the July release is only a draft, and a public hearing follows. Operator opposition is organized and the co-payment question is politically sensitive, so the thresholds could soften or the timeline could slip. Executives should treat the July draft as the most important signal of the year for this segment — a detailed statement of which hospitals Korea intends to fund as medical providers — while recognizing that the final cut-off lines may move.

Executive Summary

The Korean Society of Nephrology (KSN) used its annual conference in Seoul this week to publish a pointed set of numbers. Dialysis patients treated at facilities without a credentialed kidney specialist die at a 10 to 13 percent higher rate than patients at accredited centres, even after adjusting for age and comorbidities. The society released the data as the Chronic Kidney Disease (CKD) Management Act — a bill that would make specialist oversight and facility accreditation mandatory — sits stalled in the National Assembly.

The dispute is narrow on its face and broad in its implications. Korea's CKD burden is growing fast: prevalence among adults reached 6.3 percent in 2024, up from 5.5 percent a year earlier, and roughly one in four Koreans over 70 now has the condition. More than 81,000 patients depend on dialysis, served by just 1,346 credentialed specialists whose numbers are growing at half the usual pace after the 2024–2025 medical workforce conflict disrupted training.

For international healthcare and MedTech leaders, this is a market-structure story. A mandatory accreditation regime would redraw Korea's dialysis clinic landscape, and the reimbursement distortions the society describes — a fee schedule that makes haemodialysis profitable and peritoneal dialysis marginal — are exactly the levers the government has begun to adjust. Companies in dialysis equipment, home therapies, and remote monitoring should treat the stalled bill as a leading indicator, not a dead letter.

What Happened

The KSN presented its CKD and Dialysis Specialist Fact Sheet 2026 on June 11, drawing on national health statistics from the Korea Disease Control and Prevention Agency (KDCA), the government's disease surveillance body, and 2024 census data. The headline finding comes from a 2022 cohort study of more than 35,000 haemodialysis patients: crude mortality of 69.6 deaths per 1,000 person-years at specialist facilities against 85.8 at non-specialist facilities, with a 10 to 13 percent excess risk remaining after adjustment.

The workforce picture explains the society's urgency. Korea added only 75 dialysis specialists last year, against a typical 100 to 200, after the standoff between the government and the medical profession disrupted residency and fellowship training. Distribution is heavily skewed. In North Jeolla Province, one specialist covers an average of 132 dialysis patients; in Seoul, the figure is 49.

Treatment patterns are skewed in parallel. Peritoneal dialysis — the home-based modality that requires far fewer clinic visits — accounts for just 5.6 percent of Korea's dialysis mix, against a KSN target of 20 percent by 2033. Society officials were explicit about the cause: the fee schedule rewards in-centre haemodialysis, which brings patients in three times a week, and makes a practice built on monthly peritoneal dialysis visits economically unviable. Fellows now finish training having barely treated a peritoneal dialysis patient.

The legislative response exists but is not moving. The CKD Management Act, introduced in February, would create a national CKD management committee, a patient registry, and a mandatory accreditation framework for dialysis facilities. The Ministry of Health and Welfare (MOHW), Korea's health ministry, has resisted the bill on the grounds that a disease-specific management law would set a precedent. Meanwhile, non-specialist clinics that recruit patients with free transport and co-payment waivers remain legal, and the society concedes its attempts to sanction them have failed for precisely that reason. One countervailing signal: in April the KDCA added CKD to the sixth National Health Promotion Comprehensive Plan, placing it alongside hypertension, diabetes, and cancer as a national chronic-disease priority.

Why It Matters

Korea's dialysis market is one of the most device- and consumables-intensive segments of its health system, and the suppliers are largely European and Japanese — Fresenius Medical Care, B. Braun, Nipro, and Vantive, the former Baxter kidney-care business. The KSN's numbers describe a market whose structure is set by reimbursement and regulation, not by clinical evidence. That structure is now contested in public, with mortality data attached. Executives should read the fact sheet as the opening argument in a regulatory negotiation rather than an academic exercise.

An accreditation mandate, if the act passes in any form, would be consequential. Mandatory specialist oversight and facility certification would squeeze the low-cost, non-specialist clinics that compete on transport and co-payment incentives. Some would close; others would need credentialed staff, upgraded water treatment, and modern machines to qualify. That points to consolidation around hospital-affiliated and accredited centres — and to an equipment and services refresh cycle concentrated in the buyers most willing to pay for quality differentiation.

The peritoneal dialysis gap is the clearer near-term opening. The government has already moved: the MOHW extended its home peritoneal dialysis management pilot in November 2025 and has announced performance-based reimbursement and better compensation for patient education. With end-stage kidney disease up roughly 2.3-fold in 13 years and specialists concentrated in Seoul, home-based therapy is the only modality that scales into the regions where the catchment for an in-centre haemodialysis practice does not exist. Vendors with home dialysis systems and remote monitoring platforms are positioned on the right side of both the demographic curve and the announced policy direction.

The workforce numbers carry their own signal. A specialty growing by 75 people a year cannot staff its way out of an 81,000-patient caseload that keeps rising. The pressure resolves toward technology — remote patient management, automated peritoneal dialysis, telemonitoring of home patients — or it does not resolve at all. Korea's supply-chain scare earlier this year, when Middle East disruptions forced the MOHW to set up a dedicated syringe hotline for dialysis clinics, is a reminder that the system is already operating without slack.

The caution is timing. The MOHW's precedent objection is institutional, not casual: a CKD-specific law invites every specialty society to demand its own statute. The act may pass amended, fold into broader chronic-disease legislation, or stall through this Assembly. The direction of travel — accreditation, registries, home-therapy incentives — is more durable than any single bill.

Executive Summary

South Korea has passed an amendment to its Medical Overseas Expansion Act that allows foreign patients, including first-time patients, to receive telemedicine from registered Korean providers. Covered services include remote consultation, diagnosis, prescription, and post-return follow-up care. The Ministry of Health and Welfare (MOHW), the ministry that runs Korea's health system, framed the change as a response to two million foreign patient visits a year.

The striking part is the sequencing. Korean citizens still face tight telemedicine limits: remote consultations are capped at 30 percent of an institution's visits and confined to clinic-level care. Broader domestic access arrives only in December 2026 under separate amendments to the Medical Service Act, and hospital-level institutions remain largely excluded. Foreign patients will be able to receive hospital-level remote diagnosis and prescriptions before most Koreans can.

For international healthcare leaders, the signal is twofold. Korea is treating cross-border telehealth as an export industry rather than a domestic care reform, and it is building the registration, platform, and oversight infrastructure that a permanent telemedicine regime requires. Both create openings for hospitals, platform vendors, and digital health companies positioned to serve the inbound patient flow.

What Happened

The National Assembly passed amendments to the Medical Overseas Expansion Act, the law that governs Korea's outbound medical industry and inbound medical tourism. Under the revision, foreign patients gain access to telemedicine at clinic-level and hospital-level medical institutions. The change covers patients who have never been treated in Korea, not just returning ones.

The permitted services are broad: continuous observation, counselling and education, diagnosis, and prescription. Providers, including specialised centres, may build systems for remote consultations and the delivery of prescription medicines. The law pairs the opening with controls. Providers must register, and registration can be cancelled for misuse.

The context explains the urgency. Foreign patient visits to Korea have grown to roughly two million a year, according to the MOHW. Most stay briefly. The ministry argued that short-stay patients need remote pre-consultation before they travel and follow-up care after they return home — neither of which Korean law clearly permitted.

Large hospitals were already operating in the gap. Asan Medical Center, one of Korea's largest hospitals, has offered telemedicine to overseas patients since 2021 and delivered 866 remote treatments to patients in 57 countries over five years. In 2025 it launched an AI-supported platform that lets international patients register, upload records and imaging, book pre-consultations, and receive remote treatment. Its international centre sees around 20,000 overseas patients a year. The amendment effectively legalises and standardises what the leading institutions were already building.

Domestic telemedicine is moving on a slower, more guarded track. In October 2025, after a 20-month medical crisis alert ended, the government reinstated restrictions: remote care limited to clinics, capped at 30 percent of an institution's consultations, with hospital-level telemedicine rolled back. Separate Medical Service Act amendments will permit local telemedicine from December 2026, but the MOHW notes that this domestic framework does not cover foreign patients — the two regimes are deliberately distinct.

Why It Matters

The dual track is the strategic information. Telemedicine for Koreans is a contested domestic issue, entangled with physician politics and the 2024–2025 junior doctor conflict. Telemedicine for foreigners is an export product with no domestic constituency to oppose it. Korea has chosen to liberalise where resistance is lowest and revenue is clearest. Executives should read the foreign-patient lane as industrial policy for medical tourism, not as a preview of a fully open domestic market.

For hospitals and platform vendors, the opening is concrete. Registered institutions will need multilingual intake, remote diagnosis workflows, cross-border data handling, and prescription delivery logistics. Asan's platform shows the template, and most of Korea's roughly 40 tertiary hospitals and many secondary hospitals court international patients. Vendors supplying telehealth infrastructure, AI translation, remote monitoring, and international health data exchange now have a legally defined market where previously there was regulatory grey space.

For foreign providers and insurers, the flow runs both ways. Remote pre-consultation lowers the friction of sending a patient to Seoul for surgery, which strengthens Korea's position against competing destinations in Asia. Insurers and employers in the Gulf states, Central Asia, and Southeast Asia — established source markets for Korean hospitals — gain a structured channel for case coordination and post-treatment follow-up. That may pull more complex, higher-value cases toward Korean centres.

The December 2026 domestic opening adds a second horizon. The registration systems, platform investments, and clinical protocols built for foreign patients will exist when local telemedicine expands. Institutions and vendors that enter through the foreign-patient lane will be operationally ahead when the larger domestic market opens. The 30 percent cap and clinic-only rules signal that domestic liberalisation will stay incremental, but the direction is now set in law on both tracks.

The risks are real but bounded. Registration cancellation gives the MOHW an enforcement lever, and the rules on cross-border prescriptions, liability, and data transfer will be defined in subordinate regulation that has not yet been published. Companies building against this opening should expect detailed implementation decrees and plan for compliance work, not a frictionless launch.

Executive Summary

A large global drugmaker is doing two things in Korea at once. Eli Lilly is putting more money into the country's research base, and it is warning that the same country may not be worth launching some new medicines in. Both messages came from Lilly Korea's general manager, John Bickel, on the sidelines of the company's 150th anniversary event in Seoul on 22 May 2026.

The combination is the point. Lilly likes Korea's science. It is less sure about Korea's market. The country spends heavily on older, off-patent drugs and comparatively little on innovative ones, Bickel argued, and global pricing pressure means some newer products now risk not being launched in Korea at all.

For healthcare and MedTech leaders, this is a clear read on where the Korean market sits in 2026. Korea is an excellent place to run a trial and a hard place to get paid. The reform now underway is meant to close that gap. Whether it does will shape which new therapies Korean patients actually get, and how Korea's prices ripple through the rest of Asia.

What Happened

Bickel spoke after a media event marking Lilly's 150th year. He praised Korea's research environment, then named the problem directly. "Korea has some of the lowest spending per GDP on innovative products," he said, and "some of the highest spend on older outdated products." He called that "backward."

His warning was specific. With current global pricing dynamics, he said, "some newer products risk not being launched and not being made available to people in Korea." A low launch price in one developed market can weaken a drugmaker's negotiating position elsewhere. So a company may simply hold back from a market where the agreed price could drag down its global pricing.

For Korean patients the gap is more concrete. Regulatory approval does not equal access. After the Ministry of Food and Drug Safety (MFDS), Korea's drug regulator, clears a product, it still has to pass reimbursement review and price negotiation before it is widely available under national health insurance. The Health Insurance Review and Assessment Service (HIRA) assesses value, and price talks follow. Bickel called Korea "one of the more difficult countries for drug approvals as well as pricing."

Korea has started to respond. A drug-pricing overhaul approved this year, outlined late in 2025, is designed to speed coverage for some new medicines while cutting prices on generics and patent-expired drugs. As part of that reset, Korea lowered the reimbursement rate for generics to 45 percent of the original drug's price, down from 53.55 percent. The intent mirrors Bickel's prescription: shift money from old drugs to new ones. He called the steps a move "in the right direction," but said the larger shift is unfinished.

The investment side is not rhetorical. Lilly entered Korea in 1982 and now employs about 250 people. It is running 64 clinical trials across 26 drug candidates, its largest local trial footprint to date, and its domestic sales ranking has climbed from 39th in 2022 to 17th in 2025. In March 2026 Lilly signed a memorandum of understanding with the Ministry of Health and Welfare (MOHW), the ministry that runs the health system, to invest $500 million in Korea over five years. The company also said it signed deals with Korean biotech firms last year with a combined potential value above $4.5 billion.

The clearest sign of the research bet is Gateway Labs, Lilly's biotech incubator. The Korean site, built with Samsung Biologics in Songdo, Incheon, is expected to open in 2027 with room for up to 30 Korean biotechs. It will be Lilly's second overseas Gateway Labs location after China, and the first built through a partnership. Resident companies will get access to Lilly's AI drug-assessment platform, Tune Labs.

Why It Matters

The split screen is the lesson. A company can deepen its research presence in a country and still question whether to sell its newest products there. Korea offers world-class trial infrastructure, strong medical centres and an active biotech startup base. Those draw R&D investment. They do not fix market access. Reading Lilly's Korea strategy as a single signal misses the structure; the trial decision and the launch decision run on different logic.

For pharma, the warning is a forecast of the access gap. If reimbursement does not reward innovation faster, the rational move for some manufacturers is to delay or skip Korean launches of high-priced therapies. That protects global pricing but leaves Korean patients waiting. It also gives Korea a reason to move on reform, because a market that approves drugs it cannot then access loses standing as a launch destination.

The reference-pricing angle widens the stakes beyond Korea. Several Asian health systems look to Korean prices when setting their own. A drugmaker that accepts a low Korean price can find that number following it across the region for years. That is why Korea's negotiating posture matters to companies that never planned to make Korea their biggest market. The reform's success or failure will be read in capitals well outside Seoul.

For MedTech and digital health, the read-across is the spending reallocation itself. Korea is signalling that it wants to fund innovation and squeeze legacy products. The generic price cut is the first concrete move. Companies whose value rests on demonstrable outcomes, including diagnostics, AI tools and devices that reduce downstream cost, are better placed in a system trying to pay for value than those competing on price against entrenched incumbents. The direction of travel favours evidence.

The risk sits on the reform's pace. Lilly's investment is committed; its launch caution is conditional. If Korea moves money toward innovation quickly, the launch risk recedes and the country strengthens as both a trial hub and a market. If reform stalls, Korea keeps the trials and loses some of the drugs. The two halves of Lilly's message are really one bet on whether the reset delivers.

Executive Summary

Korea has decided who gets to sit on its health-data rails first. In December 2025, the Ministry of Health and Welfare (MOHW), which runs the national health system, certified three organisations to receive patients' medical records through the government's MyData scheme: Kangbuk Samsung Hospital, Kakao Healthcare, and the Catholic Medical Center. They are the first healthcare names in a new licensing category, and each designation lasts three years.

The decision is small in scale and large in signal. It opens a regulated lane for hospitals and digital health companies to build consumer services on top of sensitive medical records, with the state holding the gate. For the first time, a patient can ask that records scattered across Korea's hospitals be routed to an approved private service of their own choosing.

For international healthcare and MedTech leaders, the strategic point is the architecture, not the three names. Korea is turning personal health data into a licensed market. The access is real. But it is gated by a government approval that domestic incumbents moved first to secure.

What Happened

MOHW designated the three as "specialised" personal information management institutions in healthcare. The category is new. It exists to screen entities that want to take in medical MyData and use it for tailored digital health services. The approval is valid for three years.

These are the first healthcare designations since Korea began rolling out the broader scheme in March 2025. The scheme sits under the country's MyData framework, which gives individuals the right to have their own data transferred to services they choose. Because medical information is especially sensitive, MOHW is the approving authority for healthcare-specific institutions, working alongside the Personal Information Protection Commission (PIPC), Korea's privacy regulator, and the Korea Health Industry Development Institute (KHIDI), a government health-industry agency.

The three licences bless three different service models. Kangbuk Samsung Hospital was cleared for "Medibox," a mental-health and medication service that links MyData with smartphone and wearable signals such as activity and sleep, then feeds a clinical decision-support engine designed to flag medication risks and predict adverse effects. Kakao Healthcare's "MyMEDs" is a medication assistant built around prescriptions and visit history, with same-ingredient alternatives and side-effect and allergy alerts. The Catholic Medical Center's "MyWell+" is a personal health-data hub that lets users gather and manage their records, then layers on prevention and chronic-disease content.

All three sit on the same national plumbing. My HealthWay is the state intermediary that moves a person's data once they consent and submit a transfer request. It now draws on 1,269 medical institutions and three public agencies, and it can also pull in patient-generated data from services such as Samsung Health and Apple Health. At launch it opened access to 113 categories of health information, from prescriptions to surgery and pathology records previously locked inside separate hospitals or the Korea Disease Control and Prevention Agency (KDCA), the National Health Insurance Service (NHIS), and the Health Insurance Review and Assessment Service (HIRA).

The bar to qualify is not trivial. Applicants had to clear tests of technical capability, security and operational safeguards, and financial capacity. Screening ran from document review to on-site inspection and a final evaluation, with results due within five months of application.

The legal foundation is firmer than a pilot. The data-portability provision of the amended Personal Information Protection Act (PIPA), Article 35-2, took effect on 13 March 2025. It lets individuals require a data holder to transmit their personal data either to themselves or to another provider. MyData already operated in finance and the public sector; the amendment widens it. PIPC has said medical and communications enter MyData in 2025 and energy follows in June 2026, with ten priority sectors mapped for gradual rollout.

Why It Matters

The gate matters as much as the opening. Access to Korean health data is now real and routable, but it runs through a government licence. The first three approvals went to a major hospital group, the health unit of the country's dominant tech platform, and a large Catholic hospital network. These are domestic incumbents with the security posture, scale and balance sheets to clear the bar. Foreign digital health and AI vendors that want to build on Korean records will likely need their own designation or a designated local partner, and the queue now has well-resourced incumbents at the front.

The data is also becoming commercially useful, and global pharma has noticed. The same rails that feed consumer apps can feed research. In April 2026, Kakao Healthcare signed a memorandum of understanding with Sanofi to run real-world evidence studies on medical data and to build AI models using federated learning, beginning with Fabry disease and asthma. That is the emerging template: a licensed Korean data holder supplies the platform, and a multinational supplies the therapeutic and AI expertise. For pharma and MedTech, partnership access to structured Korean clinical data is now a concrete route rather than a someday ambition.

This is durable infrastructure. The portability right is written into law, the approval process is defined, and the sector roadmap is public. Korea is building the same kind of consent-based data market in health that it already runs in banking. Companies used to fragmented hospital data in other markets should treat Korea's consolidating, consent-routed model as a structural advantage for anything that depends on longitudinal patient data: remote monitoring, medication adherence, risk prediction, and real-world evidence.

The risk is concentration and trust. A licensed lane hands a small number of approved institutions privileged positions on the most sensitive data in the system. Public privacy expectations are high, MOHW has framed the approvals as a trust-building step, and a single serious breach could slow the entire programme. The opportunity is large. So is the scrutiny.

Executive Summary

Korea has decided to pay less for copies and more for invention. On 26 March 2026, the Health Insurance Policy Deliberation Committee — the panel that sets what the national insurer covers — approved a broad overhaul of drug pricing. The central change cuts the reimbursement rate for generics and patent-expired originals to 45 percent of the original branded price, down from 53.55 percent.

This is not a routine repricing. The Ministry of Health and Welfare (MOHW), which runs the national insurance system, frames it as a structural correction. Korean generic prices sit at 2.17 times the OECD average. Generics make up about 80 percent of reimbursed drugs. Total drug spending rose 62 percent between 2017 and 2024. The government wants to slow that spending and steer support toward companies that develop new medicines rather than copy old ones.

For international pharma and MedTech leaders, the direction matters more than the single figure. Korea is rebalancing the economics of its market. Generic-dependent businesses face margin pressure. Research-led companies are offered premiums. And because several Asian systems and a new United States policy now reference Korean prices, a lower Korean price can travel well beyond Korea.

What Happened

The package was approved on 26 March 2026, after the government first set out its direction to the same committee in November 2025 and spent the following months collecting feedback from industry, patient groups, labour representatives and experts. The MOHW called it the first reduction in the public drug-cost burden in 14 years.

The core mechanism is the reimbursement rate for generics and off-patent originals. Today a generic is calculated against the originator's pre-expiry insured price, with both eventually capped at 53.55 percent of that price. The reform lowers that cap to 45 percent. The change does not land all at once. Existing listed drugs will be adjusted in groups over roughly ten years, with the first round of price work on already-listed products starting in the second half of 2026.

The reform also attacks crowding. Korea's high generic prices have encouraged a flood of near-identical products, so stepwise price cuts will now begin with the 13th generic entrant rather than the 20th, with similar pressure applied once listings for the same formulation pass 13. Quality-linked rules tighten too. Products that do not run their own bioequivalence studies, or that do not use active ingredients registered with the drug regulator, face a lower adjustment ratio of 80 percent, down from 85 percent.

The other half of the bargain is innovation. Companies recognised as innovative pharmaceutical firms will receive a 60 percent price add-on for up to four years. A new "quasi-innovative" tier will receive a 50 percent add-on for up to four years. Strategically important products — those tied to domestic raw-material production, antibiotic injectables and paediatric medicines — can earn a premium of up to 68 percent, with support running beyond ten years. The favourable repricing is weighted toward firms that invest more in research and development.

Two access measures sit alongside the cuts. The reimbursement listing period for rare-disease therapies will be shortened to within 100 days, from as long as 240 days, with tighter post-listing review using real-world outcome data. And from the second quarter of 2026, the flexible pricing contract system — which lets the National Health Insurance Service (NHIS) strike tailored deals with manufacturers — is being widened to cover newly listed drugs, off-patent originals, medicines leaving refund-based risk-sharing deals, and biosimilars.

The context for all of this is speed and cost. The MOHW notes that reimbursement in Korea takes around 18 months after approval, against three months in Japan and 15 in France. The Health Insurance Review and Assessment Service (HIRA), which evaluates clinical and economic value, and the NHIS, which negotiates price, are both meant to move faster on the medicines the government wants to reward.

Why It Matters

The first effect is pressure on generic-dependent companies, and the domestic industry has said so plainly. In March, a coalition led by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) held an emergency press conference to oppose the timing and depth of the cuts. Its director called the situation "a matter of survival." The industry said it could absorb a reduction to about 48.2 percent through hard cost-cutting, but that a drop into the mid-40s would go beyond what many smaller manufacturers could bear. One large maker described shifting its research budget into "emergency management mode." Rising import costs for pharmaceutical ingredients, driven partly by Middle East tensions, sharpen the strain. Expect consolidation among small generic houses and a harder look at low-margin product lines.

The second effect is a tilt toward research-led and multinational players. The reform's premiums reward new-drug development, and the more generous off-patent treatment goes to firms that spend on R&D. Larger and international companies are better placed to meet those criteria than small local generic makers. For a foreign innovator with local research activity, the incentive structure now leans in its favour, and the faster rare-disease pathway shortens the wait for reimbursement on exactly the high-value products these firms tend to launch. A multinational industry group has already called the plan meaningful progress.

The third effect reaches outside Korea. The United States has named South Korea as a reference country for its Most Favoured Nation drug-pricing policy, a form of international reference pricing. Korean insured prices are typically low, which means a lower Korean price can pull down a manufacturer's reference price elsewhere — and can make companies hesitate to launch early in Korea at all. Several Asian markets also look to Korean decisions. Executives setting a global launch sequence should now model Korea's new, lower generic benchmarks as an input to prices in other markets, not as a local matter.

One caution belongs in every boardroom reading of this. The reform is a trade: lower commodity prices in exchange for richer innovation rewards and faster access. Whether that trade holds depends on execution — on the premiums actually materialising, on essential-medicine supply staying stable as margins compress, and on the ten-year phase-in not being diluted under industry pressure. The government has built in preferential tracks for essential and strategic products precisely because supply risk is real. The intent is clear. The balance between savings and supply is the part to watch.

Executive Summary

Korea's drug regulator wants to be the fastest in the world. In its 2026 work plan, the Ministry of Food and Drug Safety (MFDS) — the agency that approves drugs, biologics, and medical devices — set a target to cut its longest review timelines to 240 days, and to apply that standard across new drugs, biosimilars, and devices. Minister of Food and Drug Safety Oh Yu-kyoung reported the goal to President Lee Jae Myung in December 2025.

The headline number is a sharp compression. Biosimilar reviews that could run as long as 420 days are meant to fall to 240. The path is already visible. The timeline dropped from 406 days to 295 days during 2025, with the 240-day target set for the fourth quarter of 2026. In April 2026, the ministry gave the change a legal footing by writing biosimilars into its expedited-review regulations.

For international healthcare and biopharma leaders, this is not a domestic housekeeping story. Korea is one of the world's principal biosimilar producers. A faster home regulator changes where global launches can begin, how regional prices are anchored, and how attractive Korea looks as a contract-manufacturing base. The speed is the signal. The open question is whether the agency can hold quality while it accelerates.

What Happened

In December 2025, the MFDS presented its 2026 administrative plan under a single organising idea: accelerating global market entry through bio-health regulatory innovation. The centrepiece is timeline compression. The ministry said it would reduce its maximum review period — as long as 420 days for biosimilars — to 240 days, and extend that ambition to new drugs and medical devices. Minister Oh framed the aim bluntly, saying the ministry would become "the world's fastest licensing and review service agency."

The reduction is staged, not sudden. The Seoul Economic Daily reported that the approval period fell from 406 days to 295 days during 2025, with the further cut to 240 days planned for the fourth quarter of 2026. The mechanics are procedural rather than a loosening of standards. The MFDS is adding deeper preliminary reviews to improve data quality before an application is filed. It is running assessment items in parallel rather than in sequence. It is creating dedicated review teams and expanding face-to-face consultations at each stage.

Artificial intelligence is part of the plan. The ministry intends to build an "AI Approval and Review Support System" to summarise and translate submitted data and to draft review documents, reducing the load on human reviewers. For medical devices, it is moving to a negative-list system for change approvals. Under that approach, only modifications that affect safety or performance need pre-approval; other changes can be managed by the company and reported.

In April 2026, the reform acquired a legal basis. The MFDS revised its Regulations on Product Approval and Review of Biological Products to name biosimilars explicitly as eligible for expedited review, a category from which they had previously been excluded. It also simplified manufacturing-change procedures, letting minor changes such as containers, packaging, or process nomenclature move through reporting rather than full approval. Officials described the package as a structured overhaul that improves predictability, not a simple act of deregulation.

The plan also reaches outward. The ministry tied it to support for contract development and manufacturing organisations (CDMOs) under a dedicated special act, and to international cooperation aimed at the Middle East and the wider Asia-Pacific.

Why It Matters

The context that makes this strategic is Korea's position in biologics. More than 70 biosimilars have been approved by the MFDS since 2012. The portfolio is led by Celltrion and Samsung Bioepis, and the domestic market is projected to pass one billion dollars by 2027. Korean firms also hold a meaningful share of European approvals. When a country that manufactures this much accelerates its home regulator, the effect is felt well beyond its borders.

The first implication is launch sequencing. Global biopharma companies decide where to file first based on speed, predictability, and reference value. A 240-day Korean pathway makes Seoul a more plausible early launch market rather than a late one. For products where Korea is also the manufacturing base, approving close to where the product is made shortens the distance between factory and first sale.

The second implication is the patent cliff. Industry analysts expect a wave of biologic patent expiries through 2030, exposing a large share of branded sales to biosimilar competition. The economics of that wave reward whoever can move from development to market quickly. A faster Korean regulator is a direct lever on time-to-market for the Celltrion and Samsung Bioepis cohort, and for the foreign firms that partner with or manufacture alongside them.

The third implication is reference pricing, and it cuts both ways. Several Asian health systems look to Korean prices and approvals when setting their own. Faster Korean entry can pull regional launches forward. It can also mean a Korean price is set sooner, and a low one can travel. Executives who plan a Korean launch should remember that the timeline they are about to accelerate may also anchor their prices elsewhere.

The fourth implication is the contract-manufacturing opportunity. By pairing faster approvals with formal CDMO regulatory support and GMP-training diplomacy, Korea is positioning itself as a place to manufacture for export, not only a place to sell. For companies weighing Asian manufacturing capacity, a regulator that promises speed and is building the surrounding legal scaffolding becomes part of the calculation.

One caution is worth stating plainly. Speed targets are easier to announce than to sustain. The 240-day figure depends on more reviewers, working AI tools, and parallel processing holding up under real submission volumes. Compressing timelines without diluting scrutiny is the hard part, and it is the part international partners should watch. The promise is credible. The execution is still unproven.

Executive Summary

For most of its modern history, Korea has let patients go almost anywhere they like. There is no family doctor to clear the way, and a patient can walk into a clinic or, with an easily obtained referral slip, a large hospital. That is now being tested. In December 2025, the Ministry of Health and Welfare presented a plan to pilot a Korean-style family doctor model built on a continuous relationship between patient and primary-care physician.

The plan is called the Community-Based Primary Care Innovation Pilot Project. It introduces patient registration, bundled and performance-based payment, and a defined role for primary care in preventing and managing chronic disease. It runs as a three-year pilot from July 2026 to 2028, alongside a parallel effort to push large tertiary hospitals toward severe, emergency, and rare disease care.

This is the institutional groundwork for something Korea has never had: a gatekeeper. The pilot does not impose one yet. But the direction is clear, and the strategic consequences reach well beyond Seoul.

For international healthcare and MedTech leaders, the development changes where routine and chronic care may eventually happen, what payers reward, and which product categories Korea will buy. It also comes with a familiar Korean caveat. The medical profession is divided, and the timeline is not something to bank on.

What Happened

In December 2025, the Ministry of Health and Welfare (MOHW), Korea's senior health authority, reported the Community-Based Primary Care Innovation Pilot Project to the Health Insurance Policy Deliberation Committee. That committee is the body, chaired by the ministry, that decides what the national health insurance system covers and how it pays. Reporting a plan to it is how a reform begins to acquire money and rules.

The ministry's reasoning was demographic. Korea is now a super-aged society with rising rates of chronic illness, and it argued that a patient-centred primary care system is needed to deliver continuous, preventive management rather than fragmented, episode-based treatment after disease has set in.

The design has three notable features. First, patients register with a participating clinic and are classified by health status and level of need. Registered patients receive preventive care, medication management for chronic conditions, and lifestyle support, and can be referred onward or given home visits and telemedicine where appropriate. Second, the money follows continuity rather than volume. Clinics are paid under an Integrated Fee for Primary Care Function Enhancement, which rewards patient registration and ongoing management, with multidisciplinary support and performance-based compensation also being tested. Third, the pilot begins narrow. In 2026 it starts with people aged 50 and over, the group with the highest need for integrated care, and expands later based on analysis of cost and individual risk.

The pilot does not stand alone. The ministry paired it with what it called a regionally self-contained healthcare utilisation system, and with continued work to restructure tertiary general hospitals so they concentrate on severe, emergency, and rare disease, while regional secondary hospitals are strengthened. The three-year programme will be launched from July 2026 through a public competition in regions with high demand and workable primary care infrastructure, with expansion to more regions planned for 2029.

The reform also fits a stated national agenda. In her 2026 New Year address, Minister of Health and Welfare Jeong Eun-kyeong listed revamping community-based primary care, fostering comprehensive secondary hospitals, and supporting tertiary hospitals' shift toward severe and complex disease among the year's priorities. Primary care is not a side project. It is part of how the current government intends to reshape the system.

Why It Matters

Start with the structural backdrop, because it is what makes the pilot significant rather than routine. Korea built one of the world's most accessible health systems without a gatekeeping layer. Peer-reviewed work describes a specialist-dominant setting in which primary care is weak, the functions of clinics and hospitals overlap, and patients use large-hospital outpatient departments heavily. The pilot is an attempt to build the continuity layer Korea skipped on its way to universal coverage.

The first implication is about location. If primary care becomes the registered home for chronic and preventive care, and tertiary hospitals are steered toward severe and complex cases, the centre of gravity for routine and chronic-disease care begins to move downstream — toward clinics and community networks. Procurement tends to follow care. For MedTech and digital health companies that have treated the tertiary hospital as the single point of entry to Korea, that is a different buyer map, and one that takes shape over years rather than months.

The second implication is about incentives. Registration and performance-based fees nudge providers toward prevention and sustained management, not throughput. Products that can show better chronic-disease control, higher adherence, or fewer avoidable admissions fit that logic. Tools that simply add volume do not. This is the same shift toward paying for outcomes that has reshaped purchasing in other systems, arriving in Korea through the side door of a primary care pilot.

The third implication is about demand categories. The pilot names chronic-disease medication management, lifestyle management, home visits, and telemedicine as core functions. That points to a market for remote monitoring, chronic-disease management platforms, care-coordination software, and telemedicine integration — the same labour-stretching technologies Korea's aging agenda already rewards. A vendor with credible products here has reason to track which regions win the 2026 competition and what systems they adopt.

The fourth implication is execution risk, and it is political. The Korean Association of Internal Medicine condemned the plan as a stepping stone toward socialist medicine, warned that flat-fee payment would level services downward and squeeze solo clinics, and demanded the pilot be withdrawn. The Korean Academy of Family Medicine welcomed it. That split is not noise. Korea's medical profession has repeatedly slowed or reversed reform, most visibly in the 2024 standoff over medical-school admissions, and a voluntary, regional, time-limited pilot is easier to resist than a national mandate.

It is worth being precise about what this is not. It is not yet compulsory gatekeeping. Patients keep their freedom to choose. But registration, continuity of care, and the reshaping of tertiary hospitals are the foundations on which a more channelled system would later be built. The speed is uncertain. The direction is not.

Executive Summary

Korea is now one of the most prolific producers of medical artificial intelligence in the world. The harder problem is using it. As of October 2025, sixteen AI-based radiology tools were in routine clinical use in Korean hospitals, according to the Korean Journal of Radiology. In 2025 the Ministry of Food and Drug Safety (MFDS), Korea's medical-device regulator, designated forty-five innovative medical devices, many of them built on AI. Supply is not the constraint.

Adoption is. A large share of approved tools perform well in validation and then stall before they reach sustained clinical use. The gap is not technical. It sits between the moment a device is approved and the moment a hospital chooses to pay for it and run it every day.

For foreign healthcare AI vendors, this is the part of the Korean market that the headline approval reforms do not fix. A faster route to an MFDS licence does not shorten the route to a hospital budget line. Understanding why uptake is uneven matters more than counting how many tools have been cleared.

What Happened

The figure comes from the Korean Journal of Radiology: sixteen AI radiology solutions in clinical use as of October 2025, reached through several different regulatory pathways. Korea licenses these tools through MFDS, which confirms that a device is safe and performs as claimed. That approval is real, but it is only the first gate.

Two further gates sit behind it. Clinical value and price are judged by the Health Insurance Review and Assessment Service (HIRA), which decides what the national system reimburses, and by the National Evidence-based Healthcare Collaborating Agency (NECA), which runs Korea's health technology assessment. MFDS approval confirms that a device works. It does not guarantee a reimbursement code, and it does not guarantee that a hospital will buy.

Korea has built a bridge for promising but unproven tools. The Innovative Health Technology Assessment (IHTA) lets an emerging technology be used conditionally in clinical practice for up to three years while real-world evidence is collected. A full assessment then decides whether it stays. The route is pragmatic. It is also conditional and time-limited, which means the commercial clock keeps running while the evidence is gathered.

The newest tools push the boundary further. Soombit.ai's AIRead-CXR received Class III approval as software that analyses chest X-rays and drafts preliminary radiology reports — one of the first generative-AI reporting tools cleared in Korea. The technology is moving from flagging a finding to writing text that a clinician must then verify.

The government is spending to close the adoption gap rather than widen the supply. For 2026 the Ministry of Health and Welfare plans twenty additional AI demonstration projects, which validate tools inside hospitals before broader rollout, and will expand medical-data voucher support from eight projects in 2025 to forty in 2026. The money is aimed at deployment, not invention.

Why It Matters

The Korean lesson is that approval and adoption are different markets. A device licence answers a regulatory question. A purchase answers an operational and financial one. Even when clinicians want a tool, the decision runs through a multi-layered structure of clinicians, hospital administrators and procurement teams. It often stalls on budget ownership, workflow disruption, and competing institutional priorities rather than on clinical merit.

Reimbursement is the hinge. Without a billing code or a hard return-on-investment case, vendors struggle to move a product from free pilot to paid contract. An approved tool with no reimbursement path becomes a trial that never converts. This is why the assessment by HIRA and NECA matters more to a commercial plan than the MFDS licence that precedes it. The licence opens the door. Reimbursement decides whether anyone walks through it.

Workflow integration is the second hinge. A model that performs in testing still has to fit the exam room, the imaging suite, and the electronic record. Lunit, one of Korea's leading medical-AI exporters, offers a useful gauge of the friction: its overseas screening deals take about a year to close, security reviews alone can run six months, and the value of selling through PACS — the systems hospitals use to store and view images — is fading as hospitals shift to cloud workflows. The same operational drag applies inside Korea, where a tool has to earn its place in a radiologist's daily routine.

Caution is clinical as well as financial. When the Korean Society of Thoracic Radiology surveyed its members in 2025 on AI-drafted chest X-ray reports, the verdict was measured: useful, but to be integrated carefully and under human oversight. Korean clinical culture adopts deliberately, and the more a tool touches the final report, the slower that adoption tends to be. Vendors that read slow uptake as rejection misread the market.

For an international vendor, three points follow. First, treat the MFDS licence as the entry ticket, not the finish line, and budget for the longer reimbursement and procurement cycle that comes after it. Second, lead with operational value — reporting time saved, throughput gained, staff hours freed — rather than accuracy metrics alone, because that is the language procurement uses. Third, use the conditional routes deliberately. The IHTA pathway and the 2026 demonstration projects are built to generate exactly the real-world Korean evidence that hospital buyers and HIRA later demand. A vendor that engages while those programmes are forming builds the proof that procurement will eventually require.

Executive Summary

International healthcare companies tend to treat Korea as a contained pricing problem. Win a reasonable reimbursement number from the Korean payer, the thinking goes, and the consequences stay inside Korea. That assumption is wrong, and the reasons are structural.

Korea's reimbursement system is built to push new medicines and devices toward the lowest defensible price. New products are benchmarked against comparable ones already on the list, rarely earn a separate price category, and routinely settle below United States and European levels. That much is well documented.

The less understood part is what Korea does next. When the National Health Insurance Service negotiates a new medicine's price, it looks outward — at prices in OECD countries, and specifically at Taiwan and Singapore. The direction most executives assume, in which neighbouring Asian markets peg to Korea, largely runs the other way. Korea imports low reference points as much as it exports them.

For a company managing prices across Asia, the practical conclusion is the same either way. External reference pricing now links these markets into a single web. A low number accepted in one of them does not stay there. It becomes a data point the others can use.

What Happened

Korea runs a single-payer system. The National Health Insurance Service (NHIS) covers more than 97 per cent of the population and negotiates prices. The Health Insurance Review and Assessment Service (HIRA) decides what the system will reimburse, and on what evidence. Final approval sits with the Ministry of Health and Welfare.

For medical devices, the logic is one of comparison. As the consultancy Pacific Bridge Medical describes the system, manufacturers file for reimbursement within 30 days of approval, the review runs about six months, and most devices are priced at the lowest price of comparable products already listed. A genuinely new price category is rare, and even when granted it seldom matches US or EU levels. The same conservatism applies to drugs, where it has long been a point of friction in US–Korea trade.

For new medicines, the process is more elaborate but points the same way. Since the 2007 reforms reviewed by Kwon and Godman, a new drug must clear a HIRA cost-effectiveness assessment and then a separate NHIS price negotiation. During that negotiation — a 60-day, face-to-face process — the NHIS weighs the prices of substitute drugs already on the list and, crucially, the prices in OECD countries, Taiwan and Singapore. The negotiated figure has historically landed near 87 per cent of the price HIRA was prepared to approve. Generics are then fixed by formula at roughly half the originator price.

Two mechanisms matter for what follows. The first is internal reference pricing, where Korea anchors a new product to cheaper comparators at home. The second is external reference pricing, or ERP, where Korea anchors to prices abroad. Both are designed to keep the Korean number low. Both make the Korean number sensitive to prices set elsewhere.

Why It Matters

The first correction is directional. It is common to hear that Asian payers reference Korea, and to conclude that a soft Korean price will drag down the region. The evidence is more specific. Korea's own negotiators reference Taiwan and Singapore. Taiwan, in turn, does not reference Korea at all. Its National Health Insurance Administration benchmarks against a fixed basket of ten advanced economies, known as the A10 — the United States, Canada, Japan, Australia, the United Kingdom, France, Germany, Belgium, Sweden and Switzerland. Korea is not on that list.

That detail reframes the planning problem. The risk is not simply that Korea exports a low price outward. It is that Korea imports low prices inward. A weak number accepted in Singapore or Taiwan can resurface across the negotiating table in Seoul, and a low Korean settlement can echo in the markets that do reference Korea.

The second point is that none of this is peculiar to Korea. A Duke-NUS review of pricing across the Asia-Pacific found external reference pricing in routine use by China, Japan, Korea, Taiwan, the Philippines and Vietnam, usually layered on top of internal reference pricing and other controls. The region is not a set of independent negotiations. It is an interdependent web in which most payers are, directly or indirectly, watching one another's published prices.

The Taiwan example shows how quickly that web can transmit a shock. In 2023, Taiwan's payer proposed benchmarking reimbursement to the lowest price found among its ten reference countries. IQVIA estimated the move could cut the value of the top ten products by as much as a quarter, and warned it could prompt global companies to re-evaluate their launch sequence in Taiwan. The mechanism is general. Wherever a payer references a basket and selects the floor, the lowest price anywhere in that basket becomes the price everywhere.

For an international company, three implications follow. Launch sequencing becomes a pricing decision rather than only a commercial one: the order in which a product enters Korea, Taiwan, Singapore and the OECD markets they reference determines which prices anchor which. Second, the Korean negotiation deserves more senior attention than its market size alone would justify, because the number it sets can become a regional price floor. Third, the tools Korea uses to soften a low headline price are worth pursuing for the same reason. Price-volume agreements, common in Korea since 2007, and the flexible pricing contracts introduced under the 2026 pricing reform both allow a confidential effective price to sit below a higher visible one — protecting the reference number while still granting access.

The opportunity is the mirror image of the risk. A company that maps the reference relationships before it launches can choose where to set its anchor price deliberately, rather than discover after the fact that a quiet concession in a small market has travelled.

Executive Summary

South Korea is building a fast lane for rare disease drugs. On 26 March 2026, the Ministry of Health and Welfare (MOHW) approved a comprehensive drug pricing reform that includes a new expedited listing pathway. The pathway is designed to complete the full reimbursement process for rare disease treatments within 100 days. It runs as a pilot in 2026 and is set to be institutionalised in 2027.

For orphan drug makers, this targets Korea's weakest point. Korea has been one of the slowest developed markets to put a new medicine on its reimbursement list. For rare disease treatments, the wait has been longer still. A credible 100-day route would move Korea from laggard to near the front of the queue in Asia.

The opportunity is real. The caveat is also real. Korea already ran a parallel-review pilot, launched in 2023, that aimed to cut listing times and mostly missed. The 100-day target is more ambitious than the one that already slipped. The binding constraint was never only the calendar. It was the method Korea uses to judge value.

What Happened

On 26 March 2026, MOHW convened the Health Insurance Policy Deliberation Committee and approved a sweeping reform of the drug pricing system. The reform builds on a policy direction set out in November 2025 and will be rolled out through a series of regulatory amendments. Most of the attention has gone to the parts that lower generic prices. The part that matters for orphan drug makers is narrower and more positive.

Accelerating insurance coverage for rare disease treatments is one of the current administration's 123 national policy priorities. It was also named in the Joint Government Plan for Strengthening Support for Rare, Severe, and Intractable Diseases, published on 5 January 2026. The reform turns that intent into a defined pathway.

Under the new design, the listing process for a rare disease treatment is meant to finish within 100 days. That process has two main gates. The Health Insurance Review and Assessment Service (HIRA), the body that evaluates clinical and economic value, would compress its review from around 150 days to roughly one month. The National Health Insurance Service (NHIS), the single public payer that negotiates price, would compress its negotiation from around 60 days to roughly one month. Today the same journey for a severe or rare disease drug can take up to 240 days.

Two further mechanisms sit underneath the headline. First, the reimbursement price would be benchmarked to a set percentage of the average price in selected foreign markets, rather than negotiated from scratch. Second, the listing would carry a post-listing management mechanism. Clinical outcomes would be assessed periodically once the drug is in use, with the option to adjust price or coverage based on what the real-world data show. This is the "list first, confirm value later" model that several health systems are moving toward.

The reform pairs this with two changes that orphan drug makers should track. The cost-effectiveness threshold known as ICER, which sets how much the system will pay for an added unit of health, is to be recalibrated upward with weighting for disease severity and therapeutic benefit. And a flexible pricing contract mechanism, available from the first half of 2026, lets NHIS and a company agree a reimbursement price that differs from the public list price.

Why It Matters

Start with the gap the pathway is trying to close. The European Chamber of Commerce in Korea (ECCK), in its 2025 White Paper, put Korea's average time from a drug's first global launch to local listing at 46 months. The comparable figures it cited were 4 months in the United States, 11 in Germany, 17 in Japan, 27 in the United Kingdom, and 34 in France. By the same account, new drugs make up about 22 per cent of Korean pharmaceutical spending, against 48 per cent in Japan and 61 per cent in Germany. Korea is not a small market. It has simply been a slow and conservative one for innovative medicines.

Rare disease drugs suffer most from that conservatism, for a structural reason. Orphan treatments are often tested in small, single-arm trials because the patient population is tiny. That makes them look expensive under an ICER-based review, which rewards large, clean comparative evidence. The more dramatically a drug extends life, the longer patients stay on it, and the higher the modelled cost climbs. So the category that most needs speed has been the one most likely to stall. The reform attacks this on several fronts at once: faster procedural clocks, a higher and severity-weighted ICER bar, outcome-based pricing that defers the hardest valuation questions, and flexible contracts that let price and access be decoupled from the headline number.

The execution risk is not hypothetical. Korea launched a parallel-review pilot, known by its Korean shorthand Heo-Pyeong-Hyeop, in June 2023. It ran approval, reimbursement assessment, and price negotiation in parallel, aiming to cut listing from 330 days to 150. The results have been uneven. Qarziba, a neuroblastoma treatment, moved smoothly. But Winrevair (sotatercept) for pulmonary arterial hypertension sat at the reimbursement assessment stage for around nine months after its 2025 approval. Bylvay took more than 400 days from application. Limkato, Korea's first domestically developed CAR-T therapy, had not even been approved. Patient groups issued a joint statement arguing the parallel pilot "is not working at all." The new 100-day promise is steeper than the 150-day one that already underdelivered, and it relies on the same agencies clearing the same evidentiary bar faster.

The Japan contrast sharpens the commercial point. Sotatercept was reimbursed in Japan in 2025 and now runs roughly 100 new prescriptions a month, with out-of-pocket costs capped under Japan's designated intractable disease scheme. In Korea, comparable patients have faced monthly costs above 10 million won while the listing stalled. For a pipeline company sequencing an Asian launch, that difference is the whole question. Korea's new pathway could change the sequencing logic, but only once it has a track record.

There is a pricing tail worth naming. Because the new pathway benchmarks Korean reimbursement to a percentage of foreign reference prices, and because several Asian payers in turn reference Korean prices, the level a rare disease drug accepts in Korea can echo across the region for years. Faster access is welcome. Faster access at a benchmark that anchors low is a strategic decision, not a clerical one. Orphan drug makers should model the regional price consequence before chasing the 2026 pilot slot. Companies should also note a separate friction the ECCK has flagged: MFDS, the drug regulator, has at times been reluctant to accept orphan designation applications before a foreign approval is in hand.

Executive Summary

South Korea entered super-aged status – more than 20 per cent of the population aged 65 or over – at the end of 2024. The Korean economy reached that threshold in roughly seven years. Japan, the previous record-holder, took eleven. The European Union took nineteen. Korea's transition is one of the fastest in recorded demographic history.

For Swiss and European MedTech and digital-health vendors that have spent two decades calibrating their elder-care offerings against Japan, the temptation is to read Korea as Japan with a delay. That reading is wrong in a way that matters commercially. Japan and Korea adopted long-term care insurance from a similar institutional template – Japan in 2000, Korea in 2008 – but the two systems evolved against different fiscal, family, and political constraints. Korea today buys differently, channels services differently, and prices differently than Japan.

The strategic point for international vendors is narrow and useful. The product fit is often similar. The go-to-market is not. Companies that re-use their Japan playbook for Korea will underestimate the institutional buyer, overestimate the home-care opportunity, and miss the workforce-substitution lens through which Korean procurement now reads new technology.

What Happened

South Korea officially became a super-aged society at the end of 2024, when the share of citizens aged 65 or older crossed 20 per cent. Morgan Stanley's published analysis on Korea's aging crisis frames the speed of the shift as the defining variable. Korea moved from "aged" status – 14 per cent over 65 – to super-aged status in about seven years. Japan took eleven. The European Union and its twenty-seven member economies took nineteen. The compression is fed by the world's lowest fertility rate, recorded at 0.72 in 2023, and by an ever-older base population.

The macro consequence is already named. Korea's central bank has warned that, on current trajectories, the working-age population decline could push the economy into outright contraction by 2040, against current growth of around 2 per cent. The government declared a national demographic emergency in 2024.

Korea's long-term care insurance system, known domestically as LTCI, was introduced in 2008 and was explicitly modelled on Japan's 2000 long-term care insurance. Both schemes are social-insurance based. Both cover citizens aged 65 and over, with a younger-eligibility carve-out for age-related conditions such as dementia and stroke. Both rely on a needs assessment to gate access to care benefits.

The systems diverged in implementation almost immediately. Japan's long-term care insurance was designed on the assumption that the family is the default caregiver, that institutionalisation is somewhat unusual, and that the system's job is to support care at home. Japan's broader response to its demographic curve, formalised as the Community-based Integrated Care System, targeted 2025 – the year the baby-boomer cohort crosses 75 – for full national coverage of integrated health care, nursing care, prevention, housing, and livelihood support delivered in the community.

Korea's LTCI tilted the other way at the outset. With fewer family caregivers available, faster urbanisation, and a smaller stock of community infrastructure, Korean policy-makers prioritised expanding nursing-home supply for highly disabled older adults. The result, observable in peer-reviewed comparative work on the two systems, was a Korean LTCI that grew institutional capacity faster than home-based services, while Japanese LTCI grew the home-care surface first. Korean older beneficiaries paid lower average monthly premiums than their Japanese counterparts, but the system's long-run sustainability has been questioned. Earlier projections estimated the cumulative LTCI reserve fund could be depleted as soon as 2022, and successive governments have layered cost-containment measures on top.

Korea is now overlaying a second system on top of LTCI. The Integrated Community Care Assistance Act was promulgated in March 2024 and is being implemented from March 2026. Under the new law, central and local governments are mandated to provide an integrated package – health care, disease prevention and health management, long-term care, daily-living support, and family support – to older adults and disabled people who can no longer manage independently. The 2026 rollout follows a 2019–2022 pilot in sixteen local governments. It is Korea's attempt to do, with a delay and on tighter fiscal ground, what Japan's Community-based Integrated Care System set out to do for 2025.

Why It Matters

Four implications stand out for international healthcare and MedTech leaders.

The buyer is institutional in Korea in a way it is not in Japan. Because Korean LTCI prioritised nursing-home supply over home care in its first decade, the dominant procurement channel for elder-care technology in Korea is the institution – nursing homes, geriatric hospitals, regional medical centres – rather than the home. Japanese vendors learned to sell home-care monitoring, in-home robotics, and family-facing apps because Japanese LTCI rewards that surface. In Korea, those same product categories typically need to land first through an institution that owns the patient relationship, then extend into the home as Integrated Community Care matures. Vendors that import a Japanese direct-to-home model risk landing in a country where the buyer they expect does not exist at scale.

Workforce substitution is the dominant procurement frame. Both countries face an elder-care workforce gap, but Korea's gap is sharper relative to its smaller installed base of trained carers. Korean policy and procurement documents increasingly evaluate technology against a single test: does it reduce the number of carer hours required per resident or patient. Fall detection, automated continence management, sensor-driven night monitoring, gait and sarcopenia assessment, and AI-assisted documentation all sell in Korea on labour-substitution grounds first and clinical-outcome grounds second. The order is reversed in much of Europe, and partially reversed in Japan, where outcomes and family preference still carry significant weight. Foreign vendors that lead with clinical evidence and trail with workforce arithmetic will lose to domestic competitors that do the opposite.

The fiscal envelope is tighter, and pricing has to reflect it. Japan's LTCI has been under fiscal pressure for years but operates against a much larger accumulated reserve and a longer political runway. Korea's LTCI reached projected reserve depletion within about a decade of launch and has been backfilled by premium increases and cost-containment measures since. The Integrated Community Care system is being built on the same constrained envelope. The practical result is that Korean buyers – public payors, municipal governments running pilots, and the institutions that depend on them – negotiate on price with less elasticity than Japanese counterparts. Vendors used to Japanese reference prices should expect Korean offers to land lower, with greater pressure to bundle services, finance equipment, or accept usage-based pricing.

The 2026 overlay creates a narrow product-fit window. The Integrated Community Care Act takes effect in March 2026, against the backdrop of Korea's national demographic emergency and the ongoing $645 million pan-ministerial MedTech R&D plan. For a window of roughly eighteen months, Korean municipalities and provider networks will be selecting the technology stacks that underpin the new community-care model: remote monitoring platforms, fall-prevention systems, telemedicine integrations, care-coordination software, and assistive robotics. International vendors with credible products in these categories have a real chance to be designed into the system's reference architecture if they engage now. Vendors that wait until the model has settled will be selling against entrenched incumbents and locked municipal contracts.

There is also a regional read. Asian markets that import Korean and Japanese healthcare templates – Taiwan, Singapore, and parts of Southeast Asia – increasingly look at Korea's Integrated Community Care as the more replicable model for their own demographic curves. Korea's compression of the aging timeline makes the Korean playbook the more relevant reference for countries that will reach super-aged status in less than fifteen years. A product designed into Korea's 2026 community-care rollout therefore carries an Asian reference that a Japan-only deployment does not.

The risk side is bounded but worth naming. Korea's Integrated Community Care will be implemented unevenly. Wealthier municipalities will move first. Smaller and rural regions will lag for budget and workforce reasons. Vendors should not read the 2026 launch as a single national procurement event. It is a fragmented, multi-year rollout in which early reference deployments matter more than headline coverage figures.

Executive Summary

KIMES 2026, Korea's 41st International Medical and Hospital Equipment Show, ran from 19 to 22 March at COEX in Seoul. More than 1,400 companies from around 40 countries occupied roughly 45,000 square metres across two floors. The headline numbers are familiar. What changed is the centre of gravity.

For the past several editions, KIMES was read internationally as a Korean medical-device hardware showcase with a growing digital sleeve. KIMES 2026 inverted that. The most visible Korean exhibitors framed AI not as a feature on top of a device, but as a layer woven into clinical workflow – into the exam room, the imaging suite, the ward, the claims office, and the electronic medical record. The hardware was present. The argument was about software.

For Swiss and European MedTech leaders deciding where to place their Korea bets in the second half of 2026, KIMES is a directional instrument. It surfaces which categories Korean buyers are now signalling demand for, which categories domestic suppliers are quietly occupying, and which adjacencies are still open to foreign innovation. Read carefully, the 2026 floor was as much a market-entry map as a product showcase.

What Happened

KIMES is the longest-running and largest medical-device exhibition in Korea, organised by the Korea Medical Devices Industry Association and Korea E&EX, and held annually at COEX in Seoul. The 41st edition opened on Thursday, 19 March 2026, and ran through Sunday, 22 March. Coex listed the official scale as Halls A through D, with daily opening from 10:00 to 18:00, and a final-day close at 17:00. Korea Biomedical Review's on-the-ground report counted more than 1,400 exhibiting companies from approximately 40 countries across 45,000 square metres of exhibition space spread across the first and third floors of the venue.

Two special pavilions were enlarged this year, and both signal where the organisers see commercial pull.

The "Inspire Digital Healthcare Pavilion" was expanded threefold over its 2025 footprint and relocated to the Grand Ballroom on the first floor. It featured 51 companies in medical AI, digital healthcare, wearables, and data analysis. The accompanying Inspire Open Stage ran daily theme sessions, opening with a Google-led session on "Physical AI in Healthcare" and continuing through startup-investment announcements, investor networking, cybersecurity discussions, and AI applications in the beauty and senior industries.

The "Beauty & Derma Seoul" pavilion returned 1.5 times larger after a strong 2025 debut, now spanning Hall E, the Hall E lobby on the third floor, and the Hall A lobby on the first floor. It featured medical aesthetics: skincare devices, fillers, and laser equipment.

On the main floor, the framing was consistent. DK Medical Solutions, marking its 40th anniversary, demonstrated Innovision T7, a premium digital radiography system with voice control and a PreAct AI that suggests next imaging steps and optimal positioning from patient data, paired with AI denoising for lower-dose imaging. UBcare introduced Ysarang AI, a clinical AI layer built on top of its EMR business – the company also announced a planned rebrand to GC MediAI. Waycen showed an upgraded WAYMED endo with new CADq functions including appendix recognition and procedure-time counting, positioned as a procedure-quality tool rather than only a lesion-detection tool. BIT Computer presented voice-based outpatient charting, AI-generated ward note drafts, claims-review support, and drug identification from a photograph, noting that 44 of Korea's roughly 47 tertiary hospitals already use its pre-claim review programme.

Samsung Medison introduced ONE Platform, a new ultrasound architecture designed to standardise workflow across systems with AI tools such as HeartAssist and NerveTrack. GE HealthCare Korea brought a wider lineup spanning LOGIQ R5 ultrasound with fat-fraction measurement, Venue Sprint for point-of-care ultrasound, the Vivid AI cardiac platform, CARESCAPE Canvas for hospital-wide monitoring, and its AIR Recon DL deep-learning MRI reconstruction. Philips Korea launched the Flash Ultrasound System 5100 POC for emergency rooms and intensive care. InBody pushed deeper into clinical use with InBody Touch and a GLIM Nutrition Assessment for malnutrition screening. AITRICS, marking its tenth anniversary, expanded its clinical AI suite – V.Doc, V.Doc Pro, and AITRICS-VC – covering symptom review, speech-to-text documentation, follow-up guidance, and deterioration prediction.

In the Inspire pavilion, smaller firms showed where Korean digital health is moving. AIT Studio demonstrated MediStep, a gait-analysis device generating 40 metrics from a five-metre walk filmed on an iPad, with a new sarcopenia testing layer using the Short Physical Performance Battery. Cleverus presented BeClever, a vision-AI system that detects falls, bed exits, and self-harm risks on edge devices for hospital and nursing-care settings.

Why It Matters

Four implications stand out for international healthcare and MedTech leaders.

The "AI in workflow" framing is the new floor, not a ceiling. For three editions, Korean medtech vendors used KIMES to argue that AI features could lift hardware. In 2026 they argued that AI is the product, and the hardware is the delivery surface. DK Medical Solutions' radiography demo, Samsung Medison's ONE Platform, BIT Computer's EMR-layer AI, and UBcare's clinical AI layer all carry the same message: the buying decision shifts from "which device" to "which integrated AI layer". Foreign vendors that still sell devices as standalone hardware will increasingly be asked how their products fit a Korean hospital's existing AI workflow. Those that cannot answer will lose specifications they would previously have won on hardware merit.

Korean champions are widening their category footprint, and the foreign-vendor lane is narrowing. Samsung Medison's ultrasound, BIT Computer's hospital information systems, UBcare's EMR-layer AI, and Waycen's endoscopy AI are already category-defining inside Korea. The 2026 floor confirmed that domestic players are extending into adjacent workflow and clinical-decision layers that foreign vendors might have considered open three years ago. GE HealthCare and Philips remain present at the high end of imaging, but the middle of the market is contracting for foreign brands. Vendors entering Korea now should test their category positioning against this trajectory rather than the 2023 map.

The pavilions are the procurement signal. The threefold expansion of the Inspire Digital Healthcare Pavilion and the 1.5-fold expansion of Beauty & Derma Seoul are not curatorial choices. They are demand signals that organisers and sponsoring institutions are willing to invest behind. Digital health, AI applied to clinical workflow, wearables, and medical aesthetics are the categories Korea expects to grow procurement budgets against in the next eighteen months. Foreign vendors with credible products in fall detection, gait and sarcopenia assessment, remote vital-sign monitoring, AI-assisted documentation, and medical-aesthetic devices have an unusually open window – provided they engage Korean partners, KOLs, and pavilion programmes in this cycle rather than the next.

What was missing is also a signal. Two categories were notable for their thinness on the KIMES 2026 floor: integrated surgical robotics platforms competing head-on with established Western incumbents, and molecular and genomic diagnostics anchored in international reference labs. Both sit inside the Pan-Ministerial Advanced Medical Device R&D Project's seven-year priority list, but neither produced a defining Korean exhibit this year. The gap is consistent with the broader pattern: where Korea has not yet built a national champion, it remains receptive to foreign technology. Vendors in those categories should treat 2026 as an entry window rather than a competitive moment.

There is also a regional read. KIMES is increasingly the Asian floor on which Korean tertiary-hospital adoption is benchmarked by Singapore, Taiwan, and parts of Southeast Asia. A digital-health or workflow-AI product that wins a credible Korean reference at KIMES 2026 – whether through Samsung Medical Center, Asan, Severance, Seoul National University Hospital, or a Big-Five peer – carries that reference into regional procurement conversations in 2027. A product that does not appear at KIMES at all is essentially invisible to those regional buyers. Attendance is no longer optional for vendors with serious Asian ambitions.

The risk side is bounded but worth naming. The KIMES floor over-represents companies with marketing budgets and under-represents quieter foreign players that sell through distributors. Reading the show as a complete map will mislead. It is best treated as a directional instrument: which Korean categories are heating up, which foreign categories are thinning out, and which adjacencies are still open. The qualitative signal is reliable. The headcount is not the whole market.

Executive Summary

Korea is building an AI training base inside its health system. The Ministry of Health and Welfare (MOHW) has set out a coordinated programme to link clinical data from national university hospitals into the Health and Medical Big Data Platform, expand data-use rights for AI startups, and stand up a National Integrated Bio Big Data platform covering 770,000 individuals by 2028, with phased public access starting in the second half of 2026.

The headline number circulating in international briefings – about 400 million US dollars for the biobank itself – understates the operational shift. The deeper change is institutional. Korea is consolidating fragmented hospital, registry, claims, and biobank data into a single, AI-trainable layer, and is creating the legal and review machinery – shared Data Review Boards (DRBs), standard operating procedures for Institutional Review Boards (IRBs), pseudonymised datasets – that lets that layer be used at scale.

For Swiss and European healthcare AI vendors, this is the infrastructure that the 2026 reforms – the Immediate Market Entry pathway, the AI Basic Act, the Pharmaceutical Pricing Reform – actually rest on. A regulator can shorten device review and a hospital can buy a model, but neither matters if the underlying data is not usable. Korea has decided to make the data usable. The strategic question is who gets to train on it first.

What Happened

On 10 December 2025, MOHW held the 2025 Health and Medical Data Policy Deliberation Committee meeting at the Korea Press Center, chaired by Second Vice Minister Lee Hyung-hoon. The committee, established to coordinate national policy on the secondary use of health data, set out a multi-strand plan to expand the country's AI-ready data infrastructure. Healthcare IT News Asia summarised the plan for international readers in January 2026. The same plan was reported in Korean by the Korea Biomedical Review and in summary form by AsiaMD and This Week Health.

The plan has four operational tracks.

First, clinical data from national university hospitals will be linked into the Health and Medical Big Data Platform, which currently aggregates administrative data from public bodies. The intent is to add high-fidelity clinical information – diagnoses, treatments, outcomes – to the claims and registry data that the platform already holds.

Second, the National Integrated Bio Big Data platform – a project first announced in late 2024 with an indicative scale near 400 million US dollars – will provide phased public access from the second half of 2026 and full access by 2028. The platform is designed to cover 770,000 individuals across genomic, clinical, and lifestyle data, drawn from contributing national university hospitals and research programmes.

Third, MOHW will expand support for medical data use rights from eight projects in 2025 to 40 in 2026. Under the scheme, AI startups and small enterprises can receive up to 400 million won – about 280,000 US dollars – per project to access partner-hospital medical data. In parallel, 20 new medical AI demonstration projects will be funded in 2026, allowing AI solutions to be systematically validated inside hospitals before broader adoption. Data-driven hospitals are positioned as future AI research and demonstration hubs.

Fourth, the procedural plumbing is being rebuilt. The ministry will establish standard operating procedures for IRBs and DRBs to streamline deliberation on data provision, and will create a new shared DRB system. Pseudonymised, lower-risk datasets are to be developed and made available with educational and start-up support. The Korea Disease Control and Prevention Agency's (KDCA) National Institute of Health will secure high-performance graphics processing units and expand cloud services to enable remote analysis of large datasets via the Clinical and Omics Data Archive. The National Cancer Center (NCC) will combine its public and clinical libraries and build a global-convergence national cancer big data platform. The National Health Insurance Service (NHIS) will expand its analysis centres. The Health Insurance Review and Assessment Service (HIRA) will release additional pseudonymised datasets through its open data system.

The architecture is significant on its own, but the surrounding context matters. The plan sits alongside the AI Basic Act, which took effect on 22 January 2026 and classifies healthcare AI as "high-impact"; the Immediate Market Entry pathway launched the same month for 113 AI-based digital medical devices, 83 in-vitro diagnostic categories, and three medical-robot categories; and the second phase of the Pan-Ministerial Advanced Medical Device R&D Project, the 940.8 billion won programme that runs from 2026 to 2032. Each of those programmes assumes Korea has the data to train, validate, and deploy AI at scale. This infrastructure plan is what makes that assumption work.

Why It Matters

Four implications stand out for international healthcare and MedTech leaders.

The constraint on Korean healthcare AI is shifting from access to data quality. For more than a decade, the binding constraint on AI development in Korea was data fragmentation. Hospital systems did not interoperate. Claims data sat with HIRA and NHIS in formats that were hard to combine with clinical data. Biobanks were small and disconnected. The 2025–2028 programme attacks each of those problems directly. The result is not that Korean data will be easy to access – it will not. The result is that, for the first time, the data a competent AI team needs to train a clinical model on a Korean population can be assembled through a single, defined process rather than negotiated across a dozen institutions. Vendors that have stayed away from Korea on the assumption that data work was too costly should re-examine that view in 2026.

Foreign AI vendors face a narrow but real access window. The expanded data use rights scheme, the shared DRB, the lower-risk pseudonymised datasets, and the 20 medical AI demonstration projects are not formally restricted to Korean firms. In practice, the early projects will go to Korean AI startups and SMEs with established partner-hospital relationships. International vendors that can place a credible Korean entity – a subsidiary, a joint venture, or a serious clinical partnership with a national university hospital – into the application stream during the second half of 2026 have a meaningful chance of accessing the same data on the same terms. Vendors that wait for the formal access process to mature will be applying against incumbents that have already trained on the data they want.

The infrastructure choice signals what Korea wants foreign AI to do. Korea's industrial-policy pattern, set out clearly across the $645 million MedTech R&D plan and the Immediate Market Entry list, is to invest where it intends to build national champions and to import where it cannot. Healthcare AI sits awkwardly across that line. Korean firms – Lunit, VUNO, JLK, Kakao Healthcare among others – are credible in radiology, pathology, and increasingly in primary care. They are less established in molecular and genomic AI, in rare-disease modelling, and in specialist clinical-decision support for conditions where the Korean patient population is too small to train on alone. The new infrastructure is calibrated to push Korean firms forward in the first set of categories and to invite foreign capability into the second. Vendors should map their products against that split before committing to a Korean access strategy.

Data infrastructure is the second-order moat for AI Basic Act compliance. The AI Basic Act requires high-impact AI operators to maintain risk-management plans, run impact assessments, and produce plain-language documentation, with enforcement beginning in January 2027. None of that machinery works without auditable training data. Korea's new infrastructure – pseudonymised datasets, shared DRBs, defined data lineage from national university hospitals – gives operators a defensible evidence base for the documentation the Act will eventually demand. Vendors that train Korean models on this infrastructure will have an easier compliance posture than vendors that assemble training data from less traceable sources. This is a quieter advantage than the headline market-access reforms, but it compounds over time.

There is also a regional read. Korea's biobank scale – 770,000 individuals at full opening – sits between Japan's BioBank Japan and the UK Biobank in size, but with younger, more digitally captured cohorts. The combined platform that emerges by 2028 will be one of the larger AI-trainable health data resources in Asia. Singapore, Taiwan, and parts of Southeast Asia look closely at Korean clinical references; a model trained on the integrated Korean dataset and validated at Seoul National University Hospital, Samsung Medical Center, Asan, or Severance will carry across the region in a way that an EU-only or US-only reference does not. The regional optionality is part of what makes the Korean entry worth the cost of doing it properly.

The risk side is bounded but worth naming. Korea's history with national data infrastructure has not been uniformly successful. The early opening of the platform will be partial, the DRB load will be heavy, and the political sensitivity around patient data – already visible in PIPC enforcement actions – will shape what is actually released. Vendors should assume the first cohort of access cycles will take longer than the official timeline suggests and should budget accordingly.

Executive Summary

Korea has approved a 940.8 billion won programme – about 645 million US dollars – to develop next-generation medical devices over seven years. The headline number is not the news. The news is what the four sponsoring ministries chose to fund, and what that choice tells international MedTech leaders about Korea's posture for the rest of the decade.

The second phase of the Pan-Ministerial Advanced Medical Device R&D Project, announced on 5 November 2025, runs from 2026 to 2032. It targets six world-first or world-leading devices and the localisation of thirteen essential medical devices. The priority categories are AI-based diagnostics, surgical and assistive robotics, advanced implants, and next-generation imaging. Four ministries – Science and ICT, Trade and Industry, Health and Welfare, and Food and Drug Safety – co-sponsor it.

For Swiss and European vendors deciding how to spend their Korea-strategy budget this year, the plan is a map. It identifies the categories where Korea is building its own champions and the adjacencies where it still needs international technology, evidence, and capital. The strategic question is no longer whether to enter Korea. It is whether to enter as a competitor or as a partner – and which categories make that choice for you.

What Happened

On 5 November 2025, the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare (MOHW), and the Ministry of Food and Drug Safety (MFDS) held a joint business presentation at the President Hotel in Seoul. The four ministries announced a combined 940.8 billion won investment over seven years – 838.3 billion won from government budgets and 102.5 billion won from private sector contributions.

The programme is the second phase of what Korea calls the Pan-Ministerial Advanced Medical Device R&D Project. The first phase ran from 2020 and was widely treated as a test of whether four ministries could coordinate the full medical-device development cycle. By the time the second phase was announced, the first phase had supported 467 projects, generated 433 regulatory approvals, completed 72 technology transfers, and produced 254 commercialisation cases. Two specific outputs are repeatedly cited by Korean officials: the world's first AI-based software for cerebral infarction diagnosis support, and the domestic production of hemodialysis filters that had previously been imported in full.

The second phase sets explicit numerical targets. Six devices are expected to reach world-first or world-leading positions. Thirteen essential medical device categories that Korea currently imports are slated for localisation. The funding covers the full development cycle – basic research, applied R&D, clinical trials, regulatory approval, and commercialisation support – rather than R&D alone. The named priority technologies are artificial intelligence, robotics, advanced implants, and bio-imaging. The Ministry of Science and ICT framed the plan as a national growth-engine initiative.

The Healthcare IT News Asia briefing that reported the announcement to international readers paired it with the Korea Disease Control and Prevention Agency's national AI-ready health data infrastructure work. That pairing is not editorial. The two programmes are designed to feed each other: clinical data infrastructure on one side, device development on the other, with KHIDI – the Korea Health Industry Development Institute under MOHW – running export and clinical-validation support for the resulting products.

Why It Matters

Four implications stand out for international healthcare and MedTech leaders.

Read the priority list before drafting a Korea plan. The plan's category emphasis – AI diagnostics, surgical and assistive robotics, advanced implants, bio-imaging – is the clearest public signal the Korean government has given about where it intends to build national champions in this decade. The categories named are the categories where vendors should expect well-resourced Korean competitors to emerge in three to five years. They are also the categories where the Immediate Market Entry pathway, which launched in January 2026 for 113 AI-based digital medical devices, 83 in-vitro diagnostic categories, and three medical-robot categories, will draw the strongest political attention to domestic outcomes. A foreign vendor entering one of these categories should plan its evidence, distribution, and partnership architecture on the assumption that a credible Korean competitor will exist by 2029.

Localisation targets are partnership opportunities, not threats. The thirteen device categories slated for localisation are the inverse signal. They are categories Korea has decided it must develop domestically – usually because import dependence has been identified as a supply-chain or cost vulnerability. International vendors with established positions in these categories face a choice. They can defend domestic Korean market share against subsidised competitors for the next seven years, or they can structure partnership, technology-transfer, or joint-venture arrangements that put them on the inside of the localisation programme. The first phase's hemodialysis filter case is the precedent. Korean development partners typically welcomed international technical input where it accelerated the localisation timeline, and the resulting joint structures protected the international partner's regional position rather than eliminating it.

The four-ministry structure is the operational signal. Pan-ministerial coordination in Korea is unusual and expensive. When MSIT, MOTIE, MOHW, and MFDS sign a seven-year joint programme, they are committing to coordinated regulatory, reimbursement, and procurement signals across the device's full lifecycle. For an international vendor, this means three things. Products that align with the programme's targets can expect smoother MFDS review, more constructive HIRA discussions, and active KHIDI support for export reference deployments. Products that compete with programme outputs should expect the opposite – not formal discrimination, but a steadily less helpful institutional posture. The four-ministry structure compresses Korea's institutional ambiguity into a clearer signal than vendors usually receive in Asian markets.

The KRW–USD framing matters less than the cycle length. Headlines have emphasised the 645 million dollar figure. The more strategically relevant number is seven years. Korean industrial-policy cycles of this length tend to produce category leaders by year four or five – Samsung Medison, Osstem Implant, and Vieworks were each shaped by comparable multi-year programmes in earlier decades. International vendors that wait for the programme's outputs to appear before adjusting strategy will be reacting to category leaders, not negotiating with developers. The vendors that gain the most are those that engage now, while the consortia, university partners, and clinical sites for each priority category are still being assembled.

There is also a regional read. Korea's seven-year programme will produce technologies, clinical references, and reimbursement decisions that other Asian markets watch closely. Singapore, Taiwan, Thailand, and parts of Southeast Asia look to Korean tertiary-hospital adoption when making their own procurement decisions, and several reference Korean reimbursement prices directly. An AI radiology tool that becomes the standard of care inside Seoul National University Hospital under this programme will travel across the region. An international vendor that partners into a Korean consortium can reach those references through the consortium. A vendor that competes against one will face them as obstacles.

The risk side is bounded but worth naming. Pan-ministerial Korean programmes have a mixed record on execution. Coordination problems, ministry turf disputes, and changes of administration can compress timelines or shift priorities. The 940.8 billion won figure includes private sector contributions that may or may not materialise on schedule. International vendors should treat the priority list as a strong signal of intent and a useful planning anchor, but should not assume the programme delivers every named target on time.

Executive Summary

The competitor a foreign MedTech vendor will lose to in Korea is rarely the one named in its global market map. It is more often a domestic company that ranks below the top three globally but sits inside Korea's industrial-policy perimeter – and inside the procurement habits of Korean tertiary hospitals.

Samsung Medison in ultrasound, Osstem Implant in dental implants, and Vieworks in digital X-ray detectors are the three clearest examples. Each is a category leader inside Korea. Each exports successfully. Each receives explicit, sustained support from the Korean government's industrial agenda, most recently through the $645 million MedTech R&D plan announced this year and the Korea Health Industry Development Institute's (KHIDI) export programmes.

For Swiss and European vendors arriving with the new Immediate Market Entry pathway and the AI Basic Act, the structural question has shifted. It is no longer whether Korea is open. It is which categories Korea genuinely wants foreign innovation in, and which it is quietly building its own champions to occupy.

What Happened

The Fortune Business Insights South Korea medical devices market study sets out the baseline. The market is forecast to grow from roughly nineteen billion US dollars in 2025 toward thirty-two billion US dollars by 2032, with strong domestic suppliers across ultrasound, dental, imaging detectors, in-vitro diagnostics, and certain device categories where Korean industrial policy has invested for two decades.

Samsung Medison, the medical imaging subsidiary of Samsung Electronics, is the most visible example. Originally Medison Co. and absorbed into the Samsung group in 2011, the company is one of the top global ultrasound suppliers and has a dominant share of the Korean general-purpose ultrasound market. It exports to more than one hundred countries. Inside Korea, it has the advantages a foreign vendor cannot easily replicate: an installed base across tertiary hospitals, integration with Samsung's electronics distribution, and clinical relationships that go back decades.

Osstem Implant is the comparable story in dental. Founded in 1997, listed on KOSDAQ, and one of the world's largest dental implant manufacturers by volume, Osstem holds a leading share of Korea's domestic implant market and a meaningful share across Asia. It runs its own clinical training programmes, supports dentist education, and operates a distribution model that ties customer relationships directly to ongoing professional support.

Vieworks is the third. Less recognised internationally, the company has built a strong global position in digital X-ray detectors and dental imaging systems. It supplies OEM components to imaging vendors that European hospital purchasers know by other brand names, while selling its own systems in Korea and across Asia.

The industrial-policy layer around these companies is more substantial than foreign entrants often realise. KHIDI, under the Ministry of Health and Welfare (MOHW), runs export-promotion, R&D grant, and clinical-validation support programmes targeted at domestic MedTech firms. The $645 million MedTech R&D plan reported by Healthcare IT News Asia earlier this year names AI-based diagnostics, surgical robotics, regenerative medicine, and bio-imaging as priority categories. The pattern is consistent across plans: invest where Korea can build a national champion, open the market where it cannot.

Why It Matters

Four implications stand out for international healthcare and MedTech leaders.

Map your category before you map your strategy. The single most useful pre-entry exercise is to ask whether a Korean domestic supplier already leads the category. In general-purpose ultrasound, dental implants, digital X-ray detectors, certain dental imaging systems, and a growing share of AI radiology tools, the answer is yes. In molecular diagnostics, surgical robotics platforms, advanced implants, complex imaging modalities (high-end MRI, advanced PET-CT), and several frontier device categories, the answer is no. Foreign vendors that enter against a Korean category leader without a clear technical or evidence advantage will run into structural headwinds that no regulatory reform addresses. Vendors that enter the open categories find a far more receptive market.

Industrial policy compounds incumbency. Korean domestic MedTech companies are not protected through tariffs or formal preference rules. They are supported through long-running infrastructure: KHIDI export support, R&D grants, clinical-validation funding, and quiet alignment of public-hospital procurement with domestic development priorities. The effect is not legal favouritism; it is a steady tilt in the conditions under which competition takes place. A foreign vendor competing against Samsung Medison in ultrasound is also competing, at one remove, against a national industrial agenda. Understanding which categories sit inside that agenda is part of basic due diligence.

Partnership often outperforms confrontation. Many foreign vendors that have succeeded in Korea reached scale through OEM agreements, distribution partnerships, or component supply into Korean systems rather than through head-on retail competition. Vieworks supplies detectors into systems sold by Korean and international imaging brands. Samsung Medison sells ultrasound platforms that incorporate third-party AI software. Korean hospital systems source consumables, accessories, and specialty components from foreign suppliers while purchasing the primary system locally. The strategic question is rarely whether a foreign vendor can compete with a Korean champion. It is whether it can sell into, around, or alongside that champion in a way that uses the channel rather than fighting it.

The 2026 reforms reinforce the category split, they do not undo it. The Immediate Market Entry pathway covers 113 AI-based digital medical device categories, 83 in-vitro diagnostic categories, and three medical-robot categories. The list is targeted, not universal. It opens fast access where Korea wants frontier innovation it cannot easily develop, and leaves the conventional 490-day pathway intact for categories where domestic suppliers already lead. The implicit logic is consistent with industrial-policy practice elsewhere in Asia: speed up the inputs you need, slow down the inputs that threaten your own development plan. Foreign vendors should read the list not as a procurement opportunity but as a signal of where the Korean government has decided foreign innovation is welcome.

There is also a regional read. A vendor that builds a viable Korean position – whether as a primary brand, an OEM partner, or a component supplier – gains a credible reference for Singapore, Taiwan, and parts of Southeast Asia, all of which look closely at what Korean tertiary hospitals adopt. A vendor that misreads the category map, enters against a Korean champion, and withdraws within three years gives up that regional optionality too. The decision on where to enter is, in practice, a decision on which Asian markets remain open after the Korean attempt.

The risk side is bounded but real. Domestic MedTech success has been concentrated in mid-range, volume-sensitive segments where price discipline matters more than frontier innovation. Foreign vendors with genuinely differentiated frontier technology – high-end imaging, complex robotics, novel diagnostics – still find Korean buyers receptive. The mistake is to assume that the same receptiveness extends to categories where Korean suppliers have spent twenty years building competence the buyer can already see.

Executive Summary

Korean hospital procurement is the part of Korea entry that European MedTech executives most consistently misread. The procurement decision is not made in a tender. It is made over years of trust, in conversations with clinicians at a small number of tertiary centres, with consistent physical presence, and with multi-year evidence that the vendor intends to stay.

The US International Trade Administration's most recent country commercial guide on Korea's medical equipment market is unusually explicit about this. The guide names the structural realities that foreign companies most often underestimate: relationship-driven sales cycles, dominant exclusive importer-distributors, and concentrated clinical authority at a handful of academic medical centres. None of these are inefficiencies. They are how a national health insurance system that prices new technology tightly maintains continuity in clinical practice.

For Swiss and European vendors arriving in 2026 with new market-access tools – the Immediate Market Entry pathway, the AI Basic Act, the flexible drug-pricing contract mechanism – the regulatory door has opened. The commercial door has not changed. Reading procurement correctly is now the binding constraint on Korean revenue.

What Happened

The US International Trade Administration publishes a periodic country commercial guide for South Korea's medical equipment and devices sector. The current guide identifies hospital procurement dynamics as one of the principal challenges facing foreign MedTech entrants. Sales cycles are described as long. Clinician relationships are described as central. Exclusive importer-distributor arrangements are described as the dominant commercial channel.

Korean medical device law requires a local entity to handle importation, regulatory liaison, and post-market surveillance for foreign-manufactured devices. In practice, most foreign companies appoint a single exclusive distributor that controls hospital introductions, clinician engagement, training, and after-sales service. The result is a concentrated channel in which a small number of distributors have outsized influence on which products reach which hospitals, and on what terms.

Clinical authority is also concentrated. Korea's tertiary academic medical centres – Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, Severance Hospital, and a small group of others – set the clinical evidence standard for the rest of the country. Once a leading clinician at one of these centres adopts a device and publishes outcomes, peer institutions follow. A product that fails to secure a tertiary-hospital reference rarely scales nationally.

Procurement timing is correspondingly long. New device introductions typically require multi-year clinician engagement, in-hospital pilots, internal committee approval, and only then a formal purchase. The cycle from first clinician contact to volume purchase routinely runs eighteen to thirty-six months, and longer for capital equipment.

Why It Matters

Five implications stand out for international healthcare and MedTech leaders.

The decision-maker is the clinician, not the procurement officer. European vendors used to NHS-style tenders or central-purchasing organisations mistake the buyer. Korean hospital purchasing departments execute decisions; they rarely originate them. The clinician – usually a senior consultant at a tertiary centre – chooses the product. The procurement officer validates the price and processes the paperwork. A vendor whose Korean strategy starts with the procurement department will spend two years building the wrong relationship.

Consistency of presence is a screening criterion. Korean clinicians and administrators treat the vendor's visible commitment to Korea as a proxy for long-term reliability. A senior executive who visits twice a year, attends KIMES, and supports local clinical evidence reads as serious. A vendor that flies in for a sales push and disappears for nine months reads as unserious. The same product loses to a less innovative competitor that has been visible for three years longer. This is risk management, not Korean exceptionalism. In a price-controlled system, the buyer cannot easily replace a vendor that withdraws.

The distributor choice is the most consequential commercial decision the vendor makes. Choosing the wrong exclusive distributor – too small, overcommitted, or aligned with a competing product line – can lock the vendor into years of underperformance. Korean distributor contracts are difficult to exit. Many vendors do not learn this until the third year. Pre-contract diligence on a candidate distributor's existing portfolio, hospital relationships, and capacity to invest in the new product is the single highest-return preparation a vendor can do before entering the market.

KOL engagement is a multi-year investment, not a marketing activity. Korean key opinion leaders in tertiary centres are engaged through research collaborations, society lectureships at the Korean Society of Radiology, the Korean Society of Cardiology, and comparable bodies, and through investigator-initiated clinical studies. A KOL who has co-authored evidence with the vendor will champion the product internally. A KOL who has only attended a sponsored dinner will not. Vendors that treat KOL work as a sales tactic will see returns that match.

The 2026 reforms do not change any of the above. The Immediate Market Entry pathway compresses the regulatory delay for AI-based digital devices, certain in-vitro diagnostics, and three medical-robot categories. The AI Basic Act standardises governance documentation. The Pharmaceutical Pricing Reform's flexible contract mechanism extends to some device categories. None of these reach hospital procurement. A vendor that arrives in 2026 with eighty-day market access and no Korean distributor, no clinician relationships, and no tertiary-hospital reference will lose every advantage the new pathways were designed to deliver.

There is also a structural read on why the system works this way. Korea's National Health Insurance is universal and tight. Reimbursement prices new products against the cheapest comparable predicate. Hospitals cannot recover risk through premium pricing on new technology – they recover it through certainty that the vendor will be present for service, training, and clinical support across the product's full lifecycle. Long sales cycles and relationship-driven procurement are how a price-controlled system manages clinical risk. They are not friction to be removed.

The regional read matters too. Korean clinical references travel well to Singapore, Taiwan, and Japan, all of which weight Korean tertiary-centre evidence in their own procurement decisions. A product that has built a strong reference inside one of the Big Five Korean hospitals opens regional procurement conversations that an EU or US reference, on its own, does not. This makes the Korean investment harder than other Asian markets but more strategically valuable when it succeeds.

Executive Summary

Korea has a quiet procurement problem. The country crossed into super-aged territory in 2024, and the workforce that supports its long-term care system is shrinking faster than it can be replaced. By 2028, Korea is projected to be short roughly 116,000 elder care workers. The Korea Development Institute (KDI), the country's leading public-policy research institute, projects that long-term care demand will rise more than 2.4 times between 2023 and 2043, with the steepest growth in the 85-plus cohort that needs the most intensive support.

The workforce response has two tracks. One is foreign labour — Korea is preparing visa pathways for international care workers and is under domestic pressure to treat them as skilled professionals rather than cheap labour. The other is technology — remote monitoring, fall prevention, and care robotics are explicitly named in the KDI policy implications as productivity tools that the eldercare sector should deploy.

For international MedTech and digital-health vendors, this is the most concrete demand signal Korea has issued in years. The 2026 launch of the Integrated Community Care system gives the demand a procurement structure. The question for foreign vendors is no longer whether Korea wants these technologies. It is whether they can engage the buyers — central ministries, municipal pilots, and the NHIS-funded long-term care insurance system — before domestic suppliers occupy the categories first.

What Happened

In November 2024, Korea became a super-aged society — more than twenty per cent of the population is aged 65 or older. The transition took seven years from "aged" status. Japan took eleven. Korea now ages faster than any major economy on record.

The Korea Development Institute, a state-funded think tank that informs Ministry of Economy and Finance and Ministry of Health and Welfare (MOHW) policy, published its eldercare workforce projection as part of the KDI FOCUS policy series. The headline finding is that long-term care demand will rise more than 2.4 times by 2043, driven by the 85-plus cohort, while the supply of care workers contracts. About sixty-six per cent of Korea's 657,104 care workers in 2024 were aged 60 or older. As that cohort ages out of the labour market, replacement is not on track.

The projected gap by 2028 is roughly 116,000 workers. Reporting in the Korea Herald and Korea Times has put the same figure in slightly different terms — about 800,000 care workers needed against a projected 690,000 available, leaving a shortfall in the same range. Looking further out, projections cited by major Korean newspapers reach a shortfall of approaching one million long-term care workers in twenty years.

The KDI report does not stop at the projection. It sets out three policy implications. First, improving job quality — pay, working conditions, training — is necessary but will not close the gap on its own. Second, Korea must adjust visa policy to bring in foreign care workers and integrate them into the formal long-term care system with equal labour protections. Third, care-robot and assistive technology should be actively deployed to raise labour productivity in the sector.

The procurement context tightened on 27 March 2026, when the Integrated Community Care system launched nationwide under the Act on Integrated Support for Community Care Including Medical and Nursing Services. The Act, promulgated in March 2024, redirects elderly care delivery from hospitals and institutions toward homes, supported by coordinated medical, nursing, and welfare services under local-government leadership. The long-term home care medical centre network is also expanding nationwide in 2026. Distance-health technology revenue in Korea is now forecast in the range of 1.3 billion US dollars for 2026, covering telemedicine hardware, remote vital monitors, blood pressure devices, and connected scales.

Why It Matters

Four implications stand out for international healthcare and MedTech leaders.

The workforce gap is a hard demand signal, not a soft trend. Korean care procurement has historically been shaped by family expectations, hospital-centred care, and a workforce of older women willing to do the work at modest wages. That model is breaking on demographics. When KDI — an institution that rarely overstates its conclusions — explicitly names care robotics and assistive technology as policy levers, it is signalling that central government will support procurement, not block it. Vendors that have been waiting for Korea to articulate where it wants foreign technology now have an answer in remote monitoring, fall prevention, and care robotics.

The Integrated Community Care system is the procurement chassis. Demand will not appear primarily through tertiary hospital purchasing. It will flow through municipal pilots, NHIS-funded long-term care insurance benefits, and the home care medical centres expanding through 2026. For foreign vendors, this is a different commercial channel than the academic medical centres that dominate Korean MedTech sales. The buyers are local governments, regional care networks, and home-care operators. The sales motion is closer to public-sector procurement than to hospital key-opinion-leader engagement.

The category that wins is "labour-augmenting", not "labour-replacing". Korean policy framing is careful on this point. Care robots are positioned as productivity tools that let a single caregiver support more residents — lifting assistance, transfer aids, fall detection, night monitoring, medication prompts. Vendors that position their products as augmenting human carers will fit the policy narrative. Vendors that pitch full automation will run into a workforce-policy concern that the technology displaces the very jobs Korea is trying to make more attractive. The same product can be sold either way; the framing matters.

Domestic suppliers are already moving, but the field is not closed. Samsung, LG, Hyundai Robotics, and a wave of Korean care-robot startups are active in this space. International vendors retain advantages where products carry strong clinical evidence from European or Japanese aged-care deployments, where CE-MDR or FDA clearance is in place, and where the technology fits the Immediate Market Entry pathway that launched in January 2026 for AI-based digital medical devices, in-vitro diagnostics, and three medical-robot categories. Fall-detection AI, remote vital-sign monitoring, and certain robotic transfer aids sit inside or close to the qualifying perimeter. Vendors that have already cleared a peer regulator can move faster than the conventional 490-day pathway suggests.

There is also a regional read. Korea's response to its workforce gap will be watched closely by Singapore, Taiwan, and Japan, all of which face similar demographics with different healthcare structures. A care-technology category that proves itself inside Korea's Integrated Community Care system gains a reference deployment that travels well across Asia. Conversely, a vendor that fails to navigate Korean procurement now will find the same buyers harder to reach two years from now, when domestic suppliers have locked in the early references.

The risk side is real but bounded. Korean reimbursement remains tight — the long-term care insurance system pays modestly, and benchmark pricing against the cheapest comparable product applies here as it does in acute care. The 2026 flexible pricing contract mechanism extends to some device categories but does not change the underlying institutional posture. Vendors should expect to fund the early reference deployments themselves and to negotiate reimbursement carefully once clinical outcomes are documented.

Executive Summary

Korea's AI Basic Act entered its one-year transition phase on 22 January 2026. The law is short, principles-based, and easy to summarise. The operational consequences for foreign healthcare AI vendors are harder to read from the text alone.

Healthcare AI is classified as "high-impact AI" — the most regulated of the categories the Act recognises. Vendors that touch clinical decisions, diagnosis, triage, or hospital workflows must establish a risk-management plan, run an impact assessment, document how the system works in user-readable terms, and guarantee meaningful human oversight at the point of use. The transition phase gives operators twelve months to put this evidence in order. Active enforcement begins in January 2027.

For Swiss and European vendors already preparing under the EU AI Act, much of the underlying work transfers. The Korean specifics — documentation language, hospital procurement expectations, and how MFDS, MOHW, and the Personal Information Protection Commission share oversight — do not. This piece sets out what compliance looks like in practice for an international healthcare AI company entering Korea this year.

What Happened

The Framework Act on the Development of Artificial Intelligence and Establishment of Trust, commonly called the AI Basic Act, was promulgated in early 2025. It took effect on 22 January 2026 with a one-year preparation window before active enforcement.

The Act classifies AI systems by use case rather than by technology. Generative AI receives transparency and disclosure obligations. General AI receives lighter governance duties. "High-impact AI" covers systems used in domains where errors carry significant consequences for health, safety, fundamental rights, or critical infrastructure. Healthcare is named explicitly. So are AI systems used in medical-device diagnosis, public service delivery, and employment decisions.

For high-impact AI, the Act imposes four operator duties. Operators must establish a risk-management plan covering the AI lifecycle from training data through post-market monitoring. They must conduct an impact assessment evaluating effects on users, patients, and third parties. They must publish documentation explaining how the system works in terms a non-technical user can read. And they must guarantee human oversight — a real person, with the authority to intervene, when the AI is in clinical use.

The regulatory architecture around the Act is layered. The Personal Information Protection Commission retains its existing jurisdiction over patient-data flows. The Ministry of Food and Drug Safety (MFDS), Korea's medical device regulator, continues to govern AI-based medical devices through the existing software-as-a-medical-device pathway — including the new Immediate Market Entry system launched in January 2026. The Ministry of Health and Welfare (MOHW) sets the broader policy direction. The AI Basic Act sits on top of these regimes rather than replacing them, adding a governance layer that operators must produce before sale and maintain after deployment.

Penalties for non-compliance are tiered. Administrative fines apply to documentation failures. Stronger sanctions apply to high-impact systems deployed without an impact assessment.

Why It Matters

Four implications stand out for foreign healthcare AI companies.

The classification is broader than vendors expect. "High-impact AI" is not limited to autonomous diagnostic systems. Decision-support tools that influence clinical choices fall in scope. So do triage systems, AI-based image-prioritisation tools, hospital workflow software that shapes clinician attention, and AI used in eligibility or benefit decisions for public health programmes. Vendors that assumed they were too far from the clinical decision to be regulated will need to revisit that assumption against the implementing guidance as it is published over the next twelve months.

EU AI Act work transfers — but does not substitute. Companies that have built risk-management and impact-assessment files under the EU AI Act high-risk regime will recognise most of the Korean requirements. The structures map closely. What does not transfer is the language, the regulator-facing documentation conventions, and the integration with Korean hospital procurement norms. Korean tertiary hospitals expect submissions in Korean, with specific institutional review board procedures and locally validated clinical evidence. Vendors that rely on translated European files alone routinely face follow-up requests that delay procurement by months.

Human-oversight rules change product design, not just paperwork. The Act requires meaningful oversight at the point of use, not at the developer level. For autonomous workflows — automated triage, image-only diagnostic outputs, closed-loop alerting — this often means redesigning the user interface so a clinician must review, confirm, or override before the AI's output reaches the patient record. Vendors that built their products around full automation will need a Korea-specific configuration. This is a product change, not a compliance one, and it should be scoped before the sales conversation begins.

The MFDS and AI Basic Act regimes overlap, but the documentation is not duplicated. A device with MFDS clearance and reimbursement listing still requires the AI Basic Act risk-management plan and impact assessment if the product meets the high-impact threshold. Conversely, AI Basic Act registration does not substitute for MFDS clearance where the product is a medical device. Vendors should map their product against both regimes in parallel, not sequentially. The Immediate Market Entry pathway runs concurrently with the AI Basic Act transition phase — products entering Korea in 2026 face both reviews at once.

The compliance work is meaningful but proportionate. A mid-sized foreign healthcare AI vendor with existing EU or US documentation can typically complete the Korean-specific files within three to six months if it starts now. Vendors that wait until enforcement begins in January 2027 will be doing the same work under time pressure, with hospital customers already asking for evidence the vendor cannot yet produce.

There is also a quieter strategic point. Korea has chosen to govern healthcare AI through a unified Basic Act rather than through scattered ministerial guidance. That choice reduces uncertainty for serious vendors and raises the bar for opportunistic ones. The companies that benefit most will be those willing to treat documentation as a market-access asset rather than a compliance cost.

Executive Summary

In January 2026, Korea cut the timeline for innovative medical devices to reach the market from up to 490 days down to as little as 80. The headline number is dramatic. The detail is more selective.

The new Immediate Market Entry Medical Technology system applies to a defined list — 113 categories of AI-based digital medical devices, 83 in-vitro diagnostic categories, and three medical-robot categories. Devices outside that list still travel the conventional route, which can still take more than a year. For foreign MedTech leaders deciding where to deploy Korea-strategy resources this year, the practical question is no longer whether Korea is faster. It is whether your specific product sits inside the qualifying perimeter.

What Happened

The Ministry of Food and Drug Safety (MFDS), Korea's medical device regulator, launched the Immediate Market Entry pathway on 26 January 2026. The mechanism is straightforward in principle. Devices that have already cleared an internationally recognised regulatory body, such as the US FDA, the EU notified-body process under the Medical Device Regulation, or Japan's PMDA, can apply for a parallel-track Korean evaluation that runs alongside reimbursement listing rather than after it.

The previous timeline reflected a sequential process. MFDS approval came first. Reimbursement listing through the Health Insurance Review and Assessment Service (HIRA) and the National Health Insurance Service (NHIS) came afterwards. The combined wait routinely exceeded a year, and on contested categories stretched to the cited 490-day figure.

Under the new system, MFDS and HIRA review concurrently. The eligible product list is published and finite. As of the launch announcement reported by Seoul Economic Daily, it covers 113 AI-based digital medical device categories, 83 in-vitro diagnostic categories, and three medical-robot categories. Categories outside this list — including most conventional surgical devices, implants, and durable medical equipment — continue to use the standard pathway.

Why It Matters

Three implications stand out for international companies.

The reform is targeted, not universal. The category list is the product of an industrial-policy choice, not an across-the-board liberalisation. Korea is opening a fast lane for categories where it cannot easily develop competitive domestic products itself — frontier AI imaging, molecular diagnostics, and certain surgical robotics — while leaving slower pathways in place for categories where Samsung Medison, Osstem Implant, Vieworks, and other domestic suppliers already compete. Foreign vendors should treat the list as a signal of where Korea welcomes their innovation and where it does not.

Eligibility is conditional on prior regulatory clearance. A product that has only national clearance in a smaller market will not qualify. The mechanism presumes the company has already cleared a peer regulator and is willing to share that evaluation dossier. For Swiss and European MedTech vendors with CE-MDR certification and US FDA 510(k) or De Novo clearances, this is a routine fit. For smaller domestic-European vendors that have not pursued FDA clearance, Korea has effectively raised the bar before lowering the wait.

Reimbursement still negotiates the price. Faster market entry is not the same as favourable reimbursement. Korea's pricing approach — benchmark against the cheapest comparable product, demand cost-effectiveness evidence, rarely create new price categories — applies in the new pathway as much as the old one. The 2026 Pharmaceutical Pricing Reform's flexible contract mechanism extends to certain device negotiations, but the underlying institutional posture has not changed. Companies that win 80-day market access can still receive a reimbursement decision that compresses their global pricing strategy, particularly because several Asian markets reference Korean prices.

Operational readiness is the binding constraint. Korean buyers — academic medical centres, tertiary hospitals, public health authorities — will not commit to a new vendor in 80 days simply because regulatory permission arrived faster. Hospital procurement remains relationship-driven and consensus-driven. Korean import distributorship law still requires a local entity to handle the device. The new pathway compresses the regulatory delay but leaves the commercial sales cycle untouched. Vendors that arrive with no Korean distributor, no key-opinion-leader engagement, and no clinical-evaluation evidence prepared in Korean will lose the time they just saved.

The categories that win clearly are AI-based radiology and pathology decision-support tools, molecular and companion diagnostics with established international validation, and surgical robotic systems with peer-regulator clearance. These are exactly the categories where Korea's domestic industry has been investing but has not yet reached export competitiveness — and where international clinical evidence is already well-developed.

The categories that still face the long path are most conventional surgical instruments, orthopaedic and dental implants, imaging hardware in segments where domestic suppliers already lead, and any product whose primary regulatory clearance is from a market MFDS does not recognise as a peer evaluator.

Executive Summary

Korea is one of Asia's most advanced healthcare markets. Hospitals are technically sophisticated. Adoption of new clinical methods is fast. The population is aging quickly, creating strong demand for innovation.

Yet many foreign MedTech companies underperform in Korea. Some never reach scale. Some withdraw. Others stay for years without commercial traction.

The Five Structural Challenges

1. Pricing pressure is built into the system. Korean reimbursement pricing benchmarks new products against the cheapest existing comparable product. A new price category is rarely created.

2. The distributor model is concentrated and powerful. Importers and distributors are legally required for medical device imports. Most foreign companies appoint one exclusive distributor — creating dependency and information asymmetry.

3. Domestic competition is underestimated. Samsung Medison, Osstem Implant, and Vieworks have strong distribution networks and decades of hospital relationships.

4. Hospital procurement is relationship-driven. Korean hospital culture values consistency, demonstrated commitment, and physical presence over annual sales cycles.

5. Korean regulatory culture is detail-oriented. MFDS and HIRA both expect detailed, well-organised submissions. Documentation gaps that pass elsewhere create long delays in Korea.

What Changes in 2026

The Immediate Market Entry system, Pharmaceutical Pricing Reform, and AI Basic Act transition phase reshape part of the picture. They reduce regulatory speed and innovation recognition barriers. The distributor concentration, domestic competition, and hospital relationship dynamics remain unchanged.

Executive Summary

Korea has one of the most efficient public health insurance systems in the world. It covers nearly the entire population. It controls costs tightly. It rewards proven clinical value and pushes back on premium pricing.

For international healthcare and MedTech companies, Korea's reimbursement system is the single most important gate to the market.

The Three Institutions

MOHW sets policy. NHIS is the single insurer. HIRA is the technical gatekeeper — it evaluates clinical effectiveness, safety, and cost-effectiveness, assigns reimbursement codes, and monitors prescribing patterns.

MOHW writes the rules. NHIS pays. HIRA decides who gets paid.

Why Korean Pricing Is Tight

Most new products are priced against the cheapest comparable product already on the market. HIRA's evaluation emphasises cost-effectiveness from the public insurer's perspective. New price categories are rarely created. Korea is an access market, not a premium one.

The 2026 Immediate Market Entry System

Launched in January 2026, the system lets innovative devices with international-standard clinical evaluation enter the Korean market in as little as 80 days, down from up to 490. It applies to AI-based digital medical devices, certain IVDs, and medical robots.

Executive Summary

Korea's healthcare system is moving fast in 2026. The government is rewriting how new drugs and devices reach patients, how AI is governed inside hospitals, and how the country prepares for a workforce shortage in elder care.

1. Pharmaceutical Pricing Reform Now Live

The March 2026 reform introduced a flexible pricing contract mechanism, a 45 percent generic base rate, and a 100-day expedited rare-disease listing pathway. For European and Swiss pharma, this changes the negotiation playbook.

2. AI Basic Act Enters Force for Healthcare

Korea's AI Basic Act, in transition since 22 January 2026, classifies healthcare AI as "high-impact." Operators must publish risk-management plans, conduct impact assessments, and maintain human oversight in clinical use.

3. Immediate Market Entry Cuts Approval to 80 Days

Launched 26 January 2026. Internationally validated innovative devices can enter Korea in 80 days instead of up to 490. About 113 digital medical devices, 83 IVDs, and 3 medical-robot categories qualify.

4. Elder Care Workforce Shortage Becomes a National Priority

More than 21 percent of Koreans are 65+. A shortfall of roughly 116,000 elder care workers is projected by 2028. Integrated Community Care rolled out nationwide in March 2026. The workforce gap is now a procurement driver for remote monitoring and care robotics.